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ABSTRACT 
Nuclear lamins are type V intermediate filaments which form a proteinaceous 
meshwork, termed the nuclear lamina, which underlines the inner nuclear membrane 
and provides mechanical strength to the nucleus and maintains nuclear shape. A-type 
lamins in particular have been implicated in DNA replication, the regulation of gene 
transcription, apoptosis and nuclear migration. Expression of lamin AlC is closely 
associated with the differentiated phenotype and loss of lamin AlC expression has been 
correlated with increased proliferation, especially in tumours. I sought to investigate the 
expression and regulation of A- and B-type lamins during colorectal cancer (CRC) 
progressIOn. 
Preferential down-regulation of lamin A expression over lamin C was observed in the 
most dedifferentiated CRC cell lines. Semi-quantitative RT-PCR suggested that this was 
achieved by both transcriptional and post-transcriptional mechanisms. A connection 
between loss of lamin AlC and proliferation was ruled out. Instead 
immunohistochemical analysis of CRC tissue sections indicated loss of lamin A may 
correlate with the differentiation status of cells. In normal colonic crypts lamin AlC 
expression was greatest in the differentiated compartment, whereas lamin A was absent 
and lamin AlC was present at barely detectable levels in Dukes' A malignant polyps 
with high grade dysplasia. 
Stable re-expressIOn of lamin A constructs in SW480 colon cancer cells which 
expressed almost no endogenous lamin A rescued two-dimensional growth. Subsequent 
RNA profiling of 325 genes with reported relevance to colorectal carcinogenesis and 
general tumourigenesis confirmed that proliferation indices were unaffected by changes 
in the level of lamin A. Synemin, a cytoskeletal linker protein, was found to be 
significantly down-regulated in SW480 GFP-lamin A transfected cells versus SW480 
GFP transfected cells. This suggests that lamin A functions to maintain nuclear and 
cellular integrity by indirect modulation of components of cytoskeletal architecture. 
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CHAPTER 1 - INTRODUCTION 
1.1 Colorectal cancer 
1.1.1 National perspective 
Cancer is a major cause of morbidity and mortality in the UK. Annually more than a 
quarter of a million people are newly diagnosed with cancer and more than 150,000 
people die from the disease (Toms, 2004). Nationally colorectal cancer (CRC) is the 
third most commonly diagnosed cancer with 35,000 new cases detected every year 
(Figure 1.1). Incidence is similar in men (14% of all new cancer cases) and women 
(12% of all new cancer cases), although more men present with rectal cancer and show 
a higher rate of incidence above 40 years of age. CRC accounts for about 10% of all 
cancer deaths which translates into more than 16,000 people a year (Figure 1.2) (Toms, 
2004). Only lung and prostate cancer account for more male cancer deaths. In females 
CRC is also third in importance as a cause of cancer death, behind lung and breast 
cancer. Compared to the rest of the European Union, the UK has the 14th highest 
incidence of CRC and the 12th highest mortality rate, based on year 2000 estimates 
(Toms, 2004). Consequently CRC constitutes a major burden on public health. 
In an attempt to improve the prospects for patients diagnosed with cancer, the UK 
Department of Health has invested in Centres of Excellence for cancer treatment and 
care throughout the country. The James Cook University Hospital which serves the 
South Tees area of Northern England has been designated a Centre of Excellence for 
research and treatment of CRC. The predominant reason for this is the high incidence of 10 
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Figure 1.1 The most commonly diagnosed cancers, UK 2001. 
Source: Cancer Research UK (October 2005), 
http://info.cancerresearchuk.orglcancerstats/incidencelcommoncancersl. 
CRC in this area. Approximately 200 patients are seen each year with CRC (Prof. R.G. 
Wilson, personal communication). Ten percent of patients present with the earliest 
stages of the disease and usually survive, however, 25% have advanced tumours when 
first admitted and can often only be offered palliative treatment. In addition, 
approximately 20% of patients have a family history of the disease. A similar 
distribution of cases is seen across the whole Northern Region of England. In 2004, the 
Northern Region Colorectal Cancer Audit Group (NORCCAG) published an audit of all 
patients with a primary diagnosis of CRC who were treated in the 17 participating 
hospitals in the Northern Region of England during 2002. Out of 1413 patients who 
underwent abdominal surgery, 15.92% had Dukes' stage A (early stage) tumours, 
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30.29% had Dukes' stage B tumours, 29.30% had Dukes' stage C tumours and 21.44% 
had Dukes' stage D (late stage) tumours which had already spread to a secondary site. 
(N.B. Dukes' staging was not recorded for 3.04% of cases.) A positive family history 
was found in the records of between 10 - 15% of patients (NORCCAG, 2004). 
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Figure 1.2 The 20 most common causes of cancer death, UK 2003. 
Source: Cancer Research UK (October 2005), 
http://info.cancerresearchuk.orglcancerstats/mortalitylcancerdeaths! 
The benchmark indicator of successful diagnosis and management of cancer patients is 
survival rate. In 2001 the national five year relative survival rate (standardized against 
age) for colon cancer in men was estimated to be 52% and for women, 53% (Toms, 
2004). Based on data from the Northern Region, NORCCAG have demonstrated that 
survival rate after surgery is progressively reduced the later the stage of the resected 
tumour. They observed that more than 80% of patients with Dukes ' A tumours were 
alive after three years, whereas less than 20% of patients with Dukes ' D tumours were 
alive after three years (NORCCAG, 2004). By reflecting on the situation being faced in 
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the South Tees area and by the Northern Region of England as a whole it becomes 
apparent that patient prognosis could be improved in two ways: First, by earlier 
diagnosis of tumours and second, by improved understanding of advanced tumours. If 
scientific investigators were to learn more about the nature of changes in late stage 
tumours it could lead to among other benefits: 1) Identification of new drug therapy 
targets and 2) An insight into the differences between an individual who responds well 
to therapy and an individual who responds badly so that treatment regimes may be 
tailored to suit the individual. 
1.1.2 Population-based screening for colorectal cancer 
The main reason that so many eRe patients present with advanced tumours is due to 
the asymptomatic nature of the disease in the initial stages when it can be most 
effectively treated. Accordingly different methods of screening have been trialled which 
aim to identify those members of the population most at risk from developing eRe. 
Two screening methods have so far been piloted in the UK: faecal occult blood (FOB) 
testing and flexible sygmoidoscopy (Alexander and Weller, 2003; Atkin, 2002; 
Hardcastle et ai., 1996). The first randomised trial of screening using FOB testing took 
place in Nottingham and looked at individuals between 45 - 75 years of age (Hardcastle 
et ai., 1996). The screened group were subjected to biennial FOB tests and those 
patients giving a positive result underwent further colonoscopic investigation. The 
control group was not invited to participate in any screening tests. FOB screening 
detects non-visible or 'occult' blood in stools which can be indicative of colorectal 
neoplasia. FOB screening was found to be a good predictor of neoplasia in 46% of 
cases. In addition a larger proportion of tumours detected by screening were Dukes' A 
(early stage tumours) suggesting that FOB testing facilitated earlier diagnosis. 
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Importantly Hardcastle et al. (1996) also reported a positive effect on survival. The 
mortality rate in patients who took the FOB test when first invited to do so was reduced 
by 39% compared to the control group. 
These findings were generally supported by those of a similar study carried out in 
Minnesota, US (Mandel et ai., 1993; Mandel et ai., 1999). The Minnesota study made 
additional comparisons between the effectiveness of biennial FOB testing and annual 
FOB testing and reported a more favourable reduction in mortality rate in the group 
which were offered annual screening than in the group who were screened biennially, 
compared to the control group. These studies indicated that FOB screening may have 
potential benefits for improving survival if applied to the whole population. 
To determine the feasibility of screening for CRC in the UK population using FOB 
testing, the UK Colorectal Cancer Screening Pilot was established in 2000 and an 
independent report commissioned by the UK Department of Health. A population-based 
trial was set up in two pilot sites: Coventry and Warwickshire in England and Fife, 
Tayside and Grampian in Scotland. Men and women between 50 and 69 years of age 
were invited to participate and close to 60% took up the offer of a FOB test. Overall the 
outcome was positive and the UK Colorectal Cancer Evaluation Team concluded in 
their final report that the benefits of FOB testing for the whole population in enabling 
earlier CRC diagnosis and improved survival far outweighed the financial costs, 
logistical considerations and risks from complications associated with follow-up 
colonoscopy in the event of a positive FOB test (Alexander and Weller, 2003). To this 
effect the National Bowel Cancer Screening Programme is due to be implemented 
across the UK from April 2006 and aims to monitor all individuals in their sixth decade. 
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The benefit of single flexible sygmoidoscopy screening has also been investigated in a 
multicentre randomised controlled trial in the UK (Atkin, 2002). Flexible 
sygmoidoscopy is the visual examination of the rectum and sigmoid colon with a 
flexible endoscope. It has the additional advantage of being able to detect pre-malignant 
lesions or polyps which the FOB test is less likely to pick up. However it is associated 
with a greater risk to the individual due to accidental perforations of the bowel which 
can occur during the procedure. Atkin (2002) reported that almost three quarters of 
cancers detected in the screened group were localized, i.e. Dukes stage A or B, of which 
62% were Dukes stage A. (Polyps were generally removed by diathermy snare the same 
day.) This is a much higher percentage than was detected in the Nottingham study 
suggesting flexible sygmoidoscopy may be more sensitive than FOB. Additionally there 
was only one case of a perforated bowel out of 40,000 patients receiving 
sygmoidoscopy, indicating that it is both safe and effective. There is however one 
caveat with this screening method. The estimated cost of a diagnostic colonoscopy is 
£127, whereas the cost of a FOB test including processing is estimated at £5 (Alexander 
and Weller, 2003). Screening by flexible sygmoidoscopy would have to deliver vast 
improvements in early diagnosis and CRC survival rate for the benefits of rolling out 
such a programme nationwide to outweigh the associated financial burden on the UK 
Nation Health Service. 
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1.2 Colorectal carcinogenesis 
1.2.1 Epithelial versus mesenchymal tumours of the colon 
The adult gastrointestinal tract is radially organized into four histologically distinct 
layers: the mucosa, submucosa, muscularis propria and serosa (Burkitt et aI., 1993). 
Colonic crypts are folds of simple columnar epithelium adjacent to the lumenal surface 
which are embedded in the mucosa and underlined by layers of mesenchymal tissue. 
Figure 1.3 shows the histological organization of the colorectum. Colorectal cancer in 
the context of this thesis constitutes epithelial tumours which have arisen in the colonic 
crypt. Epithelial tumours are by far the most common cancerous lesion of the 
colorectum and the best studied. Smooth muscle and stromal tumours of the colon and 
appendix do occur in the form of leiomyomas and leiomyosarcomas, although they are 
rare by comparison to the prevalence of their epithelial counterparts (Hatch et aI., 2000). 
However, similar to epithelial tumours, one of the most common sites for smooth 
muscle tumours is the sigmoid colon (Hatch et ai., 2000; Toms, 2004). 
Metastasis from a colon carcinoma occurs by either lymphatic or haematogenous 
spread. The most common sites for metastases of epithelial tumours are the liver and the 
lungs. Lower rectal carcinomas metastasize first to the lungs, while upper rectal tumours 
tend to colonize the liver and are further disseminated by the arterial route to the lungs 
(Weiss and Ward, 1988). Other less common sites of secondary colon tumours include 
brain and bone (Hammoud et ai., 1996; Sundermeyer et ai., 2005), skeletal muscle 
(Torosian et ai., 1987), adrenal glands (Murakami et ai., 2003), bladder and chin 
(Hobdy et ai., 2003) and oral soft tissues (Bhutani and Pacheco, 1992). It has been 
determined that if metastases to the brain are involved, other organs are most likely also 
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Figure 1.3 Four-layer histology of the colorectum, defined by immunoperoxidase 
staining with lamin AlC antibodies and counterstaining with haematoxylin. 
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to harbour metastatic deposits (Alden et ai., 1996). The most common malignancy to 
metastasize to the colon is malignant melanoma, although it is more likely to colonize 
the small intestine (Reintgen et ai., 1984). 
1.2.2 Genetic control of colonic crypt topology and its implications for colorectal 
cancer development 
Healthy colonic crypts contain three specialized cell types which are mainly 
concentrated in the upper third of the crypt: mucus-secreting goblet cells, absorptive 
enterocytes and the less abundant enteroendocrine cells which function to lubricate the 
passage of waste material, absorb water and salts and secrete hormones respectively 
(Marshman et aI., 2002; Potten et ai., 1997). Cell turnover at the intercrypt table is very 
high, therefore the differentiated population must be perpetually replenished by 
unidirectional transit amplification and lineage-specific differentiation of multipotent 
stem cells located in the base of the crypt (Booth and Potten, 2000; Gordon· and 
Hermiston, 1994; Marshman et ai., 2002). The transition from proliferation to 
differentiation in healthy crypts constitutes the crypt-villus axis which is maintained by 
the canonical Wnt signalling pathway (Figure 1.4). This is considered to be the most 
significant regulator of normal crypt homeostasis and CRC development (Bienz and 
Clevers, 2000; Giles et ai., 2003; Pinto and Clevers, 2005; van de Wetering et ai., 
2002). 
Wnt factors are secreted glycoproteins thought to emanate in the base of intestinal 
crypts and / or underlying mesenchymal tissue, although their exact location has not 
been determined (Batlle et aI., 2002; Pinto and Clevers, 2005). They pervade the 
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Figure 1.4 The canonical Wnt signalling pathway functional in colonic crypts. 
intestinal epithelium, imposing a proliferative phenotype through FrizzledILRP -
mediated stabilization of the cytoplasmic protein, ~-catenin, leading to transcription of 
Wnt target genes (Logan and Nusse, 2004; Pinto et aI., 2003; Pinto and Clevers, 2005). 
The process is negatively regulated by adenomatous polyposis coli (APC) (Korinek et 
aI., 1997), a key component of the multiprotein degradation complex which presents ~­
catenin for phosphorylation, consequently targeting it for ubiquitination by ~-transducin 
repeat-containing protein (~-TrCP) and subsequent degradation by the proteasome in 
the absence of a Wnt signal (Bienz and Clevers, 2000). In addition to APC, the 
multiprotein degradation complex comprises a scaffold protein, Axin and two 
serine/threonine kinases, glycogen synthase 3~ (GSK3~) and casein kinase I (CKI). 
Upon activation of the canonical Wnt signalling pathway [reviewed in depth by Logan 
and Nusse (2004)], interaction of Wnt ligands with their membrane spanning co-
receptors, Frizzled (Fz) and LRP5/6, at the cell surface results in the recruitment of 
Axin and another protein, Dishevelled (Dsh), to the plasma membrane. Consequently, 
the multiprotein complex is dissociated, liberating ~-catenin and leaving it free to 
translocate to the nucleus. When there is no Wnt signal, members of the T-cell factor / 
lymphoid enhancing factor (TCFILEF) family of transcription factors are bound to the 
transcriptional repressor Groucho (Cavallo et aI., 1998). In the presence of Wnt, ~­
catenin overcomes this repression by direct association with TCFILEF factors, namely 
TCF-4 in the colon, trans activating the transcription of genes such as c-MYC which 
represses the cell cycle inhibitor p21 elP I/wAFl and pushes cells from G 1 to S phase of the 
cell cycle. Thus active ~-cateninITCF-4 complexes appear to preserve a stem cell and 
proliferating progenitor population in the lower crypt region which is essential for 
sustaining the turnover of differentiated cells at the surface (van de Wetering et aI., 
1997; van de Wetering et aI., 2002). 
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Wnt signalling is switched off in the differentiated compartment of intestinal crypts, but 
appears to be re-initiated at the earliest stage of colorectal tumour development. 
Immunohistochemical studies have shown accumulation of ~-catenin in the nucleus of 
aberrant crypt foci (ACF) which are the benign precursors of colorectal cancer (van de 
Wetering et aI., 2002). In addition, mutations in APe which constitutively activate ~­
cateninfTCF signalling (Korinek et ai., 1997; Morin et ai., 1997) are estimated to 
account for 85% of all colorectal tumours (Kinzler and Vogelstein, 1996). It has 
therefore been reasoned that activation of ~-cateninfTCF-4 may constitute the dominant 
switch in the malignant transformation of colon epithelial cells by imposing a 
proliferative phenotype at an early stage (van de Wetering et ai., 2002). 
1.2.3 Molecular basis of colorectal carcinogenesis 
Colorectal carcinogenesis IS a multistep process characterized by well-defined 
histopathological and morphological changes which have an underlying molecular basis 
(Fearon and Vogelstein, 1990). CRC development encompasses four distinct stages: 
aberrant crypt foci - adenoma - carcinoma - metastasis. In tum adenomas are 
subdivided into early (small), intermediate and late (large) stages. Early adenomas are 
also known as polyps. Malignant adenomas are termed carcinoma in situ (cis) or non-
invasive cancer because they have yet to breach the colonic wall. 
Hyperproliferation of the intestinal epithelium is the foremost preneoplastic event in 
CRC characterized by morphological changes in the colorectal mucosa, termed aberrant 
crypt foci. First identified by Bird (1987) in an animal model, ACF represent the clonal 
expansion of cells associated with the earliest stages of CRC in both rodent and human 
(Bird and Good, 2000; Roncucci et al., 2000). ACF display expanded lumenal openings 
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and vary in histology from hyperplasia to dysplasia, although dysplastic morphology 
appears to be associated with increased size of ACF (Siu et aI., 1997). Up-regulation of 
~-catenin, which is essential for transducing the proliferation-driving Wnt signal, has 
been associated with ACF (van de Wetering et aI., 2002). (See Section 1.2.2 for a 
description of Wnt signalling.) This is most likely the result of loss or inactivation of 
APC, a tumour suppresor gene (TSG) which negatively regulates ~-catenin (Korinek et 
aI., 1997). Mutations in APC are present only in dysplastic ACF (Jen et aI., 1994) and 
have come to be considered as the leading mutations predisposing individuals to CRC 
(Fodde et aI., 2001). 
'Polyp' is a descriptive term for any elevation in the intestinal surface. They are 
categorized as neoplastic, hamartomatous, inflammatory (pseudopolyp) or metaplastic. 
Neoplastic or dysplastic polyps are considered pre-malignant lesions. Other types of 
polyp have the potential to become malignant, although this is not the case for 
metaplastic polyps in which trans differentiation from columnar to stratified epithelium 
occurs (Misiewicz et aI., 1988). Dysplastic polyps are the first visible sign of the onset 
of CRC which can be diagnosed by colonoscopy or barium enema. Dysplastic polyps 
protrude like a mushroom stalk from the lumenal wall of the colon and develop from 
dysplastic ACF, therefore they are associated primarily with loss of APe. They can take 
on three forms representing increasing malignant potential: tubular (single projection 
only), tubulo-villous (projection with finger-like fronds) and villous (projection with 
multiple fronds). 
Activation of the oncogene K-ras by somatic mutation has been associated with the 
development of intermediate adenomas based on the observation that the majority of 
adenomas greater than 1 cm in diameter exhibit mutations in ras (Vogel stein et aI., 
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1988). Progression to a large adenoma appears to require loss of the Dee gene, which 
stands for Deleted in colorectal cancer (Fearon et aI., 1990). 
Finally the development of a full-blown carcinoma is caused by a change in one of the 
most ubiquitous cancer-associated TSGs, TP53 (Nigro et aI., 1989). Chromosome 17p 
allelic losses were found to correlate with advancement of the disease and were at a 
maximum level in carcinomas (Vogelstein et aI., 1988). The tumour suppressor gene 
TP53 was mapped to the common region of loss on chromosome 17p (Baker et aI., 
1989) and is consequently considered the key genetic alteration driving the progression 
of a large colorectal adenoma into a carcinoma (Fearon and Vogelstein, 1990). To 
encapsulate this evidence a genetic model for colorectal tumourigenesis was proposed 
by Fearon and Vogelstein (1990). Importantly they emphasized that the pre-requisite 
accumulation of multiple genetic and possibly epigenetic alterations was more critical 
for colorectal carcinogenesis than the order of specific alterations. Furthermore, hitherto 
unidentified genetic alterations are required after loss of TP53 for a carcinoma to spread 
to a secondary site. Figure 1.5 highlights the key molecular alterations during the 
progression of CRC. 
Mutations in APe are associated with chromosomal instability (CIN) which is a feature 
of both sporadic and inherited form of CRC and leads to genetic instability. A second 
pathway leading to genetic instability has also been identified, termed microsatellite 
instability (MSI) and results from defects in genes involved in the DNA mismatch 
repair (MMR) system. MSI is a particular feature of the hereditary form of CRC, 
Hereditary non-polyposis colorectal cancer (HNPCC). The effect of defective APe and 
DNA MMR genes on genetic stability in CRC is reviewed by Narayan and Roy (2003). 
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Figure 1,5 Key molecular changes during the development of colorectal cancer. 
1.2.4 Sporadic versus familial colorectal cancer 
Sporadic cases of colorectal cancer are estimated to account for 75% of all CRC cases 
and are strongly associated with the aged population (Toms, 2004). Figure 1.6 
illustrates the age distribution of CRC incidence. The majority (85%) of cancers are 
diagnosed in patients over 60 years of age. CRC causing genetic alterations 
are understood to start accumulating approximately 10 years prior to the development of 
cancer. Cases of CRC in younger individuals are likely to be the result of an inherited 
predisposition to the disease. 
Sporadic cases of CRC are generally later onset and thought to be related to certain risk 
factors including diet (high fat / low consumption of fruit and vegetables) and exposure 
to chemicals (Potter, 1999; Terry et ai., 2001). Patients have two normal germ-line APC 
alleles. Somatic mutations in both APC alleles are required for polyps to form. Inherited 
cases of CRC, on the other hand, are the consequence of a genetic predisposition. 
Patients generally inherit a mutation in one allele of the gene and only require a somatic 
mutation in the other for a tumour to develop (discussed by Muller et al. (2000)]. 
Genetic predisposition greatly increases the chances of polyps forming and leads to 
earlier onset of the disease. Hereditary forms of the disease are autosomal dominant and 
categorized according to symptoms, tumour pathology and age of onset. 'Cancer 
families' have been identified which carry a hereditary CRC-causing mutation. The first 
such family to be diagnosed with hereditary bowel cancer in Britain originates from 
West Cornforth, County Durham (Dunstone and Knaggs, 1972). Three types of 
hereditary CRC syndrome are recognized and described below. In most cases the 
predisposing germ-line aberration has been identified. 
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Figure 1.6 Number of new cases and rates by age and sex, colorectal cancer, UK, 2000. Source: Toms (2004). 
1.2.4.1 Familial adenomatous polyposis 
Familial adenomatous polyposis (F AP) represents 0.2 - 1 % of all colorectal cancers. It 
is easy to identify clinically because it is characterized by a colorectal mucosa which is 
studded with hundreds of polyps [reviewed by Muller et al. (2000) and de la Chapelle 
(2004)]. Patients with this disease have statistically a much higher chance of contracting 
CRC by virtue of the multiple polyps that arise. FAP is known to be caused by an 
inherited germ-line mutation in one APC allele. The most acute cases are observed 
when the germ-line mutation resides between co dons 1250 - 1330 (Nagase and 
Nakamura, 1993). The unaffectedAPC allele is lost prior to adenoma appearance. 
1.2.4.2 Hereditary non-polyposis colorectal cancer 
HNPCC accounts for 2 - 10% of all CRC cases making it the most common inherited 
CRC predisposition and increases a sufferers life-time risk of cancer to 80 - 85% 
(Aarnio et aI., 1995; de la Chapelle, 2004; Lynch and de la Chapelle, 1999). Also 
known as Lynch syndrome, affected individuals have a higher chance of contracting 
cancer in at least seven other organs, including endometrium, stomach, ovaries, small 
bowel and brain. It is caused by inactivating mutations in DNA MMR genes which 
enable deleterious mutations in familiar cancer genes (APC, K-ras, TP53) to persist 
(Parsons et aI., 1993; Thibodeau et aI., 1993). It differs from FAP because fewer polyps 
form and crypts with APC mutations are found side by side normal crypts without APC 
mutations. 
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1.2.4.3 Hamartomatous polyposis syndromes 
Hamartomatous polyposis can be subdivided into four separate syndromes: Cowden 
syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRR), Juvenile polyposis 
syndrome (JPS) and Peutz-Jeghers syndrome (PJS) (Muller et ai., 2000). All are 
characterized by the presence of gastrointestinal hamartomatous polyps and an 
increased risk of gastrointestinal malignancy. A germ-line mutation in the tumour 
suppressor gene PTEN has been implicated in CS, BRR and JPS (Li et ai., 1997; Marsh 
et ai., 1998), while germ-line mutations in serine/threonine kinases LBKI & STKll 
have been implicated in PJS (Hernminki et ai., 1998; Jenne et ai., 1998). PTEN & 
STKII mutations are rarely seen in sporadic CRe. 
1.2.5 Clinicopathological classification of colorectal cancer 
The pathologist Cuthbert Dukes studied the progression of rectal cancer in detail and 
classified it into distinct stages based on the extent of tumour spread (Dukes, 1932). The 
resulting Dukes' staging system was subsequently used to categorize colorectal 
tumours. Dukes' stage A tumours are localized to the bowel; stage B tumours extend 
through the colonic wall, i.e. they breach the serosa; stage C tumours show evidence of 
regional lymph node invasion as well as mural invasion; stage D was added later by 
Turnbull et ai. (1967) and indicates that secondary deposits have been found. Dukes' C 
tumours can be further subdivided according to the extent of lymph node invasion. C1 
tumours are positive only in perirectal nodes; C2 tumours show positive invasion of 
nodes at the point of mesenteric blood vessel ligature (Gabriel et ai., 1935). 
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Dukes' staging of colorectal tumours is still used routinely, although the TNM method 
of tumour identification, last modified in 1997 (AJCC, 1997), is often used in 
conjunction with the Dukes' system because it is more precise. The TNM staging 
system categorizes tumours according to depth of migration through the histological 
layers of the colon (T), the number of lymph nodes involved (N) and the presence of 
distant metastses (M). 
One other staging system exists for the classification of CRC, the Astler-Coller (AC) 
staging system (Astler and Coller, 1954). It has elements which liken it to both the 
Dukes' and TNM systems and describes both extent of mural invasion and lymph node 
involvement. AC stage A tumours are limited to the mucosa, stage B 1 tumours remain 
within the boundaries of the serosa, while B2 tumours have begun to invade extra-
colonic tissues. Stage C 1 and C2 are stage B 1 and B2 tumours respectively, but with 
nodal metastases. 
Although the Dukes' staging system has undeniably been of great benefit in diagnosing 
patients, it has been in use for the best part of a century and does not accurately predict 
prognosis or response to therapy. Ideally a staging system based on the molecular 
characteristics of the disease is required which may enable earlier diagnosis, tailored 
therapy and more accurate predictions of patient survival. 
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1.3 Architecture of the metazoan nucleus and implications for disease 
1.3.1 The nuclear envelope 
The eukaryotic cell is characterized by compartmentalization into two distinct regions: 
the nucleus and the cytoplasm. The nucleus is demarcated by a double membrane 
structure, termed the nuclear envelope, punctuated by nuclear pore complexes (NPCs) 
[reviewed by Franke et ai. (1981), including an historical perspective]. This results in 
the physical separation of genetic material and the transcriptional apparatus, which 
reside in the nucleus, from other organelles and the process of translation which occurs 
in the cytoplasm. The major architectural components of the nucleus are shown in 
Figure 1.7 (not to scale). 
The outer nuclear membrane (ONM) represents the cytoplasmic face of the nuclear 
envelope and is physically and functionally continuous with the endoplasmic reticulum 
(ER). The inner nuclear membrane (INM) faces the nucleoplasm. Together they enclose 
a lumenal or perinuclear space, thereby creating a dynamic structure estimated to be 
30 nm in width (Franke et ai., 1981; Gerace and Burke, 1988). The perinuclear space 
may provide an optimal environment for signal transduction between the nucleus and 
the cytoplasm (Sullivan et ai., 1993). In higher eukaryotes or metazoans a proteinaceous 
network, termed the nuclear lamina (NL), underlines the INM on the nucleoplasmic 
surface (Gerace, 1986; Gerace and Burke, 1988) and is composed of filamentous units 
known as lamins (Aebi et ai., 1986; Gerace and BIobel, 1980). Since they were first 
observed in rat liver lamina (Gerace et ai., 1978) several functions have been ascribed to 
lamin polypeptides including: Provision of mechanical support, organization of 
interphase chromatin and regulation of DNA replication, cell cycle progression, nuclear 
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shape and size, differentiation, transcription and apoptosis [reviewed by Gruenbaum et 
ai. (2003) and Hutchison (2002»). 
1.3.2 The nuclear lamina 
The NL was first isolated from rat liver nuclei (Dwyer and BIobel, 1976) and has been 
reported to vary in thickness between 10 - 100 nm (Aaronson and Blobel, 1975; Dwyer 
and BIobel, 1976; Fawcett, 1966; Hoger et ai., 1991; Scheer et ai., 1976). Stabilization 
of the nuclear lamina is mediated though interactions with various integral membrane 
proteins of the INM. The best characterized binding partners of lamins are lamina-
associated proteins (LAPs), emerin, MAN1 and lamin B receptor (LBR) (Hutchison, 
2002). 
Nuclear lamins are classified as type V intermediate filaments based on similarities in 
secondary structural organization and striking sequence homology to the characteristic 
a-helical rod domain of intermediate filaments (Fisher et ai., 1986; McKeon et ai., 
1986). Intermediate filaments (IFs) in conjunction with microfilaments and 
microtubules, which are two other distinct filament systems, provide an architectural 
scaffold within eukaryotic cells (Herrmann and Aebi, 2000). IFs in particular are 
considered to be mechanical integrators of cellular space (Lazarides, 1980). 
The common secondary structure of intermediate filaments compnses a non-helical 
amino-terminal (N-terminal) head domain and a carboxy-terminal (C-terminal) tail 
domain positioned either side of a central coiled-coil a-helical domain (rod). The rod 
domain is further subdivided into four helical regions, termed lA, 1B, 2A and 2B, 
characterized by heptad repeats and separated by three non-helical linker segments 
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(Fuchs and Weber, 1994). Compared to vertebrate cytoplasmic IFs, lamins possess an 
extended rod domain by virtue of a 42 amino acid (six heptad repeat) insertion within 
coil IB (Erber et ai., 1998) and a shorter head domain (Fisher et ai., 1986). To facilitate 
targeting of lamins to the nucleus they harbour a nuclear localization signal (NLS) in 
their tail domain (Loewinger and McKeon, 1988) and most lamins (except lamin C) 
have a C-terminal CAAX motif (C, cysteine; A, any aliphatic residue; X, any amino 
acid) which is important for localization at the INM (Nigg, 1992). 
Upon reviewing the literature it would appear that the more complex the organism, the 
more lamin genes and splicing isoforms it possesses. A single lamin (LMN-l) has been 
identified in nematodes (Caenorhabditis elegans) (Liu et aI., 2000), two lamin sub-
types (DmO and lamin C) have been reported in arthropods (Drosophila melanogaster) 
(Bossie and Sanders, 1993; Gruenbaum et aI., 1988; Riemer et aI., 1995), three in birds 
(Lehner et aI., 1987) and five in amphibians (Benavente et ai., 1985; Hofemeister et ai., 
2002; Stick, 1988). Seven lamins have been identified in mammalian cells. They are 
categorized into two groups, A-type and B-type, based on their biochemical properties 
(i.e. isoelectric point), ultrastructural characteristics and mitotic fate (Gerace and Blobel, 
1980; Gerace et ai., 1984; Gerace and Burke, 1988). 
Lamins A, A~lO, C and C2 are A-type and are alternatively spliced products of the 
LMNA gene (Fisher et aI., 1986; Furukawa et aI., 1994; Machiels et aI., 1996; McKeon 
et aI. , 1986) located at chromosome lq21.1 - 21.3 (Lin and Worman, 1993; Wydner et 
aI., 1996). Lamins Bl, B2 and B3 are B-type. Lamin Bl is the only product of LMNB1, 
located at chromosome 5q23.3 - 31.1 (Lin and Worman, 1995; Wydner et ai., 1996); 
while both lamins B2 and B3 are alternatively spliced products of LMNB2 (Furukawa 
and Hotta, 1993), chromosome locus 19p13.3 (Biamonti et ai., 1992). Both lamin C2 
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and B3 have only been detected in male germ cells (Furukawa and Hotta, 1993; 
Furukawa et ai., 1994). Consequently lamins A, C, A~lO, Bl and B2 are important in 
somatic cells. 
The LMNA gene is composed of twelve exons. Codon 566, situated in exon 10, 
constitutes the alternative splice site for prelamin A and lamin C and gives rise to the 3'-
most amino acid common to both lamin A and lamin C (Lin and Worman, 1993). 
Codons 567 to 572 follow on from codon 566 and are lamin C-specific. Lamin C 
terminates at the amino acid encoded by codon 572. For prelamin A the remaining 743 
nucleotides of exons 11 and 12 adjoin the 3'-end of codon 566, making exons 11 and 12 
lamin A-specific. Lamin A~lO retains the lamin A-specific tail domain, but is missing 
all 30 amino acids (90 nucleotides) encoded by ex on 10 (Machiels et ai., 1996). Thus 
lamin A, lamin C and lamin A~lO only differ in the sequence of their tail domains. 
Alternative splicing of the LMNA gene is diagrammatically represented in Figure 1.8 
(not to scale). 
The mam difference between A-type and B-type lamins is that A-type are 
developmentally regulated and synthesis appears to accompany cellular differentiation, 
whereas B-type are believed to be essential for cell survival because at least one B-type 
lamin is expressed at every point of development (Broers et ai., 1997; Coates et ai., 
1996; Lebel et ai., 1987; Lehner et ai., 1987; Paulin-Levasseur et ai., 1989; Rober et ai., 
1989; Stewart and Burke, 1987; Stick and Hausen, 1985). 
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1.3.3 Dynamic behaviour of the nuclear envelope 
Vertebrate cells undergo open mitosis which is accompanied by complete, but reversible 
dissassembly of the nuclear membranes, the nuclear lamina and NPCs. Signs of 
disassembly are first observed at prometaphase (Georgatos et ai., 1997). Components 
are reassembled in a co-ordinated, step-wise process in late anaphase / telophase 
(Chaudhary and Courvalin, 1993). 
Nuclear envelope dynamics have been investigated in the Xenopus cell-free system. 
Studies by Vigers and Lohka (1991) suggested that nuclear envelope components 
become vesicularized upon NE disintegration as NE protein-enriched vesicles were 
assembly competent. Groups such as Drummond et al. (1999) have further extended this 
idea by charting the progress of NE assembly by immunolabelling specific markers of 
two distinct vesicle populations, known as NEP-A and NEP-B, which appear to be NE 
precursors. Temporal and functional differences between NEP-A and NEP-B vesicles 
were determined. NEP-B were recruited first to chromatin and bound to it. The arrival 
of NEP-A vesicles followed. While NEP-A were unable to bind chromatin, they 
possessed fusogenic properties and appeared to support the expansion of the NE by 
fusing to NEP-B vesicles. Recruitment of NE precursor vesicles seems to be triggered 
by the association of NPC proteins with chromatid surfaces (Belgareh et ai., 200 1 ; 
Bodoor et aI., 1999). 
Whether vesicularization of NE components occurs in vivo has been called into question 
as a result of studies in somatic systems (mammalian culture cells) which have reported 
dispersal of NE proteins in the ER in metaphase (Ellenberg et al., 1997; Yang et al., 
1997). However, what does seem clear is that NE disassembly is regulated by 
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phosphorylation of both nuclear membrane and lamin proteins and accompanied by 
mechanical dismption. During prophase the minus-end-directed microtubule associated 
motor protein dynein translocates the mitotic spindle which is cross-linked to 
invaginated regions of the nuclear membrane via centrosomes. This physically tears 
apart the lamina and nuclear membranes, a process completed by metaphase (Beaudouin 
et ai., 2002; Salina et ai., 2002). 
The NL itself plays an important role in the breakdown and reassembly of the NE. The 
integrity of the NL is heavily dependent on the phosphorylation status of individual 
lamin polypeptides (Ottaviano and Gerace, 1985). Dephosphorylation of the NL 
concomitant with NE disassembly appears to be regulated primarily by the maturation 
promoting factor (MPF), a p34cdc2 kinase / cyclin B complex activated early in mitosis, 
but also by other protein kinases such as protein kinase C (Collas et ai., 1997; Dessev et 
ai., 1991). Phosphorylation of serine residues close to the lamin rod domain drives 
lamin polymer assembly (Dessev et ai., 1991; Peter et ai., 1990; Ward and Kirschner, 
1990). 
The mitotic fate of A-type and B-type lamins was originally thought to be quite distinct. 
Gerace and BIobel (1980) were the first to report that lamins A and C were solubilized 
and not associated with membrane fractions in mitotic cells, whereas lamin B was 
insoluble. Lamin B was predicted to remain associated with membrane fragments upon 
nuclear disassembly as dismption of membranes with detergent resulted in almost 
complete solubilization of lamin B. Similar observations were made in chicken (Stick et 
ai., 1988). More recent investigations have proposed that both A- and B-type lamins 
become soluble upon depolymerization of lamin polymers (Beaudouin et ai. , 2002; 
Daigle et ai., 2001). 
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By contrast reformation of the NL follows dephosphorylation of individual components. 
Clear temporal variation in the recruitment of lamin sub-types to decondensing 
chromosomes at the end of mitosis has been demonstrated, although the exact timing of 
these events is still a matter of debate. Independent of their fate upon onset of mitosis, 
B-type lamins are the first to be incorporated into an organized polymeric meshwork at 
the nuclear periphery (Moir et aI., 2000a; Moir et aI., 2000b). They are rendered 
functional by post-translational modifications. Permanent famesylation of the cysteine 
residue in their very C-terminal isoprenylation signal, the CAAX motif; subsequent 
endoproteolytic cleavage of the AAX tripeptide and carboxymethylation of the terminal 
cysteine appears to facilitate anchorage to the INM and interaction with integral proteins 
of the INM, such as LBR (Farnsworth et aI., 1989; Firmbach-Kraft and Stick, 1993; 
Sobotka-Briner and Chelsky, 1992). Studies completed so far have not led to conclusive 
agreement regarding the exact timepoint at which B-type lamins start accumulating at 
the nuclear periphery, but they are believed to localize at some point between late 
anaphase and late telophase / cytokinesis (Daigle et aI., 2001; Moir et aI., 2000b). 
Incorporation of B-type lamins into the NL is regulated by the activity of protein 
phosphatase 1 (PP1) which is dependent on binding to the membrane associated protein 
AKAP149 (Steen and Collas, 2001). 
By following the progress of GFP-tagged nuclear lamins, it has been determined that A-
type lamins do not migrate to the nuclear periphery until the end of cytokinesis when 
the entire NE has been fully reconstituted (Broers et aI., 1999) and appear to persist in 
the nucleoplasm in a soluble form for a few hours into G 1 phase of the cell cycle (Moir 
et aI., 2000b). A-type lamins are considered non-essential for NE assembly because 
they are absent at the earliest stages of development, but their importance in maintaining 
a proper functioning nucleus is underlined by a growing number of diseases which are 
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the result of specific mutations in LMNA or lamin NC interacting proteins. Lamin A 
specifically is synthesized initially as a precursor molecule, termed prelamin A. It 
undergoes similar processing to B-type lamins inside the nucleus, except a further 15 
amino acids are removed from the carboxy terminus (Sasseville and Raymond, 1995; 
Sinensky et ai. , 1994; Weber et ai., 1989). Isoprenylation of the CAAX box is a pre-
requisite for all other processing steps (Sinensky et al., 1994). It appears that prelamin 
A is assembly competent when isoprenylation activity is artificially suppressed, but 
under normal circumstances lamin A is converted into a mature form within four hours 
and the lamin A precursor molecules are restricted to intranuclear foci (Sasseville and 
Raymond, 1995). 
Thus the skeleton of the NL is first outlined by a lattice arrangement of lamins Bland 
B2 which is fleshed out by subsequent incorporation of A-type lamins which is entirely 
dependent on the prior organization of B-type lamin filaments (Dyer et ai., 1999; Moir 
et al., 2000b). 
1.3.3.1 Lamin filament assembly 
Models of NL assembly have been proposed and modified over the past two decades 
based on both in vitro and in vivo observations. The formation of larnin filaments is 
thought to result from the following series of sequential steps. First, parallel unstaggered 
coiled-coil dimers are formed involving the a-helical central rod domain, similar to 
cytoplasmic IF assembly (Aebi et ai., 1986; Heitlinger et ai., 1991; Heitlinger et al., 
1992). Subsequently, lamin dimers associate head-to-tail, but unlike vertebrate 
cytoplasmic IFs, they extend longitudinally to form long protofilaments before making 
lateral associations. In vitro, lateral growth of protofilaments results in the formation of 
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paracrystals with a 24 - 25 nm transverse banding repeat. This has been interpreted to 
represent anti-parallel, half-staggered associations of Iamin head-to-tail polymers 
(protofilaments) which give rise to -10 nm wide mature filaments. The organization of 
these filaments was first observed in Xenopus oocytes where they were arranged into a 
two-dimensional orthogonal lattice with an average crossover spacing of 52 nm (Aebi et 
aI., 1986; Goldberg et aI., 1999; Heitlinger et aI., 1991; Heitlinger et al., 1992; Moir et 
aI., 1991; Stuurman et aI., 1998). 
In 2001, Hutchison and co-workers (Hutchison et aI., 2001) proposed a model by which 
lamins A and C are incorporated into the NL once B-type lamins have associated with 
the INM. Lamin C does not possess an isoprenylation signal, therefore it was suggested 
that it becomes incorporated into the lamina on the back of lamin A. The group 
proposed that lamin A and lamin C form anti-parallel, half-staggered tetramers which 
then make head-to-tail associations with lamin B tetramers which are already arranged 
subjacent to the INM. Subsequently, Vaughan et al. (2001) reported that lamin C and 
emerin are dependent on lamin A for localization at the NE. The presence of lamin C 
and emerin may be essential to stabilize the NL as emerin's interaction with the NL is 
destabilized in the absence of lamin C (Vaughan et aI., 2001). 
1.3.4 Functions of the nuclear lamina 
1.3.4.1 Structural organization of the nuclear envelope and DNA replication 
Increased awareness of the process of NL formation during NE assembly has greatly 
enhanced our understanding of the functions of the NL. First of all, the NL is essential 
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for the organization of the nuclear envelope. Using a cell-free system based around the 
mitotic components of Chinese hamster ovary cells, Burke and Gerace (1986) reported 
inhibition of NE formation after immunological depletion of the lamin complement. 
Dabauvalle et ai. (1991) made a similar connection between lamin activity and NE 
assembly. Benevente and Krohne (1986) reported that lamin-depleted nuclei were also 
unable to decondense chromatin and reform nucleoli, rendering the nucleus structurally 
and functionall y incompetent. 
However, some researchers have found that the NE can reform in the absence of a lamin 
pool, but observed that cells depleted of functional B-type lamins could not support 
DNA replication (Meier et ai., 1991; Newport et aI., 1990). Goldberg et al. (1995) 
. provided the first direct evidence that lamins influence DNA replication. Upon addition 
of purified lamin B3 (Liii) to depleted extracts in the Xenopus nuclear assembly system, 
they observed that DNA replication was reinitiated. Nevertheless, it is clear that the 
absence of a functional lamina leads to extreme mechanical fragility of the NE (Liu et 
aI., 2000; Newport et al., 1990) resulting in nuclear deformities, such as invaginations 
and herniations and a much reduced resistance to physical pressure (Broers et ai., 2004). 
Localization of lamins to the nuclear periphery is also believed to be important for the 
assembly and spatial organization of NPCs (Lenz-Bohme et ai., 1997; Liu et ai., 2000; 
Stuurman et al., 1998) and more specifically the recruitment of nucleoporin NUP153 
(Smythe et al., 2000), one of the proteins making up the terminal ring of the nuclear 
pore basket [reviewed by Bagley et al. (2000)]. 
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1.3.4.2 Role for lamins in apoptosis and nuclear migration 
In the context of this study it is very interesting that a role for nuclear lamins has been 
proposed in the regulation of apoptosis, the programming of nuclear migration and the 
regulation of gene transcriptional activity - all functional targets in cancer. I will briefly 
explain the current position regarding lamin involvement in apoptosis and nuclear 
migration before concentrating on the functional consequences of lamin influence on 
interphase chromatin in Section 1.3.4.3. 
Classic morphological features of apoptosis including chromatin condensation, 
clustering of NPCs and membrane blebbing are also seen in lamin-deficient nuclei 
(Sullivan et aI., 1999; Tzur et aI., 2002). In vertebrates, caspase induced cleavage of 
lamins appears to be one of the earliest events in apoptosis and thus constitutes a critical 
and possibly rate-limiting step which precedes DNA fragmentation (Rao et aI., 1996; 
Takahashi et aI., 1996) and degradation of other INM-associated proteins (Buendia et 
aI., 2001; Duband-Goulet et aI., 1998). 
Morphological changes in nuclear shape and size, plus translocation of nuclei from a 
basal to apical position are classic features of colorectal epithelial dysplasia. The degree 
of nuclear migration correlates with malignant potential. During the normal 
development of C. elegans nuclear migration has been associated with microtubule-
lamina connections mediated by SUN (~ad1 / UNC-84 homology) domain proteins that 
traverse the double membrane structure of the NE (Lee et aI., 2002; Starr et aI., 2001). 
The microtubule network and corresponding motor proteins responsible for nuclear 
positioning exist in the cytoplasm, therefore SUN domain proteins are emerging as one 
of two candidate groups of nuclear membrane-associated proteins (the other group 
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being the spectrin-repeat proteins, nesprins) predicted to mediate influence of the NL on 
cytoarchitechture. In C. elegans, two SUN domain proteins - UNC-84 (which associates 
with the INM and colocalizes with Ce-Iamin) and UNC-83 (which is located at the 
ONM) - are predicted to interact within the perinuclear space of the NE (Gruenbaum et 
ai., 2005; Starr et ai., 2001). UNC-84 is expected to interact with or initiate a signalling 
cascade which modifies the cytoplasmic microtubule network resulting in nuclear 
migration (Lee et ai., 2002). Certainly, further work is required to elucidate all the 
components regulating nuclear migration in C. elegans and to confirm a similar 
relationship in mammalian cells. In mammals only one SUN domain protein has been 
described so far, UNC-84/Sun. It is anticipated that UNC-84 may form a bridge linking 
nesprin-2 molecules which localize to both the nucleoplasmic and cytoplasmic faces of 
the NE, thereby co-ordinating a functional link between lamin AlC, nesprin and actin 
(Libotte et aI., 2005). 
1.3.4.3 Rolefor lamins in the regulation of transcription 
Lamins appear to affect gene transcription through interaction with transcriptional 
machinery, chromatin or transcriptional repressors. Lamins do not always bind directly 
to transcriptional regulatory complexes or transcription factors, but may influence 
transcription indirectly through interactions with their binding partners which either 
associate with chromatin or with class II nuclear components. 
The main lamin-interacting proteins integral to the INM are the so-called LEM domain 
proteins [1AP2, gmerin and MAN!], although interaction between lamins and MAN! 
has not been determined. [See Foisner (2001) for a diagrammatic representation of 
lamin interactions at the INM and with peripheral heterochromatin.] The LEM domain 
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is a characteristic 43 amino acid sequence in the N-terminal domain of these proteins 
(Cohen et ai., 2001). Seemingly independent of lamins, LAP2P interacts with chromatin 
via BAF (barrier-to-autointegration factor) and its LEM domain (Furukawa, 1999). It 
also binds the transcription factor GCL (germ-ceIl-less), a peripheral INM protein, and 
represses activity of the E2F-DP transcriptional complex, known to be under tight 
control by the retinoblastoma protein (pRb) in G 1 phase of the cell cycle (Nili et al., 
2001). The LAP2u isoform is one of only two LAP2 sub-types out of a total of six 
currently recognized which do not integrate into the INM (Berger et aI., 1996; Dechat et 
ai., 1998). It binds chromatin and targets lamin AlC to intranuclear sites during 
interphase where the two proteins form tight complexes and have consequently been 
implicated in the structural organization of the nucleus (Dechat et ai., 1998; Dechat et 
ai., 2000). Hence it is conceivable that changes in lamin AlC activity could be reflected 
in chromatin modification by LAP2u. 
Emerin probably represents one of the most interesting integral membrane protein 
targets of lamin AlC. It binds to both lamin AlC and BAF (Lee et al., 2001), 
constituting a functional link with chromatin. Its localization to the INM is highly 
sensitive to the availability of lamin A polymers (Vaughan et ai., 2001) and it is 
redistributed to the cytoplasm, presumably the ER when the lamina is not properly 
formed (Gruenbaum et ai., 2002). Additionally, mutations in the STA gene which 
encodes emerin cause the muscle wasting disease X-linked Emery-Dreifuss muscular 
dystrophy (Bione et ai., 1994) which exhibits very similar clinical features to autosomal 
dominant Emery-Dreifuss muscular dystrophy which is caused by mutations in LMNA 
(Bonne et ai., 1999). Other class II nuclear proteins also interact with lamins, including 
LBR which binds lamin B (Ye et aI., 1997) and LAPl proteins which bind all lamin 
sub-types (Foisner and Gerace, 1993). 
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In the context of cancer biology, the reported interaction between pRb and lamin A is 
particularly noteworthy and suggests a mechanism by which A-type lamins may 
promote tumour development. Hypophosphorylated pRb represses transcription of 
genes necessary for G 1 - S phase transition and activates genes which promote 
differentiation by negatively regulating the activity of E2F transcriptional complexes 
(Chellappan et ai., 1991; Korenjak and Brehm, 2005). Lamin NC in complex with 
LAP2u was found to interact with hypophosphorylated pRb via pocket C of pRb, thus 
tethering pRb at the nuclear periphery during G 1 phase of the cell cycle (Markiewicz et 
ai., 2002). Evidence suggests that nuclear anchorage of pRb is essential for its 
appropriate function because deletion mutants in pocket C of pRb are no longer tethered 
to the nucleus and have been shown to have oncogenic properties (Mittnacht and 
Weinberg, 1991). 
Finally, lamins also appear to regulate gene transcription by modulating RNA synthesis. 
Addition of headless lamin A to BHK cells or transcriptionally active Xenopus nuclei 
caused disintegration of the NL and specifically abrogated the activity of RNA 
polymerase II (Spann et ai., 2002). The dissolved units of the NL formed nuclear foci 
which sequestered some transcription factors. Splicing factors were redistributed into 
unrelated nuclear speckles. 
1.3.5 Lamins in disease 
In recent years lamin NC has been found to be responsible for a plethora of human 
genetic disorders which generally display tissue-specific phenotypes and are 
collectively known as the laminopathies. These diseases can be subdivided into the 
following groups: Those that primarily affect striated muscle - muscular dystrophies and 
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cardiomyopathies; those that primarily affect fat distribution - the lypodystrophies; 
those that affect bone formation; those that predominately affect nerve conduction and 
lastly, the premature ageing syndromes. No disease has so far been reported to be 
caused by mutations in LMNBl or LMNB2, possibly reflecting an essential role in cell 
survival (Gruenbaum et ai., 2005). 
1.3.5.1 Diseases affecting striated muscle 
1.3.5.1.1 Emery-Dreifuss muscular dystrophy (EHMD) 
Three inherited forms of EDMD are recognized, an autosomal dominant (AD) form, an 
autosomal recessive form and an X-linked (XL) form. Both the autosomal forms are the 
result of mutations in the LMNA gene (Bonne et ai., 1999; Raffaele Di Barletta et ai., 
2000), whereas the X-linked form arises through loss-of-function mutations in emerin 
(Wulffet aI., 1997), an integral protein of the INM. Both autosomal dominant and X-
linked forms of the disease display a similar triad of clinical features, including early 
contractures of the elbows, Achilles tendons and posterior cervical muscles; progressive 
weakness and wasting of skeletal muscles, particularly humeral and peroneal muscles; 
and cardiac conduction defects (cardiomyopathy) which can result in sudden heart 
failure and therefore represent the most life-threatening clinical feature of the disease 
(Dreifuss and Hogan, 1961; Emery and Dreifuss, 1966; Miller et aI., 1985). 
The locus for AD-EDMD was mapped to chromosome lqll-q23, a regIOn which 
contains the LMNA gene, in a large French pedigree. Mutations in the LMNA gene co-
segregated with the disease in five families. Consequently, this became the first 
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inherited disorder to be explained by mutations in a component of the nuclear lamina, 
namely lamin NC (Bonne et at., 1999). Mutations in the head, rod and tail domain of 
LMNA have been identified in AD-EDMD patients (Raffaele Di Barletta et at. , 2000). 
Only one case of EDMD has been reported to involve both LMNA alleles (Raffaele Di 
Barletta et ai., 2000). The patient experienced severe muscle wasting and contractures, 
although there were no cardiac abnormalities. 
The X-linked form of Emery-Dreifuss muscular dystrophy, a recessive disease with 
100% penetrance in the second / third decade of life was first reported by Dreifuss and 
Hogan (1961) and later by Emery and Dreifuss (1966). The locus responsible for 
inheritance of XL-EDMD was mapped to chromosome region Xq28 (Bione et ai., 
1993). This region contained the STA gene (now also known as the EMD gene) which 
encodes emerin, a protein comprised of 254 amino acids and recognized as a 34 kDa 
product on a western blot (Manilal et ai., 1996). Unique mutations in the emerin gene 
were found in five XL-EDMD patients resulting in loss or truncation of the protein 
(Bione et ai., 1994). Further mutations in emerin were identified by Wulff et ai. (1997) 
at novel locations along the gene, therefore it appears that mutations in emerin are 
widely distributed and there is no particular hot spot. However, the majority of 
mutations in emerin are associated with the lamin A binding domain and are known to 
disrupt emerin - lamin A interaction (Lee et ai., 2001). Perhaps this explains the 
weakened interaction of mutant emerin with the nuclear lamina (Ellis et ai., 1999). A 
role for emerin as a nuclear membrane anchorage element was proposed by Cartegni et 
ai. (1997). Immunofluoresence studies have shown positive emerin staining is localized 
to the nuclear membrane in normal tissues, similar to that of lamin A (Manilal et ai., 
1996; Manilal et ai., 1999; Nagano et ai., 1996). However, emerin is noticeably absent 
from skeletal and cardiac muscle in XL-EDMD patients (Nagano et ai., 1996). 
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1.3.5.1.2 Limb girdle muscular dystrophy IB (LGMD-IB) 
LGMD-IB is another autosomal dominant syndrome associated with progressive 
muscle weakness and cardiac conduction defects (van der Kooi et ai., 1996). 
Symmetrical weakness in proximal lower-limb muscles begins before the age of 20 
years, progressing to the upper-limb muscles at about 30 - 40 years of age. Overall the 
phenotype is milder than EDMD with a much reduced occurrence of contractures. 
Similar to EDMD, cardiological abnormalities are the most life-threatening clinical 
manifestation of the disease. The disorder was linked to chromosome 1 q ll-q21 (van der 
Kooi et ai., 1997) and mutations in LMNA were subsequently identified as the causative 
lesion upon genetic analysis of three LGMD-IB families (Muchir et aI., 2000) . 
1.3.5.1.3 Dilated cardiomyopathy-IA (CMD-IA) 
Dilated cardiomyopathies per se affect cardiac function and show minimal skeletal 
muscle involvement (Olson and Keating, 1996). Sudden heart failure is the primary 
cause of death. The familial form of the disease (i.e. CMD-IA) is inherited in an 
autosomal dominant pattern and is characterized by the onset of cardiac conduction 
defects in the third or fourth decade of life. Mutations in the LMNA gene account for the 
autosomal dominant form and occur predominantly within the coiled-coil regions lA 
and IB of the rod domain (Brodsky et aI. , 2000; Fatkin et aI., 1999), but result in varied 
skeletal muscular dystrophic phenotypes. Interestingly, lamins A and C can be affected 
independently, with the R571S mutation substituting an arginine residue in the lamin C-
specific carboxy terminus (Bonne et ai., 2000) and the R644C mutation, also 
substituting an arginine residue, but in the unique lamin A tail domain (Genschel et ai., 
2001). 
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1.3.5.2 Diseases of adipose tissue, bone and nerve 
1.3.5.2.1 Dunnigan type - familial partial lipodystrophy (FPLD) - affects adipose 
tissue 
Similar to dilated cardiomyopathy, FPLD is a family of diseases with only one form 
(Dunnigan type) being associated with mutations in lamin AlC. Clinical features of 
FPLD are evident with the onset of puberty and are characterized by abnormal 
distribution of subcutaneous fat. In Dunnigan type - FPLD, adipose tissue progressively 
disappears (lipoatrophy) from upper and lower extremities, gluteal and truncal areas, yet 
accumulates on the face, neck, back and groin (Dunnigan et aI., 1974). Patients 
generally develop insulin resistance. The disease was linked to chromosome 1q21 and 
missense mutations in LMNA were identified in five Canadian families (Cao and 
Hegele, 2000). Unlike muscular dystrophy-associated mutations, which are mostly 
found within the core of the C-terminal globular Ig domain of lamin A and expected to 
disturb lamin structure (Krimm et aI., 2002), Dunnigan type - FPLD-associated 
mutations are mostly distributed on the surface of the Ig domain and therefore not 
expected to disturb lamin structure (Hegele et aI., 2000; Speckman et aI., 2000), but 
contribute to NE fragility and disorganization, resulting in herniations such as those 
reported in lipodystrophic patients by Vigouroux et al. (2001). 
1.3.5.2.2 Mandibuloacral dysplasia (MAD) - affects bone 
MAD patients exhibit progeria-like abnormalities in bone and skin growth with 
lipodystrophic elements. The disease has an autosomal recessive character and only 
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homozygous patients show the classic clinical features of postnatal growth retardation; 
craniofacial malformations including an hypoplastic mandible producing severe dental 
crowding; skeletal abnormalities including hypoplastic clavicles; atrophy of the skin 
over hands and feet with mottled cutaneous pigmentation; alopecia and partial 
lipodystrophy of either pattern A or B, often accompanied by extreme insulin resistance 
(Cutler et ai., 1991; Simha and Garg, 2002; Young et a!., 1971). Only MAD sufferers 
with type A lipodystrophy have been found to harbour a homozygous mutation, R527H, 
in the lamin AlC tail domain (Novelli et aI., 2002; Simha et aI., 2003) which appears to 
affect the normal distribution of lamin AlC at the NE resulting in lobulations and a 
'honey-comb' staining pattern (Novelli et al., 2002). 
1.3.5.2.3 Charcot-Marje-Tooth type 2Bl (CMT2Bl) - affects neural lineages 
Charcot-Marie-Tooth disease is another group of disorders which appear clinically and 
genetically heterogeneous, affecting motor and sensory nerves, particularly nerve 
conduction velocity, in the second decade of life. They are inherited in an autosomal 
recessive pattern. CMT type 1 (CMTl) describes the demyelinating form of the disease, 
whereas CMT type 2 (CMT2) describes the axonal form which can be further 
subdivided into CMT2B 1 and CMT2B2 according to genetic linkage. CMT2 patients 
experience reduced nerve conduction velocity concomitant with weakness and wasting 
of distal lower limb muscles and proximal muscle involvement in a subset of cases. In 
separate studies on consanguinous families with CMT2B 1 the disorder was linked to 
chromosome region lq21 which harbours the LMNA gene (Bouhouche et aI., 1999). A 
unique homozygous mutation was later identified in the rod domain of lamin AlC in 
three consanguinous Algerian families (De Sandre-Giovannoli et aI., 2002). The locus 
for the CMT2B2 was otherwise mapped to chromosome 19q13.3 (Leal et aI., 2001). 
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1.3.5.3 Progeroid / premature ageing syndromes 
1.3.5.3.1 Hutchinson-Gilford progeria syndrome 
Hutchsinson-Gilford progeria syndrome (HGPS) is a premature ageing syndrome which 
can result from both consanguinous and non-consanginous unions suggesting both 
autosomal recessive and autosomal dominant modes of inheritance. The HGPS gene 
was initially mapped to chromosome lq by observing two cases of uniparental 
isodisomy of 1 q and one case with a 6 megabase paternal interstitial deletion. Identical 
de novo single-base substitutions affecting codon 608 (GGC > GGT) which do not 
result in an amino acid change in ex on 11 (lamin A-specific), but partially activate a 
cryptic splice site were identified in 18 out of 20 patients with classic HGPS (Eriksson 
et aI., 2003). In one case a G-A transition was reported in the same codon, G608S (GGC 
> AGC), resulting in a substitution of serine for glycine. Activation of the cryptic splice 
site results in a 50 amino acid deletion at the C-terminal end of lamin A removing the 
site for endoproteolytic cleavage as well as the site for cell-cycle-dependent 
phosphorylation (Ser 625), both of which are necessary for the post-translational 
modification of prelamin A into mature lamin A. It is thought that incompletely 
processed lamin A may act as a dominant negative mutant at the NE (Eriksson et aI., 
2003). 
Mouse models carrying an autosomal recessive mutation in LMNA (LMNAL530PIL530P) 
show demonstrable defects in A-type lamins and many of the clinical features 
associated with HGPS in humans including growth retardation, abnormal dentition, loss 
of subcutaneous tissue, alopecia, reduced bone density, incomplete sexual maturation 
and poor muscle development (Mounkes et aI., 2003). HGPS patients usually suffer 
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disproportionate craniofacial development and atherosclerosis and die of congestive 
heart failure in the first or second decade of life. The mouse model for HGPS was 
shown to have a much smaller heart and smaller myocytes compared to wild-type. 
Mutant mice also presented with defects in nuclear morphology (Mounkes et aI., 2003). 
Immunofluorescence and electron microscopic investigations using fibroblasts derived 
from HGPS patients with the G608G mutation demonstrated age-dependent defects in 
nuclear structure, including nuclear lobulations, thickening of the NL, clustering of 
nuclear pores and loss of peripheral heterochromatin (Goldman et aI., 2004). 
1.3.5.3.2 Werner syndrome 
Werner syndrome comprises clinical features such as premature arteriosclerosis, 
scleroderma-like skin changes, subcutaneous calcification and a wizened / aged facial 
appearance (McKusick, 1963). Atypical Werner Syndrome has a more severe phenotype 
than the 'typical' form which is caused by homozygous mutations in the DNA helicase-
like gene, RECQL2. Four atypical Werner Syndrome patients were found to express 
normal RECQL2, but were heterozygous for novel missense mutations in LMNA (Chen 
et aI., 2003). Changes in nuclear morphology and mislocalization of lamins in 
fibroblasts of a patient with mutation L140R were described (Chen et aI., 2003). 
Therefore atypical Werner Syndrome is characterized by autosomal dominant 
inheritance of LMNA mutations believed to induce nuclear malformations. 
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1.3.5.4 Differentiallamin expression in cancer 
Differential expression of lamins, particularly lamin AlC has been associated with 
epithelial, lymphoid and mesenchymal tumours, including basal skin cell carcinoma 
(Tilli et aI., 2003; Venables et aI., 2001), human non-small cell lung cancer, small cell 
lung cancer (Broers et aI., 1993; Kaufmann et aI., 1991), acute lymphoblastic 
leukaemia, non-Hodgkin's lymphoma (Stadelmann et al., 1990), metastatic 
leiomyosarcoma, rhabdomyosarcoma and chondrosarcoma (Cance et aI., 1992). Two 
groups have investigated the changes in lamin AlC and lamin B 1 expression in 
colorectal neoplasms, but their findings appear somewhat contradictory. Cance et aI., 
(1992) reported constitutive expression of lamin B and heterogeneous expression of 
lamin AlC in two colon adenocarcinomas, as determined by immunohistochemistry; 
whereas Moss et al. (1999) reported reduced nuclear immunostaining for both lamins 
AlC and B 1 in colon adenomas and adenocarcinomas, compared to normal tissue. 
Venables et al. (2001) correlated down-regulation of lamin A in basal cell carcinoma 
(BCC) of the skin with a high proliferation index and a loss of lamin C with slower 
growing tumours. However, a relationship between loss of lamin A and increased 
proliferation was not borne out in work completed by Oguchi et al. (2002) which 
associated loss of lamin AlC with poor differentiation status in keratinocytic tumours of 
the skin and not increased proliferation. Therefore the relationship between A-type 
lamins and proliferation / differentiation appears not to be straightforward. This was 
highlighted by analyses of keratinocytic tumours carried out by Tilli et al. (2003). 
Lamin AlC expression correlated with well-differentiated tumours and more cells 
expressed Ki67 in poorly differentiated tumours. However, simultaneous expression of 
lamin AlC and Ki67 occurred in approximately 50% of the proliferating cells in BCC 
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and squamous cell carCInoma (SCC), indicating that proliferating cells may also 
maintain a certain degree of differentiation and that lamin AlC and Ki67 are not 
mutually exclusive. 
1.3.5.5 Structural hypothesis versus gene expression hypothesis for laminopathies 
Debate surrounds the function of the nuclear lamina - whether its functions are merely 
architectural or extend to regulating gene transcription, and how it may achieve this. 
The study of laminopathies which affect striated muscle has led to the formation of a 
structural hypothesis for the role of lamins in these diseases. Lamin-associated 
lipodystrophies, on the other hand, are less readily explained by loss of mechanical 
integrity. The gene expression hypothesis is a more plausible explanation for these 
diseases. 
The structural hypothesis proposes that the lamina maintains the structural integrity of 
the nucleus and resists mechanical pressure which could damage cells (Goldman et aI., 
2002; Hutchison et ai., 2001). Degradation of the NL would lead to weakness in the NE 
making it less resistant to deformation. Morphological abnormalities of the NE 
including herniations (abnormal shape), invaginations and honeycombs (tears in the 
NE) are reported features in laminopathy patient fibroblasts. Under normal 
circumstances skeletal and cardiac muscles are subjected to harsh mechanical stress. 
Together, this strongly suggests a link between lamin mutations and structural weakness 
of the nuclear envelope in muscular dystrophies and cardiomyopathies. 
However, diseases such as Dunnigan type - FPLD and CMT2B 1 affect adipose tissue 
and neurons which are not placed under great mechanical strain, therefore the loss of 
45 
lamin AlC must impact on another important function of the NL, other than or as well 
as maintenance of nuclear architecture. This led to the proposal of the gene expression 
model, whereby diseases arise through altered gene expression in specific tissues 
(Cohen et aI., 2001). The strongest evidence comes from studies on Dunnigan type -
FPLD. FPLD mutations in LMNA cause a decrease in the binding of prelamin A to 
SREBP1 which is proposed to reduce the pool available for activation of peroxisome 
proliferator activator receptor gamma (PP ARy) (Capanni et aI., 2005), a transcription 
factor which activates adipogenic genes (Akerblad et aI., 2005). 
1.4 Aims of this thesis 
The implications of non-functional lamin AlC are borne out in tissue-specific familial 
disorders such as autosomal inherited EDMD, MAD, Dunnigan type - FPLD and 
CMT2B 1. In addition mutations in the lamin A binding region of emerin also give rise 
to an X-linked fonn of EDMD with identical clinical features to AD-EDMD. 
Biochemical and immunofluorescence analyses of lamin distribution in a broad range of 
malignancies affecting epithelial, mesenchymal and lymphoid tissue have demonstrated 
altered expression of A-type lamins and to a lesser extent B-type lamins in relation to 
nonnal cells. Changes in expression of lamin AlC in colorectal cancer has been 
reported, but the exact nature of these alterations and the driving force behind them has 
not been investigated. Previous work on keratinocytic tumours of the skin suggests that 
both the proliferation and differentiation status of a tumour may influence lamin 
activity. 
Chapter 3 describes the simple cancer model set up to observe changes in expression of 
nuclear lamin sub-types A, C, B1 and B2 during CRC progression. It comprised 
46 
cultured colorectal carcinoma cells derived from tumours representing different degrees 
of differentiation. A down-regulation of lamin A was detected but it did not appear to 
correlate with proliferation indices, but rather the progression of the disease to a pre-
metastatic stage. It coincided therefore with increasing dedifferentiation. 
Chapter 4 further explores the relationship between lamin A and cellular proliferation / 
differentiation in SW480 colon cancer cells which express almost no endogenous lamin 
A and show highly abnormal growth characteristics. Ectopic expression of lamin A was 
able to rescue two-dimensional growth and normal cell morphology. cDNA microarray 
analysis identified down-regulation of a cytoplasmic intermediate filament protein, 
synemin, upon re-expression of lamin A. This suggested that lamin A may influence 
cell morphology through functional interactions with components of cytoarchitecture. 
Finally, Chapter 5 demonstrates successful re-exposure of lamin A and lamin C epitopes 
in paraffin-embedded sections of colorectal tumour and normal colon tissue. A-type 
lamin expression in Dukes' stage A, B, C, D and metastasized tumours was examined 
by immunoperoxidase staining in a pilot study. In healthy colonic crypts lamin NC 
expression correlated with the differentiated phenotype, whereas analysis of Dukes' A 
malignant polyps determined a relationship between aberrant nuclear morphology and 
loss of lamin AlC expression. 
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CHAPTER 2 - MATERIALS AND METHODS 
2.1 General chemicals / materials 
All general chemicals were purchased from BDH Laboratory Supplies (VWR 
International Ltd, Leicestershire, England), Sigma-Aldrich Company Ltd, Dorset, 
England or Melford Laboratories Ltd, Suffolk, England, unless otherwise stated. 
Chemicals from BDH were AnalaR® analytical grade and all other reagents were 
Molecular Biology grade. All plasticware for tissue culture was supplied by Greiner 
Bio-One Ltd, Gloucestershire, GB. 
2.2 Mammalian cell culture and transfection 
2.2.1 Cell lines 
Colon carcinoma cell lines HT29, SW948, SW480 and T84 were obtained from the 
European Collection of Cell Cultures (ECACC), Wiltshire, UK as growing cultures. 
These cell lines were chosen because they represented different stages of colorectal 
cancer from grade II to metastasis. They were routinely cultured in 75 cm2 plastic tissue 
culture flasks (25 cm2 flasks for SW948) under the following conditions: HT29 -
McCoy's 5A medium (Sigma) supplemented with 10% foetal bovine serum (FBS), 
2 roM L-Glutamine and 100 units/ml penicillin / 100 Ilglml streptomycin (Invitrogen 
Ltd, Paisley, UK); SW948 and SW480 - L-15 (Leibovitz) medium with 2 roM L-
Glutamine (Invitrogen) supplemented with 10% FBS, 100 units/ml penicillin and 100 
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Ilglml streptomycin and T84 - DMEM / Ham's F-12 (1:1) medium with 2 mM 
Glutamax® (Invitrogen) supplemented with 10% FBS, 100 units/ml penicillin and 100 
Ilglml streptomycin. All cultures were maintained in a humidified environment at 37°C 
with 5% CO2, except SW948 and SW480 which were grown without CO2. For all 
experiments cells were cultured in FBS from lot 111K3366, obtained from Sigma. Cells 
were routinely subcultured between 70 - 80% confluency, detached from the substrate 
in the presence of 0.25% trypsin in 0.5 mM EDT A / phosphate-buffered saline (PBS) at 
37°C, 5% CO2 in a humidified atmosphere for 2 minutes (cell lines HT29 and SW480), 
4 minutes (SW948), 5 - 10 minutes (T84) or 30 seconds - 1 minute (transfected SW480 
cells) and neutralized in the corresponding serum-containing medium. HT29 were 
routinely split 1:10 - 1:12, SW948 were split 1:2, SW480 were split 1:4 and T84 were 
split 1:3. In the case of SW948, cells were additionally centrifuged at 200 x g for 5 
minutes before re-seeding in tissue culture flasks. This was to help create a single cell 
suspension as these cells tended to aggregate upon trypsinization. 
2.2.2 Transfection of GFP-reporters into cell line SW480 
2.2.2.1 DNA constructs 
SW480 cells were transfected with DNA constructs encoding fusion proteins of EGFP-
lamin A, EGFP-emerin or EGFP. EGFP-Iamin A full length was a gift from Dr M. 
Ozumi, Institute of Physical and Chemical Research, Saitama, Japan and EGFP-emerin 
was a gift from Dr W.G.F. Whitfield, University of Dundee, UK. 
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2.2.2.2 Transfection using Gene]ammer® transfection reagent 
In preparation for transfection cells were grown in 6-well plates (35mm diameter) until 
60% confluent, under standard culture conditions outlined in Section 2.2.1. The culture 
medium was aspirated and cells were washed once with fresh culture medium. A 
transfection mixture of 100 ~l L-15 (Leibovitz) media (non-supplemented), 6 ~l 
GeneJammer® transfection reagent (Stratagene, La Jolla, CA) and chosen DNA 
construct [3 ~l EGFP-Iamin A (1 ~g1~I), 1 ~l EGFP-emerin (1 ~g1~I) or 1 ~l EGFP 
(1 ~g1~I)] was prepared according to the manufacturer's instructions and added 
dropwise to 900 ~l fresh serum-containing media [L-15 (Leibovitz) + 10% FBS] in a 
tissue culture well. The transfection mixture was swirled gently to evenly distribute it 
over the cells. Initially cells were incubated for 3 hours in a humidified environment at 
37°C, without C02, after which 1 ml media [L-15 (Leibovitz) + 10% FBS + 2% PIS] 
was added. For stable tranfection cells were grown for 5 days, with one media change 
after 48 hours, under standard growth conditions and then split 1:3 into standard growth 
media. Geneticin® (G-418 sulphate, Invitrogen) selective antibiotic was added to a final 
concentration of 200 ~g/ml 24 hours later. Thereafter media was changed every 72 
hours with fresh Geneticin added. The presence of transfected colonies was determined 
when all cells from the negative control (DNA construct replaced by 1 ,.11 ddH20 in 
transfection mixture) died off. 
2.2.2.3 Single cell cloning of stably-tranfected colonies 
Once transfected colonies had been established transfectants were cloned out by limited 
dilution in 96-well plates. Single cell clones were scaled up using standard growth 
conditions and kept under constant antibiotic selection. 
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2.2.2.4 Determining GFP-reporter stability within clones 
Loss of GFP-reporter expression over time when cells were not under constant 
antibiotic selection proved a problem in the first few weeks after transfection, hence 
cells were kept under constant antibiotic selection during single cell cloning and scaling 
up of cultures. To confirm the GFP-reporter stability, all cloned cell lines were split 1 :2. 
One flask of cells was cultured in media containing Geneticin® (200 /-lglml), while the 
other flask was grown in Geneticin ® -free media. After four weeks culture, cells were 
seeded at high density on glass covers lips for 24 hours and then fixed in methanol I 
acetone (v/v, 1:1), 4°C, for 10 minutes and mounted in Mowiol mountant containing 
2.5% DABCO (l,4-diazabicyclo[2.2.2]octane) and 1 /-lglml DAPI (4' ,6-diamidine-2-
phenyl indole) (see Appendix I, A). GFP expression in clones grown with or without 
antibiotic selection was examined using a Zeiss Axioskop microscope (Carl Zeiss 
MicroIrnaging, Inc., Thornwood, NY) equipped for epifluorescence. Any single cell 
cloned line showing loss of expression when grown without Geneticin® was pronounced 
unstably transfected and discarded. All other cell lines which showed no difference in 
GFP expression were grown in Geneticin®-free media for all subsequent work. 
2.2.2.5 Basis for selection of clones for oligonucleotide microarray analysis 
Out of 47 EGFP-Iamin A, 12 EGFP-emerin and 6 EGFP stably transfected single cell 
clones successfully grown out, 6, 3 and 2 clones respectively were eventually selected 
on the basis of their GFP expression (assessed by fluorescence microscopy). To 
maximize future experimental possibilities, clones with low, medium and high levels of 
GFP expression were chosen, where possible. Assignation of different GFP expression 
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levels was based on the overall range of GFP expression levels observed across all the 
single cell cloned lines. 
To enable selection of the final clones to be used in microarray analysis, GFP-reporter 
and endogenous protein expression was quantified by western analysis (see Section 2.4) 
using antibodies against lamin AlC (JoL2), emerin and GFP (see Tables 2.1, a & b). 
The following clones were chosen: GFP-Iamin A 2bb3, GFP-emerin 2 and GFP 2. 
The SW480 colon adenocarcinoma cell line is populated by two cell types: One, bipolar 
and the other, epithelial-like (polygonal shaped) and over time epithelial-like cells have 
predominated (Leibovitz et ai., 1976). In the absence of evidence to the contrary, 
distinction was made between single cell cloned colonies that appeared to be composed 
entirely of bipolar-shaped or polygonal-shaped cells. The final clones selected for 
micro array analysis were, to the best of our ability, identified as being of polygonal 
shape and therefore epithelial-like. 
2.3 Indirect immunofluorescence 
CRC cell lines HT29, SW948, SW480 and T84 were seeded at an initial density of 
4.1 x 105, 1.0 X 106, 1.0 X 106 and 5.0 x 105 cells/well respectively in 35 mm diameter 
tissue culture wells containing 13 mm diameter glass covers lips pre-coated with Poly-
D-Iysine (0.01 mg/ml) for 16 hours prior to use. Cells were grown for 24 hours, washed 
once in PBS, then fixed in methanol/acetone (1:1, v/v, chilled to -20°C) for 10 minutes 
at 4°C, washed 3 times in PBS, 5 minutes/wash at room temperature (RT) and air dried 
for 5 - 10 minutes before immunostaining. GFP-Iamin A, GFP-emerin and GFP 
transfected SW480 cells were grown to 70% confluency, washed once in PBS, 
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incubated in pre-warmed (37°C) 4% Paraformaldehyde in PBS, pH 7.4 for 12 minutes at 
RT, permeabilized using 0.5% Triton X-lOO in PBS for 5 minutes at RT and washed 
twice in PBS, 4 minutes/wash at RT. This was followed by a blocking step involving 
incubation in 1% newborn calf serum (NCS) in PBS for 30 minutes at RT. Coverslips 
were then washed twice in PBS, 5 minutes/wash at RT and air dried for 5 - 10 minutes. 
Cells were single- or double-stained with primary antibodies (25 Jll/coverslip) for 1 hour 
at RT in a wet chamber, using dilutions detailed in Table 2.1 (a) and 2.1 (b) and then 
washed 5 times in PBS. Incubation with Rhodamine (TRITC)- or Fluorescein (FITC)-
conjugated IgG secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., 
West Grove, PA) was for 1 hour at RT in a wet chamber, followed by 5 washes in PBS. 
Coverslips were mounted in Mowiol mounting media containing 2.5% DABCO and 1 
Jlglml DAPI (see Appendix I, A). Single indirect immunofluorescence images were 
captured using a Zeiss Axiovert 10 microscope equipped with a Plan-Neofluar 40x N/A 
1.3 oil immersion lens and a 12 bit CCD camera, directed by IPLab software. Images of 
double immunostained cells were captured using a Zeiss Axioskop microscope 
equipped with a Plan-Neofluar 40x / 1.3 oil immersion lens and fitted with a Bio-Rad 
Radiance 2000 confocal scanning system, operated by LaserSharp 2000™ software 
(Zeiss). Z-series were collected in Sequential mode using Kalman averaging (4 times) at 
a resolution of 1024 x 1024 pixels with an additional 2x digital zoom. Images were 
projected into z-stacks. Immunocytochemical analyses on GFP-Iamin A, GFP-emerin 
and GFP transfected SW480 cells were completed using a Zeiss LSM 51O-META 
microscope equipped with a Plan-Neofluar 40x / 1.3 oil immersion lens. Images were 
collected with a Zeiss Axiocam CCD camera directed by Zeiss Axiovision software, 
version 3.0. Parameters were set individually for each antibody and DAPI, depending 
on the microscope being utilized, and were kept constant thereafter. Images were 
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Table 2.1 (a) Lamin antibodies and corresponding secondary antibodies used for immunofluorescence, SDS-PAGE and 
immunohistochemistry. 
Immunofluorescence Undiluted TRITC / FITC-DaM 1:50 
JolA LaminA tail Mouse/m Dyer et al. (1997) 
Western blot 1:200 DaMHRP 1:2000 
Gift from J.L.V Broers# 
133A2 Lamin A tail Mouse/m Immunohistochemistry 1:50 Biotinylated DaM HRP 1:400 
/ Hozak et al. (1995) 
Immunofluorescence 1:10 or 1:25 TRITC / FITC-DaM 1:50 
JoL2 Lamin AlC tail Mouse/m Dyer et al. (1997) Western blot 1 :200 / 1 :400 DaMHRP 1 :2000 / 1 :4000 
Immunohistochemistry 1:100 Biotinylated DaM HRP 1:400 
Immunofluorescence 1:20 FITC-DaR 1:50 
RaLC Lamin C tail Rabbit/p Venables et al. (2001) Western blot 1:150 DaRHRP 1 :2000 
Immunohistochemistry 1:20 Biotinylated GaR HRP 1:400 
LaminB 
Santa Cruz§ Immunofluorescence 1:25 TRITC / FITC-DaG 1:50 LaminBI Goat/p 
(M-20) Western blot 1:250 DaGHRP 1:2000 
Gift from E.B Lane¥ / 
Immunofluorescence 1:10 or 1:25 TRITC / FITC-DaM 1:50 
LN43 Lamin B2 Mouse/m Kill and Hutchison 
Western blot 1:250 DaMHRP 1:2000 (1995) 
m = monoclonal antibody; p = polyclonal antiserum, affinity purified; HRP = horse-radish peroxidase 
#Dr J.L.V. Broers, University of Maastricht, The Netherlands. 
§Santa Cruz Biotechnology, Inc., Santa Cruz, CA. \lProfessor E.B. Lane, University of Dundee, UK. 
Table 2.1 (b) Other primary antibodies and corresponding secondary antibodies used for immunofluorescence and SDS-PAGE. 
Emerin, clone 
Novocastra' / Yector<l> 
Immunofl uoresence 
Emerin Mouse/m 
4G5 Western blot 
aGFP GFP Mouse/m ClontechT Western blot 
Ki67 Ki67 Rabbitlp Dako* Immunofluorescence 
Ki67 , clone Ki67 Ki67 Mouse/m Dako* Immunofl uorescence 
PCNA PCNA Humanlp Immuno Conceots¢ Immunofl uorescence 
Actin, Sigma~ 13-actin Mouse/m Western blot 
clone AC-40 
Ul m = monoclonal antibody; p = polyclonal antiserum, affinity purified; HRP = horse-radish peroxidase. 
Ul 
' Novocastra Laboratories Ltd, Newcastle-upon-Tyne, UK. 
<l>Yector Laboratories Inc., Burlingame, CA. 
tBD Biosciences Clontech, Palo Alto, CA. 
*DakoCytomation Denmark AlS, Glostrup, Denmark. 
¢Immuno Concepts N.A. Ltd, Sacramento, CA. 
~Sigma-Aldrich Company Ltd, Dorset, England. 
1:50 TRITCDaM 1:50 
1:250 DaMHRP 1:4000 
1:500 DaMHRP 1:4000 
1: 100 TRITCDaR 1:50 
1:10 TRITCDaM 1:50 
1:10 TRITC GaH 1:50 
1:1500/ 1 :2000/ 
DaMHRP 
1:1750 1:4000 
organized using Adobe® Photoshop® 7.0 (Adobe Systems, Inc., San Jose, CA). 
2.4 One-dimensional SDS-PAGE and immunoblotting 
Cultured cells were harvested at 80% confluency and protein was extracted from 7 x 106 
cells per cell line. Cell pellets were re-suspended in 500 )..1.1 Lysis buffer [10 mM Tris-
HCl (pH 7.4), 10 mM KCI, 3 mM MgClz, 0.1 % Triton X-100 and IX Protease inhibitor 
cocktail (Sigma)] and then incubated with 0.1 units/)..I.l DNase I on ice for 10 minutes. 
Cell extracts were dissolved in 500 )..1.1 2X Sample buffer [125 mM Tris-HCl (pH 6.8), 
2% Sodium dioecyl sulphate (SDS), 2 mM Dithiothreitol (DTT), 20% Glycerol, 5% p-
mercaptoethanol and 0.25% Bromophenol blue (w/v)], boiled at 95°C for 3 minutes and 
finally centrifuged at 14,000 x g for 3 minutes. Protein samples were resolved using 
one-dimensional SDS-PAGE on a 10 or 12% poly-acrylamide resolving gel with a 5% 
poly-acrylamide stacking gel (see Appendix I, B), both made using ProSieve® 50 
acrylamide gel solution (Cambrex Bio Science Wokingham Ltd, Berkshire, UK) and 
containing 0.1 % SDS. Samples were run at 100 volts (V) for 2 hours in Tank buffer (25 
mM Tris, 192 mM Glycine and 0.1 % SDS) and transferred to nitrocellulose membrane 
(Protran®, grade BA85, Schleider and Schuell BioScience Inc., Keene, NH) at 30 V for 
16 hours at 4°C in Transfer buffer (25 mM Tris and 192 mM Glycine, pH 9.2, plus 20% 
methanol and 0.1 % SDS). Nitrocellulose membranes were subsequently washed once in 
Blot rinse buffer (BRB) [10 mM Tris-HCI, 150 mM NaCI and 1 mM EDTA, pH 7.4, 
plus 0.1 % Tween® 20 (v/v)] and incubated initially in 4% blocking buffer [4% skimmed 
milk powder (w/v) in BRB] for 10 minutes at RT on a shaker, after which the blocking 
buffer was replaced with fresh blocking solution for a further 16 hours at 4°C with 
constant agitation. After blocking, nitrocellulose membranes were washed twice in BRB 
for 5 minutes. Detection of individual lamins and other proteins was accomplished 
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using a series of specific antibodies listed in Table 2.1 (a) and Table 2.1 (b). ~-actin 
was used as a control for loading. Nitrocellulose membranes were incubated with 
primary antibodies diluted to their optimum concentration in BRB + 1 % NCS for 1 hour 
at RT on a shaker and then rinsed 3 times with BRB, 5 minutes/rinse at RT on a shaker. 
Secondary antibodies were horse-radish peroxidase (HRP)-conjugated IgG and used at a 
concentration of 1:2000 - 1:4000 in BRB + 1 % NCS. Membranes were incubated with 
secondary antibodies for 1 hour at RT with continuous agitation and then washed with 
BRB, 3 times for 5 minutes and Tris buffered saline (TBS) (20 mM Tris and 0.5 M 
NaCl, pH 7.5), once for 3 minutes to remove Tween® 20. Nitrocellulose membranes 
were exposed to ECLTM western blotting reagents 1 and 2 (1:1, v/v) (Amersham 
Biosciences, Buckinghamshire, UK) for 1 minute and immunoreactivity was measured 
by recovering the signal of chemiluminescence on HyperfilmTM ECL films (Amersham 
Biosciences) using a Compact X4 Automatic X-ray Film Processor (Xograph Imaging 
Systems Ltd, Gloucestershire, UK). Differences between lamin expression were 
quantified using densitometry (see Section 2.10.1). 
2.5 Flow cytometry 
Cells were grown to 70% confluency and trypsinized according to standard procedures 
(see Section 2.2.1). Media was added up to 10 rn1 and cells were pelleted at 200 x g for 
5 minutes. The supernatant was aspirated and cells re-suspended in 0.5 ml PBS. Cells 
were fixed in 4.5 ml methanol (pre-chilled to -20°C) added drop-wise with constant, 
mild vortexing of cells. After incubation at -20°C overnight, cells were centrifuged at 
1500 x g for 5 minutes, re-suspended in 5 ml PBS and pelleted again by centrifugation 
at 1500 x g for 5 minutes. The supernatant was removed and cells re-suspended in 
400 J.!l PBS. 100 J.!glml RNase and 25 Ilglml Propidium iodide (PI) (Sigma) was added 
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and samples incubated for 5 minutes on ice before further centrifugation at 1500 x g for 
5 minutes to remove enzyme and PI stain. Finally cells were re-suspended in 1 m1 PBS 
and placed on ice. Flow cytometric analyses were carried out using a Coulter® EPICS® 
XL-MCLTM Flow Cytometer (Beckman Coulter, Inc., Fullerton, CA) using System IJTM, 
version 3.0 software. A monodisperse suspension of cells were excited at 488 nm by an 
argon ion laser and fluorescence from PI was collected through a 620 nm band-pass 
filter, transmitting light between 605 - 635 nm to the fluorescent channel 3 (FL3) 
sensor. 
The parameters set for forward scatter (FS) and side scatter (SS) of light as cells pass 
through laser and for the PI fluorescence collector, FL3, are given in Table 2.2 for each 
cell line. For non-transfected cell lines HT29 and SW480 - see Table 2.2 (a), SW948 -
see Table 2.2 (b) and T84 - see Table 2.2 (c). For transfected cell lines SW480 GFP-
lamin A 2bb3 - see Table 2.2 (d), SW480 GFP-emerin 2 - see Table 2.2 (e) and 
SW480 GFP 2 - see Table 2.2 (0. Data for a minimum 10,000 single cell events was 
collected for each sample. 
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Voltage Gain 
FS 593 1.0 
SS 689 2.0 
FL3 650 1.0 
Table 2.2 (a) Parameters 
for HT29 and SW 480-
untransfected. 
Voltage Gain 
FS 593 1.0 
SS 689 2.0 
FL3 750 1.0 
Table 2.2 (d) Parameters 
for SW480 GFP-Iamin A 
2bb3. 
Table 2.2 (a - f) 
Flow cytometry 
parameters. 
Voltage Gain Voltage Gain 
FS 593 1.0 FS 593 1.0 
SS 689 2.0 SS 689 2.0 
FL3 810 1.0 FL3 568 1.0 
Table 2.2 (b) Parameters Table 2.2 (c) Parameters 
for SW948. for T84. 
Voltage Gain Voltage Gain 
FS 443 1.0 FS 393 1.0 
SS 509 2.0 SS 499 2.0 
FL3 620 1.0 FL3 710 1.0 
Table 2.2 (e) Parameters Table 2.2 (0 Parameters for 
for SW480 GFP-emerin 2. SW480GFP2. 
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2.6 Preparation of cells for electron microscopy 
In untransfected and transfected SW480 cultures, cells floating in the media were 
separated from those adhering to the culture dish. Media was removed from 70 - 80% 
confluent cultures and floating cells were collected by centrifugation at 200 x g for 5 
minutes. Adherent cells were harvested using standard procedures and pelleted at 200 x 
g for 5 minutes. All pelleted samples were re-suspended in Karnovsky's fixative 
(Karnovsky, 1965) - 2% Paraformaldehyde, 2.5% Glutaraldehyde in 0.1 M Sodium 
cacodylate buffer, pH 7.3 - for 1 - 1.5 hours at 4°C. Fixative was replaced with 2% 
Osmium tetroxide buffered with an equal volume of 0.2 M Sodium cacodylate, pH 7.3 
for 30 minutes to 1 hour at 4°C. Fixative was poured off and cells were dehydrated 
through an ethanol series: 70%, 3 times 5 minutes; 95%, 3 times 5 minutes and 100%, 3 
times 10 minutes. Subsequently cells were infiltrated with intermediate solution - 100% 
ethanol and Propylene oxide, combined 1: 1 (v/v) - 3 times 10 minutes and Propylene 
oxide alone, 3 times 10 minutes. Cells were then infiltrated with Propylene oxide / 
araldite resin [49% Araldite CY212, 49% Dodecenylsuccinic anhydride (DDSA) and 
2% Benzyl dimethyl amine (BDMA)] combined 1:1 (v/v) for 30 minutes at 45°C or 
overnight at RT in tubes with the lids off and with pure araldite for 30 minutes at 45°C 
in tubes with the lids off. Samples were orientated and embedded in a suitable mould, 
covered with fresh araldite and left to polymerize for 12 hours at 45°C and for a further 
24 hours at 60°C. 
Samples were sectioned at a thickness of 60 - 90 nm using a Reichert Ultracut S (Leica 
Microsystems (UK) Ltd, Milton Keynes, Buckinghamshire, UK), collected onto 
Formvar® coated copper grids (Agar Scientific Ltd. Stansted, Essex, England) and 
stained with uranyl acetate and Reynolds' lead citrate (Reynolds, 1963) for 10 minutes 
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each at RT. Sections were examined for evidence of apoptosis on a Phillips 400 
Transmission Electron Microscope (TEM) (FE! UK Ltd, Cambridge, UK) or a Hitachi 
H7600 TEM (Hitachi High-Technologies Corporation, Tokyo, Japan). 
2.7 Immunohistochemistry 
2.7.1 Colorectal tissue specimens 
Normal and tumour human tissues were procured from the Department of Pathology, 
University Hospital, Maastricht, The Netherlands without patient identifying codes. 
Thirty-six tumour specimens were selected from the archive based on their clinical 
stage, along with 11 examples of normal mucosa. The number of Dukes' stage A and D 
specimens available was limited, therefore the following tumour types were included for 
immunohistochemical analysis of A-type lamin expression: Dukes' stage A (n = 2), 
Dukes' stage B (n = 10), Dukes ' stage C (n = 11), Dukes ' stage D (n = 2), metastasis to 
liver (n = 8), lung (n = 1), pancreas / duodenum (n = 1) and small intestine (n = 1). All 
specimens had been grossly dissected and immersed in 4% formalin fixative for 30 
minutes at 35°C. Dehydration and embedding of tissues was fully automated and the 
procedure was as follows: 70% ethanol, 60 minutes at 35°C; 70% ethanol, 60 minutes at 
37°C; 96% ethanol, 60 minutes at 37°C; 96% ethanol, 1 hour 30 minutes at 40°C; 100% 
ethanol, 1 hour 30 minutes at 40°C and 100% ethanol, 2 hours at 45°C. Samples were 
cleared in xylene for 15 minutes at 45°C, 15 minutes at 50°C, followed by another 30 
minutes at 50°C before embedding in paraffin at 60°C for two 60 minute periods and 
finally for 1 hour 30 minutes. The clinical stage was confirmed histologically. 
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2.7.2 Antigen retrieval 
Fonnalin-fixed, paraffin-embedded tissue specimens were sectioned into 4 )..tm thick 
slices and left overnight at 37°C to bond to Starfrost® adhesive microscope slides 
(Knittel Glaser, Braunschweig, Gennany). Tissue sections were de-paraffinized in 
xylene, 2 times for 5 minutes and rehydrated through an ethanol series: 100% ethanol, 5 
minutes; 100% ethanol, 5 minutes; 96% ethanol, 2 minutes and 70% ethanol, 2 minutes. 
The process of antigen retrieval used was adapted from the method described by Barker 
et al. (1999). Endogenous peroxidase activity was quenched in 1.5% H20 2 in methanol 
(fresh) for 20 minutes at RT. Thereafter tissue sections were immersed in 0.01 M citrate 
buffer, pH 6.0 (pre-heated to 90°C) for 15 minutes in a water bath at 90°C. Afterwards 
slides were placed directly into PBS for at least 10 minutes to cool and to limit 
evaporation. 
2.7.3 Peroxidase staining 
Non-specific binding was blocked using 2% goat serum / 2% bovine serum albumin 
(BSA) in PBS or 2% rabbit serum / 2% BSA in PBS, depending on the animal the 
secondary antibody was raised in, 100 )lVsection, for 25 minutes at RT. Sections were 
washed 3 times with PBS and incubated with primary antibody diluted in 0.1 % BSA in 
PBS, 100 )lVsection, for 45 minutes at RT. Primary antibodies were used at the 
following concentrations: JoL2, 1:100; 133A2, 1:50 and RaLC, 1:20 (see Table 2.1, a). 
Antibody was removed by washing 3 times in PBS. Biotinylated IgG secondary 
antibodies were used at a concentration of 1:400 in 0.1 % BSA in PBS, 100 )lVsection, 
for 45 minutes at RT. Sections were washed 3 times with PBS followed by a 30 minute 
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incubation at RT with StreptABComplex / i-IRP (DakoCytomation, Glostrup, Denmark) 
[50 f..ll Streptavidin and 50 f..ll biotinylated peroxidase in 5 ml wash buffer (0.1 % BSA in 
PBS)], 100 f..ll/section, prepared 30 minutes prior to use. The complex was removed by 
washing 3 times with PBS. Immunological detection was achieved by adding 100 f..ll 
activated DAB chromogen (DakoCytomation) at working concentration (0.0225% H20 2 
in 1 mg/ml filtered DAB in PBS). DAB was added directly to tissue sections for the 
following lengths of time: 10L2-stained sections for 3 minutes, 133A2-stained sections 
for 6 minutes and RaLC-stained sections for 5 minutes. Reactions were stopped by 
immersing sections in dH20. All incubations were carried out in a humidified staining 
box. Negative controls were sections stained as above, except the primary antibody was 
replaced with 0.1 % BSA in PBS. 
2.7.4 Counterstaining 
To visualize all nuclei, sections were counterstained with undiluted Ehrlich's 
haematoxylin (Raymond A Lamb Ltd, Eastbourne, East Sussex, UK) for 3 minutes and 
rinsed in tap water for 1 minute. The stain was differentiated using 1 % acid-alcohol (1 % 
HCI in 70% ethanol) for 1 minute 15 seconds and ripened in 0.04% aqueous ammonia 
for 30 seconds which was washed away by dipping in and out of dH20 for 1 minute. 
Sections were dehydrated through a graded ethanol series and cleared as follows: 70% 
ethanol for 2 minutes, 96% ethanol for 2 minutes, 96% ethanol for 2 minutes, 100% 
ethanol for 2 minutes, 100% ethanol for 2 minutes, xylene for 3 minutes and xylene for 
3 minutes. Specimens were covers lipped with Entellan ® (Merck kGaA, Darmstadt, 
Germany) and left to dry overnight. 
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2.7.5 Analysis 
Colorectal tissue sections were analysed usmg a Nikon Diaphot 300 inverted 
microscope (Nikon Corporation, Tokyo, Japan) equipped for bright-field microscopy 
with Plan 4x I 0.13, lOx I 0.25, 20x I 0.4 and 40x I 1.3 lenses. Images were collected 
with a Nikon DXMI200 digital camera controlled by Nikon Act-I, version 2.20 
software. Image processing was carried out in Adobe® Photoshop® 7.0. Intensity of 
staining was scored using the + I - system. 
2.8 Semi-quantitative RT-PCR 
2.8.1 Primer design 
Primers specific for the coding sequence (cds) of human lamin A (NM_170707), lamin 
C (NM_005572), lamin B2 (NM_032737) and p-actin (NM_OOllOl) were designed 
using the Primer3 web interface (http://frodo.wi.mit.edulprimer3/primer3_code.html), 
developed by the Whitehead Institute, Cambridge, MA and the Howard Hughes 
Medical Institute, Chevy Chase, MD. It selects suitable primers from a given DNA 
sequence based on a number of parameters including product size, primer length, melt 
temperature (T m) and GC%. The software was programmed to design primers between 
18 and 27 bases long and select primers with a minimum T m of 57°C, a maximum T m of 
63°, with a maximum T m difference between the sense and antisense primers of 4°C. 
The GCI AT ratio was important and a GC content between 45 - 70 % was ensured. 
NetPrimer online software (PREMIER Biosoft International, CA I 
http://www.premierbiosoft.com/netprimerlindex.html) also predicted primer melt 
64 
temperature, using the nearest neighbour thermodynamic theory, and enabled 
examination of secondary structures in primer pairs, incorporating hairpin loops, self-
dimers, cross-dimers, palindromes, runs and repeats, which could impinge their function 
or lead to non-specific products_ Table 2.3 shows primer sequences_ 
Accession Pl-imer Start Product 
Gene Deox\'oligonucleotide sequence,S' - 3' 
numbel- direction (5' - 3') . size (bp) 
sense 727 GATGCGCTGCAGGAACTACG 
laminA NM_170707 1137 
antisense 1863 CGTGACACTGGAGGCAGAAGAG 
sense 727 GATGCGCTGCAGGAACTACG 
laminC NM_005572 993 
antisense 1719 TCAGCGGCGGCTACCACTCA 
sense 980 ACAAGTTCCGGAAGATGCTG 
lamin B2 NM_032737 481 
antisense 1460 ACCTGCCTCTTGATTCTCCA 
sense 514 TCCACCTCCAGCTTGTACCTG 
c-myc VOO568 557 
antisense 1070 CGCCTCTTGACATTCTCCTCG 
sense 277 CCAGAGTGCTGTGCAGTGTTC 
c-raf X03484 589 
antisense 865 AGGCTGATTCGCTGTGACTTC 
sense 53 ACGAAGTGGTAACCCGAGAAT 
RPL31 NM_OOO993 322 
antisense 374 TTCTCATCCACATTGACTGTCTG 
sense 1920 CGTTACCAGTATCCTGAAGCAG 
synemin AJ310522 518 
antisense 2437 CGTGAGTCGTGTTCTCCTGA 
sense 257 GGCACCACACCTTCTACAATGAGC 
~-actin NM_OOII01 834 
antisense 1090 CGTCATACTCCTGCTTGCTGATCCAC 
Table 2.3 Primers for semi-quantitative RT -peR. 
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2.8.2 RNA isolation 
Total RNA was isolated from three different passages of CRC cell lines HT29, SW948, 
SW480 and T84 using TRI ReagentTM (Sigma). The procedure was executed principally 
as described in Sigma's Technical Bulletin MB-205 (Sigma, 1999). Transfected SW480 
cells expanded to approximately 70% confluency in 75 cm2 tissue culture flasks were 
lysed directly on the culture surface with 2 ml TRI Reagent™ per flask and allowed to 
stand for 10 minutes at RT. Lysates were transferred to 1.5 ml RNase-free microfuge 
tubes and centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant which 
contains RNA was removed and placed into a fresh tube to which 200 J.lI RNase-free 
chloroform was added for every ml of TRI Reagent™ used. Samples were vortexed for 
10 seconds and left to stand for 15 minutes at RT or until mixture separated into two 
layers. Samples were further centrifuged at 12,000 x g for 15 minutes at 4°C. The 
aqueous phase alone was immediately transferred to a fresh tube and 0.5 ml RNase-free 
isopropanol per ml of TRI Reagent™ used was added. Samples were inverted 3 times 
and incubated for 10 minutes at RT before centrifugation at 12,000 x g for 10 minutes at 
4°C. The supernatant was aspirated to leave a maximum of 50 J.lI liquid. The RNA 
precipitate was washed with 1 ml 75% ethanol in DEPC-treated dH20 per ml TRI 
Reagent™ used and pelleted again at 10,000 x g for 10 minutes at 4°C. All supernatant 
was removed and samples air-dried for 5 - 10 minutes in a laminar flow hood and re-
suspended in 15 - 20 J.lI Nuclease-free water, depending on expected RNA yield. RNA 
samples were solubilized at 50°C for 2 minutes and stored at -20°C. 
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2.8.3 Confirmation of RNA integrity 
Validation of RNA quality, purity and concentration was carried out as explained in 
Section 2.9.4. Additionally, the human gene ~-actin was used to exclude the possibility 
that genomic DNA (gDNA) may have been co-isolated with total RNA. Before RT-
PCR was undertaken, primers to an 834 bp fragment of ~-actin were used to amplify 
any contaminating gDNA in 0.5 Jlg RNA which had not been reverse transcribed. PCR 
was carried out in a 25 JlI reaction volume comprising IX ReddyMixTM PCR Master 
Mix (ABgene, Epsom, Surrey, UK) [25 units/ml Thennoprime Plus DNA polymerase 
(Taq), 75 mM Tris-HCI (pH 8.8 at 25°C), 20 mM (Nl-4)2S04, 2.5 mM MgCh, 0.01 % 
Tween® 20 (v/v) and 200 JlM each dNTPs], 0.4 pmol/JlI ~-actin sense primer and 0.4 
pmol/JlI ~-actin antisense primer. Cycling conditions were dependent on the thermal 
cycler used, see Section 3.8.4 for specific details. The total volume of PCR product (25 
JlI) was electrophoresed on a 1 % agarose I 0.8X Tris-borate EDTA (TBE) gel with 0.3 
Jlg/ml Ethidium bromide (EtBr). RNA samples showing evidence of gDNA 
contamination were treated with 0.075 units/Jlg/JlI RQ1 RNase-free DNase (Promega) in 
IX reaction buffer [40 mM Tris-HCI (pH 8.0), 10 mM MgS04, 1 mM CaCh] for 15 
minutes at RT. The reaction was tenninated by incubating samples with 1 JlI DNase 
stop solution (20 mM EGTA, pH 8.0) for 10 minutes at 65°C. 
RNA was precipitated with 1/10 of the total reaction volume of DEPC-treated 3 M 
Sodium acetate (NaOAc), pH 5.2 and 3 volumes 100% extra-clean ethanol (-20°C), 
vortexed for 5 seconds and incubated overnight at -20°e. To recover RNA, samples 
were centrifuged at 12,000 x g for 10 minutes at 4°C, the supernatant removed and 
pellets washed with 1 ml 70% extra-clean ethanol (in DEPC-treated dH20). 
Centrifugation was repeated at 12,000 x g for 5 minutes at 4°C, the supernatant 
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aspirated and residual ethanol allowed to evaporate for 5 - 10 minutes in a laminar flow 
hood. The resulting pellet was re-suspended in 20 III DEPC-treated dH20 and the 
quality, purity (A2601A28o) and concentration (A260) of RNA was measured as described 
in Section 2.9.4. 
2.8.4 Reverse transcriptase - polymerase chain reaction 
Reverse transcription and amplification of human ~-actin, lamin A and lamin C mRNA 
was completed in one step using Promega's AccessQuick™ RT-PCR System; for lamin 
B2 it was carried out in 2 stages using Promega' s Reverse Transcription System 
(A3500) and peR Master Mix (M7502). For all samples, RT-PCR was completed in 
triplicate, except in the case of lamin B2 where samples were analysed in duplicate. In 
preparation for RT-PCR, all components and samples were kept on ice until loaded into 
a thermal cycler. 
Reactions utilizing Promega's AccessQuick™ RT-PCR System were down-scaled to 
50% of the original volume recommended, to a final volume of 25 Ill. A master mix 
comprising IX AccessQuick™ Master Mix (Tfl DNA Polymerase, dNTPs, MgCh and 
reaction buffer), 0.15 pmoVll1 sense primer, 0.15 pmoVll1 antisense primer and water 
was mixed thoroughly and aliquoted, 24 III per PCR tube. One microlitre RNA template 
(0.1 Ilg/Ill) was added to each tube, except the negative control in which RNA was 
replaced by RNase-free water. RNA was denatured at 72°C for 5 minutes and then 
cooled on ice for a further 5 minutes. Avian Myeblastosis Virus - Reverse Transcriptase 
(AM V -RT) (5 units/ill) (Promega) was added as the final component to a final 
concentration of 0.1 units/ill. To repudiate contamination of any RT-PCR reaction 
components with DNA, controls in which AMV-RT was replaced with water were 
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analysed for each RNA sample. Finally, all components were gently vortexed and 
briefly spun down before loading into a PTC-0200 DNA Engine Gradient Cycler (Bio-
Rad Laboratories, Hercules, CA). Optimized cycling conditions were as follows: RNA 
was reverse transcribed at 45°C for 60 minutes and the resulting cDNA denatured 
initially at 94°C for 2 minutes, followed by 26 cycles of 94°C for 30 seconds, 59°C 
(lamin A primers) or 60°C (~-actin and lamin C primers) for 1 minute (annealing) and 
72°C for 1 minute, concluding with a final elongation at 72°C for 5 minutes. 
For lamin B2, RT -PCR was separated into two stand-alone reactions. First, a cDNA 
template was synthesized in a 20 III reaction using Promega's Reverse Transcription 
System. Two microlitres total RNA (0.5 1lg/IlI) and 1 III Random primers (0.5 1lg/IlI) 
were incubated together in a thin-walled microfuge tube at 70°C for 10 minutes, tap 
spun and snap chilled on ice. A reverse transcription master mix comprising IX AMV-
RT buffer [50 mM Tris-HCI (pH 8.3 at 25°C), 50 mM KCI, 10 mM MgCb, 0.5 mM 
spermidine and 10 mM DTT), 1 mM each dNTP mixture, 1 unit/Ill Recombinant 
RNasin® Ribonuclease inhibitor and Nuclease-free water was prepared and ali quoted 
equally between tubes of denatured RNA and Random primers. AMV -RT (10 unitS/ill) 
(Promega) was added to a final concentration of 0.75 units/ill (15 units/Ilg RNA), except 
for -AMV -RT controls where AMV -RT was replaced by an equivalent volume of 
Nuclease-free water for each sample. Reactions were flick mixed, spun briefly and 
incubated at RT for 10 minutes, followed by 42°C for 30 minutes. Heating samples at 
95°C for 5 minutes inactivated AMV -RT and samples were subsequently chilled on ice. 
cDNA was stored at -20°C. 
~-actin was amplified from all cDNAs and their accompanying -AMV-RT controls, 
plus the negative control where no RNA was added, to show that equals amounts of 
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cDNA had been reverse transcribed, that there was no contamination in any of the 
reaction components and that the reverse transcription and PCR reactions were working 
successfully. A 481bp fragment of lamin B2 was amplified from all reverse 
transcription reaction products which had AMV-RT added, plus a negative control. A 
25 f.!l reaction volume contained IX Promega PCR Master Mix [25 units/ml Taq DNA 
polymerase in buffer (pH 8.5), 200 f.!M each dNTPs and 1.5 mM MgCh], 0.4 pmollf.!l 
sense primer, 0.4 pmol/f.!l antisense primer, 2 !J.I cDNA template and Nuclease-free 
water. Samples were mixed well and spun down. The succeeding optimized PCR 
profiles for lamin B2 and ~-actin were carried out on an Eppendorf Mastercycler® 
Gradient Thermal Cycler (Eppendorf UK Ltd, Cambridge, UK): 94°C for 3 minutes, 26 
cycles at 94°C for 1 minute, 54°C (lamin B2) or 60°C (~-actin) for 1 minute 30 seconds 
and 72°C for 3 minutes, and finally 72°C for 5 minutes. 
2.8.5 Analysis 
Amplified products were run on 1 % agarose / 0.8X TBE gels, containing 0.3 f.!glml 
EtBr, at 70V for 60 minutes. Product size was compared to a 100 bp DNA ladder 
(Promega) and bands were visualized using a Gel Doc™ 2000 UV transilluminator and 
Quantity One™ software, version 4.0.3 (Bio-Rad). Differences between lamin A, C and 
B2 mRNA levels were quantified using densitometry (see Section 2.10.1) and expressed 
as a ratio against ~-actin expression. 
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2.8.6 DNA sequencing 
Lamin A, lamin C and lamin B2 RT-PCR products were purified using Promega's 
Wizard® SV Gel and PCR Clean-Up System. An equal volume of Membrane Binding 
Solution was added to 50 I.Ll PCR product, after which DNA was purified by micro-
centrifugation as described in section V.A. of Promega's Technical Bulletin No. 308 
(2002). DNA was eluted in 20 - 40 III Nuclease-free water, depending on the expected 
yield. 
Concentration of DNA was determined by running purified samples against DNA of 
known concentrations on a 1 % agarose / 0.8X TBE gel containing 0.3 Ilg/ml EtBr, at 80 
V for 45 minutes. By measuring intensity qf DNA bands of known concentration, using 
densitometry, to produce a standard curve, the concentration of individual purified DNA 
samples was determined. 
Lamin A, lamin C and lamin B2 were sequenced with primers lamin A antisense, lamin 
C antisense and lamin B2 sense respectively (primer sequences given in Table 2.3) 
using an ABI Prism® 377 XL automated DNA sequencer (Applied Biosystems, Foster 
City, CA) which can sequence approximately 800 bp when cDNA concentration is 
between 20 - 250 ng/Ill and the sequencing primer is at the optimum concentration of 
3.2 pmol/Ill. The sequences were analysed using the Nucleotide-nucleotide BLAST 
database (BLASTN 2.2.11) [http://www.ncbi.nlm.nih.govIBLAST / Altschul et al. 
(1997)]. 
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2.9 Glass slide oligonucleotide microarray analysis 
2.9.1 Design of Colorectal Cancer Oligonucleotide Chip 
A umque DNA array comprising 332 oligonucleotide sequences, representing 325 
different human genes was designed to investigate the affect of a loss of lamin A 
expression on the activity of colorectal cancer-associated genes. Genes were chosen 
according to their association with colorectal cancer and their known role in the 
development and progression of malignancy in general. Genes were sorted into 
functional groups (see Appendix II, A) and spotted onto the chip generally in these 
groups. 
2.9.2 Spotting of oligonucleotide array 
HPSP® purified oligonucleotides were synthesized by MWG Biotech Ltd, London, UK 
to a scale of 0.01 /-Lmole based on the GenBank® accession numbers for each mRNA 
sequence (see Appendix II, B). Each oligonucleotide was reconstituted in 50% 
Nuclease-free water / 50% Dimethyl sulphoxide (DMSO) to a concentration of 50 /-Lmol 
and placed in a pre-determined location in a 384-well plate (see Appendix II, C). 
The oligonucleotide chip was produced by a GeneTACTM G3 Arrayer (Genomic 
Solutions, Inc. Ann Arbor, MI) containing a 12 x 4 pin spotting tool. Oligonucleotides 
were spotted in quadruplicate in 8 x 4 patches, arranged in a 12 x 4 grid, on MWG 
Epoxy glass slides. The pins were cleaned according to the following procedure 
between the spotting of each set of oligonucleotides: sonic bath (ddH20) for 10 seconds, 
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a second bath of ddH20 for 5 seconds, 80% ethanol in ddH20 for 5 seconds, air dry for 
5 seconds and heat for 5 seconds. After spotting, slides were arranged spotted side up on 
a platform in a lidded wet chamber containing 150 ml of a saturated NaCI solution and 
incubated at 42°C overnight. The next day slides were placed back-to-back in a 50 ml 
conical tube containing 0.2% SDS in ddH20 and inverted 5 times. Slides were then 
transferred to another tube and washed 3 times in ddH20, inverting tube 5 times per 
wash. Lastly, slides were removed to fresh ddH20, pre-warmed to 50°C and incubated 
for 20 minutes at 50°C away from the light, before drying at 42°C for 10 - 15 minutes 
and storing in the dark at RT for a maximum of six months. 
2.9.3 Total RNA isolation 
Total RNA was extracted from three different passages of SW480 GFP-Iamin A 2bb3, 
SW480 GFP-emerin 2 and SW480 GFP 2 using TRI ReagentTM, exactly as described in 
Section 2.8.2, except RNA was stored at -80°C. 
2.9.4 Confirmation of quality, purity and concentration of RNA 
Total RNA quality was assessed by gel electrophoresis. RNA was diluted in 6X RNA 
loading buffer [6X Tris-acetate EDT A (T AE) buffer, 8 M urea, 15% ficoll, 0.25% 
Xylene cyanol FF (w/v) and 0.25% Bromophenol blue (w/v)] and heated at 70°C for 5 
minutes before adding Ethidium bromide to a final concentration of 7 nglJ.Ll. Samples 
were separated alongside RNA Millennium™ size markers (Ambion, Inc., Austin, TX) 
on 1% agarose gels in 0.8X TBE buffer at 80 V for 1 hour 10 minutes. Bands were 
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visualized using a Gel DOC™ 2000 UV transilluminator and Quantity One™, version 
4.0.3 software (Bio-Rad). 
Purity was determined by measuring the ratio of absorbance in 10 mM Tris-HCI, pH 7.5 
at 260 nm and 280 nm (A2601A28o) in a GeneQuest CE2301 Analyser (Cecil Instruments 
Ltd, Cambridge, UK) and the concentration was calculated by measuring the 
absorbance in DEPC-treated dH20 at 260 nm (A260). 
2.9.5 Hybridization 
2.9.5.1 Preparation of RNA for hybridization 
Total RNA was prepared for hybridization to our unique oligonucleotide chip using the 
Micromax™ Direct labelling kit (PerkinElmer Life Sciences, Boston, MA). Control 
RNA samples were always assigned Cyanine 3-dUTP (Cy3) fluorescent dye and test 
RNA samples, Cyanine 5-dUTP (Cy5) fluorescent dye. RNA was reverse transcribed in 
the following way: To 70 ~g test and control RNA, 1 ~l Random primers was added and 
the total volume made up to 20 ~l with DEPC-treated water. Samples were given a 
pulse spin and incubated for 10 minutes at 65°C in a water bath and then for 5 minutes 
at RT. To each tube 2.5 ~l Buffer (A), 1.0 ~l Cy3 or Cy5 dye and 2.0 III Enzyme mix 
(E) were added in order and incubated for 60 minutes at 42°C in a water bath. Once the 
fluorescent dyes had been incorporated into the cDNA, samples were kept away from 
the light as much as possible. When the reverse transcription reaction finished 2.5 III 
0.5 M EDTA, pH 8.0 (RNase-free) and 2.5 III 1 M Sodium hydroxide (NaOH) (fresh) 
was added to stop the reaction and degrade residual RNA. The tube contents were 
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~htly mixed (not vortexed) and incubated at RT for 15 minutes. At this point the two 
robes were combined. Any residual probe left in the empty tube was collected by 
dding 350 f.ll Tris / EDTA (TE) buffer (10 mM Tris / 1 mM EDTA in DEPC-treated 
later) and transferring the contents to the tube containing the combined samples and 
uixing. The combined samples were pipetted into a Microcon ® purification column 
Millipore Corporation, Bedford, MA) and centrifuged at 11,000 x g for 7 minutes. It 
;vas essential that a small volume of probe remained in the column, so it was checked 2 
minutes before the centrifugation step was due to end. The flow-through was removed 
and 400 f.ll more TE buffer was added to the column, plus 10 f.ll Human Cot-l DNA ® (1 
mg/ml) (Invitrogen) to block cross-hybridization of human repetitive DNA sequences 
within target. The column was spun at 11,000 x g for 5 minutes or until approximately 
80 f.llliquid remained in the column. The column was inverted into a fresh RNase-free 
microfuge tube and the whole set-up was spun at 600 x g for 1 minute to collect probe. 
If less than 80 f.ll was collected the volume was made up to 80 f.ll with TE buffer and the 
labelled sample was denatured at 94°C for 5 minutes. To the denatured sample, an 
equivalent volume (80 f.ll) of EasyHyb® Hybridization Solution (U-Vision Biotech Inc., 
Taiwan), pre-incubated for 2 minutes at 42°C, was added, pipette mixed very gently to 
avoid bubbles forming and spun down briefly. 
2.9.5.2 Hybridization and wash cycles 
Samples were kept at 50°C before loading into the GeneTACTM Hybridization station 
(Hyb. station) (Genomic Solutions). The Hyb. station was pre-warmed to 42°C and the 
prepared probe was introduced to the module, position 1, containing one 
oligonucleotide chip, counterbalanced by an unspotted glass slide in position 2. The 
Hyb. station was programmed to complete hybridization of RNA to chip in 1 hour 50 
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minutes at 42°C. Subsequently the chip was washed in buffers of increasing stringency 
to remove any unbound probe. The optimized wash cycle programme was completed as 
follows at 25°C: 
1. Purge manifold 
2. Wash slide 1, Reservoir 2 (Wash I), 1 minute 
3. Wash slide 2, Reservoir 2 (Wash I), 1 minute 
4. Hold at temperature Wash I, 2 minutes 
5. Purge manifold 
6. Wash slide 1, Reservoir 3 (Wash 11), Pass 1, 1 minute 
7. Wash slide 2, Reservoir 3 (Wash 11), Pass 1, 1 minute 
8. Hold at temperature Wash 11,2 minutes 
9. Wash slide 1, Reservoir 3 (Wash II), Pass 2, Iminute 
10. Wash slide 2, Reservoir 3 (Wash II), Pass 2, Iminute 
11. Hold at temperature Wash II, 2 minutes 
12. Purge manifold 
13. Wash slide 1, Reservoir 4 (Wash III), 1 minute 
14. Wash slide 2, Reservoir 4 (Wash III), 1 minute 
15. Hold at temperature Wash III, 2 minutes 
16. Slide 1 and 2, drain and dry, 1 minute 
The components of the wash buffers, Wash I, Wash II and Wash III, also known as 
Reservoirs 2, 3 and 4 respectively are detailed in Table 2.4. It was essential to dilute 
Solution B (part of EasyHyb@ Hybridization Solution Kit) in ddH20 before adding 
Solution A (part of EasyHyb@ Hybridization Solution Kit). 
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Resen'oir / Wash Solution Volume 
Reservoir 2 / Wash I B 20mI 
ddH20 178 mI 
A 2ml 
Total 200mI 
Reservoir 3 / Wash II B 2mI 
ddH20 196 ml 
A 2ml 
Total 200ml 
Reservoir 4 / Wash III B 1mI 
ddH20 199 mI 
Total 200mI 
Table 2.4 Components of GeneT ACTM Hybridization station wash buffers 
2.9.6 Image acquisition and analysis 
Arrays were scanned immediately after hybridization in a GeneTACTM LS IV Biochip 
Analyzer operated by GeneTAC GT LS, version 3.11 software (Genomic Solutions). 
Scanning was stopped at a particular Gain when the landmarks in positions Al.a1, 
A12.a1, Dl.a1 and D12.a1 lit up, to enable alignment of array. Gain for Cy3 did not 
exceed 55, Gain for Cy5 was never greater than 65. The Black (Offset) was adjusted to 
give minimum background. Scan dimensions were X = 1000, Y = 3000 with 5 point 
averaging. 
Image analysis was enabled by the GeneTACTM Integrator, version 3.3.0 microarray 
analysis software (Genomic Solutions). A 12 x 4 patch grid was overlaid and landmarks 
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assigned to spots positioned in A1.al, A12.al, D1.al and D12.al (see Appendix II, B & 
C). Spacing of grid circles was standardized at 50b !lm and circle diameter set to 
350 !lm. The grid was moved to align with the majority of spots. Each patch was 
examined individually and any bad spots (i.e. ones which were not uniform in size, did 
not fit into their grid circle or did not follow the same pattern as other replicates) were 
flagged as such and excluded from analysis. 
Only arrays with a Mean Normalisation Factor greater than 0.8 were included in the 
analysis. In addition a linear relationship between Cy3 and Cy5 intensities was desired. 
Fold changes were given relative to the control channel, Cy3. The reports of composite 
ratios between Cy5 / Cy3 were filtered to show genes which were 1.5 fold or more up-
or down-regulated in test versus control samples. 
Microarray analysis of cell lines SW480 GFP-Iamin A 2bb3, GFP-emerin 2 and GFP 2 
was done in a three-way pair-wise manner, where each pair of cell lines were analysed 
in triplicate and significant gene changes common to all repeats were chosen to be 
confirmed by RT-PCR. 
2.9.7 RT-PCR confirmation of changes in expression of selected genes 
Primers to c-myc (V00568), c-raf (X03484), ribosomal protein L3l (RPL3l) 
(NM_000993) and synemm, isoform H (AJ310522), were designed (Table 2.3) as 
described in Section 2.8.1, Primer design. Semi-quantitative RT-PCR was set up exactly 
as for lamin B2, including the appropriate negative controls (see Section 2.8.4), using 
the same total RNA isolated for micro array analysis. Thus RT-PCR using each pair of 
primers was replicated on three separate RNA samples for each cell line. 
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Optimized PCR cycling conditions fot c-myc and synemin: 1 cycle at 94°C for 2 
minutes, 25 cycles (26 cycles for synemin) at 94°C for 45 seconds, 59°C for 1 minute 
and 72°C for 1 minute and 1 cycle at 72°C for 5 minutes; c-raf: 1 cycle at 94°C for 2 
minutes, 25 cycles at 94°C for 45 seconds, 60°C for 1 minute and noc for 1 minute and 
1 cycle at 72°C for 5 minutes and RPL31: 1 cycle at 94°C for 2 minutes, 25 cycles at 
94°C for 45 seconds, 56°C for 1 minute and 72°C for 40 seconds and 1 cycle at 72°C for 
5 minutes. B-actin RT-PCR was performed as a positive and loading control utilizing 
the same PCR profile standardized in Section 2.8.4. 
PCR products were analysed by gel electrophoresis and subsequent densitometry as 
outlined in Section 2.8.5 and Section 2.10.1. Products were confirmed by DNA 
sequencing with c-myc antisense, c-raf antisense, synemin antisense and RPL31 
antisense primers (Table 2.3) using an ABI Prism® 377 XL automated DNA sequencer 
(Applied Biosystems), exactly as described in Section 2.8.6. 
2.10 Miscellaneous: applications relevant to more than one experimental 
procedure 
2.10.1 Densitometry 
Western blot and RT-PCR bands were digitally scanned in a Fujifilm Intelligent Dark 
Box II (Fujifilm Medical Systems, Edison, NJ) directed by Fujifilm Image Reader LAS-
1000 Pro Ver. 2.11 software and intensities quantified in Image Gauge version 4.0 
(Fujifilm). 
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CHAPTER 3 - CHARACTERIZATION OF COLORECTAL 
CANCER CELL LINES 
3.1 Introduction 
3.1.1 Nuclear lamin expression in cancer 
Differential expressIOn of lamins, particularly lamin AlC has been associated with 
epithelial, lymphoid and mesenchymal tumours, including basal skin cell carcinoma 
(Tilli et aI., 2003; Venables et aI., 2001), human non-small cell lung cancer, small cell 
lung cancer (Broers et aI., 1993; Kaufmann et aI., 1991), acute lymphoblastic 
leukaemia, non-Hodgkin's lymphoma (Stadelmann et aI., 1990), metastatic 
leiomyosarcoma, rhabdomyosarcoma and chondrosarcoma (Cance et aI., 1992). Two 
groups have investigated the changes in lamin AlC and lamin B 1 expression in 
colorectal neoplasms, but their findings appear somewhat contradictory. Cance et aI., 
(1992) reported constitutive expression of lamin B (antibody did not differentiate 
between lamin Bland B2) and heterogeneous expression of lamin AlC in two colon 
adenocarcinomas, determined by immunohistochemistry; Moss et al. (1999) reported 
reduced nuclear immunostaining for both lamins AlC and B 1 in colon adenomas and 
adenocarcinomas, compared to normal tissue. Neither group was able to corroborate 
their observations by western blot analysis. 
After considering the findings by Venables et al. (2001) which correlated a down-
regulation of lamin A in basal skin cell carcinomas with a high proliferative index and a 
loss of lamin C with slower growth, the following seemed clear: First, that examining 
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the changes in expression of lamin AlC together may not in fact disclose the true nature 
of the relationship between A-type lamins and the development and progression of 
colon cancer. Second, that a panel of highly sensitive antibodies specific for individual 
lamin sub-types was required to quantify any change in lamin expression by western 
analysis. Fortunately, in our laboratory we have access to such a panel of lamin 
antibodies. 
Monoclonal antibody loL4 (anti-lamin A) reacts only with the lamin A tail domain, 
amino acids (aa) 573 to end and detects a 70 kDa band on a western blot of whole cell 
extracts. Monoclonal antibody loL2 (anti-lamin AlC) reacts with the common domain 
of the lamin AlC tail, aa 464 - 572 and identifies both lamins A and C, seen on an 
immunoblot as 70 and 65 kDa bands respectively (Dyer et ai., 1997). An additional 
antibody, RalC (anti-lamin C), was raised in rabbit against the last eight amino acids of 
the lamin C tail domain making it specific for lamin C only (Venables et ai., 2001). This 
antibody detects a band of 65 kDa on western blot. LN43 (anti-lamin B2) is a 
monoclonal antibody specific for lamin B2 (Bridger et ai., 1993; Kill and Hutchison, 
1995), seen as a 68 kDa band on immunoblot (Venables et ai., 2001). GaLB1 (anti-
lamin B1), a polyclonal lamin B1 antibody raised in goat, was commercially obtained 
(Santa Cruz) and is visualized as a 67 kDa band on western blot (Venables et ai., 2001). 
Original investigations into the presence of A- and B-type lamins in mammalian 
somatic cells led to the conclusion that they were constitutively expressed [reviewed by 
Gerace (1986)]. However, subsequent biochemical studies on developing mouse 
embryos, young animals and embryonal carcinoma (EC) cells and their differentiated 
derivatives revealed that expression of lamins A and C is not only developmentally 
regulated (Stewart and Burke, 1987) in a cell-type specific manner (Rober et ai., 1989), 
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but is closely associated with differentiation (Lebel et aI., 1987; Stewart and Burke, 
1987). In general, an increased expression of lamin AlC appears to accompany tissue 
and cellular differentiation (Broers et aI., 1997; Coates et aI., 1996; Lebel et aI., 1987; 
Paulin-Levasseur et aI., 1989; Rober et aI., 1989; Stewart and Burke, 1987). Some of 
these studies show the synthesis of B-type lamins to be unaffected during differentiation 
(Lebel et aI., 1987; Paulin-Levasseur et aI., 1989), but analyses on adult human tissues 
using antibodies which distinguish between lamin Bland B2 suggest individual B-type 
lamins may have different patterns of expression. Broers et aI. (1997) found lamin B2 
was universally distributed in all normal human tissues, except hepatocytes, whereas 
lamin B 1 was expressed in a more cell-specific manner which appeared to be inversely 
correlated with differentiation in epithelial cells. 
Originally described as units of architecture, lamins are type V intermediate filaments 
which form an orthogonal meshwork underlining the inner nuclear membrane, termed 
the nuclear lamina, which conveys mechanical strength to the nucleus (Aebi et al., 
1986), resisting deformation (Broers et aI., 2004; Lui and et aI., 2000; Moir et aI., 
2000b) and regulating nuclear shape (Schirmer et al., 2001; Sullivan et aI., 1999) and 
size (Spann et aI., 1997). Lamins shape the nucleoskeleton by anchoring integral 
proteins of the inner nuclear membrane, positioning nuclear pore complexes and 
recruiting lamins to the nuclear lamina itself [reviewed by Hutchison (2002)]. Current 
evidence implicates lamins in the control of DNA replication and most interestingly, 
suggests they may organize interphase chromatin and play a role in regulating 
transcription. 
In the quest to elucidate the function of lamins, nuclear binding partners of lamin AlC 
have been identified, revealing a possible mechanism by which A-type lamins may 
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promote tumour development. Markiewicz et ai. (2002) demonstrated that lamin AlC in 
complex with LAP2a interacts with hypophosphorylated retinoblastoma protein, via 
pRb's nuclear localization signal sequence, located in pocket C, thus tethering it in the 
nucleus in G 1 phase of the cell cycle. Previously, in vitro interaction between pRb and 
lamin A has been described by Ozaki et ai. (1994). Hypophosphorylated pRb functions 
to silence genes necessary for cell proliferation by negatively regulating the 
transcription factor E2F (Chellappan et ai., 1991). Evidence suggests that nuclear 
anchorage of pRb is essential for its appropriate function: deletion mutants in pocket C 
of pRb, which are no longer tethered in the nucleus, have been shown to have oncogenic 
properties (Mittnacht and Weinberg, 1991). In addition, down-regulation of lamin A has 
been shown to accompany rapid tumour advancement (Venables et ai., 2001). 
Based on these findings our group proposes that there is a causal link between lamin A 
expression and loss of pRb silencing function in tumour cells. We believe that down-
regulation of lamin A will promote hyper-proliferation and dedifferentiation during 
carcinogenesis through an epigenetic mechanism. Here colorectal cancer is used as a 
model system for testing our hypothesis. 
3.1.2 Selection of colorectal cancer cell lines 
Colorectal carCInoma is known to develop over many years through a senes of 
pathologically and histologically distinct stages. By explanting tissue from individual 
stages, cell lines can be created representing each order of malignancy, thus enabling in 
vitro studies of the molecular characteristics concomitant with disease progression. The 
initial aim of this project was to assemble a model system of cell lines with which the 
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nature of lamin expression with respect to colorectal cancer development could be 
investigated. 
ECACC is an international provider of cell lines, particularly those derived from 
tumours. From this source the following four cell lines were selected which best 
represented the different Broders' grades (Broders, 1925) recognized in CRC: HT29 - a 
grade II colon adenocarcinoma cell line originating from a malignant primary tumour in 
a 44 year old Caucasion female (Fogh and Trempe, 1975); SW948 - a colon 
adenocarcinoma cell line isolated from a grade III (Dukes' class C) tumour in an 81 
year old Caucasian female (Leibovitz et aI., 1976); SW480 - established from a grade 
IV (Dukes' class B) adenocarcinoma of the colon in a 50 year old Caucasian male 
(Leibovitz et aI., 1976) and T84 - a cell line derived from lung metastases of a colon 
carcinoma in a 72 year old male (Murakami and Masui, 1980). Metastatic tumour tissue 
was inoculated subcutaneously into BALB/c athymic mice, serially transplanted and 
established in in vitro culture without any change to the original histological 
characteristics of the tumour (Murakami and Masui, 1980; Reid et aI., 1978). Both 
SW948 and SW480 produce carcinoembryonic antigen (CEA) , SW948 significantly 
more than SW480. Although HT29 was derived from a grade II colon adenocarcinoma 
it actually forms well-differentiated cultures consistent with grade I primary colonies, 
therefore an additional cell line, SWll16, was selected originally to be incorporated 
into this study. SWl116 represented a grade II adenocarcinoma of the colon which 
extended into the muscularis mucosae and was isolated from a 73 year old Caucasian 
male (Leibovitz et aI., 1976). However, this was later withdrawn from use in any 
experiments as it proved impossible to culture successfully. All cell lines used had an 
epithelial-like morphology. 
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3.1.3 Broders' grading compared to Dukes' staging of CRC tumours 
At this point it is pertinent to explain how the classification of our CRC cell lines into 
grades compares to the accepted clinicopathological classification of colon carcinomas 
according to the Dukes' staging system (Dukes, 1932). As detailed in the Chapter 1, 
Section 1.2.5, the Dukes' staging system comprises Dukes' stages A, B and C and is 
based on the extent of spread. Stage D was added later by Turnbull et al. (1967) and 
indicates that a tumour has metastasized. On the other hand, Broders (1925) pioneered a 
system of categorizing tumours histologically according to their degree of 
differentiation. Tumours with 75 - 100% of cells differentiated are classified as grade I, 
tumours with 50 - 75% of cells differentiated as grade II, those with 25 - 50% of cells 
differentiated as grade III and those with 0 - 25% of cells differentiated as grade IV. 
Thus the CRC cell lines HT29, SW948 and SW480 can be thought of as representing 
increasing levels of dedifferentiation. The metastasized cell line T84 falls outside both 
Dukes' (1932) and Broders' (1925) original classification schemes because the cells 
were derived from a secondary site (lung). 
However, the two systems of classification appear to compare favourably. Dukes (1932) 
showed that most grade I cases could also be categorized as Dukes' stage A; most grade 
II tumours were stage B and the majority of grade III and IV tumours were stage C. 
However, there was a degree of overlap and Dukes' stages A, Band C could not be 
correlated absolutely with Broders' grades I, II, III and IV. This system of grading also 
appears to correlate with prognosis, in that patients with grade I adenocarcinomas have 
the best prospects for survival after one year and the outlook becomes progressively 
poorer the higher the grade of tumour (Dukes, 1932; Rankin and Broders, 1928). 
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3.1.4 Summary 
Previous analyses investigating the expression of nuclear lamins in colorectal cancer 
have proved inconclusive (Cance et ai., 1992; Moss et ai., 1999). Here a comprehensive 
expression study of lamins A, C, B1 and B2 in CRC cell lines HT29, SW948, SW480 
and T84 using a panel of antibodies specific for individuallamin sub-types is presented. 
Correlation between proliferation / differentiation status of tumours and alteration in 
lamin behaviour is examined. 
3.2 Results 
3.2.1 Optimization of cell culture conditions 
The cell lines described previously were grown following the culture conditions 
stipulated by ECACC, recorded verbatim in Chapter 2, Section 2.2.1. Importantly, 
HT29 and T84 were grown in a 5% CO2 equilibrated environment, whereas SW948 and 
SW480 were cultured under atmospheric conditions, necessitated by the use of 
Leibovitz's L-15 medium which was developed without a sodium bicarbonate buffering 
system and therefore formulated to support cells in a non-C02 environment (Leibovitz, 
1963). The benefits of weaning all the cultures onto the same media and growing all in 
5% C02 were considered. However, it was deemed judicious to maintain the cell lines 
in the growth conditions recommended by the supplier as, for the most part, they were 
those under which the cell lines had been isolated originally and therefore had been 
shown previously to give rise to healthy cultures (Fogh and Trempe, 1975; Leibovitz et 
ai., 1976; Murakami and Masui, 1980). Additionally, it was felt that altering the culture 
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conditions may, in fact, also alter some molecular characteristics which may 
inadvertently affect the accuracy of future data. 
During the process of establishing the cell lines in our laboratory, it was necessary to 
make some modifications to the sub-culture routine of all the cell lines, despite 
consistent adherence to the culture conditions prescribed by ECACC, to ensure the 
healthiest cultures for experimental analysis. The improvements were mainly related to 
split ratio / re-seeding density and the trypsinization procedure. In brief: HT29 was the 
most robust cell line and grew more vigorously than any other, hence it was necessary 
to increase the split ratio recommended by ECACC to 1: 10 - 1: 12. SW948 had to be 
maintained at a high density and therefore was not split more than 1:2 in order to 
counteract the cells' predisposition to growing on top of each other. If allowed, this 
resulted in a sparse culture that never became fully confluent, but formed colonies that 
were extremely difficult to disaggregate. SW480 grew most actively if split no more 
than 1:4, while T84 were always slow growing and best if split 1:3. Interestingly, T84 
proved more challenging to dissociate from the culture surface than the other cell lines. 
The optimized procedure involved 10 minutes incubation in 0.25% trypsin / EDT A at 
37°C, yet still up to 20% of cells ordinarily remained adhered to the substrate. 
3.2.2 Morphological and growth characteristics 
From the outset it was clear that each cell line had distinctive morphological and 
developmental features, despite all cultures being epithelial in origin. Figure 3.1 shows 
our model CRC cell system in a series of phase contrast micrographs which illustrate all 
the significant features of morphology and growth associated with each cell line. 
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Cell line HT29 grew as a homogeneous culture comprising cells shaped as moderately 
elongated spheres with a high nucleoplasmic to cytoplasmic ratio. It formed closely 
associated, adherent colonies which converged to form a monolayer. Contact inhibition 
was not obvious at sub-confluent levels, but when grown beyond 100% confluency cells 
continued to proliferate and became progressively more tightly packed. HT29 appeared 
least predisposed to cellular stratification, rather overgrowth ultimately led to 
monolayer sloughing. 
In T84, examples of stratified (multi-layered) growth were only seen if cells were 
seeded too thinly, or if they were allowed to become over-confluent. Growth of T84 
cells was noticeably constrained when cells were seeded at less than 25% density. In 
this situation, rather than expanding across the surface of the dish, cells accumulated in 
multi-layered clusters and took longer to fill the culture plate. As a rule healthy T84 
cells were polyhedral in shape and formed a tightly packed and adherent monolayer. 
Neither cell size nor nucleoplasmic to cytoplasmic ratio appeared uniform. Cells varied 
from small size, with a high nuclear compared to cytoplasmic volume to large size with 
a low nucleoplasmic to cytoplasmic ratio. Nucleoli were sharply demarcated at 32X 
objective magnification, roundish to irregular in shape, sometimes presenting as bi-
lobed structures, and varied greatly in diameter. Nuclei often contained more than the 
maximum number of four nucleoli expected in normal cells. 
In contrast, SW948 and SW480 cells were highly anchorage independent. Cellular 
stratification was a feature of the cultures from the beginning and there was no clearer 
exponent of this phenomenon than SW480, a grade IV cell line. These cells were 
significantly larger than SW948, predominately epithelial-like (polygonal shaped cells), 
although a sub-population were bipolar, and frequently multinucleate. It was not 
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uncommon to see up to eight nuclei within a single cell. They grew in an uninhibited 
and non-unifonn fashion. Some cells would grow as a single layer, while a proportion 
of neighbouring cells would grow in multiple layers (Figure 3.1, C). In contrast to the 
observation by Leibovitz et ai. (1976) that only the bipolar cell population grew 
individually, I observed the epithelial-like cells fonning islands and growing as 
individuals. A large proportion of cells were routinely observed floating in the media. 
At 32X magnification these 'floaters' were seen to be round, shrunken and displaying 
small, pericellular, bulbous protrusions (Figure 3.1, G). Although this culture appeared 
highly proliferative, these observations were thought to indicate that a high level of 
apoptosis was occurring within the culture. 
SW948 cells were small and fonned highly aggregated, stratified colonies making it 
impossible to identify individuals at 32X magnification. Although essentially adherent, 
their propensity to form multiple layers left them susceptible to mass detachment unless 
the culture was maintained above 50% density, seeded as monodisperse as possible and 
provided with fresh media every 48 hours. These cells have been reported to contain 
both microvesicular bodies and an evident glycocalyx (Leibovitz et ai., 1976). Similar 
to SW480, healthy cultures displayed increasing numbers of floating cells as the number 
of days growth increased. Again this was thought to be the consequence of apoptosis 
which is addressed in Section 3.2.3. 
3.2.3 Cell cycle analysis 
To detennine the proportion of cells in each phase of the cell cycle and the presence of 
cells undergoing apoptosis, cell lines HT29, SW948, SW480 and T84 were expanded to 
70% confluency, fixed in methanol, stained with the DNA intercalating dye Propidium 
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iodide (25 Ilglml) containing 100 Ilglml RNase to remove RNA and subjected to flow 
cytometric analysis. 
Overall SW480 and T84 cells spent proportionally more time in S and G21M phases of 
the cell cycle than in GOIG 1, compared to HT29 and SW948 cells (Figure 3.2). 
Approximately two thirds of HT29 and SW948 cells were in GOIG 1 and therefore 
proportionally less were in Sand G21M phases. The difference between the proportion 
of HT29 and SW948 cells compared to SW 480 and T84 cells in GOIG 1 was significant 
and indicates that while all cultures were proliferating, SW480 and T84 exhibited a 
higher rate of cell growth compared to HT29 and SW948. 
Nuclear fragmentation, incorporating DNA fragmentation and DNA loss, is a key 
feature associated with apoptosis, thus apoptotic cells can be identified through their 
reduced stainability with PI resulting in a sub-GOIGI peak (Sgonc and Gruber, 1998). A 
distinct region below the GOIGI peak was expected but not detected for SW480. 
However, this may be explained by the method used to prepare the cells (see Chapter 2, 
Section 2.5). All floating cells were removed and discarded prior to trypsinization and 
consequently adherent cells only were prepared for flow cytometry. Hence this protocol 
may have resulted in the inadvertent removal of any apoptotic population. Nevertheless 
a sub-GO/G 1 peak was identified in SW948 cells, supporting the idea that a degree of 
apoptosis was occurring in this culture. In all replicate analyses of T84 it appeared that a 
very small proportion of cells exhibited reduced PI staining which may therefore be 
indicative of low-level apoptosis within this culture. No evidence of apoptosis in HT29 
cells was apparent, however the potential inadequacies of the protocol used should be 
taken into consideration before making any firm conclusions regarding the four cell 
lines examined. 
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3.2.4 The relationship between lamin expression and colorectal cancer progression 
3.2.4.1 Lamin A is down-regulated in pre-metastatic cells 
To investigate the expression pattern of individual lamins in relation to the degree of 
tumour differentiation, both western blotting and immunofluorescence techniques were 
applied to the colorectal carcinoma cell lines HT29 , SW948, SW480 and T84 which 
represented tumour grades II, III, IV and a lung metastasis of a colon carcinoma 
respectively. 
Protein expression profiles (Figure 3.3) revealed differential expression of lamin A (A) 
and B2 (D) with respect to the degree of cellular differentiation. Lamin C and B 1 
expression appeared unchanged. Lamin A expression was significantly decreased in 
tumour grades III and IV. Expression was reduced by an average 52% in grade III and 
57.7% in grade IV tumour cells compared to grade II cells (Figure 3.4, A). Higher 
levels of lamin A expression were maintained in grade II and metastasis samples, 
although lamin A expression in lung metastasis cells was, on average, 15.5% greater 
than in grade II cells. Standardizing the level of lamin C expression against p-actin 
showed that it was overall similar at every stage of the disease (Figure 3.4, B). 
Expression in grade II, IV and metastasis cultures was nearly 100%, although a 20.5% 
reduction in lamin C expression between grade II and grade III cells was observed. 
Expression of lamin B 1 was similar, if not identical across all grades of colorectal 
carcinoma - no cell line exhibited less than 90% expression compared to the grade IV 
sample which was designated 100% (Figure 3.4, C). Densitometric analysis of lamin 
B2 immunoblots (Figure 3.4, D) demonstrated that the average expression of lamin B2 
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increased by 29.5% between grade II and grade III, reduced by 68% between grades III 
and IV before recovering in the metastasized cells to a level of expression which was 
22% higher than in grade IV, but 46% lower than in grade II. 
To analyse the nuclear distribution of lamins in our model system of colorectal cancer 
cell lines, single indirect immunofluorescence with the aforementioned panel of anti-
lamin antibodies was performed (Figures 3.5, 3.6 & 3.7). Double immunostaining 
analyses followed to investigate the relationship between lamin A and AlC expression 
and cellular proliferation, using proliferation indices Ki67 and PCNA (Figure 3.8). 
Initial attempts to perform single indirect immunofluorescence with the lamin A-
specific antibody JoLA resulted in poor quality staining, therefore JoL2 (anti-Iamin AlC) 
was used preferentially to determine the distribution of lamin A (Figure 3.5.1) 
compared to the distribution of lamin C, ascertained by single staining with the lamin C-
specific antibody, RaLC (Figure 3.5.2). 
Lamin AlC staining (Figure 3.5.1) was nuclear specific in all colorectal cancer cell 
lines and was generally localized to the nuclear rim. Only in T84 did a minority of cells 
show nucleoplasmic distribution of lamin AlC. The majority of cells were positive for 
lamin AlC. Limited cells in HT29, SW948, SW480 and T84 were not stained, although 
the intensity of staining was brightest in HT29 and T84 cells. HT29 nuclei exhibited 
multiple lamin AlC positive invaginations (arrows). Using RaLC, lamin C appeared 
evenly distributed around the nuclear rim in all cancer cell lines and the intensity of 
staining was equivalent across all grades (Figure 3.5.2). All cells, barring a negligible 
number of T84 cells, were positive for lamin C. 
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Indirect immunofluorescence of B-type lamins showed that, as expected, staining was 
associated very strongly with the nuclear envelope. Lamin B 1 staining was similar in all 
cancer grades (Figure 3.5.3), whereas lamin B2 exhibited dynamic changes in 
expression levels as the cell lines became progressively more neoplastic (Figure 3.5.4). 
All SW948 cells strongly expressed lamin B2, compared to HT29 and T84 cells which 
showed positive, but weaker staining. SW480 cells displayed a unique mosaic pattern of 
lamin B2 expression. While 41.7% of cells were brightly positive (for example, see 
arrows in panels G and I), 58.3% of cells were lamin B2 negative (for example, see 
arrow heads in panels G and I). Two hundred cells were analysed. 
To confirm that this mosaic-like pattern of lamin B2 expression was a consistent feature 
of SW480 cells alone, all cell lines were immunostained with the lamin B2 antibody, 
LN43, serially diluted from 1: 10 to 1: 100 (Figure 3.6). Concomitant with increasing 
antibody dilution, the intensity of lamin B2 staining decreased in cell lines HT29 
(Figure 3.6.1), SW948 (Figure 3.6.2) and T84 (Figure 3.6.4), but the protein remained 
uniformly expressed in all cells. In SW480 (Figure 3.6.3), cells expressing lamin B2 
showed a reduction in staining intensity as antibody concentration decreased, but 
positive staining was still detected at 1: 100 antibody dilution. However, a large 
population of lamin B2 negative cells was always present. This offers an explanation as 
to why there was a 68.1 % reduction in lamin B2 protein levels between grade III and 
grade IV cells when assessed by western blot (Figure 3.3, D / 3.4, D): It is not the 
overall level of lamin B2 expression which is diminished across the SW480 culture, but 
rather a selective loss of lamin B2 in the majority of cells. 
To confirm immunoblotting and immunofluorescence data indicating that lamin A is 
down-regulated to a pre-metastatic stage, the colorectal cancer cells lines were stained 
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with JoL2 at a dilution of 1:50 which just detected lamin NC expression in the cell line 
HT29 (Figure 3.7). The aim of this experiment was to accurately observe differences in 
lamin NC expression between the cell lines by ensuring the signal was not saturated. 
Interesting differences became apparent. While lamin NC staining was readily 
detectable in HT29 and SW948 cells, it was almost completely absent from SW480 
cells. Staining was comparatively high in T84 cells . Western analysis indicated that 
SW480 cells express the least amount of lamin A (Figure 3.3, A / 3.4, A) and this 
immunocytochemical experiment supports a uniform down-regulation of lamin A in 
grade IV CRC cells. 
3.2.4.2 Down-regulation of lam in A in SW948 and SW480 cells does not correlate 
with proliferation indices 
Given that reduced expression of lamin A has been associated with more proliferative 
cell types (Broers et aI., 1997; Venables et aI. , 2001) and our CRC cell lines represent 
progressive dedifferentiation, it was reasoned that loss of lamin A expression in the least 
differentiated cell lines SW948 and SW480 may be concomitant with increased 
expression of proliferation markers Ki67 and PCNA. To investigate this hypothesis the 
CRC cells lines were subjected to further immunocytochemical analyses involving 
double-staining with lamin antibodies, JoL4 (anti-Iamin A) or JoL2 (anti-lamin NC) 
and proliferation marker antibodies, Ki67 or PCNA (Figure 3.8). 
Importantly, Figures 3.8.1 and 3.8.3 confirm that there is a down-regulation of lamin A 
in SW948 and SW480 cells compared to HT29 and T84, demonstrated by reduced 
nuclear staining with JoL4. However, there appeared to be no correlation between loss 
of lamin A or NC expression and expression of proliferation marker Ki67 (Figures 
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3.8.1 & 3.8.2) or PCNA (Figures 3.8.3 & 3.8.4). For each cell line co-stained with anti-
lamin AlC and Ki67, two hundred cells were analysed. In each cell line the percentage 
of Ki67 expressing cells was comparable at approximately 95% (HT29 - 95%, SW948 -
98%, SW480 - 99% and T84 - 94.5%), although clear variations in lamin AlC 
expression were observed. 
3.2.4.3 Loss of lamin A in SW948 and SW480 cells appears to be the result of both 
transcriptional and post-transcriptional mechanisms 
The loss of expression of lamin A from SW948 and SW480 cells leads to the question: 
At what level is expression of lamin A regulated in these cells? Lamin A and lamin C 
mRNA instability or preferential use of the alternative splice site, favouring the 
generation of one mRNA over the other, have been suggested previously as mechanisms 
for transcriptional control of cell-type specific expression of A-type lamins (Lin and 
Worman, 1997). Hence the amount of lamin A and lamin C transcript present in each 
colorectal cancer cell line was assessed. 
Semi-quantitative RT-PCR was carried out on equal concentrations of total RNA 
(verified by ~-actin RT-PCR - Figure 3.9, C) using primers specific for lamin A 
(Figure 3.9, A) and lamin C (Figure 3.9, B). The LMNA gene yields three transcript 
variants in somatic cells - lamin A, lamin C and the less abundant lamin A~lO - by 
alternative splicing of exon 10 (Machiels et al., 1996). Although the lamin C messenger 
sequence lacks the whole of exon 11 and 12 it is in complete consensus with lamin A 
but for 21 nucleotides at the 3' terminus which constitutes six lamin C-specific codons 
and a TGA termination codon which are spliced during the synthesis of prelamin A (Lin 
and Worman, 1993). Therefore to amplify lamins A and C independently a system was 
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used whereby a universal sense primer complementary to lamin AlC was combined 
either with an antisense primer specific for exons 11 / 12 in order to amplify lamin A, or 
with an antisense primer specific for the unique 21 bases at the 3' end of lam in C in 
order to amplify lamin C specifically. Consequently the lamin A and lamin C RT-PCR 
products could be separated by size on an agarose gel. Primers for this experiment were 
already available in the laboratory, but were originally designed for Allelic Refractory 
Mutation Specific - Polymerase Chain Reaction (ARMS-PCR) to detect single 
nucleotide polymorphisms in AD-EDMD cell lines with known mutations in the LMNA 
gene (Alvarez-Reyes, 2003). The ARMS-PCR strategy necessitates a mismatch in the 
second or third last base of one primer, in this case the sense primer, whether it is to be 
used to distinguish the mutant or the wild-type allele. 
Thus the lamin AlC wild-type sense primer used in this thesis had the sequence: 
5'-GATGCGCTGCAGGAACTACG- 3'. 
But the actual wild-type lamin AlC sequence is: 
5'-GATGCGCTGCAGGAACTGCG-3'. 
However, this mismatch was designed to stabilize the primer and facilitate a more 
efficient RT-PCR, rather than restrict it. 
RT -PCR experiments revealed that in grade III (SW948) cells levels of lamin A mRNA 
were largely reduced compared to the other CRC cell lines examined (Figure 3.10, A). 
The difference in lamin A mRNA expression between grade II (HT29) and grade III 
cells was statistically significant. Grade N (SW 480) cells expressed similar levels of 
lamin A messenger as grade II and metastasis (T84) cells, suggesting that lamin A is 
down-regulated at the protein level by different mechanisms in grade III and grade N 
CRC cells. Quantitative variation in the amount of lamin C transcript in each cell line 
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was calculated using densitometry (Figure 3.10, B), but deviation between replicates 
meant that relative differences in lamin C mRNA expression were not significant. 
Sequence analysis of lamin A and lamin C RT-PCR products demonstrated that the 
primers used were sub-type specific (Figure 3.11). 
3.2.4.4 Changes in lamin B2 expression are transcriptionally regulated 
Grade II, III, IV and metastasis CRC cell lines were subjected to semi-quantitative RT-
PCR using primers specific for lamin B2 (Figure 3.12). Changes in lamin B2 at the 
mRNA level followed a similar pattern to those observed at the protein level (Figure 
3.3, D & Figure 3.4, D). Grade III cells exhibited the highest level of mRNA expression 
which correlates with their protein profile. Lamin B2 mRNA expression in grade IV and 
metastasis cells also followed the same pattern as that seen at the protein level, i.e. the 
metastasis cells displayed more lamin B2 transcript than grade IV cells. However, in 
grade II cells messenger RNA expression appeared proportionally lower than protein 
expression, relative to grade III cells. In general it appears that the dynamic changes in 
lamin B2 protein expression observed in CRC cell lines HT29, SW948, SW480 and T84 
(Figure 3.3, D & Figure 3.4, D) are predominantly the result of transcriptional 
regulation. Sequence analysis of lamin B2 RT-PCR products confirmed the specificity 
of the lamin B2 primers (Figure 3.13). 
3.3 Discussion 
Expression and distribution of nuclear lamins A, C, Bland B2 was investigated in a 
model system of cell lines representing the progression of colorectal cancer from a 
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relatively differentiated phenotype (Broders' grade II) to a highly dedifferentiated 
phenotype (Broders' grade IV), to metastasis . Protein profiling and indirect 
immunofluorescence analyses identified changes in the expression of lamins A and B2 
during the advancement of CRC. In contrast lamin C and B 1 expression appeared 
constant in all grades of the disease. Specifically, lamin A was down-regulated in the 
more dedifferentiated cell lines SW948 and SW480 (grade III and IV respectively) 
which displayed morphological abnormalities including loss of contact inhibition, 
stratified growth and an apparently weaker adherence to the tissue culture substrate. 
Lamin A expression was not similarly reduced in the lung metastasis cell line T84 
which displayed a higher level of lamin A expression than in HT29 (grade II) cells. 
Interestingly, although T84 is derived from metastases, in the presence of serum it has 
been shown to grow in a monolayer, establish tight junctions between cells and form 
microvilli on the plasma membrane facing the media (Dharmsathaphom et ai., 1984). In 
short it retains the structural polarity and morphology associated with differentiated 
epithelial cells. The corollary of this is that loss of lamin A appears to accompany 
dedifferentiation of colorectal cancer cells and therefore their progression towards 
neoplasia. 
Lamin B2 expression appeared to be dynamically regulated in CRC cells, primarily at 
the level of transcription, given that SW948 cells were found to exhibit the highest 
relative level of protein expression and the highest relative transcript copy number. 
However, unlike lamin A, changes in lamin B2 expression cannot be described as a 
dedifferentiation-associated event. Despite a very large reduction in relative protein 
expression between SW948 and SW480 cells, HT29 cells expressed only very low 
levels of lamin B2 compared to the less well differentiated SW948 cell line. However, it 
was established that lower levels of lamin B2 expression in a cell line were not 
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necessarily the result of uniform diminution of the protein across all cells, but could be 
attributed to large variations within a cell line. This was demonstrated in SW480 cells in 
which the majority of cells displayed complete loss of expression, while the remaining 
cells expressed lamin B2 at levels similar to those observed in cell lines expressing 
uniformly high levels of lamin B2. 
The first evidence of a differential relationship between lamins A and C and tumour 
growth was presented by Venables et al. (2001). Studies on lamin expression in basal 
cell carcinomas of the skin found a correlation between loss of lamin A and fast tumour 
growth, whereas a down-regulation of lamin C appeared to coincide with slower tumour 
growth. Hence I decided to investigate the relationship between lamin A, C, Bland B2 
expression and the proliferative capacity of CRC cells. 
Flow cytometric analyses showed HT29 and SW948 cells to be slow growing and 
SW480 and T84 cells to be faster growing. Comparative immunofluorescence analyses 
revealed that Ki67 expression was fairly constant in all cell lines despite a clear 
reduction in lamin A expression in SW948 and SW480 cells. In addition, no appreciable 
relationship between PCNA expression and lamin A levels was observed. Thus no 
correlation between lamin A expression and overall cell growth rate or proliferation 
status could be engendered in our chosen colorectal cancer cell lines. There does appear, 
however, to be an inverse correlation between lamin B2 expression and growth rate -
the slower growing cells (HT29 and SW948) expressed the highest level of lamin B2. 
The loss of lamin A in SW948 and SW 480 cells posed the intriguing question: Was this 
regulated at the level of transcription or post-transcriptionally? Semi-quantitative RT-
PCR was performed on RNA extracted from all four CRC cell lines using primers 
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which differentiated between lamin A and lamin C transcript variants. As expected no 
significant change in lamin C mRNA levels was observed. In SW948 cells, the lamin A 
message was barely detectable, whereas in HT29, SW480 and T84 cells it was more 
strongly expressed. This suggests that loss of lamin A in SW948 cells is regulated at the 
level of transcription, but in SW480 cells it is most likely regulated post-
transcriptionally. Essentially, down-regulation of lamin A appears to result from two 
different mechanisms in the cell lines investigated. 
Previously, transcriptional regulation of lamin Me gene expression has been reported. 
Research by Kaufmann et ai. (1991) demonstrated that an up-regulation of lamins A and 
C in v-rasH -expressing small cell lung carcinoma (SCLC) cells was the result of an 
augmentation in mRNA synthesis. Later, Broers et ai. (1993) ascribed down-regulation 
of lamin NC in the SCLC sub-type to the absence of A-type lamin transcripts. 
Furthermore, the same group observed preferential repression of lamin A expression 
relative to lamin C in a human lung adenocarcinoma cell line. Similar to our findings 
with SW948 CRC cells this imbalance was later shown to be controlled at the mRNA 
level (Machiels et ai., 1995). Recently, studies on the premature ageing disease 
Hutchinson-Gilford progeria syndrome have also illustrated a post-transcriptional 
mechanism by which lamin A expression may be abrogated but lamin C unaffected. In 
HGPS loss of functional lamin A has been attributed to incomplete processing of 
prelamin A to mature lamin A as the result of single-base substitutions in the lamin A 
tail domain which do not affect lamin C (Eriksson et aI., 2003). 
In summary these results indicate that lamin A alone is down-regulated by both 
transcriptional and post-transcriptional mechanisms in morphologically abnormal 
cultured colorectal carcinoma cells. Furthermore the regulation of lamin A expression 
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appears not to be correlated with cell proliferation, but rather the differentiation status of 
cells. This suggests that expression of lamin A may be functionally significant in 
maintaining the typical epithelial morphology associated with differentiated tissue. 
Performing a functional rescue of lamin A negative cells would enable the effect of 
lamin A on morphology to be studied. Comparing overall gene expression profiles in 
lamin A positive and lamin A negative cells would facilitate more detailed 
investigations into the role of lamin A as a possible epigenetic regulator of colorectal 
cancer-associated genes. 
o 
101 
3.4 Figures 
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Figure 3.1 
Morphology of colorectal cancer cell lines. Phase contrast micrographs of human 
colon cancer cell lines HT29, SW948, SW480 and T84 were taken at lOX (panel I) and 
32X (panel II) objective magnification. These cell lines formed the basis of a model cell 
system used to investigate changes in lamin expression with respect to CRC 
progression. HT29, SW948 and SW480 originated from grade II, III and IV colon 
adenocarcinomas respectively and T84 represents a lung metastasis of colon carcinoma. 
HT29 and T84 cells formed compact, adherent colonies (A) which converged, in 
general, to form a single sheet of cells (B). SW948 and SW480 cells were 
conspicuously anchorage independent. The tightly packed colonies formed by SW948 
were universally stratified and in SW480 islands of epithelial cells (C) were consistently 
observed. SW480 contained a mixture of epithelial-like (E) and bipolar (F) cells, 
epithelial cells predominating, and exhibited a high proportion of multinucleate cells 
(M). 
Few floating cells (D) were observed in HT29 and T84 cultures, but significantly more 
were routinely found in SW948 and SW480 cultures. In SW480 these 'floaters' (G) 
appeared shrunken and displayed small, pericellular protuberances. 
Scale bar: Panel I - 40 ~m; panel II - 20 ~m. 
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Figure 3.2 
Cell cycle characteristics of human colorectal cancer cell lines. HT29 (grade II), 
SW948 (grade III), SW480 (grade IV) and T84 (metastasis) cells, upon reaching 70% 
confluency, were fixed in ice-cold methanol, stained with a 25 Ilg/ml Propidium iodide 
solution and analysed by flow cytometry. Relative cell size and granularity is 
characterized by forward scatter (FS) and side scatter (SS) intensity, left panels (a, c, e 
& g). Data for more than 10,000 monodisperse events were collected and PI 
fluorescence is shown in the right panels (b, d, f & h). Cells in 00/01 are indicated by 
gate E, cells in S-phase, by gate F and cells in 021M, by gate O. The proportion of cells 
in 00/01 phase of the cell cycle [given as mean ± standard deviation (s.d) of three 
replicates] was significantly higher in HT29 and SW948 cells comp~red to SW480 cells 
(HT29: t = 4.46, df = 4, P < 0.05; SW948: t = 3.77, df = 4, P < 0.05) and in HT29 and 
SW948 cells compared to T84 cells (HT29: t = 7.73, df = 4, P < 0.005; SW948: t = 
3.71, df = 4, P < 0.05) showing that HT29 and SW948 cells were less proliferative than 
SW480 and T84 cells. Student's t-test was 'two-tailed'. 
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Figure 3.3 
Characterization of A- and B-type lamin expression in colorectal cancer cell lines 
by western analysis. Whole cell extracts from cells lines representing different grades 
of colon carcinoma - grade II (HT29) - lane 1, grade III (SW948) - lane 2, grade IV 
(SW480) - lane 3 and metastasis (T84) - lane 4 - were resolved on 10% SDS-PAGE, 
transferred to nitrocellulose and immunoblotted with one of monoclonal antibody 
JolA - anti-Iamin A (A), rabbit polyclonal antibody RaLC - anti-Iamin C (B), goat 
polyclonal anti-Iamin B1 (C) and monoclonal antibody LN43 - anti-Iamin B2 (D). p-
actin was used as a loading control (A - D). Molecular weight markers (MW) are in 
kDa. 
Immunoblots using specific anti-Iamin A antibody, JolA, revealed a down-regulation of 
lamin A to a pre-metastatic stage. Lamin C protein profiles appeared to change little as 
colon cancer developed. 
It was expected that the B-type lamins would be equivalent in all grades of colorectal 
carcinoma as at least one B-type lamin is required for cell survival. While SDS-PAGE 
for lamin B 1 supported this theory - lamin B 1 expression was similar across all cell 
lines, lamin B2 exhibited dynamic changes as the disease progressed. A strong up-
regulation was observed in grade III colorectal cancer cells compared to grade II cells, 
followed by a dramatic decline in expression in grade IV samples. In metastasized cells 
lamin B2 protein expression was partly recovered, but to a level lower than that detected 
in grade II cells. 
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Figure 3.4 
Expression of lamins during colorectal cancer progression, normalized against 
p-actin. Protein expression profiles of lamins A, C, Bland B2 in grade II (HT29), 
grade III (SW948), grade IV (SW480) and metastasis (T84) colon carcinoma cells, see 
Figure 3.3, were digitally scanned in a Fujifilm LAS-lOOO Intelligent Dark Box II 
Image Reader and quantified by densitometry using Fujifilm Image Gauge software, 
version 4.0. Measurements (in arbitrary units) of individual protein levels in each cell 
line were standardized against p-actin expression for both replicate experiments and an 
average taken. Relative expression levels for individual lamins were calculated, 
considering the cell line with the highest average expression level for each protein to be 
100%. 
106 
(A) Lamin A elqression (B) Lamin C elqression 
120 120 
~ 100 ~ 100 
'-' 
'-' 
c 
0 80 
"iii 
III 
~ 
.. 60 Co 
c 
0 80 
"iii 
III 
~ 
.. 60 Co 
)0( 
~ 
;.( 
~ 
c 40 ] 
0 
.. 20 ~ 
c 40 ] 
0 
.. 20 ~ 
0 0 
II III IV M II III IV M 
Grade Grade 
(C) Lamin Bl elqression (D) Lamin B2 elqression 
120 120 
~ 100 ~ 100 
'-' 
c c 
0 80 0 80 
"iii "iii 
III III 
~ ~ 
.. 60 .. 60 Co Co 
;.( ;.( 
~ ~ 
c 40 c 40 
"0; ~ .... 
0 0 
.. 20 .. 20 ~ ~ 
0 0 
II III IV M II III IV M 
Grade Grade 
Figure 3.4 
Figure 3.5 
An immunocytochemical study of lamin distribution in colon tumour cells. Grade II 
(HT29), III (SW948), IV (SW 480) and metastasis (T84) colorectal carcinoma cells were 
fixed in methanol:acetone (1:1) and co-stained with either mAb anti-lamin AlC - JoL2, 
diluted 1: 10 (Figure 3.5.1), rabbit anti-lamin C - RaLC, diluted 1 :20 (Figure 3.5.2), 
goat anti-lamin Bl, diluted 1:25 (Figure 3.5.3) or mAb anti-lamin B2 - LN43, diluted 
1: 10 (Figure 3.5.4) and DAPI to reveal the distribution of DNA. Lamin and DAPI 
staining are displayed separately in black and white micrographs (left panels - A, D, G 
& J and central panels - B, E, H & K) and as a composite image (right panels - C, F, I & 
L) in which lamin staining is shown in red or green, superimposed over DNA staining, 
shown in blue. Scale bar = 10 /lm. 
Figure 3.5.1 - arrows indicate nuclear invaginations. 
Figure 3.5.4 - arrows demarcate lamin B2 positive cells, arrow heads indicate lamin B2 
negative cells. 
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Figure 3.6 
Lamin B2 displays a unique pattern of distribution in SW480 cells which is not 
affected by antibody dilution. HT29 (Figure 3.6.1), SW948 (Figure 3.6.2), SW480 
(Figure 3.6.3). and T84 (Figure 3.6.4) colorectal carcinoma cells were immunostained 
with anti-Iamin B2 - LN43 serially diluted 1:10 (panels A, B and C), 1:25 (panels D, E 
and F), 1:50 (panels G, H and I) and 1:100 (panels J, K and L) after fixation in 
methanol:acetone (1:1). The distribution of DNA was detected by co-staining with 
DAP!. Composite two-colour images (panels C, F, I and L) show lamin expression in 
red, superimposed over DNA staining, identified in blue. Individual black and white 
micrographs show lamin (panels A, D, G and J) and DAPI (panels B, E, H and K) 
staining separately. Scale bar = 10 j.lm. 
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Figure 3.8.3 
Figure 3.7 
Colorectal carcinoma cell lines stained with lamin AlC antibody JoL2 at the lowest 
dilution required for signal. HT29, SW948, SW480 and T84 cells representing tumour 
grades II, III, IV and metastasis respectively were immunostained with mAb JoL2, 
diluted 1:50 after fixation in methanol:acetone (1:1). The distribution of chromatin was 
revealed using DAPI. Panels A, D, G and J show lamin AlC staining. Panels B, E, H 
and K show DNA staining. Panels C, F, I and L show two-colour merged images in 
which antibody staining is shown in red and DAPI staining in blue. Scale bar = 10 Ilm. 
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Figure 3.8 
The expression of lamin A in colorectal carcinoma cells is independent of their 
proliferation status. The relationship between the distribution of A-type lamins and the 
expression of proliferation markers Ki67 and peNA was investigated in four grades of 
colorectal carcinoma by double indirect immunofluorescence. 
Figures 3.8.1 and 3.8.2 
Grade II (HT29 , panels A - e), grade III (SW948, panels D - F), grade IV (SW480, 
panels G - I) and metastasis (T84, panels J - L) colorectal carcinoma cells were fixed in 
methanol:acetone (1:1) and co-stained with either mAb anti-Iamin A - JoL4 (Figure 
3.8.1) or mAb anti-Iamin Ale - JoL2 (Figure 3.8.2) and rabbit anti-Ki67 after 72 hours 
in culture. Panels A, D, G and J show lamin stained images; panels B, E, Hand K show 
Ki67 stained images and panels e, F, I and L show merged images in which lamin is 
presented in green and Ki67 in red. Scale bar = 10 )lm. 
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Figure 3.8.3 and 3.8.4 
Grade II (HT29, panels A - C), grade III (SW948, panels D - F), grade IV (SW480, 
panels G - I) and metastasis (T84, panels J - L) colorectal carcinoma cells were fixed in 
methanol:acetone (1:1) and co-stained with antibodies JoL4 - anti-Iamin A and PCNA 
- human anti-PCNA (Figure 3.8.3) or antibodies JoL2 - anti-Iamin NC and PCNA 
(Figure 3.8.4) after 16 hours in culture. Panels A, D, G and J show lamin stained 
images; panels B, E, Hand K show PCNA stained images and panels C, F, I and L 
show merged images in which lamin is presented in green and PCNA in red. Scale bar = 
10 11m. 
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Figure 3.9 
Analysis of lamin A and C mRNA expression in different grades of colorectal 
cancer by semi-quantitative RT-PCR. One-step RT-PCR was perfonned on 0.1 )lg 
total RNA isolated from three different passages of grade II (HT29) - lane 1, grade III 
(SW948) - lane 2, grade IV (SW480) - lane 3 and metastasis (T84) -lane 4 CRC cell 
lines under non-saturating conditions. Expression of the LMNA gene was investigated 
using primers specific for the lamin A transcript, yielding a 1137 bp product (A) and the 
lam in C transcript, yielding a 993 bp product (B). Equal loading of RNA in each sample 
was verified by monitoring the transcriptional level of ~-actin (C). Primers produced an 
834 bp product. 
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Figure 3.10 
Densitometric assessment of lamin A and C transcript levels. Messenger RNA 
expression levels for lamins A (A) & C (B) in grade II, III, IV and metastasis colorectal 
carcinoma cells was determined by semi-quantitative RT-PCR, followed by 
densitometry. Bands were digitally scanned in a Fujifilm Intelligent Dark Box II 
operated by Image Reader LAS-lOOO Pro Ver. 2.11 software and intensities measured 
using Fujifilm Image Gauge, version 4.0. For each of three replicates, mRNA 
expression was standardized against ~-actin and relative expression of lamin A and C 
transcripts calculated, considering the cell line with the highest band intensity to be 
100%. Values are mean ± standard deviation. 
The level of lamin A mRNA expression in grade III (SW948) cells (mean = 33.0 : 
21.3%) was significantly lower than in grade II (HT29) cells (mean = 96.5 ± 6.0%), t: 
4.97, df = 4, P < 0.01 in 'two-tailed' Student's t-test. The difference in mRNP 
expression between grade III and grade IV (SW480) cells (mean = 79.4 ± 31.2%) an' 
grade III and metastasis (T84) cells (mean = 75.8 ± 28.2%) was not statistical' 
significant. 
Lamin C mRNA expression did not change significantly between grades. Grade 
mean = 45.8 ± 35.3%; grade III, mean = 26.4 ± 16.9%; grade IV, mean = 61.7 ± 37. 
and grade metastasis, mean = 89.3 ± 18.6%. 
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Figure 3.12 
Figure 3.11 
Confirmation of lamin A and lamin C primer specificity. Lamin A and C RT-PCR 
products were sequenced in the reverse direction using an ABI Prism® 377 XL 
automated DNA sequencer. The 3'-most end of the sequences were compared using the 
Nucleotide-nucleotide BLAST database (BLASTN 2.2.11). The figure shows three of 
the highest scoring BLAST hits for the lamin A (A) and lamin C (B) RT-PCR products, 
plus an example sequence alignment for each. The BLAST results show that the lamin 
A RT-PCR products align preferentially with lamin A specific mRNA sequences, while 
the lamin C RT-PCR products align more significantly with lamin C specific mRNA 
sequences. 
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Figure 3.12 
Study of lamin B2 mRNA expression in eRe cell lines by semi-quantitative RT-
peR. Total RNA extracted from cell lines delineating grade II (HT29), III (SW948), IV 
(SW480) and metastasized (T84) colorectal tumours was reverse transcribed and 
subjected to 26 rounds of amplification using primers to a 481 bp fragment of lamin B2 
(A). Equal loading of eDNA in each sample was monitored using primers to an 834 bp 
fragment of ~-actin (B). 
C. Densitometric evaluation of lamin B2 transcript level. Measurements (in arbitrary 
units) for each replicate were nonnalized against ~-actin. Values are average relative 
mRNA expression, considering tumour grade III with the highest copy number to be 
100%. Relative expression of lamin B2 mRNA was 32.2% in grade II cells, 100% in 
grade III cells, 51.8% in grade IV cells, rising to 74.2% in metastasized cultures. 
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8 NCBI \ results of 
A. Lamin A 
Score E 
Sequences producing significant alignments: (Bits) Value 
qi1347827651qb1BC018863.21 
qi1570140461qb1AY847597.11 
qi 1274369451 ref 11m 170707.11 
Homo sapiens lamin A/C, mRNA (cDNA cl 
Homo sapiens lamin A/ C transcript ... 
Homo sapiens lamin A/ C (LMNA), tran 
le-40 
le-40 
le-40 
> 0 qi 1274369451 ref 11m 170707.11 I!IiI Homo sapiens lamin A/C (LMNA) , transcript 
Length=3181 variant 1, mRNA 
Score = 170 bits (86), Expect = le-40 
Identities = 90/92 (97%), Gaps = 0/92 (0%) 
Strand=P lus/P lus 
Query 1 TCGGGGGACCCCGCTGAGTACAACCTGCGCTCGCGCACCGTGCTGTGCGGGACCTGCGGG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 1929 TCGGGGGACCCCGCTGAGTACAACCTGCGCTCGCGCACCGTGCTGTGCGGGACCTGCGGG 
Query 61 CAGCCTGCCGACAANGCATNTGCCAGCGGCTC 92 
11111111111111 1111 111111111111 
Sbjct 1989 CAGCCTGCCGACAAGGCATCTGCCAGCGGCTC 2020 
B. Lamin C 
Sequences producing significant alignments: 
qi 1274369441 ref lID! 005572.21 Homo sapiens lamin A/C (LMNA), tran 
qi1339910681qb1BC000511.21 Homo sapiens lamin A/C, transcript ... 
qi 11869251 qb I H13451. 11 HtJHLM!C Human lamin C mRNA, complete cds 
Score 
(Bits) 
180 
180 
180 
60 
1988 
E 
Value 
le-43 
le-43 
le-43 
> 0 qi 1274369441 ref I rm 005572.21 I!ISI Homo sapiens lamin A/C (LMNA), transcript 
Length=2032 variant 2 , mRNA 
Score = 180 bits (91), Expect = le-43 
Identities = 94/95 (98%), Gaps = 0/ 95 (0%) 
Strand=Plus / Plus 
Query 1 CACTGGGGAAGAAGTGGC CATGC GCAAGCTGGTGC GCTCAGTGACTGTGGTTGAGGAC GA 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 1811 CACTGGGGAAGAAGTGGC CATGC GCAAGCTGGTGC GCTCAGTGACTGTGGTTGAGGAC GA 
Query 61 CGAGGATGAGGATGGAGATGACCTGCTCCCTCACC 95 
11111111111111111111111111111 I II II 
Sbjct 1871 CGAGGATGAGGATGGAGATGACCTGCTCCATCACC 1905 
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Figure 3.13 
Confirmation of lamin B2 primer specificity. Lamin B2 RT-PCR products were 
sequenced in the forward direction using an ABI Prism® 377 XL automated DNA 
sequencer. The sequences in GenBank® with greatest homology were identified using 
the Nucleotide-nucleotide BLAST database (BLASTN 2.2.11). The figure shows three 
of the highest scoring BLAST hits for the lamin B2 RT-PCR products, plus an example 
sequence alignment. 
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results of LAST 
Lamin B2 
Sequences p~oducing significant alignments: 
gi1338735491gb1BC006551.21 Homo sapiens lamin B2, mRNA (cDNA ... 
giI186918Igbl}194362.1IHUMLAMBBA Human lamin B2 (LAMB2) mRNA, pa~ 
giI27436950IreflN}1032737.21 Homo sapiens lamin B2 (LMNB2) , mRNA 
Sco~e 
(Bits) 
198 
198 
198 
> D gi 127436950 I ref INM 032737.21 I!IiI Homo sapiens lamin B2 (LMNB2) , mRNA 
Length=4653 
Sco~e = 198 bits (100), Expect = 5e-49 
Identities = 100/100 (100%), Gaps = 0/100 (0%) 
St~and=Plus/Plus 
Que~y 1 ATGCGGGACGTGATGCAGCAGCAGCTGGCCGAGTACCAGGAGCTGCTGGACGTGAAGCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 1114 ATGCGGGACGTGATGCAGCAGCAGCTGGCCGAGTACCAGGAGCTGCTGGACGTGAAGCTG 
Que~y 61 GCCCTGGACATGGAGATCAACGCCTACCGGAAGCTCCTGG 100 
1111111111111111111111111111111111111111 
Sbjct 1174 GCCCTGGACATGGAGATCAACGCCTACCGGAAGCTCCTGG 1213 
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CHAPTER 4 - STABLE RE-EXPRESSION OF LAMIN A 
CONSTRUCTS IN SW480 COLON CANCER CELLS 
4.1 Introduction 
4.1.1 Embryonic development of the gastrointestinal tract 
Embryonic development is understood to be a highly regulated series of events which 
are subject to fine genetic control (Touchette, 1994; Wolpert, 1994). The key elements 
of vertebrate embryogenesis are cell division, determination, migration, differentiation 
and apoptosis (Raven and Johnson, 1996; Touchette, 1994; Wolpert, 1994). 
Organogenesis is characterized by the differentiation of positioned cells into pre-
determined functional tissues and organs and is accompanied by large-scale cell 
expansion (Raven and Johnson, 1996). The purpose of cell determination, tissue 
patterning and differentiation during development is to make sure a cell identifies with 
and performs the specific function required of it. The consequences of a failure to co-
ordinate developmental signals can be seen in a plethora of human disorders which have 
a broad phenotypic spectrum. Hirschsprung's disease is one such disorder affecting the 
colon. It is characterized by impaired enteric innervation of the large intestine resulting 
in chronic constipation and intestinal obstructions in the infant, often requiring surgery 
immediatel y after birth. This disease is thought to be the result of defects in the 
migratory pattern of neural crest stem cells (NCSCs) which are responsible for the 
formation of the gastrointestinal nervous system. Ordinarily, NCSCs colonize the entire 
developing digestive tract, but in embryos with Hirschsprung's disease they do not 
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reach the primitive hindgut, rendering it incapable of generating a normal, functioning 
nervous system of it own (Iwashita et aI., 2003). 
The vertebrate gastrointestinal tract (GI tract) first appears as a hollow tube of 
undifferentiated stratified endoderm surrounded by undifferentiated splachnic 
mesoderm. The former gives rise to the epithelial lining of the gut, while the latter 
differentiates into the mesenchymal components. The entire structure is innervated by 
the ectoderm-derived enteric nervous system [discussed by Kedinger et al. (1998) and 
de Santa Barbara et al. (2003)]. 
Development of the GI tract is characterized by the patterning of embryonic gut along 
four axes of symmetry [reviewed by de Santa Barbara et al. (2003) and Stanier (2005)]. 
Differentiation along the anterior-posterior or longitudinal axis compartmentalizes the 
gut into three regions known as the foregut, midgut and hindgut which develop into the 
specialized structures of the adult gut along a functional gradient. The pharynx, 
oesophagus and stomach are derived from the foregut, the small intestine originates 
from the midgut and the colon develops predominantly from the hindgut. Part of the 
colon, from caecum to right two-thirds of the transverse colon, is derived from the 
midgut (Sadler and Langman, 2000). Patterning along the dorsoventral and left-right 
axes determines the body position of the digestive organs as well as derivatives of the 
GI tract such as the lungs, liver, pancreas and thyroid which bud from the foregut early 
in embryonic development. Development along the radial axis gives rise to regional 
morphological specialization of the gut epithelium. In the large intestine this results in 
the formation of tubular invaginations, called crypts, interrupted by flat surface 
epithelium (intercrypt table) which maximize the available surface area, facilitating the 
absorptive function of the colon (de Santa Barbara et aI., 2003; Potten et aI., 1997). 
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4.1.2 Genetic control of colonic epithelial morphogenesis and its implications for 
CRC development 
The adult GI tract is radially organized into four histologically distinct layers: the 
mucosa, submucosa, muscularis propria and serosa (Burkitt et ai., 1993). Colonic crypts 
are folds of simple columnar epithelium, analogous to the crypts of Lieberkuhn of the 
small intestine, which form part of the mucosa and are adjacent to the lumenal surface. 
They possess three specialized cell types which are found in the upper part of the crypt: 
mucus-secreting goblet cells, absorptive enterocytes and the less abundant 
enteroendocrine cells which function to lubricate the passage of waste material, absorb 
water and salts and secrete hormones respectively (Marshman et ai., 2002; Potten et ai., 
1997). The differentiated cells are perpetually extruded into the lumen and replenished 
through a process of transit amplification and lineage-specific differentiation of 
multipotent stem cells located in the base of the crypt (Gordon and Hermiston, 1994; 
Marshman et aI., 2002). In the colon, maturing cells migrate unidirectionally from the 
crypt base to the intercrypt table (Marshman et aI., 2002). 
In many ways the perpetual self-renewal of the colonic epithelium, involving 
proliferation of stem cells followed by differentiation, migration and finally 
programmed cell death of mature cells, recapitulates the process of embryonic 
development described above (de Santa Barbara et ai., 2003). Similarly, homeostasis of 
the intestinal epithelium is necessarily kept under tight genetic control through the 
modulation of mUltiple signalling pathways (Radtke and Clevers, 2005; Sancho et ai., 
2004). Likewise, failure to activate or repress the correct signals can result in a 
disastrous outcome. If this occurs within the colonic epithelium, one of the 
consequences is cancer (Radtke and Clevers, 2005; Sancho et aI., 2004). 
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Research into the pathology of colorectal cancer has revealed as much about the 
molecular mechanisms of disease development as it has about the physiological 
maintenance of crypt topology in normal colonic epithelium. Currently the canonical 
Wnt signalling pathway (see Chapter 1, Figure 1.4) is considered to be the most 
significant regulator of normal crypt homeostasis and CRC development (Bienz and 
Clevers, 2000; Giles et al., 2003; Pinto and Clevers, 2005; van de Wetering et ai., 
2002). 
Normal colonic crypts can essentially be divided into three compartments (see Chapter 
5, Figure 5.2). Lying above the stem cell niche located at the crypt base, is the transit 
amplifying region which contains the proliferative progenitor cells. Together they 
occupy the lower two thirds of the crypt. The differentiated region which harbours fully 
functional differentiated cell types is located in the upper third of the crypt and will 
hereafter be additionally described as the villus· (Booth and Potten, 2000; Marshman et 
ai., 2002). The transition from proliferation to differentiation constitutes the crypt-villus 
axis which is maintained by the Wnt signal (Pinto and Clevers, 2005; van de Wetering 
et ai., 2002). 
Wnt factors are secreted glycoproteins thought to emanate in the base of intestinal 
crypts and / or underlying mesenchymal tissue, although their exact location has not 
been determined (Batlle et ai., 2002; Pinto and Clevers, 2005). They pervade the 
• Strictly speaking the colonic epithelium does not possess villi. In the small intestine 
the differentiated epithelial compartment involved in digestion and absorption is 
morphologically distinguishable as a long, finger-like projection (villus) into the gut 
lumen, but this is replaced by flat surface epithelium in the colon (de Santa Barbara et 
ai., 2003). However, explaining the signalling mechanisms which control homeostasis 
in normal colonic epithelium and which become dysregulated in CRC is made simpler 
by referring to the differentiated zone in the epithelium of both the small and large 
intestines as the villus. 
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intestinal epithelium, imposing a proliferative phenotype through FrizzledILRP -
mediated stabilization of the cytoplasmic protein, ~-catenin, leading to transcription of 
Wnt target genes (Logan and Nusse, 2004; Pinto et ai., 2003; Pinto and Clevers, 2005). 
The process is negatively regulated by APC (Korinek et aI., 1997), a key component of 
the multi protein degradation complex which presents ~-catenin for phosphorylation, 
consequently targeting it for ubiquitination by ~-TrCP and subsequent degradation by 
the proteasome in the absence of a Wnt signal (Bienz and Clevers, 2000). In addition to 
APC, the multiprotein degradation complex comprises a scaffold protein, Axin and two 
serine/threonine kinases, GSK3~ and CKI. Upon activation of the canonical Wnt 
signalling pathway [reviewed in depth by Logan and Nusse (2004)], interaction of Wnt 
ligands with their membrane spanning co-receptors, Fz and LRP5/6, at the cell surface 
results in the recruitment of Axin and another protein, Dsh to the plasma membrane. 
Consequently, the multiprotein complex is dissociated, liberating p-catenin and leaving 
it free to translocate to the nucleus. When there is no Wnt signal, members of the 
TCFILEF family of transcription factors are bound to the transcriptional repressor 
Groucho (Cavallo et aI., 1998). In the presence of Wnt, p-catenin overcomes this 
repression by direct association with TCFILEF factors, trans activating the transcription 
of downstream targets (van de Wetering et aI., 1997). 
TCF-4, the most prominently expressed member of the TCFILEF family in epithelial 
cells of the colon, forms functionally active complexes with p-catenin (Korinek et al., 
1997). Latterly the Wnt-induced p-cateninfTCF-4 complex has been described as the 
principal governor of cell dynamics at the crypt-villus junction, preserving a stem cell 
and proliferating progenitor population in the lower crypt region essential for sustaining 
the turnover of differentiated cells at the surface (van de Wetering et aI., 2002). By 
inhibiting the p-cateninfTCF-4 complex with inducible expression of dominant negative 
121 
TCF-4 (dnTCF-4), van de Wetering et al. (2002) were able to demonstrate: First, a 
concomitant G 1 arrest. Second, a down-regulation of intestinal markers of proliferation 
such as EPHB2, c-MYB, BMP4, ENC], CD44 , CLDN] and c-MYC which were known 
to or subsequently shown to be expressed in the proliferative compartment of normal 
crypts. Third, an up-regulation of intestinal markers of differentiation including 
carbonic anhydrase II (CA2), fatty acid binding protein 1, liver (FABP1) and most 
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cateninffCF-4 complex appears to be c-myc which is known to push cells from G 1 to 
S-phase of the cell cycle and is a well-known oncogene (He et ai., 1998; Oster et ai., 
2002). Expression of c-myc at endogenous levels in dnTCF-4 cells caused re-entry into 
the cell cycle and p21 CIP1IWAFl expression was reduced. Thus ~-cateninffCF-4 
complexes appear to maintain a progenitor / stem cell phenotype in intestinal crypts 
through c-myc-mediated repression of the cell cycle inhibitor p21 CIP1IWAFl. ill the 
differentiated compartment the Wnt signal is absent, ~-catenin is exported from the 
nucleus by APC and sequestrated by the aforementioned degradation complex. c-MYC 
is not activated, therefore p21 CIPlIWAFl expression is induced, facilitating cell cycle arrest 
and differentiation (van de Wetering et ai., 2002). 
Immunohistochemical studies have clearly shown accumulation of ~-catenin in the 
nucleus of crypt progenitor cells and in aberrant crypt foci which are the benign 
precursors of colorectal cancer (van de Wetering et ai., 2002). This indicates that Wnt 
signalling is re-initiated in colon tumour cells. In addition, mutations in APC which 
constitutively activate ~-cateninffCF signalling (Korinek et ai., 1997; Morin et ai., 
1997) are estimated to account for 85% of all colorectal tumours (Kinzler and 
V ogelstein, 1996). It has therefore been reasoned that activation of ~-catenin/TCF-4 
may constitute the dominant switch in the malignant transformation of a colon epithelial 
cell by imposing a proliferative phenotype at an early stage (van de Wetering et ai., 
2002). The corollary of this is that the development and progression of colorectal cancer 
is a process of dedifferentiation, as well as increased proliferation. Essentially it is the 
story of a colon epithelial cell losing its identity with the intestine step-by-step and 
could be viewed as development in reverse. 
In the light of my own findings that lamin A is down-regulated in late grade, highly 
dedifferentiated colorectal cancer cell lines (see Chapter 3), it was postulated that loss of 
lamin A may be an important event in the progression of CRC. Fundamentally, lamin A 
provides mechanical support to the nucleus (Aebi et ai., 1986; Broers et ai., 2004). 
However, evidence has been accumulating which suggests that it may also function as a 
regulator of gene transcription (Csoka et ai., 2004; Hutchison, 2002; Spann et ai., 
2002). Consequently a DNA microarray approach seemed the most effective method to 
investigate the downstream implications of a loss of lamin A and thereby determine if 
lamin A affects global gene expression of CRC-associated genes in a way that promotes 
dedifferentiation, hyperproliferation and disease advancement. 
4.1.3 DNA microarray analysis 
4.1.3.1 Relevance to this study 
The development of cancer involves the accumulation of genetic mutations over a long 
period of time. Colorectal cancer is no exception (Fearon and Vogel stein, 1990). 
Research carried out over the last decade has also brought scientists attention to the 
possible role of epigenetic changes as the result of DNA promoter methylation in the 
123 
progression of cancer (Herman and Baylin, 2003; Jones and Laird, 1999). For example, 
CpG island promoter hypermethylation of the iamin Ale gene in leukaemias and 
lymphomas has been correlated with abrogation of lamin A expression at the level of 
transcription and has been associated with poor survival in diffuse large B-cell 
lymphomas (Agrelo et ai., 2005). It was speculated that loss of lamin A may have an 
equivalent epigenetic influence on the development of CRe. In summary, where cancer 
is concerned a complicated picture emerges in which the expression of mUltiple genes 
can be affected as the result of direct mutation and/or by epigenetic silencing. 
To investigate all possible genetic aberrations in cancer using traditional techniques is 
inconceivable, hence the development of genetic expression micro array technologies 
has revolutionized our understanding of the cancer genome because they can evaluate 
changes in expression of thousands of genes at once (Basik et ai., 2003; Clarke et ai., 
2001; Stremmel et ai., 2002). DNA micro arrays have enabled high-throughput 
identification of novel diagnostic and prognostic indicators which would not have been 
discovered otherwise (Agrawal et ai., 2002; Dhanasekaran et ai. 1 2001; Korkola et ai., 
2003). Additionally they have enabled classification of tumours according to their 
genetic signature (Fuller et ai., 2002; Golub et ai., 1999; Korkola et ai., 2005; Perou et 
at., 2000) and allowed genome-wide investigations into chemotherapeutic drug targets 
(Marton et ai., 1998; Scherf et ai., 2000) which is necessary if new treatments are to be 
found. 
In 2002 a US research group performed oligonucleotide arrays on different stages of 
colon cancer and identified osteopontin as a possible marker of tumour progression out 
of a total of 8900 genes on the chip (Agrawal et ai., 2002). Most micro array studies like 
this one aim to screen for the activity of as many genes as possible. Affymetrix 
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GeneChip® technology now offers the ESTs of the whole human genome, that is 
approximately 33,000 genes, on one chip. While this all-encompassing approach leaves 
no stone untumed, it is highly unlikely that any more than 10% of the genome will be 
differentially regulated at anyone time. Furthermore, micro array analysis on this scale 
can produce copious amounts of insignificant data which must be processed. Therefore, 
it was reasoned that a targeted micro array approach would best suit the purpose of this 
chapter. To this end, a unique chip was created in-house comprising 325 genes. 
4.1.3.2 Selection of genes for the Colorectal Cancer Oligonucleotide Chip 
The genes included on our Colorectal Cancer Chip were organized into functional 
groups and are tabulated in Appendix II, A. The list was assembled by myself and Dr 
Rekha Rao, a former post-doctoral scientist in our laboratory. It was the product of both 
a review of the literature as it stood at the end of 2002 and to a larger extent 
contributions made by Prinicipal Investigators at the School of Biological and 
Biomedical Sciences, University of Durham. The result was an oligonucleotide chip 
comprising 325 genes. The majority of the genes were associated with either intestinal 
epithelial morphogenesis, maintenance of the proliferative and differentiated 
compartments of mature crypts, the promotion of colorectal cancer or had been 
established as commonly affected in neoplasms. This included important tumour 
suppressor genes and oncogenes. Given the involvement of other researchers in 
developing this list, there were inevitably a few genes included on the basis of personal 
interest alone and consequently expression in normal colon or colorectal tumours was 
not expected. One such example is FOXE3 which is expressed exclusively in lens 
epithelial cells (Blixt et aI., 2000). However, due to the strict localization of its 
expression, FOXE3 could be considered an unorthodox negative control. 
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A large proportion of the chip was made up of downstream targets of the Wnt-activated 
~-cateninffCF-4 complex which were identified using DNA microarray analysis by van 
de Wetering et al. (2002). Canonical Wnt signalling has been implicated in the control 
of the intestinal crypt-villus axis and appears to be turned on in the earliest stages of the 
disease (van de Wetering et ai., 2002). [N.B. One downstream target of the p-
cateninffCF-4 complex, c-MYC and the upstream regulator of p-catenin levels, APC 
were not placed in the Wnt signalling group because they are recognized oncogenes and 
were classified according to this function (see Appendix II, A).] All the genes were 
divided into 22 different groups in all. 
The following gene sets are also particularly noteworthy. Fifty-two genes known to be 
involved in early stem cell differentiation were included on the chip because our 
laboratory had previously identified differential expression of a subset of these genes in 
cells expressing different levels of lamin A (unpublished). The cell cycle progression / 
cell proliferation and growth cluster of genes was compiled because an increase in their 
expression would generally indicate loss of proliferative control, therefore they were 
prime candidates for alteration in colorectal cancer. The number of nucleoskeletal and 
cytoskeletal genes added to this chip reflects the common interest of the main research 
groups in our department who contributed genes to the final list. The requisite positive 
(p-actin and GAPDH) and negative controls (Oct4 / POU5F1 and muscarinic receptors, 
M1 - MS) were naturally incorporated into the array. 
4.1.4 Summary 
This chapter describes a genomic study which was undertaken to understand the 
implications of lamin A dysregulation in colorectal cancer cells. This included RNA 
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profiling using microarray analysis with a colorectal cancer-specific oligonucleotide 
chip. This approach was employed on lamin A-transfected SW480 cells versus control 
cells to study how changes in lamin A levels would affect global gene expression. 
4.2 Results 
4.2.1 Establishment of GFP-reporter transfected SW480 cell lines 
Previously (Chapter 3) I showed by western blotting and immunofluorescence that 
lamin A expression is diminished in SW948 and SW480 colon carcinoma cells. To 
explore the downstream implications of this molecular change on the expression of 
genes associated with intestinal epithelial morphogenesis and colorectal cancer, SW480 
cells were transfected with three different enhanced GFP-reporters. (SW480 cells were 
chosen because they were easier to culture and individual cells could be visualized at 
relatively low magnification.) These included GFP-Iamin A, GFP-emerin and GFP. 
Both GFP-emerin and GFP were originally intended to be controls. Emerin is one of a 
group of lamina-associated proteins responsible for the association of the nuclear lamina 
with the inner nuclear membrane (Vaughan et ai., 2001) and is mutated in X-linked 
Emery-Dreifuss muscular dystrophy (Bione et aI., 1994). No role has been reported for 
emerin in tumourigenicity. 
Forty-seven GFP-Iamin A, 12 GFP-emerin and six GFP stably transfected clones were 
successfully scaled up and the percentage of GFP positive cells was examined. Six 
GFP-Iamin A (11, 12, 1a3, 2c3, 1b4 and 2bb3), three GFP-emerin (1, 2 and 3) and two 
GFP (1 and 2) clones with 100% of cells expressing the GFP-reporter (Figure 4.1) were 
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selected and maintained in culture. The GFP-Iamin A clones were grouped on the basis 
of GFP fluorescence intensity. Clones 11, 12 and Ib4 had low expression, clones la3, 
2c3 and 2bb3 had medium expression. The intention was to investigate changes in gene 
expression in lamin A negative cells versus cells expressing lamin A equivalent to the 
normal endogenous level. Accordingly, cells strongly expressing GFP-Iamin A were 
rejected as this represented a commensurate over-expression of lamin A. 
4.2.2 Endogenous lamin A and emerin remains localized to the nuclear membrane 
in GFP-reporter transfected cell lines 
Sub-confluent GFP-reporter transfected cells were fixed in Paraformaldehyde and 
stained with monoclonal anti-emerin (GFP-Iamin A clones), anti-Iamin A - lolA (GFP-
emerin clones) or both (GFP clones) (Figure 4.1). Endogenous emerin staining was 
strongly associated with the nuclear rim in both GFP-Iamin A and GFP transfected cells. 
Endogenous lamin A was located at the nuclear rim in GFP transfected cells, but 
appeared also in the cytoplasm of GFP-emerin transfected cells. All GFP fusion proteins 
localized predominantly to the nucleus. Only GFP-emerin showed some cytoplasmic 
localization. 
4.2.3 Expression levels of lamin A, emerin and GFP-reporters in transfected cell 
lines 
Protein expression profiles were determined for endogenous and exogenous lamin A, 
emerin and GFP in each of the selected clonal lines: SW480 GFP-Iamin A 11, 12, la3, 
2c3, Ib4 and 2bb3; SW480 GFP-emerin 1, 2 and 3 and SW480 GFP 1 and 2 (Figure 
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4.2.1). No endogenous lamin A was present in SW480 GFP 1 cells and it was barely 
detectable in SW480 GFP 2, GFP-emerin 1 and GFP-Iamin A 1a3 cells. Generally, 
more endogenous lamin A was present in GFP-emerin and GFP-Iamin A transfected 
clones, compared to GFP transfected clones, possibly due to the stabilization of 
endogenous lamin A by GFP-emerin and GFP-Iamin A. SW480 GFP-Iamin A clones 
2bb3 and 12 showed appreciable levels of GFP-Iamin A fusion protein. Expression was 
highest in 2bb3 cells, effectively doubling the endogenous level of lamin A (Figure 
4.2.1, A). 
Endogenous emenn expressIOn levels were variable, but generally higher in GFP-
emerin transfected clones and clonal lines with the highest level of GFP-Iamin A 
reporter (clones 2bb3 and 12), suggesting reciprocal stabilization of endogenous emerin 
by the GFP forms of both emerin and lamin A (Figure 4.2.1, B). Cells transfected with 
GFP expressed the lowest levels of emerin. Blotting with anti-GFP antibodies 
confirmed the variation in GFP-reporter expression between clones which had been 
identified using anti-Iamin A and anti-emerin antibodies (Figure 4.2.1, C). 
Clones over-expressmg GFP-Iamin A were excluded by visual screen. From the 
remaining clones SW480 GFP-Iamin A 2bb3, GFP-emerin 2 and GFP 2, which 
expressed the highest level of their respective GFP fusion protein, were selected for 
comparison using micro array analysis. These cell lines were compared on the same 
western blot (Figure 4.2.2) which confirmed that GFP 2 cells expressed almost no 
endogenous lamin A (Figure 4.2.2, A). In GFP-emerin 2 cells endogenous lamin A 
levels were eqivalent to the combined amount of endogenous and exogenous lamin A in 
GFP-Iamin A 2bb3 cells. Consequently, rather than functioning as a negative control, 
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SW480 GFP-emerin 2 represented a second cell line expressing essentially normal 
levels of lamin A and therefore equivalent to SW480 GFP-Iamin A 2bb3 in that respect. 
4.2.4 Up-regulation of lamin A promotes an epithelial-like phenotype 
To begin to determine the consequences of re-expressing lamin A in SW480 cells, cell 
morphology was investigated using phase contrast microscopy (Figure 4.3). There were 
significant differences between the morphology of SW480 GFP 2, GFP-emerin 2 and 
GFP-Iamin A 2bb3 clones in culture. GFP 2 cells displayed an identical phenotype to 
untransfected SW480 cells: Cells grew in multiple layers and were not contact inhibited. 
However, GFP 2 cells did appear to grow more slowly than the parental cell line, 
probably due to the load placed on the cells by the large GFP construct. A complete 
rescue of an epithelial-like phenotype was achieved by transfecting SW480 cells with 
GFP-Iamin A. Cells grew in a monolayer and contact inhibition was reintroduced. 
Transfection of GFP-emerin appeared to constitute a partial rescue of a more normal, 
epithelial-like phenotype; the vast majority of the culture grew as a monolayer, but the 
presence of multinucleated cells persisted. 
Next, cell growth characteristics were investigated in each cell line by flow cytometry 
(Figure 4.4). Forward and side scatter analysis revealed a reduction in cell size 
variability and granularity in GFP-emerin 2 and GFP-Iamin A 2bb3 cells compared to 
GFP 2 cells (Figure 4.4, panels a, c & e). This correlated with the rescue of a more 
normal epithelial morphology in these two clonal lines. There were, however, no 
statistically significant differences in cell cycle distribution between cell lines (Figure 
4.4, panels b, d & f). 
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A common feature of all the transfected cell lines and SW480 untransfected cells was 
the propensity of the cells to dislodge from the culture substrate, resulting in an adherent 
and a floating population of cells. It was hypothesized that this may be the result of 
apoptosis. However, flow cytometry revealed no pre-G 1 peak: (Figure 4.4, panels b, d & 
f) and ultrastructural studies of the cells uncovered no other evidence that apoptosis was 
occuring in any cell population (Figure 4.5). However electron microscopy did reveal 
an increased incidence of nuclear invaginations in SW480 GFP 2 cells compared to all 
other cells lines. This could be the result of a malfunctioning nuclear lamina due to the 
lack of lamin A, consequently reducing the ability of the nucleus to maintain its shape. 
Additionally there appeared to be a loss of peripheral heterochromatin in SW480 
untransfected cells compared to SW480 GFP-lamin A 2bb3 cells. 
4.2.5 Lamin A facilitates the maintenance of an epithelial-like phenotype through 
down-regulation of the cytoskeletal protein synemin 
A microarray was designed comprising 325 genes associated with intestinal epithelial 
homeostasis and colorectal / general cancer development and progression. The 
construction ofthe array is described in Section 4.1.3.2. Three-way pair-wise analysis of 
the gene expression profiles of SW480 GFP 2, GFP-emerin 2 and GFP-Iamin A 2bb3 
cells was performed as detailed in Figure 4.6. Equal quantities of control and test RNA 
of suitable quality (Figure 4.7) were labelled with Cy3 and Cy5 fluorescent dyes 
respectively and hybridized to specific oligonucleotide sequences immobilized on a 
glass chip. Arrays were laser-scanned producing a dotted image of gene activity (Figure 
4.8). Hybridization was quantified by measuring the fluorescence from each fluor. 
Differences in expression of each gene were calculated as a ratio of Cy5 / Cy3 and 
given as a fold change. (The average fold change for each gene in each replicate array is 
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tabulated in Appendix II, D.) All genes less than 1.5 fold up- or down-regulated in each 
array were excluded from further analysis. The remaining genes which were expressed 
1.5 fold higher or lower in test versus control samples are shown in Table 4.1. The most 
reproducible results were obtained for the intermediate filament proteins synemin and 
paranemin, the oncogenes c-myc and c-raf, the stem cell marker REST and ribosomal 
protein L31. Synemin, paranemin, c-MYC and c-RAF appeared to be down-regulated in 
cells expressing the highest levels of lamin A, whereas REST and RPL31 appeared to be 
up-regulated. The positions of four of these genes on the microarray are indicated in 
Figure 4.8. 
To corroborate the relationship between expression of synemin, c-MYC, c-RAF and 
RPL31 and the level of lamin A, semi-quantitative RT-PCR was carried out on the same 
RNA samples used in the microarray experiments (Figure 4.9). Densitometric 
assessment confirmed that down-regulation of synemin mRNA correlated with 
increased expression of lamin A (Figure 4.10, A). The amount of synemin transcript 
was significantly reduced in SW480 GFP-Iamin A 2bb3 cells compared to GFP 2 cells 
(P < 0.05). However, RT-PCR showed that c-myc, c-raf and RPL31 mRNA levels were 
similar in all cell lines (Figure 4.10, B - D). Primer specificity was demonstrated by 
sequencing all RT-PCR products (Figure 4.11). 
4.3 Discussion 
The implications of a loss of lamin A in colorectal cancer cells was investigated using 
the SW480 cell line which had been shown previously (Chapter 3) to express 
diminished levels of lamin A relative to the more differentiated cell line HT29, but 
retain lamin C. Transfection of these cells with GFP-emerin or GFP-Iamin A elevated 
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the levels of lamin A and rescued an epithelial-like phenotype in culture which was 
completely absent from untransfected and GFP transfected SW480 cells. GFP-Iamin A 
transfected cells in particular displayed increased uniformity in size and growth 
characteristics. Altogether these observations suggested that loss of lamin A may be 
important in the development of colorectal cancer through a direct or indirect influence 
on cell morphology. 
To understand how lamin A may influence cell morphological changes in the 
development of colorectal cancer, RNA profiles of three GFP-reporter transfected cell 
lines expressing increased levels of lamin A (cell lines SW480 GFP-Iamin A 2bb3 and 
SW480 GFP-emerin 2) or no lamin A (cell line SW480 GFP 2) were compared using 
micro array analysis with a unique colorectal cancer-specific oligonucleotide chip. Fifty-
seven percent of the genes (186 out of 325) on the chip showed differential regulation in 
at least one microarray experiment and of these, changes in expression of six genes 
were reproducible. Four leads were followed up. Primers to c-MYC, c-RAF, synemin 
and RPL31 were used to amplify cDNA transcribed from the original RNA samples 
used in the microarray analyses. Using the robust technique of RT-PCR, a significant 
down-regulation in synemin between SW480 GFP 2 and SW480 GFP-lamin A 2bb3 
cells was confirmed. However, changes in expression of the other three genes were not 
confirmed. 
Collectively these data suggest that lamin A does not have a role in the Wnt signalling 
pathway because expression of c-MYC, which is directly regulated by the downstream 
target of Wnt, ~-catenin, and promotes proliferation (van de Wetering et ai., 2002), 
remained unchanged in the transfected cell lines. Consistent with this observation, cell 
proliferation indices also remained unaltered. However, RT-PCR confirmation of 
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changes in the mRNA levels of synemin indicates that the phenotypic manifestations of 
lamin A down-regulation observed in cultured cells may reflect alterations in the 
cytoskeleton. 
Communication between the nuclear matrix and cytoskeleton can be achieved through 
two possible mechanisms: The nuclear pore complex (Allen et aI., 2000; Stoffler et aI., 
1999) or integral proteins of the nuclear envelope which bridge the gap between the 
nucleoskeleton and the cytoskeleton (Padmakumar et aI., 2004; Zhen et aI., 2002). 
Nesprins have emerged as important proteins hypothesized to connect the nuclear 
lamina to elements of the microfilament system in the cytoplasm (Libotte et aI., 2005). 
Similar to other members of the a-actinin superfamily, nesprin-l giant, which is also 
known as Enaptin (Padmakumar et aI., 2004), and nesprin-2 giant, which is also termed 
NUANCE (Zhen et aI., 2002), are able to bind to actin fibres and facilitate actin 
bundling by virtue of their N-terminal a-actinin-related actin binding domain (ABD) 
(Padmakumar et aI., 2004; Zhen et aI., 2002). What distinguishes nesprins from other 
members of the spectrin family is their C-terminal Klarsicht-like domain (KLS) which 
contains a transmembrane domain (TMD) and targets the proteins to the nuclear 
membrane (Padmakumar et at., 2004; Zhang et ai., 2001; Zhen et at., 2002). 
Localization of nesprin-2 giant to both sides of the nuclear envelope has been 
demonstrated, as well as direct interaction of nesprin-2 giant with both lamin AlC and 
emerin (Libotte et at., 2005; Zhen et at., 2002). Likewise nesprin-l giant and nesprin-la 
[previously named syne-l (Apel et aI., 2000) and myne-l (Mislow et aI., 2002a)] 
immunostaining has been detected at the nuclear membrane of smooth and skeletal 
muscle and found to overlap with that of lamin AlC and emerin (Mislow et aI., 2002a; 
Zhang et aI., 2001). In addition, direct interaction between nesprin-l a, lamin A and 
emerin has been shown by Mislow et a1. (2002b), as well as cytoplasmic staining of 
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nesprin-l giant in COS7 cells (chick cardiac myocytes) (Padmakumar et ai., 2004). 
Based on this evidence Libotte et al. (2005) have proposed a model in which giant 
nesprin isoforms congregate at the ONM, where they bind actin, and at the INM, where 
they interact with nuclear lamin AlC and emerin and lie in close proximity to 
heterochromatin. Via UNC-84/Sun and other hitherto unidentified peripheral and 
integral membrane proteins nesprins are predicted to form molecular bridges between 
lamins, emerin and the actin cytoskeleton. If this is the case alterations in nucleoskeletal 
elements might be expected to have an impact on the form and function of the 
cytoskeleton. 
Synemin was originally identified as an IF-associated protein (IFAP) , but was later 
demonstrated to be a unique member of the IF superfamily and possess the 
characteristic -310-amino acid IF rod domain (Becker et ai., 1995; Bellin et ai., 1999). 
Based on its domain structure it has been classified as a type VI intermediate filament 
protein (Mizuno et ai., 2001; Steinert et ai., 1999). Synemin is believed to require one 
or both of type III IF proteins desmin and vimentin to assemble and functions as an 
effective cytoskeletal cross-linker (Bellin et ai., 1999; Bilak et ai., 1998). As such it 
could be very important in maintaining cytoskeletal architecture. 
Synemin was first identified in avian smooth muscle (Granger and Lazarides, 1980). 
Two splice variants of the human synemin gene have been identified, a and p (Titeux et 
ai., 2001). In mouse a third, smaller isoform has recently come to light (Xue et ai., 
2004). The majority of research has focused so far on understanding the nature of 
synemin's heteropolymeric interactions in muscle (Bellin et ai., 1999; Bilak et ai., 1998; 
Mizuno et aI., 2004), however work by ling et al. (2005) now suggests a role for 
synemin in promoting tumourigenicity. ling and co-workers showed that a- and p-
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synemin were expressed at higher levels in reactive and malignant astrocytes compared 
to normal brain tissue. They reported that all astrocytoma tissues reacted with synemin 
antibodies, independent of grade. Additionally they found that a- and ~-synemin were 
differentially increased in some glioblastoma cell lines. Generally a-synemin appeared 
predominately up-regulated with comparable variation in expression seen at the mRNA 
level. Interestingly, in these cell lines synemin was found to associate specifically with 
a-actinin in ruffled membranes which are actin-rich semicircular leading edges 
important in cell motility. Both nesprin-l giant and nesprin-2 giant isoforms have also 
been immunodetected in membrane ruffles / leading edges (Padmakumar et aI., 2004; 
Zhen et ai., 2002). Nesprin-l was shown to largely colocalize with the actin-binding 
protein a-actinin, while nesprin-2 colocalized with the actin networks. Taken together 
this evidence suggests a dual role for nesprins and synemin in cell motility. 
Cell motility is an important aspect of carcinogenesis and facilitates metastasis. Changes 
to nuclear shape, including elongation and enlargement, and polarity are strong 
indicators of dysplasia in colorectal cancer. Experiments by Zhen et ai. (2002) have, in 
the first place, implicated nesprin-2 giant in the control of nuclear shape. Drug-induced 
depolymerization of the actin cytoskeleton in COS7 cells resulted in aberrant nuclear 
morphology and perinuclear accumulations of nesprin-2 giant and actin, suggesting 
nesprin-2 functions to mediate control of nuclear shape by the actin cytoskeleton. 
(Interestingly, irregularly shaped nuclei which also presented several invaginations were 
a feature of GFP-transfected SW480 cells which expressed almost no endogenous lamin 
A.) The nesprin-la isoform was first identified as a novel protein which selectively 
associated with the nuclear envelope of synaptic nuclei of smooth and striated 
myotubes, therefore it was considered most likely to be involved in the migration and/or 
anchorage of myonuclei at the postsynaptic apparatus (Apel et aI., 2000). Due to the 
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strong sequence homology between nesprin-la and nesprin-2 giant, Zhen et al. (2002) 
have proposed a similar function for nesprin-2 although a direct connection remains to 
be investigated. 
Expression profiles of human nesprin-l giant and nesprin-2 giant transcripts have been 
analysed by probing a human multiple tissue expression array (Padmakumar et ai., 
2004; Zhen et aI. , 2002). With respect to the colon, the following was discovered. 
Healthy colon tissue expressed medium levels of nesprin-l and low levels of nesprin-2. 
In the colon carcinoma cell line SW480 they reported no change in the level of nesprin-
2 compared to normal tissue, but a down-regulation of nesprin-l to an almost 
undetectable amount. The same panel of cancer cells lines were tested by both groups 
and it was noticeable that all expressed little or no nesprin-l and the majority had only 
traceable amounts of nesprin-2. 
At this point only tentative proposals can be made regarding the possible connection 
between lamin A, located on the nucleoplasmic face of the nuclear envelope; synemin, 
which has so far only been reported in the cytosol and the maintenance of cellular 
integrity. Loss of lamin A affects nuclear and cellular morphology in SW480 cells. A 
normal epithelial-like phenotype can be rescued by transfection of lamin A and to a 
lesser extent emerin. RNA profiling of 325 genes predicted to have some importance in 
the development and progression of colon cancer revealed that synemin was 
significantly down-regulated in lamin A positive versus lamin A negative cells. It has 
been noted that synemin is expressed in reactive and neoplastic astrocytes, but not in 
normal astrocytes (ling et aI. , 2005), suggesting that expression of synemin may 
promote a tumourigenic phenotype. It is therefore plausible that lamin A expression 
may promote a more normal epithelial-like phenotype in SW480 cells by influencing 
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the expression of cytoskeletal linker proteins, such as synemin. Nesprins, by virtue of 
their affinity for lamin polypeptides and a-actinin and their prominence on both sides of 
the nuclear envelope, have emerged as the most likely mediators of lamin A -
cytoplasmic IF interaction. 
Of course it should not be forgotten that this chapter has only examined the expression 
of synemin at the mRNA level. Future work should focus on determining whether 
equivalent changes in synemin expression are seen at the protein level. The data 
presented in this chapter suggests further investigations into the expression of other 
cytoskeletal proteins and their organization with respect to the expression of nuclear 
lamins will be highly beneficial to our understanding of nucleoskeletal - cytoskeletal 
communication. 
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4.4 Figures 
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Figure 4.1 
Comparative assessment of the localization of endogenous lamin A and emerin in 
SW480 cells transfected with one of GFP-Iamin A, GFP-emerin or GFP. One 
hundred percent stable transfection of SW480 colorectal cancer cells with GFP-Iamin A 
(A), GFP-emerin (B) and GFP (C & D) was achieved (shown in green) as a result of 
antibiotic selection and subsequent single cell cloning of positive cells. The GFP-
reporters localized to the nucleus. Endogenous emerin expression (shown in red) in 
GFP-Iamin A and GFP transfected cells was strongly associated with the nuclear rim. 
Similarly, endogenous lamin A expression (shown in red) was specific to the nuclear 
periphery in GFP transfected cells, as determined by staining with the mAb JolA, but 
was more heterogeneous in GFP-emerin transfected cells. Here, lamin A expression 
appeared to be both nucleoplasmic and cytoplasmic. Nuclear shape was uniformly 
round in GFP-Iamin A transfected cells, but varied in GFP-emerin and GFP transfected 
cells which generally presented elongated, oval shaped nuclei. DNA was stained with 
DAPI (shown in blue) and a three-colour merge of the green, red and blue channels was 
created and shown in the final column. Scale bar = 10 J..lm. 
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Figure 4.1 
Figure 4.2 
Quantitative characterization of GFP-reporter, endogenous A-type lamin and 
endogenous emerin expression in transfected SW 480 clones. 
Figure 4.2.1 
Whole cell extracts from two GFP (lanes 1 & 2), three GFP-emerin (lanes 3 - 5) and six 
GFP-Iamin A transfected clones (lanes 6 - 11) were resolved on 10% (A) or 12% (B & 
C) SDS-PAGE, transferred to nitrocellulose and immunoblotted with mAb JoL2 - anti-
lamin NC (A), monoclonal anti-emerin (B) and monoclonal anti-GFP (C). Equal 
loading was confirmed by co-blotting for p-actin (A). Molecular weight markers (M) 
are given in kDa. 
Transfected SW 480 clones run in each lane: 
Lane Transfected SW480 clone 
lane 1 SW480 GFP 1 
lane 2 SW480GFP2 
lane 3 SW480 GFP-emerin 1 
lane 4 SW480 GFP-emerin 2 
lane 5 SW480 GFP-emerin 3 
lane 6 SW480 GFP-Iamin A la3 
lane 7 SW480 GFP-Iamin A 2c3 
lane 8 SW480 GFP-Iamin A Ib4 
lane 9 SW480 GFP-Iamin A 2bb3 
lane 10 SW480 GFP-Iamin All 
lane 11 SW480 GFP-Iamin A 12 
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Figure 4.2.2 
SW480 GFP 2 (lane 1), GFP-emerin 2 (lane 2) and GFP-Iamin A 2bb3 (lane 3) cells 
were selected on the basis of their GFP-reporter expression. Whole cell extracts were 
resolved on 10% (A) or 12% (B & C) SDS-PAGE, transferred to nitrocellulose and 
immunoblotted with mAb loL2 - anti-Iamin NC (A), monoclonal anti-emerin (B) and 
monoclonal anti-GFP (C). Equal loading was confirmed by co-blotting for p-actin (A). 
Molecular weight markers (M) are given in kDa. 
142 
A 
B 
c 
209 
120 
99 
M 
53 -
38 
29 
M 
209 
120 
99 
,-
_ J 
38 
29 
19 
M 
209 -
120 
99 
53 -
38 -
29 -
19 -
2 3 
+- GFP-lamin A 
+- lamin A 
+- lamin C 
_ _ _ +- ~-actin 
2 
2 
3 
3 
+- GFP-emerin 
+- emerin 
+- non-specific hand 
+- GFP-Iamin !\ 
+- GFP-emerin 
- +- GFP 
Figure 4.2.2 
Figure 4.3 
Morphology of SW 480 parental cell line and its transfected derivatives. Phase 
contrast images of SW480 colon carcinoma cells (far left panel), found previously to 
express minimal lamin A, were transfected with GFP, GFP-emerin or GFP-Iamin A 
using Statagene's GeneJammer® tranfection protocol. Stably transfected cells were 
selected using Geneticin ® antibiotic and cloned out by limited dilution. Three specific 
clones identified as GFP 2, GFP-emerin 2 and GFP-Iamin A 2bb3 were chosen on the 
basis of their GFP-reporter expression, as determined by western analysis (see Figure 
4.2) and were used in all subsequent experimental work. Clear morphological 
. differences were apparent between the cell lines in culture and are presented in the 
panels entitled GFP transfected, GFP-emerin transfected and GFP-Iamin A transfected 
respectively. 
Transfection of colon carcinoma cells with GFP had no effect on cell morphology - the 
entire culture continued to display highly disorganized, multi-layered growth (A). A 
partial rescue of SW480 cells was achieved by the transfection of GFP-emerin - the 
majority of cells grew in a monolayer, although there was a high proportion of 
multinucleated cells (B). A complete rescue of cell morphology was achieved when 
GFP-Iamin A was transfected. Normal epithelial growth was observed - cells grew in a 
monolayer and there was no evidence of stratified growth. Compared to GFP-emerin 2, 
the proportion of multinucleate cells (B) was very small. 
Images were captured at lOX (panel I) and 20X (panel II) objective magnification. Scale 
bars = 20 )lm (panel I) and 10 )lm (panel II). 
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Figure 4.4 
Cell cycle characteristics of GFP-reporter transfected SW480 colorectal cancer 
cells. Growth rate, cell size and granularity of GFP, GFP-emerin and GFP-lamin A 
transfected SW480 cell lines GFP 2, GFP-emerin 2 and GFP-lamin A 2bb3 were 
examined by flow cytometry. Cells were fixed in ice-cold methanol upon reaching 70% 
confiuency and stained with 25 ~glml Propidium iodide. Data for more than 10,000 
single cell events were collected. Left panels (a, c & e) show forward scatter (FS) versus 
side scatter (SS); right panels (b, d & f) show PI fluorescence relative to cell number 
(count). Cells in GO/G 1 are indicated by gate E, cells in S-phase, by gate F and cells in 
G21M, by gate G. 
Panels a, c and e showed appreciable differences in overall cell size and granularity 
between the transfected cell lines. GFP 2 cells varied markedly in cell dimension and 
granularity, while the GFP-emerin 2 cell population was less heterogeneous. GFP-lamin 
2bb3 cells displayed the greatest uniformity in cell size and granularity. Differences 
between the proportion of transfected cells in GO/G 1 phase of the cell cycle (given as 
mean ± s.d. of three replicates) were not statistically significant (P > 0.05 - 'two-tailed' 
Student's t-test), demonstrating that morphological variation had no impact on growth 
rate. 
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Figure 4.5 
Transmission electron micrographs of untransfected and transfected SW480 cells. 
70 - 80% confluent cultures of SW480 colon cancer cells (first column) and their stably 
transfected derivatives SW480 GFP 2 (second column), SW480 GFP-emerin 2 (third 
column) and SW480 GFP-Iamin A 2bb3 (fourth column) were separated according to 
their adherence to the tissue culture substrate and prepared for electron microscopy 
using Kamovsky's method. There was no evidence of apoptosis in either the adherent 
(top panels) or floating (bottom panels) population of cells, but pronounced cytoplasmic 
blebbing, particularly in transfected cells which had been dislodged from the culture 
surface, was observed. GFP 2 cells exhibited prominent nuclear invaginations (arrows). 
Scale bar = 2 !lm, except GFP-emerin transfected 'floating' cell, bar = 5 !lm. 
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Figure 4.4 
SW480 untransfected GFP transfected GFP-emerin transfected GFP-lamin A transfected 
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Figure 4.6 
Schematic overview of glass slide microarray analysis. A selection of 332 
oligonucleotides, representing 325 different genes, were robotically spotted in 
quadruplicate in pre-defined locations on a glass slide, creating a DNA chip. 
Differential levels of corresponding RNA transcripts in transfected SW480 cancer cells 
were measured by means of simultaneous, two-colour fluorescence hybridization on the 
chip. The relative intensity of fluorescence signals determined the direction and order of 
magnitude of any change in gene expression. 
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GLASS SLIDE MICROARRAY ANALYSIS 
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displayed as a coloured dot plot. Fluorescence measurements 
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Figure 4.6 
Figure 4.7 
Quality and purity of total RNA used in microarray experiments. Total RNA was 
extracted from three different passages of SW480 GFP 2 (lanes 1,4 & 7), SW480 GFP-
emerin 2 (lanes 2, 5 & 8) and SW480 GFP-Iamin A 2bb3 (lanes 3, 6 & 9) cells using 
TRI Reagent™. Quality was verified by gel electrophoresis. All the hallmarks of good 
quality RNA were demonstrated. The 28S and 18S ribosomal RNA bands were clearly 
distinguished, the 28S band being at least twice the intensity of the 18S band. No 
evidence of DNA contamination or RNA degradation was apparent. RNA purity was 
determined by measuring the ratio of absorbance in 10 mM Tris-Hel, pH 7.5 at 260 and 
280 nm (A2601280). An A2601280 >1.8 indicates very pure RNA. Only one RNA sample 
(lane 7) did not meet this specification. M - RNA size markers, shown in kilobases (kb). 
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Figure 4.7 
Figure 4.8 
Two-colour dot plots of hybridized microarrays. For each microarray experiment 
hybridized chips were scanned in a GeneTACTM LS IV Biochip Analyzer and Cy5 
fluorescence signals superimposed over Cy3 fluorescence signals. Green spots 
correspond to genes down-regulated in test versus (vs) control cells. Red spots 
correspond to genes up-regulated in test vs control cells. Genes expressed at 
approximately equal levels in both cell lines appear yellow. The position of the replicate 
spots for the four genes encoding RPL31, synemin, c-raf and c-myc, which showed 
significant fold changes between SW480 GFP 2 (labelled GFP) , GFP-emerin 2 
(labelled Emerin) and/or GFP-Iamin A 2bb3 (labelled Lamin A) cell lines, are 
highlighted. A red arrow indicates the gene was significantly up-regulated, a green 
arrow indicates the gene was significantly down-regulated. Example microarray dot 
plots shown: A. Lamin A (test) vs GFP (control); B. Emerin (test) vs GFP (control) and 
C. Lamin A (test) vs emerin (control). 
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A. Lamin A vs GFP 
RPL31 synemm c-raf c-myc 
B. Emerin vs GFP 
RPL31 synemm c-raf c-myc 
c. Lamin A vs Emerin 
RPL31 synemm c-raf c-myc 
Figure 4.8 
Table 4.1 
Genes expressed 1.S fold higher or lower in microarray analyses. Three-way pair-
wise analysis of differential gene expression in SW480 GFP 2, GFP-emerin 2 and GFP-
lamin A 2bb3 cells (denoted GFP, Emerin and Lamin A respectively) identified 185 
genes which were either 1.5 fold up- or down-regulated in one or more microarray 
experiments. Pair-wise analysis was repeated three times. For each replicate (denoted 1, 
2 or 3) the genes expressed at least 1.5 fold higher (Up) or lower (Down) in test 
compared to control samples are indicated by a black dot. The most reproducible 
changes were observed for the genes REST, paranemin, synemin, c-MYC, c-RAF and 
RPL31, highlighted in grey. 
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Table 4.1 All genes differentially expressed by at least 1.5 fold. 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up Down Up Down 
Gene symbol 112 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 Gene description 
A]2oQtosis and aQoQtotic inhibitors 
AMID/PRG3 • • p53-responsive gene 3 
BAKI • BCL2-antagonistlkiller 1 
CASP3 • • • caspase 3, apoptosis-related cysteine protease 
CAST • calpastatin 
FASLG • Fas ligand (TNF superfamily, member 6) 
LITAF • lipopolysaccharide-induced TNF factor 
NCKAP 1 / NAP 1 • NCK-associated protein I 
TNFRSF10A /TRAILRI • tumor necrosis factor receptor superfamily, member lOa 
Cell adhesion 
CTNNAl • • catenin (cadherin-associated protein), alpha I, 102kDa 
Cell cvcle progression / cell t roliferation and growth 
CCNAl • cyclin AI 
CCNBI • cyclin Bl 
CCNB2 • • cyclin B2 
CCNDl • cyclin DI 
CCND3 • • cyclin D3 
CDC2 • cell division cycle 2, G I to Sand G2 to M / cdk I 
CDKNIB • cyclin-dependent kinase inhibitor lB (p27, Kip I) 
CHKl • checkpoint kinase Chkl 
CHK2 • checkpoint kinase Chk2 
CSPG2 • • • chondroitin sulfate proteoglycan 2 (versican) 
EGF • • epidermal growth factor 
FGF5 • • fibroblast growth factor 5 
Table 4.1 cont 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up Down Up Down 
Gene symbol 11213 11213 112 3 1 2 3 1 2 3 1 2 3 Gene description 
Cell cycle Qrogression I cell Qroliferation and growth cont. 
GPC3 • • glypican 3 
IGF2 • • insulin-like growth factor 2 (somatomedin A) 
TGFA • transforming growth factor, alpha 
TGFBI / BIGH3 • transforming growth factor, beta-induced, 68kDa 
VEGF • vascular endothelial growth factor 
Cytoskeleton and nucleoskeleton 
ACTGl • actin. gamma 1 
KRTl • • keratin 1 
KRTl8 • keratin 181 Genbank® accession no. NM 000224 
KRT8 • keratin 81 Genbank® accession no. X74929 
LCPl • • • lymphocyte cytosolic protein 1 (L-plastin) 
LMNA (lamin C) • lamin C I GenbankQ9 accession no. X03445 
LMNBI • lamin Bl 
MACFI • microtubule-actin cross linking factor I 
NEBL • nebulette 
NEFH • neurofilament, heavy polypeptide 200kDa 
Iparanemin • • • • • IparllOemiri " . 
,', 
-,;.r.o, ", I • • 
PLS3 • • • plastin 3 (T isoform) 
PPL • • periplakin 
ISYN • • • • • • • synemin 
'''; , I 
TMPO (A) • thymopoietin alpha I lamina-associated polypeptide 2 alpha 
TMPO (B) • • • thymopoietin beta I lamina-associated polypeptide 2 beta 
TUBB2 • tubulin, beta 2 
TUBG • tubulin, gamma 1 
VCL • vinculin 
VIL2 • villin 2 (ezrinL 
- - -- - - --------
Table 4.1 cont. 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up Down Up Down 
Gene symbol 11213 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 Gene description 
Cytoskeleton and nucleoskeleton cont. 
VIM • vimentin 
DNA reQlication and reQair 
ATM • ataxia telangiectasia mutated 
MLHI • • mutL homolog 1, colon cancer, nonpolyposis type 2 
MSH2 • mutS homolog 2, colon cancer, nonpolyposis type I 
NBSI • Nijmegen breakage syndrome I (nibrin) 
PARPI • poly (ADP-ribose) polymerase family, member I 
PRKDC • • DNA-dependent protein kinase catalytic subunit 
RPAl • replication protein AI, 70kDa 
XRCC4 • DNA-repair protein XRCC4 
XRCC5 • • Ku autoantigen, 80kDa 
Extracellular matrix: comQonents, Qrocessing, cellular attachment, Qroteases and Qrotease inhibitors 
BGN • • biglycan 
COLlA2 • collagen, type I, alpha 2 Genbank® accession no. NM 000089 
FN]IFN • • fibronectin, aIt splice I Genbank® accession no. X0276 1 
HPSE • • • heparanase 
ITGA] • • integrin, alpha I 
ITGA2 • integrin, alpha 2 
ITGA3 • integrin, alpha 3 
ITGAV • • integrin, alpha V (vitronectin receptor) 
ITGB] • • integrin, beta I 
LAMA4 • laminin, alpha 4 
LAMB] • • • laminin, beta 1 
MMP]4 • • matrix metalloproteinase 14 (membrane-inserted) 
MMP3 • matrix metalloproteinase 3 (stromelysin J, progelatinase) 
----
-~ 
- -- --
Table 4.1 cont. 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up 1 Down Up Down 
Gene symbol 11213 11213 112[31[213 112[3 1[213 Gene description 
Extracellular matrix: components, processing, cellular attachment, proteases and protease inhibitors cont 
SDC4 • syndecan 4 (amphiglycan, ryudocan) 
SPP] • secreted phosphoprotein I (osteopontin) 
TIMP] • tissue inhibitor of metalloproteinase 1 
Oncogenes 
ABLl • v-abl Abelson murine leukemia viral oncogene homolog I 
HRAS • v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
JUN • • • v-jun sarcoma virus 17 oncogene homolog 
KRAS • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
MOS • v-mos Moloney murine sarcoma viral oncogene homolog 
IMYC 
, 
• • " ~:mY:Cmyetp~Yt9rnatosis' viraloricogene hom.olog ' , I • • - , ~, • • , 
MYCN • N-myc proto-oncogene protein 
IRAFI • 
"'i 
' . . - i' ,'" 
• • 
.' 
vCl'afJl ' niiitine leukeiniaviraloncogene homolog 1 > 
" 
- '- " I 
SRC • • v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
Protein translation, Qrocessing, transQort and degradation 
AIM] • • absent in melanoma I 
E1F3S2 • eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa 
hsp20 • Sequence 109 from Patent W09954460 / hsp 20 
HSP70-] • heat shock 70kD protein I 
HSPA8 / HSC70 • • constitutive heat shock protein 70 
HSPB2 • heat shock 27kDa protein 2 
NUP]53 • nucleoporin 153kDa 
RPL2] • ribosomal protein L21 
lRPL31 • • • • • • • • ribosomal protein L31 
-- ---
-1......- -- -_ 
- -
Table 4.1 cont 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up I Down Up Down Up Down 
Gene symbol 1\2\3 1\2 3 1 2 3 1 2 3 1 2 3 1 2 3 Gene description 
Regulation of gene eXQression {transcriQtion} 
GTF3A • general transcription factor IlIA 
RARA • retinoic acid receptor, alpha 
RXRA • retinoid X receptor, alpha 
TCFl • transcription factor 1, hepatic 
TCF4 • • transcription factor 4 
ZFP9l • • • zinc finger protein 91 homolog (mouse) 
Signal transduction 
CCR7 • • • chemokine (C-C motif) receptor 7 
CDl4 • CD 14 antigen 
FCGR2B • IGFR2 / Fc fragment of IgG, low affinity lIb, receptor 
GNAL • G-s-alpha / guanine nucleotide binding protein (G protein) 
MAPKl • mitogen-activated protein kinase 1 
PlK3CG • phosphoinositide-3-kinase, catalytic, gamma polypeptide 
PTK2BIPKB • PTK2B protein tyrosine kinase 2 beta 
RAC1 • rho family, small GTP binding protein Racl 
RGS2 • • Regulator of G-protein signaling 2 (GO/G 1 switch regulatory protein 8) 
TlAMl • T-cell lymphoma invasion and metastasis I 
Stem cell differentiation 
ANlL • astrocytic NOV A-like RNA-binding protein 
ASTN • • Astrotactin 
BMP4 • bone morphogenetic protein 4 
BMP6 • bone morphogenetic protein 6 
CR1PTO • cripto protein 
FNJ • • cellular fibronectin / Genbank® accession no. M10905 
FUT1 • • fucosyltransferase I 
-- --
_ .. . -
Table 4.1 cont . 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up Down Up Down 
Gene symbol 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 Gene description 
Stem cell differentiation cont. 
FUT2 • fucosyltransferase 2 (secretor status included) 
GAP43 • growth associated protein 43 
GJA1 • gap junction protein, alpha 1, 43kDa (connexin 43) 
LAMB 1 • • • laminin, beta 1 
MAPTITAU • • microtubule-associated protein tau 
MASH1 • Achaete-scute homolog 1 
MASH2 • • • achaete-scute complex-like 2 
MYOD1 • myogenic factor 3 
NEFL • neurofilament, light polypeptide 68kDa 
NEFM • • • Neurofilament medium polypeptide 
NES • • nestin 
NEUROD2 • neurogenic differentiation 2 
NEUROD3 • • • neurogenic differentiation 3 
NEUROD4 • neurogenic differentiation 4 
NHLH2 • • nescient helix loop helix 2 
NOTCH2 • • Notch homolog 2 (Drosophila) 
NSE • • Neuron-specific enolase 
PAX6 • • • • paired box gene 6 (aniridia, keratitis) 
PLP • • proteolipid protein 
iREST • • • • • • RE I-silencing transcription factor I 
SOX1 • SRY (sex determining region Y)-box 1 
SOX17 • SRY (sex determining region Y)-box 17 
SOX2 • SRY (sex determining region Y)-box 2 
SYP • synaptophysin 
T • • T, brachyury homolog (mouse) 
TDGF1 • teratocarcinoma-derived growth factor 1 
TF • transferrin 
_.- --
-
Table 4.1 cont 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up Down Up Down 
Gene symbol 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 Gene description 
Stem cell differentiation cont. 
VTN • • vitronectin 
Stress resQonse 
SODI • superoxide dismutase 1, soluble 
SOD2 • • superoxide dismutase 2, mitochondrial 
TransQorters, carriers 
A TP2A3 • ATPase, Ca++ transporting, ubiquitous 
SLCI6AI • solute carrier family 16 (monocarboxylic acid transporters), member I 
SLC2AI / GLUTI • solute carrier family 2 (facilitated glucose transporter), member 1 
Tumour sUQQressor genes 
APC • adenomatosis polyposis coli 
DCC • deleted in colorectal carcinoma 
RBI • • • retinoblastoma 1 
TP53 • • tumor protein p53 (Li-Fraumeni syndrome) 
Wnt signalling 
BIRC5 • apoptosis inhibitor 4 - survivin 
CDKNIA • cyclin-dependent kinase inhibitor lA (p21, Cipl) 
CEACAMI / BGPI • • carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotei 
CHAFlA • chromatin assembly factor I, subunit A (p 150) 
CLDNI • claud in I 
CLDN4 • • • claudin 4 
DLEUJ • • deleted in lymphocytic leukemia, I 
ENCI • • • ectodermal-neural cortex (with BTB-like domain) 
EPHBl • EPH receptor B I 
Table 4.1 cont. 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up Down Up Down 
Gene symbol 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 Gene description 
Wnt signalling cont. 
EPHB2 • EPH receptor B2 
ET52 • v-ets erythroblastosis virus E26 oncogene homolog 2 
FABP] • fatty acid binding protein I, liver 
GPX2 • glutathione peroxidase 2 (gastrointestinal) 
JPO] / LOC442] 72 • • c-Myc target JPO I 
MCM3 • MCM3 minichromosome maintenance deficient 3 
MUC2 • mucin 2, intestinal/tracheal 
MYB • Myb proto-oncogene protein (C-myb) 
PRKCD • protein kinase C, delta 
RBBP4 • retinoblastoma binding protein 4 
5CFIKITLG • • stem cell factor / kit ligand precursor / Mast cell growth factor (MGF) 
TCOFl • • Treacher Collins-Franceschetti syndrome I 
UNG • uracil-DNA glycosylase 
Xenobiotic and drug metabolism / detoxification 
ABCB] • • P glycoprotein l/multiple drug resistance I 
Miscellaneous enzymes 
PTG52/COX2 • prostaglandin-endoperoxide synthase 2 (cyc\ooxygenase) 
51 • sucrase-isomaltase (alpha-glucosidase) 
Miscellaneous 
CLCNKB • chloride channel Kb 
TIB • T-18 
Function not well elucidated 
KLRBJ • NKR-PIA 
-
Table 4.1 cont. 
Lamin A vs GFP Emerin vs GFP Lamin A vs Emerin 
Up Down Up Down Up Down 
Gene symbol 112 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 Gene description 
Function not well elucidated cont. 
LGALS2 • • galectin 2 
PROXI • • prospero-related homeobox 1 
REGIB • regenerating protein I beta 
RSAD2 • • • radical S-adenosyl methionine domain containing 2 / cig5 / viperin 
ZBTBl6 • PLZF / zinc finger and BTB domain containing 16 
Negative controls 
CHRM2 • • cholinergic receptor, muscarinic 2 
CHRM5 • cholinergic receptor, muscarinic 5 
Figure 4.9 
Expression of synemin, c-myc, c-raf and RPL31 in GFP-Iamin A, GFP-emerin and 
GFP transfected SW480 colon carcinoma cells. Microarray analysis identified 
reproducible changes in the levels of six RNA transcripts, four of which were further 
investigated by semi-quantitative RT-PCR. Primers were designed to amplify synemin 
(A), c-myc (B), c-raf (C) and RPL31 (D) in cell lines GFP 2 (lane 1), GFP-emerin 2 
(lane 2) and GFP-lamin A 2bb3 (lane 3). RT-PCR products were distinguished 
according to their size: Synemin - 518 bp, c-myc - 557 bp, c-raf - 589 bp and RPL31 -
322 bp. Equal loading of starting material was verified by monitoring the transcriptional 
activity of ~-actin (E), seen as an 834 bp product. M = DNA size markers, shown in 
base pairs (bp). 
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Figure 4.9 
Figure 4.10 
Semi-quantitative RT -PCR confirmed a down-regulation of synemin in GFP-Iamin 
A compared to GFP transfected SW480 colon carcinoma cells. Messenger RNA 
expression levels for synemin (A), c-myc (B), c-raf (C) and RPL31 (D) in GFP 2 
(GFP), GFP-emerin 2 (GFP-emerin) and GFP-Iamin A 2bb3 (GFP-Iamin A) cells 
were determined by semi-quantitative RT-PCR, followed by densitometry. Bands were 
digitally scanned (Fujifilm Intelligent Dark Box II) using Fujifilm Image Reader LAS-
1000 Pro Ver. 2.11 software and quantified in Fujifilm Image Gauge, version 4.0. For 
each transcript three replicate RT-PCRs were completed. Messenger RNA expression 
was normalized against p-actin and relative expression of synemin, c-myc, c-raf and 
RPL31 was calculated. Values are mean ± standard deviation. 
Differences in c-myc, c-raf and RPL31 expression between cell lines GFP 2, GFP-
emerin 2 and GFP-Iamin A 2bb3 were not statistically significant. However, the 
reduction in synemin rnRNA levels in GFP-Iamin A 2bb3 cells (mean = 45.5 ± 30.7%) 
compared to GFP 2 cells (mean = 100 ± 0.0%) is statistically significant (t = 3.07, df= 
4, P < 0.05 in 'two-tailed' Student's t-test). 
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Figure 4.11 
Nucleotide - nucleotide BLAST results for synemin, c-myc, c-raf and RPL31 RT-
PCR products. Confirmation that the products amplified by RT-PCR from SW480 
GFP 2, GFP-emerin 2 and GFP-lamin A 2bb3 cell lines using synemin-, c-myc-, c-raf-
and RPL31-specific primers were genuine was sought. Each product was sequenced 
with the corresponding antisense primer using an ABI Prism® 377 XL automated DNA 
sequencer. The resulting sequences were compared with those on the BLASTN database 
and the three most significant hits and one example alignment are shown for synemin 
(A), c-myc (B), c-raf (C) and RPL31 (D). 
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~ '. ~ NCBI .~ results of 
A. Synemin 
Score E 
Sequences producing significant alignments: (Bi ts) Value 
qi1186983231emb1AJ310522.11HSA310522 Homo sapiens mRNA for synem 198 
ai1186983211emb1AJ310521.11HSA310521 Homo saniens mRNA for svnem 198 
qi1220276371refl~r 145728.11 Homo sapiens desmuslin (DMN), trans 198 
5e-49 
5e-49 
5e-49 
> []giI18698323IembIAJ310522 .1IHSA310522 IB Homo sapiens mRNA for synemln (SYN gene ) , 
Length=7337 isoform H 
Score = 198 bits (100), Expect = 5e-49 
Identities = 100/100 (100%), Gaps = 0/100 (0%) 
Strand=Plus/Plus 
Query 1 ATCATCAACCTCGGCCTGAAAGGGAGGGAGGGGAGAGCAAAGGTCGTCAACGTGGAGATC 60 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 2299 ATCATCAACCTCGGCCTGAAAGGGAGGGAGGGGAGAGCAAAGGTCGTCAACGTGGAGATC 2358 
Query 61 GTGGAGGAGCCCGTGAGTTATGTCAGCGGGGAGAAGCCGG 100 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I " I I I I I I I 
Sbjct 2359 GTGGAGGAGCCCGTGAGTTATGTCAGCGGGGAGAAGCCGG 2398 
B. c-myc 
Score 
Sequences producing significant alignments: (Bits ) 
qi1546964011qb1BT019768.11 Homo sapiens v-myc myelocytomatosi .. . 198 
qil315432151refiNM 002467.21 Homo sapiens v-myc myelocytomato .. . 198 
qi1348151emb1V00568.11HSUYCl Human mRNA encoding the c-myc oncog 198 
E 
Value 
5e-49 
5e-49 
5e-49 
> 0 gi 1348151 emb I V00568. 11 HSUYCI I!IiII Human mRNA encoding the c-myc oncogene 
Length=2121 
Score = 198 bits (100), Expect = 5e-49 
Identities = 100/100 (100%), Gaps = 0/100 (0%) 
Strand=Plus/Plus 
Query 1 CCAGCTTGTACCTGCAGGATCTGAGCGCCGCCGCCTCAGAGTGCATCGACCCCTCGGTGG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 1079 CCAGCTTGTACCTGCAGGATCTGAGCGCCGCCGCCTCAGAGTGCATCGACCCCTCGGTGG 
Query 61 TCTTCCCCTACCCTCTCAACGACAGCAGCTCGCCCAAGTC 100 
1111111111111111111111111111111111111111 
Sbjct 1139 TCTTC CCCTACCCTCTCAACGACAGCAGCTC GCCCAAGTC 1178 
Figure 4.11 A & B 
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1138 
~ ' ' ,~ NCBI .. ,' results of LAST 
c. c-raf 
Sequences producing significant alignments: 
giI52486392Irefl~! 002880.21 Homo sapiens v-raf-l murine leuk .. . 
gi1341909371gb1BC018119.21 Homo sapiens v-raf-l murine leukem .. . 
gi1358411emb1X03484.11HSRAFR Human mRNA for raf oncogene 
> D gi 1358411 emb IX03484.11HSRAFR Dill Human mRNA for raf oncogene 
Length=2977 
Score = 198 bits (100), Expect = 5e-49 
Identities = 100/ 100 (100%), Gaps = 0/100 (0%) 
Strand=Plus/Plus 
Score 
(Bits ) 
198 
198 
198 
Query 1 TGCGTCTTTGATTGGAGAAGAACTTCAAGTAGATTTCCTGGATCATGTTCCCCTCACAAC 
111111111111111111111111111111111111111111111111111 111111 111 
Sbjct 483 TGCGTCTTTGATTGGAGAAGAACTTCAAGTAGATTTCCTGGATCATGTTCCCCTCACAAC 
Query 61 ACACAACTTTGCTCGGAAGACGTTCCTGAAGCTTGCCTTC 100 
1111111111111111111111111111111111111111 
Sbjct 543 ACACAACTTTGCTCGGAAGACGTTCCTGAAGCTTGCCTTC 582 
D. RPL31 
Sequences producing significant alignments: 
gi1476826831gb1BC070373.11 Homo sapiens ribosomal protein L31 ... 
gi1361291emb1X15940.11HSRPL31 Human mRNA for ribosomal protein L 
giI15812219Irefl~! 000993.21 Homo sapiens ribosomal protein L31 
Score 
(Bits) 
198 
198 
198 
E 
Value 
5e-49 
5e-49 
5e-49 
60 
542 
E 
Value 
5e-49 
Se-49 
5e-49 
> Dgil158122191refiNM 000993.21 Dill Homo sapiens ribosomal protein L31 (RPL31 ) , 
Length=442 mRNA 
Score = 198 bits (100), Expect = 5e-49 
Identities = 100/100 (100%), Gaps = 0/100 (0%) 
Strand=Plus/Plus 
Query 1 GGTAACCCGAGAATACACCATCAACATTCACAAGCGCATCCATGGAGTGGGCTTCAAGAA 
11111111111111111111111111111111111111111111111111111111 1111 
Sbjct 87 GGTAACCCGAGAATACACCATCAACATTCACAAGCGCATCCATGGAGTGGGCTTCAAGAA 
Query 61 GCGTGCACCTCGGGCACTCAAAGAGATTCGGAAATTTGCC 100 
1111111111111111111111111111111111111111 
Sbjct 147 GCGTGCACCTCGGGCACTCAAAGAGATTCGGAAATTTGCC 186 
Figure 4.11 C & D 
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CHAPTER 5 - IMMUNOmSTOCHEMICAL ANALYSIS OF A-
TYPE LAMIN EXPRESSION IN COLORECTAL TUMOURS 
5.1 Introduction 
5.1.1 Comparative value of using cell lines and tissue sections to study tumour 
progression 
Human tumour-derived cell lines have proven themselves valuable models for studying 
the development and progression of cancer, as well as the efficacy and molecular 
pharmacology of potential anti-carcinogenic drugs [for example, Compagni and 
Christofori (2000), Ethier (1996), Paraskeva et al. (1990), Scherf et at. (2000) and 
Weinstein et al. (1997)]. Cancer cells, once established, are generally easy to grow in 
culture and provide an endless supply of living material with which to test scientific 
hypotheses. However their ability to faithfully maintain the same genotype / phenotype 
as that associated with the class or stage of tumour from which they were originally 
isolated has been called into question (Hewitt et at., 2000; Virtanen et aI., 2002). Indeed 
it is prudent to consider that tumour cells grown in vitro on a plastic substrate, 
sometimes for over one hundred passages, may well lose some characteristics associated 
with the original tumour and possibly gain other attributes through further genetic 
mutations and/or chromosome trans locations which have been reported in older · 
cultures. However, evidence also suggests that many cancer cell lines do retain a 
genotype / phenotype which is representative of their progenitor tumour, despite long-
tenn passage in vitro. Using cDNA micro array analysis Virtanen et al. (2002) have 
shown that lung cancer cell lines derived from small cell lung cancer and squamous cell 
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carcmoma generally display similar genetic signatures to their fresh tumour 
counterparts, such that they could be clustered accordingly. In another study, Hewitt et 
al. (2000) demonstrated that culture to a high passage number had no affect on the 
phenotypic features of two colorectal cancer cell lines. SW620 cells, which were 
originally explanted from a lymph node metastasis, were found to be poorly 
differentiated, more invasive and tumourigenic and to express a higher proliferation 
index compared to SW480 cells which were derived from a Dukes' B / Broders' grade 
IV carcinoma. 
Comparatively few investigations have been undertaken to explore the nature of nuclear 
lamin expression in human neoplastic tissue and cell lines. The majority of studies that 
have been published concentrate on lung cancer (Broers et al., 1993; Kaufmann et al., 
1991; Machiels et al., 1995) and keratinocytic tumours of the skin (Oguchi et ai., 2002; 
Tilli et aI., 2003; Venables et aI., 2001). Encouragingly, in a study carried out by Broers 
et al. (1993) single label immunofluorescence and immunoblot analyses on lung cancer 
cell lines indicated a loss of A-type lamin expression in SCLCs compared to non-
SCLCs which was later corroborated by immunoperoxidase staining of equivalent 
neoplastic tissues. This strongly suggests that neoplastic cell lines can prove accurate 
representative models for the examination of lamin expression in cancer. 
Accordingly our investigations into the expression pattern of lamins in CRC began in 
cell lines representing Broders' grade II, III and IV and metastasis. This work is 
described in detail in Chapter 3 of this thesis. Preliminary findings in these cells lines 
suggested that lamins A and C were differentially expressed during the progression of 
colorectal cancer towards metastasis. While lamin C expression appeared unchanged, 
lamin A was down-regulated in cell lines representing grade III and grade IV tumours. 
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These cell lines, SW948 and SW480, are also known to be derived from Dukes' C and 
Dukes' B stage adenocarcinomas respectively (Leibovitz et ai., 1976). Loss of lamin A 
expression did not appear to be related to proliferation, but rather cellular 
dedifferentiation. No changes in expression of lamin B 1 were observed. Although 
alterations in the levels of lamin B2 were clearly evident they did not follow a logical 
pattern, therefore it seemed that the contrasting patterns of lamin A and lamin C 
expression in the cell lines most warranted confirmation in colorectal tumour tissue. 
5.1.2 Summary 
In this chapter an immunohistochemical study of lamin AlC distribution in normal and 
malignant colorectal tissue is presented. Three anti-Iamin antibodies, loL2, RaLC and 
133A2, were used. Both loL2, which recognizes the lamin AlC common domain (Dyer 
et ai., 1997), and RaLC, which is lamin C specific (Venables et ai., 2001), were also 
used to chart A-type lamin expression in CRC cell lines in the first results chapter. 
Monoclonal antibody 133A2 was used exclusively for immunohistochemistry (IHC) in 
this chapter and detects only lamin A. Its epitope lies in the carboxy terminus of lamin 
A, between amino acids 598 and 611 (Hozak et ai., 1995). 
5.2 Results 
5.2.1 Immunohistochemistry methodology 
Immunoperoxidase staining of tissue sections first requITes the sequestration of 
endogenous peroxidase activity, followed by a process of antigen retrieval (AR). The 
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two methods used most frequently to re-expose epitopes are proteolytic digestion and 
heating. AR by heating can be achieved using a microwave, pressure cooker, steamer, 
autoclave or water bath (Barker et ai., 1999; Igarashi et ai., 1994; Kawai et ai., 1994; 
Shi et ai., 1991; Taylor et ai., 1996). Although microwave heating is the most widely 
used method this is due more to its simplicity and time efficiency (Mighell et ai., 1995), 
rather than any perceivable difference in the quality of staining compared to that 
produced using other heating devices (Taylor et ai., 1996). Additionally comparative 
studies have shown that AR by microwave heating produces superior staining results to 
enzyme digestion (Hazelbag et ai., 1995), particularly after long periods of fixation 
(Cattoretti et ai., 1993; Kahveci et aI., 2003). 
Despite the reported advantages of using microwave AR, I opted to use water bath 
heating to regenerate lamin epitopes. The reasons for this were two-fold. First, Barker et 
al. (1999) had already demonstrated successful antigen retrieval in colonic epithelium 
using the water bath method. Second, our own trials showed that water bath heating was 
significantly more gentle on tissues compared to microwave heating. Microwave 
heating consistently damaged the outer edge of the tissue sections tested, reducing the 
area available for effective staining and analysis by approximately 10 - 20%. 
Accordingly the method described by Barker et ai. (1999) was adopted without making 
any alterations to their AR protocol. 
5.2.2 Distribution of A-type lamin polypeptides in normal colonic tissue 
The gastrointestinal tract is radially organized into four histological layers: the mucosa, 
submucosa, muscularis propria and serosa (Burkitt et ai., 1993). Immunoperoxidase 
staining of ultra-thin sections of healthy human colon with anti-Iamin AlC antibody, 
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JoL2, showed that A-type lamins were expressed in a broad range of cell types and were 
always nuclear specific. Particular attention was paid to the two uppermost layers of 
colon histology (Figure 5.1). In the mucosa JoL2 decorated epithelial cells of the crypts 
and smooth muscle cells of the muscularis mucosae, as well as the majority of stromal 
cells. In the submucosa endothelial cells surrounding blood vessels were also positive 
for lamin NC. In contrast, A-type lamin expression was not detected in infiltrating 
lymphocytes or lymphoid aggregates which thus constituted an internal negative 
control. This observation was not unexpected. B-type lamins are thought to be the sole 
components of the nuclear lamina in early human haematopoietic lineages, a 
phenomenon which has been frequently observed in immature, proliferating T- and B-
lymphocytes (Cance et aI., 1992; Guilly et aI., 1987; Jansen et aI., 1997; Paulin-
Levasseur et aI., 1988). 
The pattern of expression of lamins A and C in healthy colonic epithelium was 
examined in detail. Using JoL2 a clear gradient of expression from the crypt base to the 
intercrypt table was observed (Figures 5.1 & 5.2). Lamin NC was not completely 
absent from cells in the stem cell compartment, but was expressed very weakly. Low 
level expression was often maintained up to the mid-crypt point (that is, in the bottom 
20 - 50% of cells). The transient amplifying region is characterized by rapid 
proliferation of precursor cells (Marshman et aI., 2002; Potten and Loeffler, 1990). This 
zone generally exhibited a steady, yet relatively incremental augmentation in lamin NC 
expression, although an increase in staining intensity was often only perceivable from 
the mid-crypt point upwards. Intense up-regulation of A-type lamin expression was 
restricted specifically to the top 20% of the crypt. While specimen to specimen variation 
in the degree of lamin NC staining in the lower 80% of the crypt was encountered, a 
dramatic increase in lamin NC expression was consistently observed in the top 20% of 
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the crypt and, as such, appears to be connected to the differentiated state of cells in this 
region. The expression of lamin A and lamin C was also investigated independently 
(Figure 5.2). The results obtained exactly mirrored the pattern of expression identified 
by JoL2. Additionally, it is worth noting that in normal epithelium Iamin staining was 
always most intense at the nuclear rim. 
5.2.3 Immunohistochemical analysis of colorectal neoplasms reveals differential 
expression of lamins A and C in metastatic tumours 
A-type lamin reactivity patterns were evaluated in relation to the clinical pathology of 
CRe. A small scale trial study incorporating two Dukes' stage A, 10 Dukes' stage B, 11 
Dukes' stage C, two Dukes' stage D and 11 distant metastasis of colorectal carcinoma 
was set up. Serial sections of tumour were single-stained by immunoperoxidase with 
antibodies raised against lamin AlC, lamin A and lamin e. Subsequent microscopic 
analysis revealed variation in lamin AlC staining (as determined by JoL2) between 
different stages and amongst tumour samples classified into the same 
clinicopathological category (Table 5.1 & Figure 5.3). Overall, expression of lamin 
AlC was very low in Duke's stage A tumours and at a medium level in Dukes' stage D 
tumours. However, due to the limited availability of these tumours, it is not possible to 
draw any definite conclusions. Instead it is more meaningful to focus on the Dukes' B, 
C and metastatic tumours for which a larger selection of samples were available. The 
majority of Dukes' stage B tumours expressed 'very low' levels of lamin AlC, whereas 
most Dukes' C tumours exhibited higher expression levels which were categorized as 
either 'low' or 'medium'. For the main part, metastatic tumours reacted most strongly 
with lamin AlC antibodies. Furthermore, staining was noticeably more heterogeneous in 
Dukes' C and metastatic tumours compared to those in the Dukes' B set. Independent of 
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stage, the staining of stomal cells was generally maximal with very little or no 
heterogeneity. 
The expression of individuallamin polypeptides was assessed using antibodies to lamin 
A (133A2) and lamin C (RaLC) (Table 5.1 & Figure 5.3). These investigations 
confirmed that both lamin A and lamin C follow a similar pattern of expression in 
Dukes' B and Dukes' C tumours, similar to that outlined by immunoperoxidase staining 
with JoL2. However, the reactivity patterns of individual A-type lamins appear to 
diverge in tumours removed from secondary sites. While the intensity of lamin C 
staining varied greatly between metastatic specimens, lamin A expression appeared to 
be preferentially down-regulated. Ninety percent of the samples examined displayed 
very low or no retrieval of lamin A antigens, whereas only 55% of samples expressed 
equally low levels of lamin C. 
The colon carcinoma metastases used in this study were from different secondary sites. 
In Table 5.1 all the metastases were clustered together to facilitate the assessment of the 
general nature of lamin expression during the progression of CRC. However, following 
the observation that lamin A is down-regulated relative to lamin C in most of the 
metastasis samples, I was intrigued to know whether the site of metastasis had any 
bearing on the expression level of lamin A. Therefore in Table 5.2 the metastases are 
subdivided according to their location and accompanying levels of lamin AlC, lamin A 
and lamin C expression are tabulated. 
All liver metastases had very low or absent expression of lamin A, generally medium 
levels of lamin AlC and an inconsistent pattern of lamin C expression, in that at least 
one specimen was assigned to each value on the intensity scale. Although the metastasis 
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to the pancreas / duodenum went against the trend of all the other samples and exhibited 
medium / high levels of lamin A, lamin C and lamin AlC, more data from the same site 
is required to determine if this is a predictable feature. 
5.2.4 Down-regulation of A-type lamins in malignant polyps correlates with 
changes in nuclear morphology 
Investigations into lamin AlC expression in the context of dysplasia were limited to the 
Dukes' A specimens. Both these specimens were malignant polyps which contained 
some area of relatively normal epithelium, therefore direct comparisons could be made 
between expression of lamins A and C in normal versus dysplastic tissue. Regions 
harbouring normal crypt-like structures could be found at the outer edge of these polyps 
juxtaposed dysplastic tissue. Normal epithelium is characterized by small, round nuclei 
with basal polarity. Clinically, nuclear morphology is a well-established marker of 
dysplasia. Enlargement and elongation of nuclei, concomitant with migration towards 
the apical pole are classic identifiers of dysplastic behaviour. On the whole expression 
of A-type lamins in these polyps was either very low or absent (Table 5.1 & Figure 5.3, 
panels A - C). Closer inspection revealed that expression of A-type lamins was strongly 
related to nuclear morphology. Lamin A expression was lost and lamin AlC staining 
diminished in nuclei exhibiting a dysplastic phenotype, compared to those with a 
normal phenotype (Figure 5.4). Some cytoplasmic staining was apparent in dysplastic 
cells, but was completely absent from cells exhibiting normal nuclear morphology. A 
similar reduction in nuclear lamin C expression was observed, but the quality of staining 
was not good enough for reproduction in this thesis. 
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5.3 Discussion 
I endeavoured to set up a system of analysis suitable for charting the pattern of 
expression of nuclear lamins A and C in healthy colonic epithelium and neoplastic 
tissue. A preliminary immunohistochemical study was undertaken using archived 
material from Maastricht University Hospital, The Netherlands. A-type lamin epitopes 
were successfully re-exposed in formalin-fixed, paraffin-embedded colorectal tissue 
sections by heating in a citric acid AR solution. In normal colonic crypts increase in 
lamin AlC staining correlated with cellular differentiation. Two groups have previously 
reported augmented lamin AlC expression in the top third of the crypt and weak staining 
in the basal region, but they did not differentiate between lamin A and lamin C (Cance 
et ai., 1992; Moss et ai., 1999). This study demonstrates parallel topological expression 
patterns for lamins A and C along the crypt / villus axis and defines the area with 
highest lamin AlC expression to the upper 20% of the crypt. 
These initial investigations revealed an ambiguous relationship between lamin 
expression and Dukes' stage. This is predominately due to insufficient availability of 
Dukes' stage A and D tumours which prevented the completion of a comprehensive 
analysis. Despite this drawback, some interesting observations were made from the 
analysis of Dukes' B, C and metastatic tumours that would be worthy of further 
research. In general, expression of lamin AlC appeared stronger in late stage tumours 
compared to early stage tumours. However in metastatic tumours lamins A and C 
became differentially expressed - a reproducible characteristic of liver metastases. The 
majority of metastatic samples analysed displayed reduced expression of lamin A 
compared to Dukes' C tumours, but a similar down-regulation was not seen in lamin C 
immunostained sections. Furthermore, A-type lamin expression was very heterogeneous 
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in the metastasis specimens which implies that down-regulation of lamin A in metastatic 
colon carcinoma cells is non-uniform. 
Histological analysis of a small sample of malignant polyps suggested a link between 
morphological transformation of nuclei and down-regulation of lamin NC expression. 
Aberrant nuclear shape and migration of nuclei to the apical pole of epithelial cells are 
strong indicators of dysplasia. Cells exhibiting such dysplastic characteristics were 
invariably negative for lamin A and negative or very weakly positive for lamin C and 
laminNC. 
Taken in toto this immunohistochemical study confirms that alterations in nuclear lamin 
expression are a feature of colorectal cancer. It would appear that the most significant 
changes occur in the earliest and latest stages of the disease. Down-regulation of A-type 
lamins was associated with dysplastic behaviour in malignant polyps and lamin A 
appears preferentially reduced in metastatic tumours. Whether loss of both lamins A and 
C in the earliest stages of this disease promotes colorectal carcinogenesis remains to be 
further investigated. A possible role for lamin A in promoting metastasis is an 
interesting one. In normal colon tissue, A-type lamin expression is associated with 
differentiation [Cance et al. (1992), Moss et al. (1999) and this thesis] . Studies on lamin 
expression in other cancers have associated loss of lamin NC with poor differentiation 
(Oguchi et ai., 2002). In particular, Machiels et ai. (1997) observed that lamin A alone 
was absent from poorly differentiated nonseminomas of the testicular germ cell. Perhaps 
loss of lamin A in CRC promotes dedifferentiation and facilitates spread to a secondary 
site? 
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Further research is certainly warranted. This pilot study needs to be extended to 
incorporate at least 20 tumours of each stage to obtain a clear picture of A-type lamin 
expression in eRe. It would also be beneficial to compare lamin expression patterns 
with patient survival data. As changes in nuclear lamin expression do not appear to be 
directly related to clinical pathology, variation in lamin A and C expression within 
tumours of the same stage may therefore emerge as a good prognostic indicator. 
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5.4 Figures 
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Figure 5.1 
Basic mucosal form of the colon illustrated by staining with lamin AlC antibodies. 
Cells expressing lamin AlC antigens (brown) were labelled by immunoperoxidase 
staining of paraffin-embedded sections of healthy colon tissue. Nuclei were weakly 
counterstained with Ehrlich's haematoxylin. The two uppermost layers in colon 
histology, the mucosa and submucosa, are clearly distinguishable; the border between 
the two being demarcated by the muscularis mucosae. The majority 'cif imclei in both 
layers are positive for lamin N.C. This includes endothelial cells surrounding blood 
vessels (b/v), smooth muscle. cells of the muscularis mucosae and epithelial cells of the 
. cblonic crypts (C). A distinct gradient of expression which increases from the base of 
the crypt to the lumenal surface is evident. There is no cytoplasmic ·statning. 
Lymphocytes were distributed as isolated cells throughout the lamina propria (LP) or in 
... : 
non-encapsulated aggregations (L) whic~ were observed in the submucosa (as depicted 
here) orfrequently breaching the muscularis mucosae and infiltrating the lamina 
, . . . 
propti~. l~ymphoid cells consistently demonstrated complete absence of lamin AlC 
expression and are therefore clearly identifiable in blue. The lamin AlC positive cells 
within the lymphoid follicles are likely to be analogous to the M cells of the small 
intestine. Scale bar = 250 ~m. 
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Figure 5.2 
A-type lamins are expressed in a gradient from the crypt base to the lumenal pole. 
The pattern of expression of lamin NC, lamin A and lamin C (staining shown in brown) 
was assessed imrnunohistochemically in eleven examples of paraffin-embedded normal 
colonic mucosa. Nuclei not expressing lamins A or C were visualized by 
counterstaining with haematoxylin (shown in blue). The same region of one patier;tt 
specimen is presented here. Independent of the anti-Iamin antibb.~YlI~ed, expression of 
, -:. ' , .. ,, ' 
lamin A and lamin C appears very low or absent in the bottom third of the crypt (sten 
cell / proliferative compartment) but increases towards the uppermost part of the cry! 
to a maximum level in the top 20% of the crypt (the differentiated compartment). Sca 
bar = 100 /lm. 
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Table 5.1 
Immunoperoxidase staining pattern of A-type lamins in colorectal tumours. Thirty-
six formalin-fixed, paraffin-embedded colon tumour specimens representing Dukes' 
stage A (n = 2), Dukes' stage B (n = 10), Dukes' stage C (n = 11), Dukes' stage D (n = 
2) and metastasis (n = 11) were stained individually with antibodies to lamin AlC 
(JoL2) , lamin A (133A2) and lamin C (RaLC). The level and heterogeneity of 
expression of each antigen was examined in both crypt (epithelial) cells and adjacent 
stromal (mesenchymal) cells (where possible). Staining intensity was scored according 
to an arbitrary scale in which - indicates absent expression, ± indicates very low level 
expression, + indicates low level expression, ++ indicates medium level expression and 
+++ indicates high level expression. Heterogeneity was measured according to the 
following scale: 
Heterogeneity score 
± 
+ 
++ 
+++ 
Lamin expression 
no variation 
- to ±, ± to +, + to ++ or ++ to +++ 
- to +, ± to ++ or + to +++ 
- to ++ or ± to +++ 
-to +++ 
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Table 5.1 Immunoperoxidase staining pattern of A-type lamins in colorectal tumours. 
[amm AJ{; (Jo[~J [amm it (I~~A~J [amm {; (Ra[{;J 
Colorectal tumours ~o. ± + ++ +++ ~o. ± + ++ +++ No. ± + ++ +++ 
Dukes' A 
Aberrant crypt nuclei 
Staining itensity 2 0 2 0 0 0 2 2 0 0 0 0 2 0 2 0 0 0 
Heterogeneity 2 0 0 2 0 0 2 I I 0 0 0 2 0 0 2 0 0 
Stromal cell nuclei 
Staining itensity 1 0 0 0 I 0 1 0 0 0 0 I 1 0 0 0 0 1 
Heterogeneity 1 I 0 0 0 0 1 0 1 0 0 0 1 I 0 0 0 0 
Dukes' B 
Aberrant crypt nuclei 
Staining itensity 10 6 I 2 0 10 4 4 0 10 3 3 3 0 I 
Heterogeneity 10 3 5 0 1 10 3 2 3 10 6 0 0 2 2 
Stromal cell nuclei 
Staining itensity 10 0 0 0 2 8 10 0 0 0 2 8 10 0 0 0 1 9 
Heterogeneity 10 7 2 1 0 0 10 6 3 1 0 0 10 6 4 0 0 0 
Dukes' C 
Aberrant crypt nuclei 
Staining itensity 11 0 I 7 3 0 10 2 3 4 I 0 11 2 3 4 2 0 
Heterogeneity 11 0 0 3 7 I 10 I 3 2 4 0 11 1 2 3 4 I 
Stromal cell nuclei 
Staining itensity 10 0 0 0 I 9 9 0 0 0 4 5 10 0 0 0 3 7 
Heterogeneity 10 5 5 0 0 0 9 4 3 2 0 0 10 6 2 2 0 0 
Dukes'D 
Aberrant crypt nuclei 
Staining itensity 2 0 0 0 2 0 2 0 0 1 1 0 2 0 2 0 0 0 
Heterogeneity 2 0 0 0 0 2 2 0 0 0 0 2 2 0 0 0 0 2 
Stromal cell nuclei 
Staining itensity 2 0 0 0 0 2 1 0 0 0 0 I 2 0 0 0 I I 
Heterogeneity 2 2 0 0 0 0 1 1 0 0 0 0 2 1 1 0 0 0 
Metastasis 
Tumour cell nuclei 
Staining itensity 11 I 2 1 6 1 11 7 3 0 I 0 11 2 4 2 2 I 
Heterogeneity 11 0 I 5 2 3 11 5 4 I 0 3 11 3 I 2 3 2 
Stromal cell nuclei 
Staining itensity 11 0 0 0 1 10 7 0 0 0 I 6 11 0 0 0 5 6 
Heterogeneity 11 9 2 0 0 0 7 2 5 0 0 0 11 6 4 I 0 0 
Figure 5.3 
Expression of lamin AlC, lamin A and lamin C in colorectal tumours. Four micron 
thick sections of Dukes' stage A (panels A to C), Dukes' stage B (panels D to F), 
Dukes' stage C (panels G to I) and Dukes' stage D (panels J to L) colon tumours, along 
with metastases of colon carcinoma (panels M to 0) were subjected to 
immunohistochemical detection of individual lamin antigens using three anti-:la~in 
.' . ., ~;.: '":. ' 
antibodies. Panels A, D, G, J & M -lamin AlC antibody (JoL2);p<\hels S;E, H, K &. N 
- lamin A antibody (133A2); and panels C, F, I, L & 0 - lamin C antibody (RaLC). 
Tissue sections were weakly counterstained with Ehrlich's haematoxylin, shown in blue 
where lamin staining is negative. Lamin staining appears brown. For each Dukes' stage 
and metastasis, examples of A-type lamin staining are presented from the'~~atri.~~bailerit. 
Scale bar = 100 11m. 
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Table 5.2 
Expression of A-type lamins in secondary tumours of colorectal cancer. Eleven 
examples of metastasis of colon carcinoma were labelled by immunoperoxidase with 
antibodies raised against lamin AlC (JoL2), lamin A (133A2) and lamin C (RaLC). 
Eight specimens represented metastasis to the liver and one example each of a lung, 
small intestine and pancreas / duodenum metastasis were included in the analysis. 
Staining intensity in both tumour cells and surrounding stromal cells (where possible) 
was scored based on an arbitrary scale where - = absent expression, ± = very low level 
expression, + = low level expression, ++ = medium level expression and +++ = high 
level expression. The · different lamin polypeptides were generally expressed 
heterogeneously throughout the tissue sections and the degree of variation was 
measured following the scale below: 
Heterogeneity score Lamin expression 
no variation 
± - to ±, ± to +, + to ++ or ++ to +++ 
+ - to +, ± to ++ or + to +++ 
++ - to ++ or ± to +++ 
+++ - to +++ 
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Table 5.2 Expression of A-type lamins in secondary tumours of colorectal cancer, determined by immunohistochemistry. 
[amID A7r (]o[~j [amID A (I33A~j [amID r (Ra[rj 
Colorectal metastases No. ± + ++ +++ No. ± + ++ +++ No. ± + ++ +++ 
MetastasIs 
Liver 
Tumour cell nuclei 
Staining itensity 8 1 1 5 0 8 6 2 0 0 0 8 2 3 1 1 
Heterogeneity 8 0 3 2 2 8 3 4 1 0 0 8 3 1 3 0 
Stromal cell nuclei 
Staining itensity 8 0 0 0 1 7 5 0 0 0 1 4 8 0 0 0 4 4 
Heterogeneity 8 7 1 0 0 0 5 0 5 0 0 0 8 6 2 1 0 0 
Lung 
Tumour cell nuclei 
Staining itensity 1 0 0 0 1 0 1 0 1 0 0 0 1 0 0 1 0 0 
Heterogeneity 1 0 0 0 0 1 1 1 0 0 0 0 1 0 0 0 0 1 
Stromal cell nuclei 
Staining itensity 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 
Heterogeneity 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 
Small intestine 
Tumour cell nuclei 
Staining itensity 1 0 1 0 0 0 1 0 0 0 0 1 0 1 0 0 0 
Heterogeneity 1 0 0 1 0 0 1 0 0 0 0 1 0 0 I 0 0 
Stromal cell nuclei 
Staining itensity 1 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 I 0 
Heterogeneity 1 I 0 0 0 0 1 1 0 0 0 0 1 0 I 0 0 0 
Pancreas I duodenum 
Tumour cell nuclei 
Staining itensity 1 0 0 0 0 1 1 0 0 0 1 0 1 0 0 0 I 0 
Heterogeneity 1 0 0 I 0 0 1 0 0 0 0 I 1 0 0 0 0 I 
Stromal cell nuclei 
Staining itensity 1 I 0 0 0 0 1 0 0 0 0 I 1 0 0 0 0 I 
Heterogeneity 1 0 I 0 0 0 1 I 0 0 0 0 1 I 0 0 0 0 
j'l 
Figure 5.4 
Loss of lamin Ale expression in colorectal polyps appears to be associated with 
loss of nuclear morphology. Serial sections of paraffin-embedded malignant polyps 
were subjected to immunoperoxidase staining with monoclonal antibodies raised against 
lamin AlC (panel A) and lamin A (panel B). Nuclei exhibiting normal polarity and size 
in crypt-like structures (fine arrows) were lamin AlC and lamin A positive. Nuclei 
displaying abnormal morphology and loss of polarity (broad arrows) were lamin A 
negative and showed significant down-regulation of lamin Ale. Lamin staining IS 
shown in brown; haematoxylin counterstaining is shown in blue. Scale bar = 100 Ilm. 
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Figure 5.4 
CHAPTER 6 - GENERAL DISCUSSION 
6.1 Background to project 
The implications of non-functional lamin NC are borne out in tissue-specific familial 
disorders such as autosomal inherited EDMD, CMD-IA, Dunnigan type - FPLD, MAD 
and CMT2Bl (Bonne et ai., 1999; Cao and Hegele, 2000; De Sandre-Giovannoli et ai., 
2002; Fatkin et ai., 1999; Novelli et ai., 2002; Raffaele Di Barletta et ai., 2000). 
Mutations in the lamin A binding region of emerin also give rise to an X-linked form of 
EDMD with identical clinical features to AD-EDMD (Bione et aI., 1994; Lee et ai., 
· 2001). Therefore a role for A-type lamins and their binding partners in tissue-specific 
diseases is well-established. Considering that such disorders are not associated with the 
development of any malignancy, it is very interesting that altered expression and 
distribution of A-type lamins has also been reported in a growing number of neoplasms 
affecting epithelial, mesenchymal and lymphoid lineages. 
The expression of nuclear lamins has been studied most extensively in lung cancer 
(Broers et al., 1993; Kaufmann et ai., 1991) and keratinocytic tumours of the skin 
(Oguchi et ai., 2002; Tilli et ai., 2003; Venables et ai., 2001), but also in acute 
lymphoblastic leukaemia, non-Hodgkin's lymphoma (Stadelmann et ai., 1990) and 
colorectal cancer (Cance et ai., 1992; Moss et ai., 1999). In general these investigations 
have reported down-regulation of lamin NC in association with increased proliferation 
and dedifferentiation of tumours. By comparison changes in expression of lamins B 1 
and B2 appear less common, although differential expression of B-type lamins has been 
noted in some healthy tissues (Broers et ai., 1997). These studies provided the first 
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indication that lamins may be important in the development and progression of cancer. 
However, immunological investigations into lamin expression in CRC have so far 
produced contradictory results (Cance et ai., 1992; Moss et aI., 1999). 
Colorectal cancer is the third most commonly diagnosed malignancy and the second 
most important cause of cancer mortality (males and females combined) in the UK 
(Toms, 2004). While methods for early detection have been developed and, in the case 
of FOB testing, are being rolled out across the UK (Alexander and Weller, 2003), 
clinicians are still relying predominately on Dukes' and TNM classification (AJCC, 
1997; Dukes, 1932; Gabriel et al., 1935; Turnbull et al., 1967) of colorectal tumours to 
determine patient treatment regimes and prognosis. Although one cannot deny the 
contribution made by pathologists such as C.E. Dukes in improving our understanding 
of this disease by determining a universal system through which it can be clinically 
described (Dukes, 1932), current morphological and pathological staging criteria are 
simply unable to provide detailed predictions of individual patient outcome [discussed 
by Johnston (2004)]. Biomarkers of tumour advancement and for prognosis have been 
proposed, including osteopontin (Agrawal et aI., 2002) and CEA (Galambos, 1973; 
Goldstein and Mitchell, 2005), but a definitive marker or genetic signature has yet to be 
demonstrated. Given the intriguing data currently being expounded on nuclear lamin 
expression in epithelial tumours of the lung and skin, it is perhaps surprising that 
detailed investigations into the expression and regulation of lamins in CRC have not 
been undertaken so far. This thesis aims to go some way in rectifying this. 
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.6.2 Expression of nuclear lam ins in CRC cell lines 
Expression and distribution of nuclear lamins A, C, Bland B2 was examined using a 
model system incorporating colorectal cancer cell lines HT29, SW948 and SW480 
which represented the progression of the disease. from a relatively differentiated 
phenotype to a highly dedifferentiated phenotype. Also included in the study was cell 
line T84 which represented a lung metastasis of a colon carcinoma. Comparative 
analysis of protein profiles and single-label immunofluorescence identified diminished 
levels of lamin A in the most dedifferentiated cell lines SW948 and SW480, but 
maltered expression of lamin C. These cultures displayed morphological abnormalities 
ncluding loss of contact inhibition, stratified growth and an apparently weaker 
ldherence to the tissue culture substrate. Concomitant with loss of protein expression, 
amin A transcript levels were significantly reduced in SW948 cells compared to HT29 
;ells, indicating that loss of expression was regulated at the level of transcription. 
However in SW480 cells lamin A mRNA levels were not similarly down-regulated. 
This suggests that a different, post-transcriptional mechanism of lamin A regulation was 
functioning in this cell line. 
Previously transcriptional and post-transcriptional regulation of A-type lamins has been 
reported. Broers et al. (1993) demonstrated that a decrease in lamin A and C mRNA 
levels accompanied down-regulation of protein expression in two SCLC cell lines. 
However, in the context of the observations made regarding SW948 colon cancer cells, 
work by Machiels et al. (1995) is particularly interesting. This group observed 
preferential repression of lamin A protein expression relative to lamin C in a human 
lung adenocarcinoma cell line and ascribed this imbalance to a reduction in the amount 
of lamin A transcript. Equally, up-regulation of lamin AlC protein expression can be 
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reflected in rnRNA levels. Expression of the mutant v-Ha-ras oncogene in a SCLC cell 
line induced a 10 fold increase in lamin NC protein levels which was paralleled by 
elevation in the corresponding mRNA species (Kaufmann et aI., 1991). Otherwise, a 
study on the premature ageing disease Hutchinson-Gilford progeria syndrome has 
illustrated a post-transcriptional mechanism by which lamin A expression may be 
abrogated but lamin C unaffected. De novo point mutations in the lamin A-specific tail 
domain are thought to prevent complete processing of prelamin A to lamin A, while 
lamin C is processed as normal (Eriksson et al., 2003). 
A reduction in lamin NC expression has been reported previously in CRC by Moss et 
al. (1999), but they did not distinguish between individual A-type lamin polypeptides. 
The first evidence of a differential relationship between lamins A and C in tumours was 
presented by Venables et al. (2001). They reported a mutually exclusive pattern of 
lamin A and Ki67 staining in BCC of the skin and correlated loss of lamin A with fast 
growing tumours. Consequently it was considered that loss of lamin A in SW948 and 
SW480 cells may be related to their proliferative capacity. This was investigated using 
flow cytometry and double-label immunofluorscence. Flow cytometric analyses showed 
HT29 and SW948 cells to be slow growing and SW480 and T84 cells to be faster 
growing. Comparative immunofluorescence analyses identified no discernible 
relationship between the expression of Ki67 or PCNA and lamin A despite a clear 
reduction in lamin A expression in SW948 and SW480 cells. Thus no correlation 
between lamin A expression and growth rate or proliferation indices could be detected 
in the selected colorectal cancer cell lines. These findings are therefore not consistent 
with the observations made by Venables et al. (2001). 
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In general, a complex relationship between lamin AlC expression and cellular 
proliferation / differentiation is emerging in the literature. A decrease in A-type lamin 
levels has been correlated with proliferation in Swiss 3T3 murine fibroblasts (Pugh et 
aI., 1997). Similarly lamin AlC expression has been inversely correlated with 
proliferation in lung tumours (Coates et aI., 1996; Rowlands et aI., 1994). However, 
many groups have reported coincident appearance of lamin AlC during tissue and 
cellular differentiation, whereas at least one B-type lamin is always expressed (Lebel et 
aI., 1987; Paulin-Levasseur et aI., 1989; Rober et aI., 1989; Stewart and Burke, 1987). 
Further to the work by Venables et al. (2001) on BCC, Oguchi et al. (2002) examined a 
range of keratinocytic tumours of the skin and reported the greatest reduction in lamin 
AlC in poorly differentiated tumours. Tilli et al. (2003) also came to the conclusion that 
A-type lamin expression was most strongly associated with well-differentiated tumours, 
but that it does not follow that these cells possess no proliferative capacity. They 
observed simultaneous expression of lamin AlC and Ki67 in approximately 50% of the 
proliferating cells in BCe and see of the skin. 
6.3 Effects of stable re-expression of lamin A in SW480 cells 
As changes in lamin A expression in the chosen eRC cell lines appeared to be unrelated 
to proliferation, I sought to investigate whether it was a dedifferentiation-driven event. 
To do this lamin A was stably re-expressed in SW480 cells and the downstream 
molecular targets were investigated using cDNA microarray analysis with a custom-
designed oligonucleotide chip comprising 325 genes reported to be relevant to 
colorectal carcinogenesis and malignancy in general. 
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Untransfected SW480 cells were highly anchorage independent, frequently 
multinucleate and grew in multiple layers. They did not adhere strongly to the culture 
surface. Ectopic expression of full-length lamin A completely rescued two-dimensional 
growth. Transfection with GFP-emerin, which stabilized endogenous lamin A at a level 
equivalent to that in GFP-lamin A transfected cells, produced a partial rescue. Cells 
grew as a monolayer but a proportion remained multinucleate. Ectopic expression of 
GFP had no affect on the morphology of the parental cell line. 
RNA profiles of each transfected cell line were compared and reproducible changes 
were confirmed by RT-PCR. Importantly, there were no significant changes in Wnt 
response elements. [Wnt controlled gene expression is essential for the maintenance of a 
proliferative phenotype in the base of normal colonic crypts. The ~-cateninffCF-4 
complex which activates transcription of Wnt targets is switched on in CRC (van de 
Wetering et aI., 2002).] In particular c-MYC, which is up-regulated by ~-cateninffCF-4 
and promotes cell proliferation (van de Wetering et aI., 2002), remained unchanged in 
the transfected cell lines. Consistent with this observation, cell proliferation indices also 
remained unaltered, supporting earlier findings that lamin A expression in CRC cells 
was not related to proliferation. However, RT-PCR did confirm significant down-
regulation in the mRNA levels of synemin in GFP-Iamin A transfected cells. Synemin is 
a type VI cytoplasmic IF protein (Mizuno et aI., 2001; Steinert et aI., 1999), therefore 
this finding suggests that the phenotypic manifestations of lamin A down-regulation 
observed in cultured cells may reflect alterations in the cytoskeleton. 
It is worth noting that phenotypic changes have previously been associated with 
expression of lamin AlC in a SCLC cell line. Insertion of oncogenically activated v-Ha-
ras into NCI-H249 cells induced a transition towards a non-SCLC phenotype, 
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coincident with a significant up-regUlation of lamin AlC and vimentin, which is another 
cytoplasmic IF (Kaufmann et ai., 1991). Consequently functional connections between 
IF networks of the nucleus and cytoplasm were speculated to result in cytoskeletal 
alterations and account for the acquired change in cell shape and growth characteristics. 
Similar to GFP-Iamin A transfected SW480 cells, NCI-H249rasH cells also began to 
grow as a monolayer (Mabry et ai., 1988). The question is, how could lamin A and 
synemin form a functional connection which regulates the morphology of CRC cells? 
Synemin was originally identified as an IFAP, but was later demonstrated to be a bona 
fide member of the IF superfamily (Becker et ai., 1995; Bellin et ai., 1999). Now two 
splice variants of the human synemin gene have been identified, a and P (Titeux et al., 
2001). Synemin cannot self-assemble, but forms heteropolymers with one or both of the 
type III IF proteins desmin and vimentin, thereby linking them to other components of 
the cytoskeleton (Bellin et aI., 1999; Bilak et at., 1998). As such synemin functions as 
an effective cytoskeletal cross-linker and could be very important in maintaining 
cytoskeletal architecture. 
The majority of research so far has focused on understanding the nature of synemin' s 
interactions in skeletal muscle where it associates with the myofibril Z-discs and is 
enriched at the neuromuscular and myotendinous junctions (Bellin et ai., 1999; Bilak et 
ai., 1998; Carlsson et aI., 2000; Granger and Lazarides, 1980; Mizuno et ai., 2004). 
Through multiprotein interactions, synemin is thought to perform a structural role 
during myofibre contraction and be involved in maintaining muscle integrity (Mizuno et 
at., 2004). Synemin has been detected in smooth muscle cells of the colon, but not in 
epithelial cells (Hirako et at., 2003). However synemin activity in the colon does not 
appear to have been studied extensively by any research group. 
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A role for synemin in promoting tumourigenicity has only recently been suggested (ling 
et al., 2005). ling and co-workers discovered that both a- and ~-synemin were up-
regulated in reactive and malignant astrocytes compared to normal brain tissue. 
[Synemin is known to be absent from mature astrocytes of adult animals (Sultana et al., 
2000).] They reported that all astrocytoma tissues reacted with synemin antibodies, 
independent of grade. Additionally a- and ~-synemin were differentially increased in 
some glioblastoma cell lines. Generally a-synemm appeared predominately up-
regulated with comparable variation m expressIOn seen at the mRNA level. 
Interestingly, in these cell lines synemin was found to associate specifically with a-
actinin in ruffled membranes which are actin-rich semicircular leading edges important 
in cell motility. Both nesprin-l giant and nesprin-2 giant isoforms have also been 
immunodetected in membrane ruffles / leading edges (Padmakumar et at., 2004; Zhen et 
at., 2002). Nesprin-l was shown to largely colocalize with the actin-binding protein a-
actinin, while nesprin-2 colocalized with the actin networks. 
Nesprins are huge spectrin-repeat proteins belonging to the a-actinin superfamily. They 
possess an N-terminal a-actinin-related actin binding domain and are involved in actin 
bundling (Padmakumar et al., 2004; Zhen et al., 2002). Unlike other members of the 
spectrin family, nesprins harbour a transmembrane domain within a C-terminal 
Klarsicht-like domain and are consequently targeted to the nuclear membrane 
(Padmakumar et al., 2004; Zhang et al., 2001; Zhen et al., 2002). In healthy colon tissue 
nesprin-l mRNA is expressed at a medium level, whereas nesprin-2 mRNA is 
expressed at a low level. In SW480 colon carcinoma cells specifically, levels of nesprin-
2 transcript are comparable to normal tissue, whereas nesprin-l mRNA levels are down-
regulated to an almost undetectable amount. Overall, cancer cell lines seem to express 
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little or no nesprin-l mRNA and only traceable amounts of nesprin-2 transcript 
(Padmakumar et ai., 2004; Zhen et ai., 2002). 
Nesprins are hypothesized to connect the nuclear lamina to elements of the 
microfilament system in the cytoplasm (Libotte et ai., 2005). Localization of nesprin-2 
giant to both sides of the nuclear envelope has been demonstrated, as well as direct 
interaction of nesprin-2 giant with both lamin AlC and emerin (Libotte et ai., 2005; 
Zhen et ai., 2002). Likewise nesprin-l giant and nesprin-la immunostaining has been 
detected at the nuclear membrane of smooth and skeletal muscle and found to overlap 
with that of lamin AlC and emerin (Mislow et ai., 2002a; Zhang et ai., 2001). In 
addition, direct interaction between nesprin-la, lamin A and emerin has been shown by 
Mislow et al. (2002b), as well as cytoplasmic staining of nesprin-l giant in chick 
cardiac myocytes (COS7 cells) (Padmakumar et ai., 2004). Based on this evidence 
Libotte et al. (2005) have proposed a model in which giant nesprin isoforms congregate 
at the ONM, where they bind actin, and at the INM, where they interact with nuclear 
lamin AlC and emerin and lie in close proximity to heterochromatin. Via UNC-84/Sun 
and other hitherto unidentified peripheral and integral membrane proteins nesprins are 
predicted to form molecular bridges between lamins, emerin and the actin cytoskeleton. 
If this is the case alterations in nucleoskeletal elements might be expected to have an 
impact on the form and function of the cytoskeleton. 
At this point only tentative proposals can be made regarding the possible connection 
between lamin A, synemin and the maintenance of cellular integrity. Currently, 
experiments undertaken in this thesis indicate the following: 1) Loss of lamin A affects 
nuclear and cellular morphology in SW480 cells. 2) Normal two-dimensional growth 
can be rescued by transfection of lamin A and to a lesser extent emerin. 3) Synemin is 
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significantly down-regulated in lamin A positive versus lamin A negative cells. It has 
been noted that synemin is expressed in reactive and neoplastic astrocytes but not in 
normal astrocytes, suggesting that expression of synemin may promote a tumourigenic 
phenotype (ling et aI., 2005). It is therefore plausible that lamin A expression may 
promote a more normal epithelial-like phenotype in SW480 cells by influencing the 
expression of cytoskeletal linker proteins, such as synemin. Nesprins are recognized 
nucleus and cytoskeletal connecting elements which bind directly to A-type lamins on 
the nucleoplasmic side of the nuclear membrane and a-actinin and actin in the 
cytoplasm (Libotte et aI., 2005; Mislow et ai., 2002b; Padmakumar et aI., 2004; Zhen et 
aI., 2002). Therefore they are primary candidates to mediate lamin A - cytoplasmic IF 
interaction, thereby functionally connecting two IF networks on opposing sides of the 
nuclear envelope believed to regulate cellular integrity. 
6.4 A-type lamin expression in CRC tissue 
To determine whether the aforementioned changes in A-type lamin expression seen in 
CRC cell lines were also a feature of neoplastic tissue, a small scale 
immunohistochemical study of colorectal tumours and normal colon tissue was 
undertaken. In normal colonic crypts lamin AlC activity correlated with cellular 
differentiation, resulting in a gradient of expression. Protein levels were barely 
detectable in the stem cell compartment but gradually increased to a maximal level at 
the intercrypt table. Two other groups have reported augmented lamin AlC expression 
in the top third of the crypt and weak staining in the basal region, but they did not 
differentiate between lamin A and lamin C (Cance et aI., 1992; Moss et aI., 1999). 
Using antibodies specific for individual A-type lamin polypeptides, this study 
demonstrates parallel topological expression patterns for lamins A and C along the crypt 
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/ villus axis and defines the area with highest lamin NC expression to the upper 20% of 
the crypt. 
Changes in nuclear morphology, including enlargement and elongation, as well as 
migration of nuclei from the basal to the apical pole of colonic epithelial cells are strong 
indicators of dysplasia. The earliest signs of dysplasia are associated with ACF, whereas 
the characteristic signs of severe dysplasia were apparent in the malignant colorectal 
polyps analysed in this study. Lamin A and lamin C antibodies noticeably decorated the 
marginal zones of these polyps which were essentially normal. However, dysplastic 
regions were invariably negative for lamin A and negative or very weakly positive for 
lamin C and lamin NC. This suggests a link between morphological transformation of 
nuclei and down-regulation of lamin NC. Clinically the degree of dysplasia within a 
tumour is determined predominately by nuclear morphology and migration. In the 
absence of a clinically relevant molecular marker of dysplasia in CRC, these data 
suggest lamin A may potentially be an ideal marker. To ascertain the suitability of lamin 
A as a marker of dysplasia, a larger immunohistochemical study will be required 
incorporating specimens with different degrees of dysplasia to establish whether a 
change in lamin expression is concomitant with the earliest signs of dysplasia or is 
associated only with the later stages. 
6.5 Final conclusions 
In summary, I have examined the expression and distribution of nuclear lamins in CRC 
using a model system of colorectal cancer cell lines and specimens of normal and 
malignant colorectal mucosa. Initially it was discovered that lamin A expression is 
down-regulated over lamin C in the most dedifferentiated cell lines and that this process 
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can be regulated at both the level of transcription and by post-transcriptional 
mechanisms. Furthermore, the proportion of cells in each phase of the cell cycle was 
measured and the expression of proliferation indices also monitored. Consequently it 
was determined that loss of lamin A was not related to proliferation. Subsequently, loss 
of lamin A was correlated with severe dysplasia in malignant polyps and was therefore 
associated with aberrant nuclear morphology and migration. Re-expression of lamin A 
in SW480 cells rescued two-dimensional, epithelial-like growth and was correlated with 
a significant reduction in the transcription of synemin, a cytoplasmic IF. The corollary 
of this is that loss of lamin A in CRC appears to accompany cellular dedifferentiation, 
alterations in nuclear morphology and abnormal three-dimensional cell growth. RNA 
profiling suggests this may be the result of a breakdown in functional interactions 
between lamin A and components of the cytoskeleton, namely cytoplasmic IFs such as 
synemm. 
Future work should focus on determining whether equivalent changes in synemm 
expression are seen at the protein level and whether changes in expression of synemin 
and lamin A correlate with cell motility and dysplastic behaviour. Identification of other 
genes involved in lamin A - cytoskeletal communication is of paramount importance. 
Comparing gene expression profiles between colon cancer cells with and without lamin 
A using Affymetrix GeneChip® micro array technology should facilitate the 
identification of different genes involved in lamin A regulated pathways or enable the 
prediction of signalling networks. Additionally it would be informative to sequence the 
tail domain of lamin A in each of the CRC cell lines used, particularly SW480, to look 
for similar destabilizing mutations as those seen in HGPS (Eriksson et ai., 2003) which 
give rise to aberrant lamin A, but normallamin C. 
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APPENDIX I 
Additional infonnation associated with Chapter 2, Material and Methods. 
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APPENDIX I 
A. Mowiol mounting media 
Mowiol® 4-88 2.4 g 12% 
Glycerol 6g 30% 
0.2 M Tris-HCI, pH 8.5 12 ml 120mM 
DABCO 2.5% 2.5% 
DAPI 1 J..lg/ml 1 J..lg/ml 
dH20 6ml 
B. SDS-PAGE gel preparation 
Resolving gel 
COffigonent 10% gel 12% gel 
Deionised water 5.3 ml 4.9 ml 
ProSieve® 50 gel solution 2.0ml 2.4 ml 
1.5 M Tris-HCl, pH 8.8 2.5 ml 2.5 ml 
10% SDS 0.1 ml 0.1 ml 
10% APS (fresh) 0.1 ml 0.1 ml 
TEMED 0.004 ml 0.004 ml 
Stacking gel (5%) 
COffigonent 5ml 
Deionised water 3.75 ml 
ProSieve® 50 gel solution 0.5 ml 
1 M Tris-HCI, pH 6.8 0.65 ml 
10% SDS 0.05 ml 
10% APS (fresh) 0.05 ml 
TEMED 0.005 ml 
APPENDIX II 
Information relating to the development of the Colorectal Cancer Oligonucleotide Chip 
which was designed and printed in-house (see Chapters 2 and 4) and data produced 
from the accompanying microarray experiments (see Chapter 4). 
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Appendix II, A 
Table of functional groups into which the genes on the Colorectal Cancer 
Oligonucleotide Chip were organized. 
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Appendix II, A. Table of functional groups into which the genes on the 
Colorectal Cancer Oligonucleotide Chip were organized. 
Gene symbol Gene Description 
Apoptosis and apoptotic inhibitors 
AMID / PRG3 p53-responsive gene 3 
BAD BCL2-antagonist of cell death 
BAKI 
BCL2 
BCL2Ll 
BIRC2 
CASP3 
CASP7 
CASP8 
CAST 
FAS 
FASLG 
LlTAF 
NCKAP I / NAP I 
BCL2-antagonistlkiller I 
B-cell CLUlymphoma 2 
BCL2-like I / bcl-X 
baculoviral lAP repeat-containing 2 / apoptosis inhibitor I 
caspase 3, apoptosis-related cysteine protease 
caspase 7, apoptosis-related cysteine protease 
caspase 8, apoptosis-related cysteine protease 
calpastatin 
Fas (TNF receptor superfamily, member 6) 
Fas ligand (TNF superfamily, member 6) 
lipopolysaccharide-induced TNF factor 
NCK-associated protein I 
TERT telomerase reverse transcriptase 
TNFRSF lOA / TRAILR I tumor necrosis factor receptor superfamily, member lOa 
TNFSFlO / TRAIL TNF-related apoptosis-inducing ligand 
Cell adhesion 
CDHI 
CTNNAI 
CTNNDI 
cadherin I, type I, E-cadherin (epithelial) 
catenin (cadherin-associated protein), alpha I, 102kDa 
catenin (cadherin-associated protein), delta I / pI20 catenin 
Cell cycle progression / cell proliferation and growth 
CCNAI cyclin Al 
CCNBI 
CCNB2 
CCNDI 
CCND2 
CCNDJ 
CCNEI 
CDC2 
CDC25A 
CDC25B 
CDC42 
CDK2 
CDK4 
CDK6 
CDKNIB 
CHKI 
CHK2 
CSPG2 
CXCL2 
EGF 
EGFR 
FGF5 
FGFRI 
FGFR4 
GPC3 
IGFlR 
cyclin BI 
cyclin B2 
cyclin 01 
cyclin 02 
cyclin 03 
cyclin El 
cell division cycle 2, Gl to S and G2 to M / cdkl 
cell division cycle 25A 
cell division cycle 25B 
cell division cycle 42 (GTP binding protein, 25kDa) 
cyclin-dependent kinase 2 
cyclin-dependent kinase 4 
cyclin-dependent kinase 6 
cyclin-dependent kinase inhibitor IB (p27, KipI) 
checkpoint kinase Chkl 
checkpoint kinase Chk2 
chondroitin sulfate proteoglycan 2 (versican) 
GRO-beta / chemokine (C-X-C motif) ligand 2 
epidermal growth factor 
epidermal growth factor receptor 
fibroblast growth factor 5 
fibroblast growth factor receptor I 
fibroblast growth factor receptor 4 
glypican 3 
insulin-like growth factor I receptor 
Accession no. 
AF337957 
AF031523 
U23765 
MI4745 
Z23115 
U45878 
AY2I9866 
NM_OOI227 
NM_001228 
DI62I7 
X83493 
038122 
NM_004862 
ABOI4509 
NM_003219 
U90875 
U37518 
Z13009 
NM_001903 
AF062339 
NM_003914 
NM_03I966 
NM_004701 
NM_053056 
NM_001759 
NM_001760 
NM_OOI238 
NM_OOI786 
NM_OOI789 
NM_021874 
NM_OOI791 
NM_OOI798 
NM_000075 
NM_OOI259 
NM_004064 
AFOl6582 
AF086904 
X15998 
M36820 
NM_OOI963 
X00588 
NM_004464 
X5I803 
NM_0020II 
NM_004484 
X04434 
Appendix II, A cont. 
Gene symbol Gene Description 
Cell cycle progression / cell proliferation and growth cont. 
lGF2 insulin-like growth factor 2 (somatomedin A) 
IL3 
MDM2 
MKl67 
PDGFA 
PDCFRA 
SPARC 
TCFA 
TCFBI 
TCFBI/ BlCH3 
TCFBR2 
VECF 
interleukin 3 (colony-stimulating factor, multiple) 
Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) 
antigen identified by monoclonal antibody Ki-67 
platelet-derived growth factor alpha polypeptide 
platelet-derived growth factor receptor, alpha polypeptide 
secreted protein, acidic, cysteine-rich (osteonectin) 
transforming growth factor, alpha 
transforming growth factor, beta 1 
transforming growth factor, beta-induced, 68kDa 
transforming growth factor, beta receptor II (70/80kDa) 
vascular endothelial growth factor 
Cytoskeleton and nucleoskeleton 
ACTAI actin, alpha 1, skeletal muscle 
ACTA2 
ACTCI 
CFLl 
DES 
DSP 
FLNA 
CFAP 
lUP 
KRTI 
KRT/o 
KRTl4 
KRTl8 
KRTl8 
KRTl9 
KRT20 
KRT5 
KRT8 
KRT8 
LCPl 
LMNA 
LMNA 
LMNBI 
LMNB2 
MACFl 
NEBL 
NEFH 
NF2 
paranemin 
PFNl 
PLECl 
PLS3 
PPL 
PRPH 
PXN 
SYN 
TMPO(A) 
TMPO (B) 
TUBA2 
actin, alpha 2, smooth muscle, aorta 
actin, gamma 1 
cofilin 1 (non-muscle) 
desmin 
desmoplakin 
filamin A, alpha (actin binding protein 280) 
glial fibrillary acidic protein 
junction plakoglobin 
keratin 1 
keratin 10 
keratin 14 
keratin 18 
keratin 18 
keratin 19 
keratin 20 
keratin 5 
keratin 8 
keratin 8 
lymphocyte cytosolic protein 1 (L-plastin) 
laminA 
laminC 
lamin Bl 
lamin B2 
microtubule-actin crosslinking factor 1 
nebulette 
neurofilament, heavy polypeptide 200kDa 
merlin / neurofibromin 2 (bilateral acoustic neuroma) 
paranemin 
profilin 1 
plectin 1, intermediate filament binding protein 500kDa 
plastin 3 (T isoform) 
periplakin 
peripherin 
paxillin 
synemin 
thymopoietin alpha / lamina-associated polypeptide 2 alpha 
thymopoietin beta / lamina-associated polypeptide 2 beta 
tubulin, alpha 2 
Accession no. 
NM_000612 
NM_000588 
AF092844 
NM_002417 
X06374 
J03278 
103040 
NM_003236 
NM_000660 
M77349 
NM_003242 
NM_003376 
NM_00I100 
K0I747 
NM_001614 
000682 
NM_001927 
NM_004415 
NM_001456 
NM_002055 
NM_002230 
NM_006121 
NM_000421 
NM_000526 
NM_000224 
X12881 
NM_002276 
X73502 
NM_000424 
NM_002273 
X74929 
NM_002298 
X03444 
X03445 
NM_005573 
M94362 
NM_012090 
Y16241 
NM_021076 
NM_000268 
XM_195022 
NM_005022 
NM_000445 
NM_005032 
NM_002705 
NM_006262 
U14588 
AJ310521 
U09086 
U09087 
K00558 
Appendix II, A cont, 
Gene symbol Gene Description 
Cytoskeleton and nucleoskeleton cont. 
TUBB2 tubulin, beta 2 
TUBG tubulin, gamma I 
VCL 
VIL2 
VIM 
vinculin 
villin 2 (ezrin) 
vimentin 
DNA replication and repair 
ATM ataxia telangiectasia mutated 
LIG4 DNA ligase IV 
MLHl 
MSH2 
NBSl 
PARPl 
PMS2 
PRKDC 
RPAl 
XRCC4 
XRCC5 
XRCC6 
mutL homolog I, colon cancer, nonpolyposis type 2 (E. coli) 
mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 
Nijmegen breakage syndrome I (nibrin) 
poly (ADP-ribose) polymerase family, member 1 
PMS2 postmeiotic segregation increased 2 
DNA-dependent protein kinase catalytic subunit 
replication protein AI, 70kDa 
DNA-repair protein XRCC4 
Ku autoantigen, 80kDa 
thyroid autoantigen 70kD (Ku antigen) 
Extracellular matrix: components, processing, cellular attachment. proteases and protease inhibitors 
BGN biglycan 
collagen, type I, alpha 2 
collagen, type I, alpha 2 
fibronectin, alt splice 
heparanase 
integrin, alpha I 
integrin, alpha 2 
integrin, alpha 3 
integrin, alpha 5 (fibronectin receptor) 
integrin, alpha 6 
integrin, alpha V (vitronectin receptor) 
integrin, beta 1 
integrin, beta 3 
integrin, beta 4 
integrin, beta 5 
laminin, alpha 4 
laminin, beta I 
matrix metalloproteinase 1 (interstitial collagenase) 
matrix metalloproteinase 14 (membrane-inserted) 
matrix metalloproteinase 3 (stromelysin 1, progelatinase) 
matrix metalloproteinase 9 
syndecan 1 
syndecan 4 (amphiglycan, ryudocan) 
Accession no. 
NM_001069 
M61764 
M33308 
NM_003379 
NM_003380 
U33841 
X83441 
U07343 
NM_00025I 
AF058696 
NM_001618 
NM_000535 
U47077 
NM_002945 
NM_022550 
NM_021141 
NM_001469 
104599 
NM_000089 
V00503 
X02761 
AFI44325 
X68742 
X17033 
M59911 
NM_002205 
NM_00021O 
NM_00221O 
M34189 
NM_000212 
X53587 
X53002 
NM_002290 
NM_002291 
NM_00242I 
NM_004995 
NM_002422 
NM_004994 
NM_002997 
NM_002999 
COUA2 
COUA2 
FNlIFN 
HPSE 
ITGAl 
lTGA2 
ITGA3 
ITGA5 
ITGA6 
ITGAV 
ITGBl 
lTGB3 
ITGB4 
ITGB5 
LAMA4 
LAMBl 
MMPl 
MMPl4 
MMP3 
MMP9 
SDCl 
SDC4 
SERPINAl 
SPPl 
TIMPl 
serine proteinase inhibitor, clade A (alpha-l antiproteinase, antitrypsin), member I X01683 
Metabolism 
FABP2 
Oncogenes 
ABU 
secreted phosphoprotein 1 (osteopontin) 104765 
tissue inhibitor of metalloproteinase 1 
fatty acid binding protein 2, intestinal Ml8079 
v-abl Abelson murine leukemia viral oncogene homolog 1 X16416 
Appendix II, A cont. 
GenesymboJ 
Oncogenes cont. 
EP300 
FOS 
HER2 
HRAS 
JUN 
KRAS 
MOS 
MYC 
MYCN 
RAFl 
SRC 
Gene Description 
E 1 A binding protein p300 
v·fos FBJ murine osteosarcoma viral oncogene homolog 
v·erb-b2 erythroblastic leukemia viral oncogene homolog 2 
v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
v-jun sarcoma virus 17 oncogene homolog 
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
v-mos Moloney murine sarcoma viral oncogene homolog 
v-myc myelocytomatosis viral oncogene homolog 
N-myc proto-oncogene protein 
v-raf-l murine leukemia viral oncogene homolog 1 
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
Protein translation, processing, transport and degradation 
AIMl absent in melanoma 1 
EIF3S2 
IPm I RANBPl 
NUP153 
RPL19 
RPL2l 
RPL3l 
TPR 
eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa 
import in 7 
nucleoporin 153kDa 
ribosomal protein Lt9 
ribosomal protein L21 
ribosomal protein L31 
nucleoprotein TPR I translocated promoter region 
Regulation of gene expression (transcription) 
BCL3 
CDX2 
E2F4 
GTF3A 
NFKBl 
RARA 
RXRA 
SPl 
TCFl 
TCF3 
TCF4 
TGIF 
USF2 
ZFP9l 
Signal transduction 
CCR7 
CD14 
FCGR2B 
GNAL 
ILK 
MAPKl 
PAKl 
PlK3CG 
PTK2BIPKB 
RACl 
RGS2 
RHOA 
RHOC 
STATl 
B-cell CLUlymphoma 3 
caudal type homeo box transcription factor 2 
E2F transcription factor 4, p 1 07/p 130-binding 
general transcription factor IlIA 
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 
retinoic acid receptor, alpha 
retinoid X receptor, alpha 
Spl transcription factor 
transcription factor 1, hepatic 
transcription factor 3 
transcription factor 4 
TGFB-induced factor (TALE family homeobox) 
upstream transcription factor 2, c-fos interacting 
zinc finger protein 91 homolog (mouse) 
chemokine (C-C motif) receptor 7 
CD14 antigen 
IGFR2 I Fc fragment of IgG, low affinity lIb, receptor 
G-s-alpha I guanine nucleotide binding protein (G protein) 
integrin-Iinked kinase 
mitogen-activated protein kinase 1 
p211Cdc42lRacl-activated kinase 1 (STE20 homolog, yeast) 
phosphoinositide-3-kinase, catalytic, gamma polypeptide 
PTK2B protein tyrosine kinase 2 beta 
rho family, small GTP binding protein Racl 
Regulator of G-protein signaling 2 (GO/G 1 switch regulatory protein 8) 
ras homolog gene family, member A 
ras homolog gene family, member C 
signal transducer and activator of transcription 1, 91 kDa 
Accession no. 
NM_OOI429 
K00650 
Mll730 
NM_005343 
J04I11 
M54968 
NM_005372 
V00568 
Y00664 
X03484 
NM_004383 
NM_016180 
NM_003757 
AF098799 
NM_005124 
NM_000981 
NM_000982 
NM_000993 
NM_003292 
NM_005178 
AH007259 
NM_OO1950 
NM_002097 
X61498 
NM_000964 
NM_002957 
AF252284 
M57732 
AB031046 
AR067642 
X89750 
NM_OO3367 
NM_053023 
AB000887 
M86511 
J04162 
AH002748 
NM_004517 
NM_002745 
NM_002576 
NM_002649 
X61037 
NM_006908 
Lt3463 
NM_OOI664 
NM_005167 
NM_007315 
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Gene symbol Gene Description 
Signal transduction cont. 
TIAMI T-cell lymphoma invasion and metastasis I 
Stem cell differentiation 
ANI L astrocytic NOV A-like RNA-binding protein 
ASTN 
BMPl 
BMP4 
BMP6 
CRIPTO 
EPHAl 
FNl 
FUTl 
FUn 
GAP43 
GATA4 
GATA4 
GJAl 
HATHl 
LAMBl 
MAP2 
MAPTITAU 
MASHl 
MASH2 
MYODl 
NEFL 
NEFM 
NES 
NEURODl 
NEUROD2 
NEUROD3 
NEUROD4 
NHLH2 
NOTCHl 
NOTCH2 
NOTCH3 
NOTCH4 
NSE 
PAX6 
PLP 
REST 
SCGlO 
SNAP25 
SOXl 
SOXlO 
SOXl7 
SOX2 
SOX8 
SOX9 
SYP 
T 
TDGFl 
TF 
Astrotactin 
bone morphogenetic protein I 
bone morphogenetic protein 4 
bone morphogenetic protein 6 
cripto protein 
EPH receptor Al 
cellular fibronectin 
fucosyltransferase I 
fucosyltransferase 2 (secretor status included) 
growth associated protein 43 
GAT A binding protein 4 
GAT A binding protein 4 
gap junction protein, alpha 1, 43kDa (connexin 43) 
atonal protein homolog I 
laminin, beta I 
microtubule-associated protein 2 
microtubule-associated protein tau 
Achaete-scute homolog 1 
achaete-scute complex-like 2 
myogenic factor 3 
neurofilament, light polypeptide 68kDa 
Neurofilament medium polypeptide 
nestin 
neurogenic differentiation I 
neurogenic differentiation 2 
neurogenic differentiation 3 
neurogenic differentiation 4 
nescient helix loop helix 2 
Notch homolog I (Drosophila) 
Notch homolog 2 (Drosophila) 
Notch homolog 3 (Drosophila) 
Notch homolog 4 (Drosophila) 
Neuron-specific enolase 
paired box gene 6 (aniridia, keratitis) 
proteolipid protein 
RE I-silencing transcription factor 
Stathmin 2 (SCGlO protein) 
synaptosomal-associated protein, 25kDa 
SRY (sex determining region Y)-box I 
SRY (sex determining region Y)-box 10 
SRY (sex determining region Y)-box 17 
SRY (sex determining region Y)-box 2 
SRY (sex determining region Y)-box 8 
SRY (sex determining region Y)-box 9 
synaptophysin 
T, brachyury homolog (mouse) 
teratocarcinoma-derived growth factor I 
transferrin 
Accession no. 
U70477 
AB006627 
M22488 
NM_001202 
NM_001718 
X14253 
MI8391 
M10905 
M35531 
D87942 
M25667 
L34357 
NM_002052 
M65188 
U61148 
M20206 
UOl828 
103778 
L08424 
U77629 
XI7650 
NM_006158 
Y00067 
X65964 
AF045 152 
U58681 
U63842 
U43843 
M97508 
M73980 
X80115 
U97669 
U95299 
X51956 
M93650 
M271 10 
U13879 
S82024 
D21267 
Y13436 
AJOO 11 83 
NM_022454 
L07335 
AF226675 
NM_000346 
U93305 
AJ001699 
M96955 
S95936 
Appendix II, A cont. 
Gene symbol Gene Description Accession no. 
Stem cell differentiation cont. 
TLE2 transducin-like enhancer of split 2 M99436 
X03168 
X92715 
VTN 
ZNF74 
Stress response 
CRYAA 
CRYAB 
HSP70-l 
HSPA8 I HSC70 
HSPB2 
HSPCA 
hsp20 
ORMl 
SODl 
sam 
Transporters, carriers 
ATP2A3 
SLCl6Al 
SLC2Al I GLUTl 
Tumour supressor genes 
vitronectin 
zinc finger protein 74 (Cos52) 
crystallin, alpha A NM_000394 
crystallin, alpha B NM_001885 
heat shock 70kD protein 1 M 11717 
constitutive heat shock protein 70 AF352832 
heat shock 27kDa protein 2 NM_001541 
heat shock 90kDa protein I, alpha X 15183 
Sequence 109 from Patent W09954460 (hsp 20) AXOl3767 
Alpha-I-acid glycoprotein I precursor (AGP I) (Orosomucoid I) (OMD I) X02544 
superoxide dismutase I, soluble NM_000454 
superoxide dismutase 2, mitochondrial NM_000636 
ATPase, Ca++ transporting, ubiquitous AF06822I 
solute carrier family 16 (monocarboxylic acid transporters), member I NM_003051 
solute carrier family 2 (facilitated glucose transporter), member I A Y034633 
APC adenomatosis polyposis coli NM_OO0038 
NM_005215 
NM_000267 
NM_00032I 
NM_000546 
NM_000378 
DCC 
NFl 
RBl 
TP53 
WTl 
Wnt signalling 
AQP3 
ASL 
BlRC5 
CA2 
CD44 
CDKNlA 
CEACAMlIBGPl 
CHAFlA 
CLDNl 
CLDN4 
CTNNBl 
DLEUl 
DRGl 
ENCl 
EPHBl 
EPHB2 
ETS2 
FABPl 
GPX2 
JPOl I LOC442172 
KLF4 
LGALS4 
MCM3 
deleted in colorectal carcinoma 
neurofibromin 1 
retinoblastoma 1 
tumor protein p53 (Li-Fraumeni syndrome) 
Wilms tumor 1 
aquaporin 3 
argininosuccinate lyase 
apoptosis inhibitor 4 - survivin 
carbonic anhydrase II 
CD44 antigen (Heparan sulfate proteoglycan) (Epican) 
cyelin-dependent kinase inhibitor IA (p2I, Cipl) 
NM_004925 
NM_000048 
NM_00I168 
NM_000067 
X66733 
NM_000389 
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotei NM_001712 
chromatin assembly factor I, subunit A (pI50) NM_005483 
elaudin I 
elaudin 4 
catenin (cadherin-associated protein), beta I, 88kDa 
deleted in lymphocytic leukemia, 1 
developmentally regulated GTP binding protein 1 
ectodermal-neural cortex (with BTB-like domain) 
EPH receptor B 1 
EPH receptor B2 
v-ets erythroblastosis virus E26 oncogene homolog 2 
fatty acid binding protein 1, liver 
glutathione peroxidase 2 (gastrointestinal) 
c-Myc target 1POI 
Kruppel-like factor 4 (gut) 
galectin 4 
MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) 
NM_021101 
NM_001305 
NM_001904 
NM_005887 
AF271994 
NM_003633 
NM_004429 
AF025304 
104102 
BC032801 
AF199441 
AY029179 
NM_004235 
NM_006149 
NM_002388 
Appendix II, A cont. 
Gene symbol 
Wnt signalling cont. 
MCM5 
MUC2 
MYB 
NSAP 1 / SYNCRlP 
PLCB2 
PRKCD 
RBBP4 
Gene Description 
minichromosome maintenance deficient 5, cell division cycle 46 
mucin 2, intestinalltracheal 
Myb proto-oncogene protein (C-myb) 
NS 1 -associated protein 1 pseudo gene 
phospholipase C, beta 2 
protein kinase C, delta 
ret'inoblastoma binding protein 4 
stem cell factor I kit ligand precursor I Mast cell growth factor (MGF) 
Accession no. 
NM_006739 
NM_002457 
Ml5024 
AFI55568 
NM_004573 
NM_006254 
NM_005610 
M59964 SCF / KITLG 
SLC7A5 
TCOFl 
TEAD4 
TFDP2 
solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 NM_003486 
Treacher Collins-Franceschetti syndrome I NM_000356 
UNG 
XRCC3 
Transcriptional enhancer factor TEF-3 (TEA domain family member 4) 
transcription factor Dp-2 (E2F dimerization partner 2) 
uracil-DNA glycosylase 
X-ray repair complementing defective repair in Chinese hamster cells 3 
Xenobiotic and drug metabolism I detoxification 
ABCBl P glycoprotein IImultiple drug resistance 1 
ABCB4 
MTlA 
Miscellaneous enzymes 
ANPEP 
CAl2 
PTGS2/COX2 
SI 
Miscellaneous 
CEACAM3 / CEA 
CLCNKB 
FOXE3 
NPMl 
SOX4 
TlB 
P glycoprotein 3/multiple drug resistance 3 
metallothionein lA (functional) 
aminopeptidase N I CD13 
carbonic anhydrase XII 
prostaglandin-endoperoxide synthase 2 (cyclooxygenase) 
sucrase-isomal tase (alpha-glucosidase) 
carcinoembryonic antigen-related cell adhesion molecule 3 
chloride channel Kb 
forkhead box E3 
nucleophosmin (nucleolar phosphoprotein B23, numatrin) 
SRY (sex determining region Y)-box 4 
T-18 
Function not well elucidated 
KLRBl 
LGALS2 
MXD3 
PITX3 
PROXl 
RALGPSl 
REGlB 
RSAD2 
SOXIl 
SOX3 
TPBG 
TSPANl 
ZBTBl6 
NKR-PIA 
galectin 2 
MAX dimerization protein 3 
paired-like homeodomain transcription factor 3 
prospero-related homeobox 1 
Ral GEF with PH domain and SH3 binding motif I 
regenerating protein I beta 
radical S-adenosyl methionine domain containing 2 I cig5 I viperin 
SRY (sex determining region Y)-box II 
SRY (sex determining region Y)-box 3 
trophoblast glycoprotein 
tetraspan NET-I 
PLZF I zinc finger and BTB domain containing 16 
House keeping I positive controls 
ACTB 
GAPDH 
actin, beta 
glyceraldehyde-3-phosphate dehydrogenase 
X94438 
NM_006286 
Y09008 
AF035586 
MI4758 
M23234 
KOl383 
M22324 
AF037335 
M90100 
NM_OOl041 
M29540 
Z30644 
AL607122 
M28699 
X70683 
AF0898 II 
UII276 
BC029063 
NM_031300 
AF041339 
BC024201 
NM_014636 
DI729l 
AF02694l 
AB02864l 
NM_005634 
NM_006670 
AF065388 
AF060568 
NM_OOIIOI 
AF261085 
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Gene symbol 
Negative controls 
CHRMJ 
CHRM2 
CHRM3 
CHRM4 
CHRM5 
POU5Fl 
Gene Description 
cholinergic receptor, muscarinic 1 
cholinergic receptor, muscarinic 2 
cholinergic receptor, muscarinic 3 
cholinergic receptor, muscarinic 4 
cholinergic receptor, muscarinic 5 
POU domain, class 5, transcription factor 1 
Accession no. 
AF385587 
AF385588 
NM_000740 
AF385590 
NM_012125 
NM_002701 
Appendix II, B 
Complete list of human genes on the CRC Oligonucleotide Chip, including gene 
symbol, description and GenBank® accession number. The corresponding well ID 
(position of gene on the chip), chip code (used to identify gene on plate template - see 
Appendix II, C) and protein name are also given. 
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Appendix II, B. Details of all genes printed on the Colorectal Cancer Oligonucleotide Chip. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
Al.al GAPDH GAPDH glyceraldehyde-3-phosphate dehydrogenase AF26l085 GAPDH 
A2.al SOXll SOX11 SRY (sex determining region Y)-box II AB02864l SOXll 
A3.al NDI NEUROD1 neurogenic differentiation I AF045 152 NEURODI 
A4.al SOX8 SOX8 SRY (sex determining region Y)-box 8 AF226675 SOX8 
A5.al SOX 10 SOXlO SRY (sex determining region Y)-box 10 AJOO1l83 SOX 10 
A6.al BRACHY T T, brachyury homolog (mouse) A1001699 brachyury 
A7.al SNAP25 SNAP25 synaptosomal-associated protein, 25kDa D21267 SNAP25 
A8.al FUT2 FUn fucosyltransferase 2 (secretor status included) D87942 FUT2 
A9.al NOTCH2 NOTCH2 Notch homolog 2 (Drosophila) X80115 NOTCH2 
AlO.al MAPT MAPTITAU microtubule-associated protein tau 103778 MAPT I TAU 
AIl.al ASTN ASTN Astrotactin ABOO6627 Astrotactin 
A12.al ACTB ACTB actin, beta NM_OOllOl ~-actin 
Al.a5 ACTA2 ACTA2 actin, alpha 2, smooth muscle, aorta K01747 ACTSA 
A2.a5 SOX2 SOX2 SRY (sex determining region Y)-box 2 L07335 SOX2 
A3 .a5 GATA4 GATA4 GAT A binding protein 4 L34357 GATA4 
A4.a5 EPHAI EPHAl EPH receptor A I M18391 EPHAI 
A5.a5 LAMBl LAMBl laminin, beta I M20206 LAMB I 
A6.a5 BMPI BMP1 bone morphogenetic protein I M22488 BMPl 
A7.a5 GAP43 GAP43 growth associated protein 43 M25667 GAP43 
A8 .a5 PLP PLP proteolipid protein M271l0 PLP 
A9.a5 FUTI FUTl fucosyltransferase I M35531 FUTl 
AIO.a5 BMP6 BMP6 bone morphogenetic protein 6 NM_0017 18 BMP6 
AIl.a5 GJAI GJAl gap junction protein, alpha I, 43kDa (connexin 43) M65188 GJAI 
A12.a5 NOTCHl NOTCHl Notch homolog 1 (Drosophila) M73980 NOTCH I 
Al.bl. PAX6 PAX6 paired box gene 6 (aniridia, keratitis) M93650 PAX6 
A2 .bl TDGFI TDGFl teratocarcinoma-derived growth factor I M96955 TDGFI 
A3.bl NHLH2 NHLH2 nescient helix 100E helix 2 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C) . 
M97508 NHLH2 
C Name of the functional protein product of each gene on the chip. 
Appendix II, B cont. 
Well IDa Chip co deb 
A8.cI SOXI 
A9.cI OCT4 
AIO.cI CLCNKB 
AIl.cl ZNF74 
AI2.cl MASHI 
Al.c5 HATH I 
A2.c5 MASH2 
A3.c5 SOXI7 
A4.c5 FOXE3 
A5.cS PRPH 
A6.cS AIM I 
A7.cS SODI 
A8.cS MI\.1P3 
A9.cS VCL 
AIO.cS PARNMN 
AIl.cS TUBO 
AI2.cS HSP70 
Al.dI HSP90 
A2.dI CRYAB 
A3.dI PROXI 
A4.dl CRYAA 
Gene symbol 
SOX! 
POU5F! 
CLCNKB 
ZNF74 
MASH! 
HATH! 
MASH2 
SOX! 7 
FOXE3 
PRPH 
AIM! 
SOD! 
MMP3 
VCL 
None ci 
TUBG 
HSP70-! 
HSPCA 
CRYAB 
PROX! 
CRYM 
Gene description Accession no. Protein namec 
SRY (sex determining region Y)-box 1 Y13436 SOXI 
POU domain, class S, transcription factor I NM_OO2701 Oct4! POUSFI 
chloride channel Kb Z30644 CLCNKB 
zinc finger protein 74 (CosS2) X927I5 ZNF74 
Achaete-scute homolog I L08424 MASHI 
atonal protein homolog 1 U61148 HATH 1 
achaete-scute complex-like 2 U77629 ASH2 
SRY (sex determining region Y)-box 17 NM_0224S4 SOXI7 
forkhead box E3 AL607122 FoxE3 
peripherin NM_006262 peripherin 
absent in melanoma 1 NM_OI6180 AIM 1 
superoxide dismutase I, soluble NM_OO04S4 SODI 
matrix metalloproteinase 3 (stromelysin I, progelatinase) NM_OO2422 MI\.1P3 
vinculin M33308 vinculin 
paranemin XM_19S022 paranemin 
tubulin, gamma 1 M61764 gamma tubulin 
heat shock 70kD protein I MI1717 hsp 70 
heat shock 90kDa protein I, alpha XISI83 hsp 90 
crystallin, alpha B NM_OOI885 CRYAB 
prospero-related homeobox 1 BC024201 proxl 
crystallin. aloha A NM_OOO394 CRYAA 
AS .dl SYN SYN synemin AJ3IOS21 synemin 
A6.dl ACTO 1 ACTGI actin, gamma 1 NM_OOI614 ACTO 1 
A7.dl HSP27 HSPB2 heat shock 27kDa protein 2 NM_OOIS41 hsp27 
A8.dl PITX3 P1TX3 paired-like homeodomain transcription factor 3 AF041339 PITX3 
A9.d I HSP20 None ci Sequence 109 from Patent W099S4460. AXOI3767 hsp 20 
AIO.dl IGFIR lGFJR insulin-like growth factorJ receptor X04434 IOFI receptor 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
d No gene name currently allocated. 
Appendix II, B cont. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
Al1.dl CDC42 CDC42 cell division cycle 42 (GTP binding protein, 25kDa) NM_001791 CDC42 
Al2.dl HSC70 HSPA8 / HSC70 constitutive heat shock protein 70 AF352832 hsp 70 
A1.d5 DSP DSP desmoplakin NM_004415 des mop lakin 
A2.d5 PAKI PAKl p211Cdc42IRac1-activated kinase 1 (STE20 homolog, yeast) NM_002576 PAKI 
A3.d5 MMP9 MMP9 matrix metalloproteinase 9 NM_004994 MMP9 
A4.d5 NF2 NF2 merlin / neurofibromin 2 (bilateral acoustic neuroma) NM_000268 merlin 
A5.d5 TIAMI TlAMl T-cell lymphoma invasion and metastasis 1 NM_003253 tiaml 
A6.d5 MMP14 MMP14 matrix metalloproteinase 14 (membrane-inserted) NM_004995 mmpl4 
A7.d5 ILK lLK integrin-linked kinase NM_004517 ilk 
A8.d5 RACI RACl rho family, small GTP binding protein Racl NM_006908 Racl 
A9.d5 VIL2 V1L2 villin 2 (ezrin) NM_003379 eznn 
AI0.d5 GPC3 GPC3 glypican 3 NM_004484 glypican 3 
Al1.d5 PPL PPL periplakin NM_002705 periplakin 
A12.d5 PLECI PLECl plectin 1, intermediate filament binding protein 500kDa NM_000445 plectin 1 
B2.al HRAS HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog NM_005343 H-ras 
B3.al KRAS KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog M54968 K-ras 
B4.al CSRC SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog NM_004383 c-src 
B5.al CABL ABU v-abl Abelson murine leukemia viral oncogene homolog 1 XI6416 c-abl 
B6.al CMOS MOS v-mos Moloney murine sarcoma viral oncogene homolog NM_005372 c-mos 
B7.al CRAP RAFl v-raf-l murine leukemia viral oncogene homolog 1 X03484 c-raf 
B8.al CMYC MYC v-myc myelocytomatosis viral oncogene homolog V00568 c-myc 
B9.al CFOS FOS v-fos FBI murine osteosarcoma viral oncogene homolog K00650 c-fos 
BlO.al CJUN JUN v-jun sarcoma virus 17 oncogene homolog 104111 c-jun 
BI1.al EIA EP300 EIA binding protein p300 NM_001429 EIA 
B2.a5 APC APC adenomatosis polyposis coli NM_000038 APC 
B3.a5 DCC DCC deleted in colorectal carcinoma NM_005215 DCC 
B4.a5 TP53 TP53 tumor protein p53 (Li-Fraumeni syndrome) NM_000546 p53 
B5.a5 RBI RBl retinoblastoma 1 NM 000321 Rb 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
Appendix II, B cont. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
B6.a5 WTl wn Wilms tumor I NM_000378 WT-l 
B7.a5 NFl NFl neurofibromin I NM_000267 NF-l 
B8 .a5 NFKB NFKBl nuclear factor of kappa light polypeptide gene enhancer in B-cells I (p I 05) X61498 NF-kappa-B 
B9.a5 ZFP91 ZFP9l zinc finger protein 91 homolog (mouse) NM_053023 PZF 
BIO.a5 RARA RARA retinoic acid receptor, alpha NM_000964 RAR-alpha 
B 11.a5 RXRA RXRA retinoid X receptor, alpha NM_002957 RXR 
B1.bl RHOC RHOC ras homolog gene family, member C NM_005167 RhoC 
B2.bl 5T4 TPBG trophoblast glycoprotein NM_006670 5T4 
B3 .bl TCFI TeFl transcription factor I, hepatic M57732 TCF-I 
B4.bl TCF3 TCF3 transcription factor 3 AB031046 TCF-3 
B5.bl TCF4 TCF4 transcription factor 4 AR067642 TCF-4 
B6.bl OCT4 POU5Fl POU domain, class 5, transcription factor I NM_002701 Oct4 / POU5FI 
B7.bl BCL2 BCL2 B-cell CLUlymphoma 2 MI4745 BCL-2 
B8.bl BCLX BCL2Ll BCL2-like I / bcl-X Z23ll5 BCL-x 
B9.bl TERT TERT telomerase reverse transcriptase NM_003219 Tert 
BIO.bl MDRI ABCBl P glycoprotein l/multiple drug resistance 1 Ml4758 MDR-l 
Bll.bl MDR3 ABCB4 P glycoprotein 3/multiple drug resistance 3 M23234 MDR-3 
B2.b5 PDGF PDGFA platelet-derived growth factor alpha polypeptide X06374 PDGF 
B3 .bS EGF EGF epidermal growth factor NM_001963 EGF 
B4.bS FGF FGF5 fibroblast growth factor 5 NM_004464 FGF 
B5.bS TGFA TGFA transforming growth factor, alpha NM_003236 TGF alpha 
B6.b5 TGFB TGFBl transforming growth factor, beta I NM_000660 TGF beta 
B7.bS PDGFR PDGFRA platelet-derived growth factor receptor, alpha polypeptide J03278 PDGF receptor 
B8 .bS EGFR EGFR epidermal growth factor receptor XOOS88 EGF receptor 
B9.bS FGFR FGFRI fibroblast growth factor receptor 1 XSI803 FGF receptor 
BlO.bS TGFR TGFBR2 transforming growth factor, beta receptor II (70/80kDa) NM_003242 TGF receptor 
B l1.bS KRTI KRTl keratin I NM_006l2l keratin I 
Bl.cl MMPI MMPI matrix metalloEroteinase I (interstitial colla~enase) NM.002421 MMPI 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
Appendix II, B cont. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
B2.c1 KRTS KRT5 keratin S NM_000424 keratin S 
B3.cl KRT8 KRT8 keratin 8 NM_002273 keratin 8 
B4.c l KRTlO KRTJO keratin 10 NM_OO0421 keratin 10 
BS.c l KRT14 KRTl4 keratin 14 NM_000S26 keratin 14 
B6.cl KRTl8 KRTl8 keratin 18 NM_000224 keratin 18 
B7.c l KRTI9 KRTl9 keratin 19 NM_002276 keratin 19 
B8.cl KRT20 KR120 keratin 20 X73S02 keratin 20 
B9.c l DES DES desmin NM_001927 desmin 
BI0.c l VIM VIM vimentin NM_003380 vimentin 
B 11.cl GFAP GFAP glial fibrillary acidic protein NM_0020SS GFAP 
B2.cS NEFH NEFH neurofilament, heavy polypeptide 200kDa NM_021076 NF-H 
B3.cS TUBA TUBA2 tubulin, alpha 2 KOOSS8 ex-tubulin 
B4.cS TUBB TUBB2 tubulin, beta 2 NM_001069 ~-tubulin 
BS .cS ACTA ACTAI actin, alpha 1, skeletal muscle NM_OOIIOO ex-actin 
B6.cS ACTB ACTB actin, beta NM_OOIIOI p-actin 
B7.cS BIINT ITGBI integrin, beta I M341 89 beta-l integrin 
B8.cS B3INT ITGB3 integrin, beta 3 NM_000212 beta-3 integrin 
B9.cS B4INT ITGB4 integrin, beta 4 XS3S87 beta-4 integrin 
BIO.cS BS INT ITGB5 integrin, beta S XS3002 beta-S integrin 
B L l.cS AIINT ITGAI integrin, alpha I X68742 alpha-I integrin 
BL.dl FLNA FLNA filamin A, alpha (actin binding protein 280) NM_0014S6 filaminA 
B2.dL A2INT ITGA2 integrin, alpha 2 Xl7033 alpha-2 integrin 
B3.dl A3INT ITGA3 integrin, alpha 3 MS9911 alpha-3 integrin 
B4.dl AS INT ITGA5 integrin, alpha S (fibronectin receptor) NM_00220S alpha-S integrin 
BS.dl A6INT ITGA6 integrin, alpha 6 NM_000210 alpha-6 integrin 
B6.dl AVINT ITGAV integrin, alpha V (vitronectin receptor) NM_002210 alpha-v integrin 
B7.dl PXN PXN paxillin Ul4S88 paxillin 
B8.dl ECADHR CDHl cadherin I, t~Ee I, E-cadherin (eEithelial) ZI3009 E-cadherin 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
Appendix II, B cont. 
Well IDa Chip co deb 
B9.dl ACATEN 
B 10.dl BCATEN 
B 11.d 1 PLAGBN 
B2.dS P120 
B3.dS SYNI 
B4.dS SYN4 
BS.dS LMNNA 
B6.dS LMNNB 
B7.dS COL 
B8.dS ALTFBR 
B9.dS NUP!S3 
BlO.dS TPR 
Bll.dS B23 
C2.al RPL31 
C3 .al RPL21 
C4.al RPLl9 
CS.a! LAMA 
C6.al LAMC 
C7.al LAMB! 
Gene symbol 
CTNNAl 
CTNNBl 
lUP 
CTNNDl 
SDCl 
SDC4 
LAMA4 
LAMBl 
COLlA 2 
FNlIFN 
NUP153 
TPR 
NPMl 
RPL3l 
RPL21 
RPLl9 
LMNA 
Gene description 
catenin (cadherin-associated protein), alpha 1, lO2kDa 
catenin (cadherin-associated protein), beta 1, 88kDa 
junction plakoglobin 
catenin (cadherin-associated protein), delta 1 / p 120 catenin 
syndecan 1 
syndecan 4 (amphiglycan, ryudocan) 
laminin, alpha 4 
laminin, beta 1 
collagen, type I, alpha 2 
fibronectin, alt splice 
nueleoporin IS3kDa 
nueleoprotein TPR / translocated promoter region 
nueleophosmin (nueleolar phosphoprotein B23, numatrin) 
ribosomal protein L31 
ribosomal protein L21 
ribosomal protein L 19 
laminA 
LMNA laminC 
LMNBl laminBI 
Accession no. 
NM_001903 
NM_001904 
NM_OO2230 
AF062339 
NM_002997 
NM_002999 
NM_002290 
NM_00229I 
NM_000089 
X0276 I 
NM_00S124 
NM_003292 
M28699 
NM_000993 
NM_000982 
NM_00098I 
X03444 
X0344S 
NM _00SS73 
Protein namec 
a-catenin 
~-catenin 
plakoglobin 
p 120 catenin 
syn-l 
syn-4 
laminin (alpha) 
laminin (beta) 
collagen 
fibronectin, alt splice 
NuplS3 
Tpr 
B23 
RPL31 
RPL21 
RPLl9 
laminA 
laminC 
laminBI 
C8.al LAMB 2 LMNB2 lamin B2 M94362 lamin B2 
C9.al LAP2A TMPO (A) thymopoietin alpha / lamina-associated polypeptide 2 alpha U09086 LAP2a 
CIO.al LAP2B TMPO (B) thymopoietin beta / lamina-associated polypeptide 2 beta U09087 LAP2~ 
C l1.a I CDK I CDC2 cell division cyele 2, G I to Sand G2 to M / cdk 1 NM_OO 1786 Cdkll cdc2 
C2.aS CDK2 CDK2 cyclin-dependent kinase 2 NM_001798 Cdk2 
C3 .aS CDK4 CDK4 cyelin-dependent kinase 4 NM_00007S Cdk4 
C4.aS CDK6 CDK6 cyelin-dependent kinase 6 NM_OOI2S9 Cdk6 
CS.aS CYCA CCNAl cyelin AI NM_003914 cyelin A 
C6.aS CYCBI CCNBl cyelinBJ NM_031966 cyelinBI 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
Appendix II, B cont. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
C7 .a5 CYCB2 CCNB2 cyclin B2 NM_004701 cyclin B2 
C8 .a5 CYCDI CCND1 cyclin Dl NM_053056 cyclin Dl 
C9.a5 CYCD2 CCND2 cyclin D2 NM_001759 cyclin D2 
ClO.a5 CYCD3 CCND3 cyclin D3 NM_001760 cyclin D3 
Cl1.a5 CYCE CCNE1 cyclin El NM_001238 cyclin E 
C2.bl CHKl CHK1 checkpoint kinase Chkl AF016582 Chkl 
C3 .bl CHK2 CHK2 checkpoint kinase Chk2 AF086904 Chk2 
C4.bl CDC25A CDC25A cell division cycle 25A NM_OOl789 Cdc25(A) 
C5.bl CDC25B CDC25B cell division cycle 25B NM_021874 Cdc25(B) 
C6.bl KU70 XRCC6 thyroid autoantigen 70kD (Ku antigen) NM_001469 Ku70 
C7.bl KU80 XRCC5 Ku autoantigen, 80kDa NM_021141 Ku80 
C8.bl DNAPKC PRKDC DNA-dependent protein kinase catalytic subunit U47077 DNA-PKcs (p350) 
C9.bl LIG IV LlG4 DNA ligase IV X8344 1 DNA ligase IV 
ClO.bl XRCC4 XRCC4 DNA-repair protein XRCC4 NM_022550 XRCC4 
C 11.b 1 RP Al RPA1 replication protein AI, 70kDa NM_002945 replication protein Al 
C2.b5 ATM ATM ataxia telangiectasia mutated U33841 ATM 
C3.b5 GATA4 GATA4 GATA binding protein 4 NM_002052 GATA4 
C4.b5 FGFR4 FGFR4 fibroblast growth factor receptor 4 NM_002011 FGFR4 
C5.b5 GAPDH GAPDH glyceraldehyde-3-phosphate dehydrogenase AF261085 GAPDH 
C6.b5 Ml CHRM1 cholinergic receptor, muscarinic 1 AF385587 cholinergic receptor Ml 
C7 .b5 M2 CHRM2 cholinergic receptor, muscarinic 2 AF385588 cholinergic receptor M2 
C8.b5 M3 CHRM3 cholinergic receptor, muscarinic 3 NM_000740 cholinergic receptor M3 
C9.b5 M4 CHRM4 cholinergic receptor, muscarinic 4 AF385590 cholinergic receptor M4 
ClO.b5 MS CHRM5 cholinergic receptor, muscarinic 5 NM_012125 cholinergic receptor M5 
C2.c I ERB2 H ER2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 M 11730 erb-b2 
C3 .cl CD14 CD14 CDI4 antigen M86511 CDI4 
C4.cl CLDNI CLDNJ c1audin 1 NM_021101 c1audin 1 
C5.c 1 CA 12 CA 12 carbonic anhydrase XII AF037335 carbonic anhydrase 12 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C) . 
C Name of the functional protein product of each gene on the chip. 
Appendix II, B cont. 
Well IDa Chip codeb 
C6.cl ASL 
C7.cl GLCTN2 
C8.cl IGF2 
C9.cl AQP3 
CIO.cl COX2 
Cll.cl NKRPIA 
Gene symbol 
ASL 
LGALS2 
IGF2 
AQP3 
PTGS21COX2 
KLRBI 
Gene description 
argininosuccinate lyase 
galectin 2 
insulin-like growth factor 2 (somatomedin A) 
aquaporin 3 
prostaglandin-endoperoxide synthase 2 (cyclooxygenase) 
NKR-PIA 
C2.cS hPMS2 PMS2 PMS2 postmeiotic segregation increased 2 
C3.cS SCL 7 AS SLC7 A5 solute carrier family 7 (cationic amino acid transporter, y+ system), member S 
C4.cS PARP PARPI poly (ADP-ribose) polymerase family, member 1 
CS.cS DRGI DRGI developmentally regulated GTP binding protein 1 
C6.cS TGIFP TGIF TGFB-induced factor (TALE family homeobox) 
C7.cS SOD2 SOD2 superoxide dismutase 2, mitochondrial 
C8.cS COLlA2 COLlA2 collagen, type I, alpha 2 
C9.cS NET 1 TSPANI tetraspan NET-I 
CIO.cS LITAF L/TAF lipopolysaccharide-induced TNF factor 
Cll.cS ATP2A3 ATP2A3 ATPase, Ca++ transporting, ubiquitous 
C2.d I GLCTN4 LGALS4 galectin 4 
C3.d 1 PIK3CG PI K3CG phosphoinositide-3-kinase, catalytic, gamma polypeptide 
C4.d 1 GSA GNAL G-s-alpha / guanine nucleotide binding protein (G protein) 
CS.dl STAT! STAT1 signal transducer and activator of transcription I, 91kDa 
C6.dl E2F4 E2F4 E2F transcription factor 4, pI07/pI30-binding 
C7.d I IgGR FCGR2B IGFR2 / Fc fragment of IgG, low affinity lIb, receptor 
C8.d 1 TRAILR TNFRSFlOA I TRAil tumor necrosis factor receptor superfamily, member lOa 
C9.dl IFBP FABP2 fatty acid binding protein 2, intestinal 
CIO.dl MSH2 MSH2 mutS homolog 2, colon cancer, nonpolyposis type I (E. coli) 
C Il.d 1 DLEUI DLEU 1 deleted in lymphocytic leukemia, I 
C2 .dS GROB CXCL2 GRO-beta / chemokine (C-X-C motif) ligand 2 
C3 .dS CFL CFLl cofilin I (non-muscle) 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C) . 
C Name of the functional protein product of each gene on the chip. 
Accession no. Protein namec 
NM_OOOO48 argininosuccinate lyase 
BC029063 galectin 2 
NM_OOO612 IGF2 
NM_OO492S aquaporin 3 
M90100 cox-2 
UI1276 hNKR-Pla 
NM_OOOS3S mutL homolog hPMS2 
NM_OO3486 SCL7AS 
NM_OOI618 PARP 
AF271994 DRG-l 
X897S0 TGIF protein 
NM_OOO636 SOD2 
VOOS03 collagen 
AF06S388 tetraspan NET-l 
NM_OO4862 TNF alpha / LIT AF 
AF068221 SERCA3 / ATP2A3 
NM_OO6149 galectin 4 
NM_OO2649 PIK3CG 
AHOO2748 G-s-alpha 
NM_0073IS STAT I 
NM_OOI9S0 E2F-4 
J04l62 leucocyte IgG receptor 
U9087S TRAIL receptor 
Ml8079 IFBP 
NM_OOO2SI MSH2 
NM_OOS887 DLEUI 
M36820 GRO-beta 
DOO682 cofilin 
Appendix II, B cont. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
C4.dS RBBP4 RBBP4 retinoblastoma binding protein 4 NM_00S610 RBBP4 
CS.dS GPX2 GPX2 glutathione peroxidase 2 (gastrointestinal) AF199441 GPX2 
C6.dS GOS8 RGS2 Regulator of G-protein signaling 2 (GO/G 1 switch regulatory protein 8) Ll3463 GOS8 
C7.dS PFNI PFNI profilin 1 NM_00S022 profilin 1 
C8.dS P27 CDKNIB cyclin-dependent kinase inhibitor 1B (p27, Kip 1) NM_004064 p27, Kipl 
C9.d5 CDl3 ANPEP aminopeptidase N / CD 13 M22324 CDI3 
CIO.dS FASL FASLG Fas ligand (TNF superfamily, member 6) D38122 FasL 
CIl.dS GTF3A GTF3A general transcription factor IlIA NM_002097 GTF3A 
Dl.al M Markere 
D2.al KLF4 KLF4 Kruppel-like factor 4 (gut) NM_00423S Kruppellike factor 4 
D3 .al MLHI MLHI mutL homolog I, colon cancer, nonpolyposis type 2 (E. coli) U07343 MLHI 
D4.al LCPI LCPI lymphocyte cytosolic protein 1 (L-plastin) NM_002298 L-Plastin 
DS.al CMYB MYB Myb proto-oncogene protein (C-myb) MIS024 cMYB 
D6.al DP2 TFDP2 transcription factor Dp-2 (E2F dimerization partner 2) NM_006286 TFDP2 
D7.al RALGPS RALGPSI Ral GEF with PH domain and SH3 binding motif 1 NM_014636 RALGPSI 
D8.al NAP 1 NCKAP I I NAP I NCK-associated protein 1 ABOl4S09 Napl 
D9.al. BAK BAKI BCL2-antagonistlkiller 1 U2376S Bak 
DIO.al NSAPI NSAP I I SYNCRI P NS I-associated protein 1 pseudo gene AFISSS68 NSAPI 
Dll.al CASP3 CASP3 caspase 3, apoptosis-related cysteine protease AY219866 caspase 3 
D12.al M Marker" 
D2.aS PKB PTK2BIPKB PTK2B protein tyrosine kinase 2 beta X61037 protein kinaseB 
D3.aS HPGl BGN biglycan 104S99 hPGI, biglycan 
D4.aS EPICAN CD44 CD44 antigen (Heparan sulfate proteoglycan) (Epican) X66733 epican 
DS.aS SCF SCF IKITLG stem cell factor / kit ligand precursor / Mast cell growth factor (MGF) MS9964 SCF 
D6.aS EIF3S2 EIF3S2 eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa NM_0037S7 P36, EIF3S2 
D7.aS CEA CEACAM31CEA carcinoembryonic antigen-related cell adhesion molecule 3 M29S40 CEA 
D8.aS ETS2 ETS2 v-ets er~throblastosis virus E26 onco&ene homolo~ 2 104102 ets-2 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
e Marker = either GAPDH or ~-actin, see well ID A I.a I and A 12.a I for accession numbers . 
Appendix II, B cont. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
D9.a5 MCM5 MCM5 minichromosome maintenance deficient 5, cell division cycle 46 NM_006739 MCM5 
D1O.a5 PKCD PRKCD protein kinase C, delta NM_006254 protein kinase C, delta 
Dl1.a5 TIMPI TIMPI tissue inhibitor of metalloproteinase I NM_003254 TIMPI 
D2.bl OSTNCT SPARC secreted protein, acidic, cysteine-rich (osteonectin) J03040 osteonectin 
D3.bl BIGH3 TGFBI I BIGH3 transforming growth factor, beta-induced, 68kDa M77349 TGF beta induced 
D4.bl RHOA RHOA ras homolog gene family, member A NM_001664 RhoA 
D5.bl EPHBI EPHBI EPHreceptorBI NM_004429 ephrinBI 
D6.bl MCM3 MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) NM_002388 MCM3 
D7.bl TRAIL TNFSFlOITRAIL TNF-related apoptosis-inducing ligand U37518 TRAIL 
D8.bl PLS3 PLS3 plastin 3 (T isoform) NM_005032 T-Plastin 
D9.bl CASP8 CASP8 caspase 8, apoptosis-related cysteine protease NM_001228 caspase 8 
D1O.bI BCL3 BCL3 B-celJ CLUlymphoma 3 NM_005178 bel-3 
Dl1.bl AGPI ORMI Alpha-I-acid glycoprotein I precursor (AGP 1) (Orosomucoid 1) (OMD I) X02544 alpha-I-acid glycoprotein I 
D2.b5 UNG UNG uracil-DNA glycosylase Y09008 uracil DNA glycosylase 
D3 .b5 CA2 CA2 carbonic anhydrase II NM_000067 carbonic anhydrase 2 
D4.b5 OSTPNT SPP} secreted phosphoprotein 1 (osteopontin) 104765 osteopontin 
D5 .b5 MCTI SLCI6AI solutecarrierfamily 16 (monocarboxylic acid transporters), member 1 NM_003051 MCn /SLC16a5 
D6.b5 FABPI FABP} fatty acid binding protein I, liver BC032801 FABPL 
D7.b5 TEF3 TEAD4 Transcriptional enhancer factor TEF-3 (TEA domain family member 4) X94438 TEF-3 
D8.b5 IL3 IL3 interleukin 3 (colony-stimulating factor, multiple) NM_OOO588 interleukin 3 
D9.b5 P21 CDKN}A cyelin-dependent kinase inhibitor IA (p21, Cipl) NM_000389 p21, Cipl 
DIO.b5 ENCI ENC} ectodermal-neural cortex (with BTB-like domain) NM_003633 ENCI 
Dll.b5 VERSCN CSPG2 chondroitin sulfate proteoglycan 2 (versican) Xl5998 versican 
D2.cl FAS FAS Fas (TNF receptor superfamily, member 6) X83493 Fas 
D3.cl VEGF VEGF vascular endothelial growth factor NM_003376 VEGF 
D4.cl MAPKI MAPK} mitogen-activated protein kinase I NM_002745 MAPKI 
D5 .cl USF2 USF2 upstream transcription factor 2, c-fos interacting NM_003367 USF2 
D6.c 1 KI67 M KJ67 antigen identified by monoelonal antibody Ki-67 NM_0024 I 7 Ki-67 antigen 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
Appendix n, B cont. 
Well IDa Chip codeb Gene symbol Gene description Accession no. Protein namec 
D7.cl lAP 1 BIRC2 baculoviral lAP repeat-containing 2 / apoptosis inhibitor 1 U45878 clAP 1 
D8.c1 P150 CHAFIA chromatin assembly factor 1, subunit A (p 150) NM_OO5483 p150 
D9.cl NBSI NSBI Nijmegen breakage syndrome 1 (nibrin) AF058696 NBSl, p95 
DI0.cl CLDN4 CLDN4 claudin 4 NM_001305 claud in 4 
Dll.cl CCR7 CCR7 chemokine (C-C motif) receptor 7 ABOO0887 CCR7, EB 1 ligand 
D2.c5 PLZF ZBTBI6 PLZF / zinc finger and BTB domain containing 16 AF060568 PLZF 
D3.c5 SURVVN BIRC5 apoptosis inhibitor 4 - survivin NM_001168 survivin 
D4.c5 HP HPSE heparanase AFI44325 heparanase 
D5.c5 RANBP7 IP07 / RANBP7 importin 7 AF098799 RANBP7 / importin 7 
D6.c5 AIATRY SERPINAI serine proteinase inhibitor, clade A (alpha-l antiproteinase, antitrypsin), member 1 X01683 alpha-I-antitrypsin 
D7.c5 MACFl MACFI microtubule-actin crosslinking factor 1 NM_012090 MACFl 
D8.c5 CAST CAST cal pasta tin D16217 CAST 
D9.c5 PRG3 AMID/PRG3 p53-responsive gene 3 AF337957 PRG3 
DlO.c5 JPOI JPOI / LOC442 I 72 c-Myc target JPOI AY029179 c-myc target protein, JPO 1 
Dll.c5 MXD3 MXD3 MAX dimerization protein 3 NM_031300 MXD3 
D2.dl MDM2 MDM2 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) AF092844 MDM2 
D3.dl REGPI REGIB regenerating protein I beta Dl7291 regenerating protein I beta 
D4.dl SPI SPI Sp 1 transcription factor AF252284 Spl 
D5.dl CIG5 RSAD2 radical S-adenosyl methionine domain containing 2 / cig5 / viperin AF026941 cig5 
D6.dl PLCB2 PLCB2 phospholipase C, beta 2 NM_OO4573 phosholipase C, beta 2 
D7.dl ALTFBR FNI/FN fibronectin, alt splice X02761 fibronectin, alt splice 
D8 .dl CASP7 CASP7 caspase 7, apoptosis-related cysteine protease NM_OO1227 caspase 7 
D9.dl NEBL NEBL nebulette YI6241 nebulette 
DlO.dl TCOFI TCOFI Treacher Collins-Franceschetti syndrome I NM_OOO356 TCOFI 
Dll.dl MTIA MTIA metallothionein I A (functional) KOl383 Metallothionein-I-A 
D2.d5 MUC2 MUC2 mucin 2, intestinal/tracheal NM_OO2457 mucin 2 
D3 .d5 SI SI sucrase-isomaltase (alpha-glucosidase) NM_OO1041 sucrase isomaltase 
D4.d5 CDX2 CDX2 caudal t~Ee homeo box transcriEtion factor 2 AHOO7259 cdx2 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
C Name of the functional protein product of each gene on the chip. 
Appendix n, B cont. 
Well IDa Chip codeb 
D5.d5 EPHB2 
D6.d5 BAD 
D7.d5 BGPI 
D8.d5 XRCC3 
Gene symbol 
EPHB2 
BAD 
CEACAMI / BGPI 
XRCC3 
Gene description 
EPH receptor B2 
BCL2-antagonist of cell death 
carcinoembryonic antigen-related cell adhesion molecule I (biliary glycoprotein) 
X-ray repair complementing defective repair in Chinese hamster cells 3 
D9.d5 Tl8 TI8 T-18 
DIO.d5 GLUT 1 SLC2AI / GLUTI solute carrier family 2 (facilitated glucose transporter), member 1 
a The position of each gene on the chip. b Code used to identify gene on the plate template (Appendix II, C). 
e Name of the functional protein product of each gene on the chip. 
Accession no. Protein namee 
AF025304 EPHB2 
AF031523 BAD 
NM_OO1712 BGPl 
AF035586 XRCC3 
AF08981l T-l8 
AY034633 GLUTl 
Appendix II, C 
The plate template shows the position of all genes on the Colorectal Cancer 
Oligonucleotide Chip. 
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Appendix II, C. Plate template for Colorectal Cancer Oligonucleotide Chip. M = marker, either Il-actin or GAPDH. 
I 2 3 4 5 6 7 8 9 10 II 12 
I 
A GAP ACT SOX SOX2 NDI GAT SOX8 EPH SOX LAM BRA BMP SNA GAP FUT PLP NOT FUT MAP BMP AST GJA ACT NOT 
DH A2 II A4 AI 10 BI CHY I P25 43 2 CH2 I T 6 N I B CHI 
PAX ND3 TOG AN NHL SYP TLE NOT SOX NOT SCG ACT TF FNI MAP VTN RE NE BMP KRT ND4 CRI ND2 MYO 
6 Fl IL H2 2 CH4 9 CH3 10 B 2 ST FL 4 18 PTO DI 
NSE HAT NES MAS SOX SOX SOX3 FOX KRT PRP NE AIM MYC SOD SOXI MMP OCT VCL CLC PAR ZNF TUB MA HSP 
HI H2 4 17 E3 8 H FM I N I 3 4 NKB NMN 74 G SHI 70 
HSP DSP CRY PAK PRO MMP CRY NF2 SYN TlA ACT MMP HSP ILK PIT RAC HSP VIL IGF GPC CDC PPL HSC PLE 
90 AB I XI 9 AA MI GI 14 27 X3 I 20 2 IR 3 42 70 CI 
B H APC K DCC C P53 C RBI C WTI C NFl C NFK C ZFP C RAR EIA RXR 
RAS RAS SRC ABL MOS RAF MYC BI FOS 91 JUN A A 
RHO 5T4 PD TCF EGF TCF FGF TCF TGF OCT TGF BCL PDG BCL EGF TER FGF MDR TGF MDR KRT 
C GF I 3 4 A 4 B 2 FR X R T R I R 3 I 
MMP KRT NEF KRT TUB KRT TUB KRT ACT KRT ACT KRT BI KRT B3 DES B4 VIM B5 GFA AI 
I 5 H 8 A 10 B 14 A 18 B 19 !NT 20 INT MIN INT NTN INT P !NT 
FLN A2 P A3 SYN A5 SYN A6 LMN AV LMN PAX COL ECA ALT ACA NUP BCA TPR PLA B23 
A INT 120 !NT I INT 4 !NT NA !NT NB L!N DHR FBR TEN 153 TEN GBN 
C RPL CDK RPL CDK RPL CDK LAM CYC LAM CYC LAM CYC LAM CYC LAP CYC LAP CYC CDK CYC 
31 2 21 4 19 6 A A C BI BI B2 B2 DI 2A D2 2B D3 I E 
CHK ATM CHK GAT CDC FGF CDC GAP KU MI KU M2 DNA M3 LIG M4 XRC M5 RPA 
I 2 A4 25A R4 25B DH 70 80 PKC IV C4 I 
ERB HPM CDI SCL CLD PAR CAI2 DRG ASL TGI GLC SOD IGF COL AQP3 NET COX LIT NKR ATP 
2 S2 4 7A5 NI P 1 FP TN2 2 2 1A2 I 2 AF PIA 2A3 
GLC GRO PIK CFL GSA RBB STA GPX E2F GOS IgG PFN TRA P27 IFB CD MSH FAS DLE GTF 
TN4 B C3G P4 TI 2 4 8 R I ILR P 13 2 L UI 3A 
D M KLF PKB MLH HPG LCP EPI C SCF DP2 ElF RAL CEA NAP ETS BAK MCM NSA PKC CAS TIM M 
4 I I I CAN MYB 3S2 GPS I 2 5 PI D P3 PI 
OST UNG BIG CA2 RHO OST EPH MCT MCM FAB TRA TEF PLS IL3 CAS P21 BCL ENCI AGP VER 
NCT H3 A PNT BI I 3 PI IL 3 3 P8 3 I SCN 
FAS PLZ VEG SUR MAP HP USF RAN KI AlA lAP MAC PI50 CAS NBS PRG CLD JPO CCR MXD3 
F F VVN KI SE 2 BP7 67 TRY I FI T I 3 N4 I 7 
MDM MUC REG SI SPI CDX CIG EPH PLC BAD ALT BGP CAS XRC NEB Tl8 TCO GLU MT 
2 2 PI 2 5 B2 B2 FBR I P7 C3 L FI TI IA 
-- '--- - --
Appendix II, D 
The mean fold change ± standard deviation (S.D.) for each gene in each replicate 
micro array experiment is tabulated here. A mean fold change between -1 and + 1 
indicates that the degree of hybridization varied between the spots and that the gene was 
not uniformly up- or down-regulated. Data highlighted in grey corresponds to the genes 
listed in Chapter 4, Table 4.1 which were at least 1.5 fold up- or down-regulated in test 
versus control samples. When only mean fold change is given without a S.D., this 
mdicates that there were less that three good spots for a particular gene. X = all four 
;pots bad, therefore gene was excluded from analysis in that particular experiment. 
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Appendix II, D. Mean fold change ± S.D. for each gene in each replicate microarray experiment. 
UROD1 
SOX8 
SOXlO 
T 
SNAP25 
Fun 
NOTCH2 
MAPTITAU 
SOX2 
GATA4 
EPHAI 
LAMB1 
1 
-0.61 
1.12 
-0.10 
-1.06 
0.02 
0.59 
-1.13 
1.160 -1.56 0.361 
0.091 -1.09 0.42 
1.340 -1.05 0.024 1.31 
0.006 0.00 1.170 -1.01 
1.550 -1..73 0.228 1.39 
1.070 -1.07 0.023 1.14 
0.111 -0.52 1.070 1.27 
x X -1.28 0.106 1.25 
-1.46 0.280 -1.47 0.170 1.23 
-0.87 2.200 -2.99 0.529 0.41 
-1 .09 0.081 -0.05 -0.52 
0.342 
1.240 
0.360 
0.013 
-1.12 0.022 -0.35 1.230 1.....1;.;..0;;...4 ....... ~-.:...:..;,...--l 
1.12 0.057 -0.41 1.230 .... ·....:1::.;7;..;4:...i..·~-I_=~ 
-1.10 0.031 1.15 0.061 
1.27 0.290 -94.10 165.000 
1.48 0.371 13.20 2.130 I 2.58 
-1.43 0.340 -0.82 1.300 1.11 
-1.23 0.132 0.04 1.280 
0.Q3 1.310 -0.33 1.200 
1.09 
1.49 
-1.l4 0.Q38 -0.03 1.55 
-0.59 1.240 -1.27 0.140 1.27 
-1.13 0.015 -0.53 1.020 
-1.05 0.014 
1.17 
-0.04 
-1.19 
-1.32 
-0.47 
-1.06 
0.076 
0.231 
1.280 
0.017 
1.27 0.040 
1.08 0.057 
-0.38 1.210 
om 1.180 
1.23 0.042 
-0.36 1.210 
-1.05 0.036 
1.09 
0.50 
0.02 
1.21 
1.12 
1.16 
1.25 
7.57 
0.093 1.24 
X 
0.01 
1.11 
1.35 
1.13 
4.86 
2.41 
1.06 
5.370 0.09 
X -3 .13 
1.190 1.16 
0.062 1.03 
0.033 
0.035 
0.30 1.260 1.10 
1.28 1.35 0.129 
1.10 I I 1.21 
0.182 -0.61 
1.090 
0.056 
1.110 
1.210 
0.037 
0.032 
0.039 
-1.61 
-0.70 
-0.95 
-1 .29 
1.46 
-0.17 
0.491 
1.770 
1.440 
0.153 
0.180 
1.540 
-1.25 
1.14 
-0.30 
-1.05 
-0.33 
0.54 
0.03 
0.087 
0.022 
1.250 
0.021 
1.210 
1.090 
1.210 
1.31 
-0.74 
-0.62 
-1.09 
-0.63 
-1.15 
-1.28 
0.103 
1.240 
1.130 
1.450 
0.139 
0.075 
1.320 I , ..; _--=-1 _... I 
1.070 
0.091 I·. ':'~~;;~~;f,~ , -0.26 
1.310 l.;sn· ~;~ ';~., -0.56 
1.250 I-~~-.;;.;.;;.;.;o-l 
0.030 1.22 
2.91 0.577 0.58 
0.070 -1.29 0.20 I -1.04 
0.019 0.40 1.470 1.09 0.107 -0.72 
0.097 -1.22 1.17 0.081 1.48 
0.021 0.94 1.470 1.26 0.019 1.40 
1.52 0.329 1.35 
-0.53 
1.89 0.243 -1.49 0.631 
1.43 0.067 1.10 0.025 
0.171 
1.350 
0.Q25 
0.083 
1.350 
1.07 0.02 1.210 __ 
1.15 0.066 1.79 ' I~ 
1.20 0.041 1.17 - . 
0.54 1.040 0.57 1.090 
-0.35 1.200 lAO 0.148 
-1.05 0.012 -1.07 
1.41 0.151 1.31 0.210 
0.36 I 1.270 I -1.07 . I ·····Y'· ' p ;;1.4·;<' It V,IQO 1.31 0.145 
1.83 I 0.566 I 2.06 0.671 0.82 1.240 
1.07 I 0.031 I -1.26 1.26 0.Q38 1.08 0.061 
Gene 
TLE2 
REST 
BMP4 
NEUROD4 
NEUROD2 
D cont. 
1.240 
0.080 
0.123 
-1.15 
-0.06 
0.51 
-1.06 
0.054 
1.280 
1.260 
0.030 
1.32 
-1.16 
-0.04 
-1.03 
0.167 
0.050 
1.270 
0.026 
-1.16 
1.23 
1.12 
0.042 
0.040 
-0.36 
1.17 
1.210 
1.200 
0.006 
1.04 
-0.57 1.050 
1.050 
-1.44 
1.39 
1.56 
0.115 
0.235 
1.16 
1.15 
1.34 
-0.02 
0.120 
0.040 1 •. _- 1 _ .• _- 1 
1.12 0.039 '"'-
-0.51 1.030 
1.27 0.204 1 - .~ - 1 _._-- 1 
-1.75 I 0.172 I -1.16 0.172 
1.09 
1.20 1 0.040, - . .. "- I 
-1.15 
-1.09 
-0.54 
0.01 
-1.58 
1.22 
0.36 
-1.06 
1.32 
-1.45 
-1.15 
0.079 -2.66 0.255 
0.075 1.12 0.017 
1.070 -1.24 0.138 
1.290 -0.59 1.090 
-1.28 1 0.110 
0.067 -3.32 0.501 
1.180 1.02 0.010 
0.042 0.57 1.050 
0.036 1.04 0.005 
0.275 -1.28 0.156 
x 
1.27 0.142 
-1.24 0.117 , .. 'v , -.'9"""1 
-1.14 0.01 8 
-1.04 0.014 
-1.09 0.008 , , , 
-1.12 0.061 I • -- 1- ____ I 
1.20 
1.14 
1.30 
0.68 
1.43 0.061 1.18 0.Ql5 
1.25 0.096 -1.32 0.10 I 
1.34 0.148 -l.l8 0.032 
-1.15 0.080 0.58 1.060 
-0.56 1.480 -3.63 0.947 
1.19 0.104 
0.Q3 
0.54 1.080 ' .. 
1.200 1 -0.40 1 1.230 1 -0.32 1 1.410 1 1.33 1 0.084 
0.113 l.l9 0.042 0.54 1.110 1.25 
1.33 2.58 I 0.211 -0.53 1.050 1.65 0.651 
X -1.09 
0.071 0.00 
1.220 -0.52 
0.044 -0.54 
0.012 0.02 
0.03 
0.150 1.26 
0.102 
1.190 .... 1 -~-_-_ -I - -.- 1 072 1.480 1 1.30 
1.010 
1.050 
1.230 
1.220 • -- I - u_ 1 
1.25 
1.11 
1.13 
-1 .05 
-1.12 
1.31 0.136 
0.073 1.250 -0.32 
0.050 
0.024 
0.035 
0.067 
-1.44 
1.24 
0.01 
-1.46 
0.209 
0.076 
-195 0.045 , 
0.140 11--_-' .""--. -11-~-~-..,..- ~. 1 
0.323 
0.197 
~:~~~ I ' ~:;~ I, ~:~~? I 
X 
1.12 
-0.05 
1.08 
-1.01 
1.86 
1.49 
-1.06 
1.40 
-1.13 
0.040 I 1.48 
1.07 
0.04 
1.49 
-0.52 
1.27 0.099 ~.. .._ ., 
1.20 0.114 , :. :. " ~ V.J~ I L':'VV I 
-1.07 .. ~ A$ .. _ .. u o:r.= 1.05 0.026 -1.64 
0.297 1.22 0.154 • _. - --~ 
1.420 1.25 0.096 0.100 
1.20 0.065 -1.32 0.312 
-1.24 0.159 2.38 
0.069 -1.42 0.162 0.13 
0.37 1.240 0.02 1.220 1.26 
1.30 0.240 1.,-' ',r. 1.13 0.173 ' J;,1. l' '. 
1.06 0.058 
-0.10 2.580 0.56 1.100 
1.860 1.25 0.033 -1.18 0.023 
0.172 1.31 0.056 1.07 0.057 
1.26 0.133 0.03 1.200 0.04 1.220 1.36 0.131 -1.04 0.025 -1.04 0.032 
-1.08 -1.06 0.010 0.00 
0.52 1.020 -0.54 1.100 0.26 
-1.05 0.005 . , . 
1.31 0.126 I . 0" ... · 1. " .... ""'d 
1.380 -1.07 
-1.28 I 0.2 15 I -2.90 0.551 -0.15 2.080 I~J~' 1 -0.12 1.350 -1.45 0.101 2.97 
-1.09 0.26 1.490 1.04 0.021 10.52T1.06() 0.52 1.040 -0.41 1.260 0.36 
1.05 0.Q35 ~. __ ' ~._._ 
1.040 -4.38 1.810 
1.090 -1.55 0.106 
1.430 0.55 
1.220 0.59 
II, D cont. 
Gene 
POU5Fi 
CLCNKB 1.29 0.065 0.52 1.030 -0.51 1.030 0.60 1.080 1.02 0.Ql8 1.26 0.042 1.13 
ZNF74 
-1.07 0.Ql5 -1.03 0.029 -1.08 0.033 1.23 0.124 -1.07 0.029 0.53 1.050 -0.76 1.340 -1.04 
MASHi 1.29 0.063 -0.01 0.63 1.090 0.119 -1.22 0.104 1.18 0.091 1.53 1.28 
1.40 0.252 -18.30 26.800 1.61 2.280 6.31 -0.60 1.090 1.56 2.34 
0.55 1.050 -8.37 4.760 154-: 0.443.: 1.25 0.097 -0.62 1.090 1.29 0.049 1.28 0.239 
-1.15 0.079 0.52 1.050 1.09 0.061 -1.20 0.078 1.16 0.070 -1.10 0.043 1.20 0.050 1.08 0.049 
-1.08 0.014 -1.04 0.045 -1.04 0.021 -1.14 0.008 -1.04 0.005 -1.03 0.010 
-1.02 0.019 
-1.13 0.035 -0.51 1.010 -0.53 1.020 -1.14 0.021 -1 .06 0.024 -1.11 0.022 0.34 1.170 
-0.36 1.290 -2040 0.863 -1.81 0.833 - lAO 0.120 0.00 1.280 -1.28 0.057 1.16 0.232 
-0.49 1.340 1.04 0.040 0.02 1.310 1.33 -1.04 0.031 0.Ql 1.200 1.25 0.087 
-1.10 -0.54 1.060 1.15 0.095 
-0.52 1.030 0.35 
-0.54 1.030 
1.37 0.076 0.57 1.050 1.09 1.43 0.066 
-1.47 0.165 
-1.56 0.176" - -1.96 1.30 0.082 
0.54 1.080 0.55 1.060 -1.09 0.03 0.35 1.280 
-1.08 0.024 X X -1.04 
-1.11 0.028 -1.06 
-1.31 0.327 -0.53 1.030 
- 1.09 0.047 0.51 1.040 1.18 0.134 1.45 0.061 1.08 1.37 0.040 -0041 1.240 
-1.08 0.010 
-1.04 0.024 
-1.05 0.008 -1.04 0.022 1.140 -1.03 
-0.53 1.040 
-0.53 1.060 
-0.53 1.080 
-0.58 1.070 -1 .35 0.104 0.57 1.580 1.25 0.054 -0.58 1.150 
-1.05 0.019 -1.03 0.025 -0.52 1020 - 1 0(\ 0 0<1(\ _1 1 () () ()?? _ 1 1 <; () ()<;7 ') f'I,) () ")1 .., 
-0.51 1.050 
-0.53 1.350 
-1.04 0.Q35 
-1.17 -.' 1.4<'· 1).03,8 1.06 0.064 1.25 0.012 0.63 1.090 1.21 0.086 1.05 0.056 
-1.08 0.D25 -1.06 0.Ql5 -0.01 1.200 -0.35 1.180 -1.06 0.033 -1.06 0.025 1.36 0.076 -l.l0 0.0 17 
-0.04 -1.28 0.136 -0.55 1.070 -1.37 0.168 -1.13 0.066 -l.l8 0.052 1.35 0.042 0.52 1.040 
-1.03 0.022 -0.35 1.170 0.00 1.180 0.046 0.Q7 1.280 0.01 1.200 1.18 0.066 -1.04 0.Q38 0.63 1.110 CDC42 -0.52 1.040 -1.05 0.028 -1.04 0.024 0.41 1.250 -1 .43 0.386 - 1.06 0.021 1.11 0.070 
HSPA8 / HSC70 -1.19 0.105 -1.06 -1 .23 0.075 
-1.04 0.Ql5 -0.66 1.550 1.05 0.025 0.35 1.230 DSP 1.05 0.053 -1.24 0.196 -1.24 0.180 -0.04 1.230 1.26 0.082 -1.10 0.070 -0.90 1.360 1.25 0.077 -0.40 1.220 
Appendix II, D cont. 
Gene 
PAKl 
MMP9 -1.22 0.059 -0.02 1.200 -1.43 0.270 -1.38 0.103 -1.05 0.030 -1.24 0.143 1.22 1.06 0.047 -1.32 
NF2 
-1.05 0.055 -0.57 1.060 -1.22 0.149 -1.25 
-1.08 0.021 -l.l7 0.022 -1.38 1.920 1.23 0.018 -1.21 
TIAMl 
-1.25 0.101 l.l4 0.032 -0.57 1.050 
-1.03 0.017 -l.l4 0.022 X X -1.22 0.111 
MMPl4 0.52 1.020 -l.l7 0.066 -l.l5 0.008 
-l.l0 0.024 -1.31 0.084 0.06 1.240 -1.49 0.081 lLK 
-1.22 0.104 -1.22 0.110 -l.l7 0.Q38 
-0.60 1.060 -1.26 0.092 l.l0 0.100 -1.38 0.125 
RAel -0.55 1.100 -1.16 0.076 1.34 0.117 1.22 0.119 -1.35 0.373 l.l2 1.05 0.067 
VIL2 l.l9 -LOS 0.022 -0.35 1.180 0.52 1.050 -0.02 1.210 1.27 0.056 -0.01 1.230 
-1.21 0.104 l.l6 1.05 0.022 
-1.26 0.130 1.40 0.096 -0.58 1.080 
-1.43 -l.l6 0.223 -l.l7 0.073 
-l.l8 0.135 1.08 0.017 -1.23 0.091 
-1 .24 0.108 X X -1.10 
-1.15 0.021 
-0.50 1.310 0.35 1.210 
-0.54 1.030 -0.54 1.060 1.19 0.045 0.52 1.010 1.27 0.029 1.16 0.111 
X X -1.76,"" . 0.215 1.13 0,106 
-1.09 0.085 -0.53 1.140 -1.53 0.144 -1.24 0,067 -0,14 1.460 
0.45 1.360 -1.37 0,131 -0,03 1,340 
-1.34 
-1.05 0,010 0,34 1.970 ~1. 6 0.441 -1.46 0,282 
0.65 1.120 -1.08 0.041 -134 o n() 
-1.34 0.149 -1.06 0.036 
-0.40 
-1.34 
-1.23 
-0.53 
-1.26 0.007 -1.05 0.015 -1.31 0.223 -1.42 0,254 -1.06 
-1.08 0.096 0.52 1.050 0,34 1.170 -1.02 0.006 -1.33 0.34 
-1.24 0.173 -1 .33 0.079 
-0.61 1.210 0.52 1.070 1.75 -1.33 0.216 -1 .28 0.166 
-1.13 0.023 0.52 1.080 
-1.17 0,044 -1.17 0.Ql8 1.04 0.017 -1.33 0,060 
1.36 0.100 -0.11 
-1.41 0.679 -1.07 0.006 0.55 1.100 1.41 
1.31 0.076 -1.41 1.09 0.116 0.55 1.060 
-1.18 0.099 -0.04 1.240 
1.14 1.17 0.022 
-1.17 0.030 -0,52 1.040 0.Ql 1.250 1.08 0.087 0.61 1.130 
0.76 1.570 -5.19 1.010 -3.46 10.300 X -1.46 0.392 1.55 0.316 X X -1.68 0.434 1 -1.42 0.061 1.06 0,031 -1.12 0.010 
-1.07 0.022 -1.38 0.279 -0,52 1.020 1.13 0.108 
0,17 1.540 -1.94 0.S12 0.58 1.420 
-0.51 1.030 -1.56 0.01 1.210 -1.69 0.659 
AppenOlX ll, U com. 
LAMIN A vs GFP EMERIN vs GFP LAMIN A vs EMERIN 
Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 
Gene symbol Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. 
RARA 
-2:02 0.086 0.04 1.210 -1.06 0.034 1.06 Om7 0.50 1.050 -0.37 1.190 -0.20 1.420 0.55 1.070 1.10 0.056 
RXRA -0.06 0.52 1.020 -1.07 0.035 1.26 0.029 -1.08 0.047 -1.04 0.006 -0.65 1.440 . -'1.9a (t276 1.21 0.079 
RHOC 1.05 0.055 -0.68 1. 180 -1 .28 0.060 X X 1.46 0.034 1.08 2.75 0.280 -1.66 0.584 -23.42 
TPBG 0.00 1.180 0.35 1.270 0.53 1.030 1.15 0.025 1.14 0.061 1.06 0.036 0.94 1.370 0.64 1.100 0.36 1.280 
TCFl 
-1.04 0.024 1.04 0.039 -1.02 0.012 -1.10 0.041 -1.02 0.017 -1.02 0.012 ·.~.J:a3,,"' 'JlJ1l~ -1.03 0.010 -1.06 0.021 
TCF3 
-1.19 0.017 0.53 1.030 -1.27 0.075 1.09 0.079 0.03 1.240 -1.03 0.012 1.49 0.425 -0.34 1.170 -1.04 0.054 
TCF4 1.43 0.154 1.06 0.015 <:~o ~~ -1.42 0.104 1.30 0.025 -1.05 0.019 .rm-,;. iBII: 1.17 0.050 1.25 0.040 POU5Fl -0.04 1.220 -1.16 0.055 -1.09 Om5 -1.40 0.260 -1.16 0.048 -1.16 0.033 1.24 0.068 -0.05 1.240 -0.60 1.090 
BCL2 -0.36 1.180 -0.52 1.010 0.03 1.280 -1.13 -1.05 0.029 -1.06 0.021 -1.06 -1.06 0.019 -1.05 0.017 
BCL2L1 -1.06 0.030 -1.01 0.010 1.07 0.010 -1.13 0.021 -1.06 0.030 -1.03 0.022 -1.47 
-1.05 0.032 -1.06 0.024 
TERT 1.29 0.164 1.23 -1 .08 0.067 -0.01 1.180 -1.08 0.047 -1.04 0.021 -0.45 1.330 1.1 1 0.034 1.18 0.096 
ABCBl -1.21 0.098 -1.16 1- .,.1,&9 - . O;~" 1.13 0.106 -1.27 0.066 -1.04 0.010 
-2M Ij;~:'~· -1.07 0.043 -1.30 0.15 1 
ABCB4 -1.07 0.076 1.05 0.006 -0.01 -1.02 0.021 -1.05 
-0.52 1.010 0.35 1.210 0.33 1.170 -0.01 
PDGFA 
-1.01 0.013 -0.52 1.010 0.53 1.040 -1.09 0.013 -0.01 1.190 0.51 1.020 -1.43 0.266 -1.02 -1.02 0.010 
EGF 1.20 0.012 1.1 7 0.041 1.37 0.099 1.14 0.046 1.08 0.021 1.13 > 'Ii: ..... ,~ 51 .~ 1.20 0.060 1',12'" ~ I'~  ~ ~ FGF5 -0.59 1.310 -1 .27 0.167 -1.34 0.159 ;2.02 ~ · O~Q1Q ; -1.10 0.028 -1.16 0.022 ~ ~~ , . • om 1.1 70 -1.16 0.031 TGFA -1.21 0.036 -1.04 0.031 -1.08 0.029 -1.11 0.012 -1.04 0.023 -1.03 Om8 ~ . ~ J ~: -1.06 0.049 -1.06 0.029 
TGFB 0.00 1.1 70 0.53 1.020 X X -1.07 0.52 1.030 -0.50 1.010 -1.11 0.047 -0.34 1.180 om 1.170 
PDGFRA -1.05 0.012 0.00 1.160 -1.03 0.005 -1.13 0.026 -1.02 0.017 -1.03 0.0 10 -1.14 0.021 -1.02 0.033 -1.10 0.021 
EGFR -1.11 0.065 -1.01 0.012 0.03 1.220 -0.57 1.060 -1.06 0.017 -1.04 0.017 -1.27 0. 145 -1.07 0.027 -1.07 0.Q25 
FGFRl 1.08 1.05 0.005 0.53 1.030 -1.07 0.025 1.02 Om7 1.04 0.0 15 -1.12 0.51 1.030 0.36 1,200 
TGFBR2 -0.33 1.460 1.40 0.045 0.01 1.200 1.26 0.058 -1.09 0.022 -0.35 1. 180 -1.57 0.292 1.23 0.057 1.13 0.059 
KRTl -1 .21 1.17 0.008 -1.32 0.139 ;,1:~ .~ -1.15 0.052 0.35 1.190 -1.41 -7.~ 6.240 1.29 0.114 
MMPl -1 .36 0.092 -1.1 7 0.089 0.61 1.150 X X 2.34 0.292 1.16 0,058 3.74 0.311 -1.34 0,203 
-18.03 
KRT5 0.54 1.030 0.57 1.040 -1.06 0.029 -1 ,04 0.024 0.51 1.040 -0.32 1.200 -1.01 1.430 1.27 0.017 -1.11 0.021 
KRT8 -0.38 1.200 1.19 0.050 -0.54 1.050 -0.04 1.240 -0.55 1.030 -0,52 1.050 . -2·24 : '. 0.321 1.11 0.013 1.16 0,054 
KRTlO -0.35 1.180 -1.02 0.021 -1.12 0.010 -1.09 0.023 -0.38 1.200 -0.36 1.200 0.02 1.650 -0.03 -1.04 
KRT14 1.32 0.085 1.10 0.062 -1.08 0.017 1.04 Om5 -1.05 0.012 -1.06 0.022 -1 .50 0.294 0.55 1.040 -1.01 0,006 
KRT18 1.17 0,010 om 1.170 0.32 1.190 -0.55 1.040 -1.03 0.031 -1.03 Om5 0.40 1.240 -1.02 0.017 -1.03 0.014 
Appendix 11, U cont. 
LAMIN A vs GFP EMERIN vs GFP LAMIN A vs EMERIN 
Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 
Gene symbol Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. 
KRTl9 1.45 0.125 1.10 0.039 -0.08 1.350 1.11 0.031 -1.12 
-1.06 0.029 -1.17 0.202 1.07 0.006 -0.56 1.050 
KRT20 1.22 0.183 -1.46 0.106 1.24 -25.70 17.300 -1.37 0.180 -1.08 0.041 -0.91 1.860 -2.85 1.170 -1.53 0.217 
DES -0.13 1.350 1.15 -1 .32 0. 194 -1.44 0.044 -1.13 0.057 -1.05 0.021 0.82 1.290 1.12 0.054 l.l2 0.032 
VIM om 1.200 -1.19 0.087 1.25 0.031 1.50 0.071 1.35 0.180 1.23 0.050 1.42 0.246 ;r~82 ' O:li9 -0.60 1.930 
GFAP om 1.200 0.52 1.050 om 1.180 -1.05 0.013 -0.51 1.010 -1.03 0.010 0.52 1.030 -0.01 
-1.03 0.014 
NEFH -2.21 1.090 -1.32 0.076 -l.l3 0.058 0.55 1.040 0.00 l.l80 1.08 0.024 .-1.82 a.308 l.l0 0.053 0.39 1.240 
TUBA2 -0.55 1.030 -0.50 1.020 -0.54 1.030 -l.l l 0.022 -1.02 0.017 -0.34 1.160 1.65 0.064 -0.51 1.010 -1.02 0.012 
TUBB2 0.02 1.230 0.55 1.050 -l.l 7 0.046 -1.04 0.053 -1.06 oms -1.04 0.029 0.77 1.760 -0.53 1.030 -1.03 0.013 
ACTAl -0.53 1.050 0.57 1.080 -1.05 0.042 1.20 0.045 -0.58 1.050 -1.07 0.033 -0.83 1.330 1.09 0.047 -0.49 l.l00 
ACTB 
-0.35 1.180 0.53 1.030 -0.34 1.190 0.36 
-
-0.01 
-1.03 0.032 -1.8 1 0.07 1 -1.02 oms -1.08 0.029 
ITGBl - 1.27 -2.21 0.423 /~~:35:t r~TJ{'1o::,. IC ;6R x x -1.08 -1.40 -1.47 0.462 -1.34 0.176 
ITGB3 1.3 1 0.263 -4.27 1.670 -16.02 -219.75 X X 0.60 1.160 1.86 0.474 l.l4 -1.50 0.253 
ITGB4 
-0.30 1.270 l.l3 0.025 -1.03 0.013 1.32 0.049 -0.50 1.050 1.05 0.021 -0.13 1.570 1.10 0.033 1.26 0.098 
ITGB5 1.10 0.036 -1.02 0.024 1.23 0.123 0.51 1.010 1.07 0.032 -1.03 0.006 -1.28 0.181 0.01 1.200 0.Q3 1.190 
ITGAl -1.24 0.155 l.l6 0.072 -1.25 0.280 0.54 1.040 -l.l0 0.068 0.55 1.350 "'1.882 ·~Q.:OS9 -15.30 6.160 1.53 0:10ic 
FLNA 1.51 2.300 -1 .85 0.326 3.01 -18.10 14.600 X X X X 376.00 733.000 X X 
ITGA2 
- l.l6 0.044 -1 .28 0.157 0.57 1.410 ~ ~ :~? 1.24 0.069 l.l0 0.098 -0.43 1.700 -1.27 0.205 1.23 
ITGA3 -0.04 1.220 1.13 0.079 -1.07 0.039 l.l2 0.017 0.52 1.020 1.07 0.006 
-2.03 ~. -1.04 0.037 l.ll 0.036 
ITGA5 0.65 1.460 -2.10 0.374 -0.66 1.770 -50.80 26.300 -0.79 1.350 -0.01 1.79 0.546 -1.60 0.175 -1.22 0.234 
ITGA6 2.58 0.049 l.l6 0.Q38 1.25 0.055 1.39 0.017 1.06 0.025 1.08 0.030 1.35 0.375 l.l7 0.031 1.27 
ITGAV 
-0.46 1.280 -1.14 0.102 • ~1 ;69 :~ ~'. ;. ;;rw ~  . -1.18 0.01 7 -0.64 1.090 1.47 0.093 om 1.200 -1.09 0.05 1 
PXN 0.58 1.070 1.15 0.024 1.05 0.035 l.l9 0.053 0.35 1.180 0.53 1.020 -1.48 0.249 l.l7 0.030 0.Ql 1.220 CDHI 1.25 0 .. 09798 1.07 0.022 l.l9 0.085 1.32 0.027 0.54 1.030 -0.53 1.020 -1.40 0.270 -0.51 1.050 0.51 1.020 CTNNA I 2.22 0.278 -0.02 1.210 1.09 0.086 -0.09 1.320 -1.09 0.028 1.05 0.042 . l.54! ' '" ,< .r,.;; 
-0.55 1.050 1.40 0. 134 .~\~-~.:: CTNNBI 
-1.23 0.025 1.04 0.013 -1.03 0.01 2 1.32 0.095 -1.06 0.Ql5 l.l5 0.051 1.31 0.089 1.09 0.046 0.63 1.100 JUP 
-0.55 1.040 0.51 1.050 0.36 1.190 -1.06 0.008 0.00 1.170 -1.01 0.Q\5 1.06 0.Q38 
-0.51 1.020 0.51 1.020 CTNNDI 
-1.29 0.152 -5.09 2.160 -0.12 1.470 -60.70 35.200 - l.l4 l.l5 0.033 X X -4.77 3.560 1.20 SDCl 0.59 1.070 1.12 0.033 - l.l5 0.044 1.06 0.033 0.D2 0.05 1.220 -1.45 0.468 0.52 1.020 1.1 2 SDC4 0.08 
-0.39 1.250 -1.42 0.225 .>tt3:78': .'ll3fr -1.06 0.028 -l.l3 0.034 0.45 1.660 l.l5 0.01 2 0.04 
Gene "" ... hol 
LAMA4 
LAMBl 
COLlA 2 
FNlIFN 
NUPl53 
TPR 
NPMl 
RPL3l 
1 
D cont. 
(lamin A) 
I L1VII'" A (lamin C) 
TMPO (A) 
TMPO (B) 
CDC2 
CDK2 
CDK4 
CDK6 
CCNAl 
CCNBl 
CCNB2 
CCNDJ 
CCND2 
CCND3 
CCNEl 
CHKl 
CHK2 
1.13 
-1.45 
0.54 
-1.49 
1.00 
-1 .31 
0.250 1.12 
1.090 -1.22 
0.210 -2.06 
0.010 l.l7 
0.097 I --.,t.v· , v.",." . , 
0.033 
0.194 
0.424 
0.046 
l.l8 I 0.055 1.03 I 0.024 
1.13 0.017 1.22 0.054 1.09 
0.47 1.120 1.15 0.055 0.66 
0.0 I 1.280 -1.27 0.176 1.22 
0.56 1.060 0.57 1.080 -0.34 
-1.1 1 
-1.12 
-1.15 
-1.68 
1.05 
0.061 
0.039 
0.029 
0.492 
1.190 
0.52 
-l.l0 
-0.54 
1.41 
-1.03 
1.06 
1.12 0.Q25 1.09 
0.54 1.050 1.15 
1.04 -0.38 
0.34 1.180 -0.33 
1.05 I 0.Q35 
-1.12 
-2.10 
-0.34 
1.12 
1.13 
0.424 
1.200 
0.048 
1.18 0.046 
1.09 0.022 
1.09 1.16 0.081 
0.02 1.220 1.35 0.103 
-1.39 0.203 -1.25 0.032 
1.180 0.33 1.170 
0.47 1.380 1.25 0.071 -0.67 1.120 -1.28 0.190 -0.51 1.020 1.17 0.55 1.050 
1.18 0.125 -1.73 0.397 0.59 1.400 ' 4:70 ;Q4!1} -1.35 1.31 
-1.11 0.131 
-0.40 1.250 -1.06 0.030 -0.28 1.290 1.17 0.048 -1.11 0.082 1.18 
-1.22 0.150 
1.07 0.051 1.28 0.044 -0.54 1.050 1.14 0.066 1.18 0.087 0.54 1.110 1.39 0.085 
1.28 0.044 -1.10 0.081 -1.08 0.055 -1.22 0.091 1.14 0.034 1.10 X X 1.23 0.044 
0.82 1.260 1.11 0.Q28 1.11 0.069 0.01 1.240 1.15 0.035 1.09 1.18 0.093 1.29 0.040 
0.61 1.090 1.18 0.064 1.05 0.037 -1.23 0.107 1.04 0.006 1.13 0.65 1.110 1.22 0.024 
-0.01 1.240 1.27 0.052 1.28 0.049 1.10 0.Q35 0.37 1.210 1.12 0.057 1.37 I 0.026 
1.22 0.155 -1.15 0.110 1.27 0.109 £.wy 1.09 0.056 -1.16 0.D75 -1.25 
1.26 0.180 1.16 0.109 1.20 -1.31 1.03 -1.08 0.051 -1.19 0.155 
1.07 0.044 1.05 0.026 0.00 1.220 1.06 0.027 1.05 0.046 0.52 1.020 1.03 0.015 
0.39 1.220 -0.0 I 1.190 1.49 0.53 1.040 1.31 0.061 1.18 0.012 1.29 0.088 
1.07 0.026 -0.31 1.190 -1.03 0.019 1.04 1.28 0.070 -1.41 0.140 0.51 1.010 
1.28 0.071 -1.21 -1.07 0.061 1.31 0.D78 -0.52 1.350 0.63 1.1 00 0.55 1.110 
1.11 0.042 -1.05 0.045 0.56 1.070 1.08 0.033 1.13 0.043 -0.70 1.340 1.22 1.39 0.120 
Gene "vlnhnl 
CDC25A 
CDC25B 
XRCC6 
GAPDH 
CHRMI 
CHRM2 
CHRM3 
CHRM4 
CHRM5 
LGALS2 
IGF2 
D cont. 
QP3 
PTGS21COX2 
KLRBI 
PMS2 
SCL7A5 
1.31 
-1.08 
1.30 
0.76 
0.59 
-0.37 
0.02 
0.15 
1.04 
1.08 
1.03 
0.01 
0.067 
0.026 
0.260 
1.710 
1.390 
1.200 
1.350 
1.360 
0.028 
0.037 
0.031 
1.170 
-0.51 
1.12 
-1 .33 
-2.12 
-2.27 
1.15 
0.05 
1.28 
1.06 
0.00 
1.06 
1.04 
1.020 
0.056 
0.137 
0.531 
0.158 
0.144 
1.250 
0.082 
0.019 
1.180 
0.029 
0.041 
1.01 
0.53 
1.06 
-0.12 
0.54 
1.27 
0.02 
0.02 
1.03 
-0.35 
1.05 
0.52 
1.15 0.042 
1.16 0.042 
0.062 -4.82 0.577 
3.400 -132.00 193.000 
1.450 -5.77 3.330 
0.062 1.33 0.047 
1.190 0.38 1.230 
1.210 -1.16 O.lll 
0.008 -1.09 0.024 
1.190 -1.03 0.029 
0.012 -1.09 0.017 
1.020 -1.05 0.017 
0.51 
1.03 
-1.07 
0.02 
-0.40 
0.35 
-1.26 
1.22 
1.03 
0.34 
1.04 
1.02 
1.010 
0.026 
0.025 
1.310 
1.270 
1.170 
0.181 
0.087 
0.Ql5 
1.170 
0.036 
0.Ql5 
-0.01 
0.35 
-2.04 
1.00 
0.24 
0.56 
0.55 
-0.07 
1.05 
-0.50 
0.51 
-1.03 
1.42 0.435 -1.47 0.178 1.50 0.077 -0.49 1.110 -1.53 
-1.18 0.021 1.10 0.029 -0.34 1.160 1.08 -1.05 0.00 
1.09 1.18 0.032 1.16 0.087 1.35 0.070 -0.52 1.030 1.21 
1.08 I 0.054 I 1.04 I I 0.38 1.230 1.38 0.063 0.Ql 1.190 
1.22 0.132 -0.54 1.030 1.21 0.052 1.19 0.088 
1.16 
1.33 I 0.062 I 0.58 
1.13 0.119 -0.54 1.040 1.10 0.057 0.013 0.55 1.170 1.20 
0.00 1.180 -1.35 0.384 -4.73 1.080 1.080 -1.13 0.031 1.60 
1.470 
-4.95 
1.16 
-1.20 
0.65 
0.35 
-1.01 
-0.33 
0.35 
3.100 
1.110 
1.170 
0.005 
1.160 
1.180 
-0.32 
-1.15 
1.39 
1.04 
-1.02 
1.05 
-0.34 
1.210 
0.090 
0.026 
0.019 
0.Ql5 
0.015 
1.170 
-2.24 0.785 0.02 1.220 
-0.01 1.160 -1.04 0.021 
0.53 1.040 1.40 0.Ql5 
1.12 0.046 1.28 0.036 
1.15 0.Q75 1.14 0.071 
1.19 1.36 0.045 
-1.17 0.070 0.54 1.040 
0.53 1.040 0.52 1.010 0.51 1.010 
1.18 
0.51 
0.51 1.030 1.03 0.030 -1.42 I 0.021 
-0.53 1.050 0.51 1.020 
1.27 0.070 -1.03 0.019 0.Ql 1.190 
-1.07 0.073 1.16 0.076 ~;r~61 , ,0.182 . -1.1 0 -1.26 0.257 
-0.52 I 1.020 I -0.03 I 1.200 I .- ._;~ .. I 1.200 1.24 0.032 
-1.47 0.113 
0.35 
0.37 1.180 1.45 0.029 1.27 0.137 0.55 1.100 1.07 0.061 
1.08 0.038 1.10 0.058 0.56 1.050 -1.04 0.021 1.06 0.029 0 .. 015 1.180 
0.36 1.590 -0.55 1.120 1.27 0.062 1.15 0.083 -0.51 1.080 0.61 1.090 
-0.41 1.240 -1.35 0.301 1.41 0.145 -5.32 2.390 X X 1.16 0.089 
-1.13 0.120 1.58 0.074 ] 
0.04 1.03 0.010 
-0.56 1.080 0.36 1.470 
-2.62 -36.60 62.600 
1.16 0.119 1.46 0.021 -1.190.0740.57 1.060 1.09 0.087 -1.190.056 -0.37 
1.37 0.255 1.18 0.040 -0.0 I 1.180 1.22 0.052 1.22 1.11 0.026 0.43 
1.290 I 1.18 0.094 1.29 0.029 
1.290 1.06 0.068 1.20 0.158 
appenolX n, J.J cont. 
LAMIN A vs GFP EMERIN vs GFP LAMIN A vs EMERIN 
Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 
Gene symbol Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. 
PARPI 1.32 0.189 -2.06 0.945 1.41 0.303 I r.;:~.!n';, I f,l)~ -0.30 1.240 0.02 1.620 X X -2.15 0.880 1.47 0.053 
DRGI -1.04 0.037 0.49 1.120 1.06 0.084 -1.31 0.047 -1.09 -1.08 0.014 -0.94 1.360 -1.07 0.055 1.24 0.069 
TGIF -1.14 0.099 1.11 0.049 -1.19 0.041 1.09 0.042 -0.35 1.220 -1.12 0.034 -0.45 2.000 -0.56 1.040 1.25 0.083 
SOD2 1.36 0.122 -0.50 1.030 -1.13 0.036 1.04 0 .006 -1.05 0.037 -1.29 0.377 li"1~§5 " ~II' ~ t;~ ~~1~9: -0.73 1.220 
COLlA 2 -0.51 1.190 1.16 0.081 -0.53 1.020 1.22 -1.09 0.094 -0.53 1.030 0.62 1.460 -1.15 0.073 1.09 0.083 
TSPANI 0.34 1.200 0.37 1.190 0.36 1.190 -1.07 0.054 O.ot 1.190 -0.33 1.230 -1.31 0.074 -0.51 1.020 0.00 1.160 
LlTAF -0.36 1.320 1.04 1.40 0.047 -1.48 0.210 0.53 1.030 0.34 1.390 'II 'I:06{' ";'(1200-
-1.11 0.071 -1.21 0.124 
A TP2A3 0.00 1.230 1.38 0.029 1.20 0.147 1.46 0.100 0.02 0.58 1.080 I ~".r. 7:1i;'I; ~~; X X 1.05 0.022 
LGALS4 0.65 1.220 O.oI 1.21 0.202 1.41 0.023 1.24 0.073 1.13 0.050 X X 0.43 1.360 1.28 0.126 
PlK3CG 1.32 0.147 -1.27 0.190 -1.33 0.361 ' :;·l~'f:· ~.O~,l -1.10 0.090 -1.10 0.107 1.57 0.162 -1.37 0.098 -0.53 1.020 
GNAL 0.45 1.390 0.54 1.050 -1.15 0.047 1.15 0.025 0.53 1.050 0.51 1.070 '/~ 1.HU'Z4: -1.29 0.038 0.54 1.140 
STATl 0.45 1.390 1.18 0.062 -1.10 0.082 -1.03 0.036 1.08 0.041 0.54 1.040 X X -1.12 O.ot8 1.40 0.021 
E2F4 1.06 0.024 0.55 1.040 1.02 0.019 -0.02 1.190 -0.51 1.030 1.06 0.048 -1.29 0.066 -1.02 0.012 -0.50 1.010 
FCGR2B X X -1.13 0.073 -1.24 0.150 -1.38 0.079 -0.61 1.100 -1.43 0.373 -1.49 0.121 r.£1;S9 · 0.149 0.37 1.220 
TNFRSF I OA I TRIALR 
-3.89 0.505 1.32 0.121 1.13 0.035 1.19 0.069 0.50 1.020 1.07 0.020 1.39 0.110 0.52 1.020 0.04 1.210 
FABP2 -0.32 1.250 -1 .26 0.116 1.34 0.038 -0.38 1.200 -1.08 0.087 1.32 0.144 1.11 0.100 -1.32 0.142 1.40 0.081 
MSH2 1.15 0.095 -0.54 1.120 1.20 1.12 0.058 -1.09 0.067 0.05 ~!i{ I. 1.08 0.050 -1.33 0.147 .C'" ,,,.. DLEUI -1.41 0.320 -0.41 1.260 1.64 0.126 -0.03 1.190 1.03 0.026 1.31 0.165 : 1/ }J~ -1.17 0.309 ·-!.§1 '· 0.:1.80 
CXCL2 1.03 0.010 1.07 0.049 1.04 0.032 -1.08 0.014 0.34 1.170 1.08 0.029 0.15 1.530 0.00 1.170 1.02 0.017 
CFLl 1.26 0.137 1.24 0.062 -1 .23 0.050 1.08 0.047 1.08 0.034 0.02 1.210 0.54 1.060 -0.32 1.310 1.22 0.165 
RBBP4 1.09 0.050 1.14 0.021 -1.14 0.046 0.00 0.000 0 .32 1.250 -1.02 0.014 J.!t~. IdJUQl' -1.23 0.079 1.45 0.083 
GPX2 -0.54 1.080 0.68 1.130 0.36 1.210 l.l1 0.026 1.08 0.026 0.53 1.040 1.13 1.480 0.52 1.030 'BE: 0.025 
RGS2 -0.14 1.540 0.51 l.l20 -1.06 0.021 ~; ;'2;~3) l o.:U9 ' -1.04 0.013 -l.l4 0.074 .,:,,~ " o~ -1.16 0.061 -0.08 1.630 
PFNI 1.42 0.435 1.03 0.029 1.37 0.056 1.28 0.120 -0.33 1.200 1.04 0.042 0.90 1.450 -1.04 0.031 0.76 1.170 
CDKNIB 
-2.47 0.755 -1.13 0.059 1.06 0.047 0.15 -1.37 0.062 -0.02 1.240 1.06 -1.44 0.076 -1.67 0.720 
A NPEP -0.57 1.120 1.14 0.045 1.11 0.061 1.04 0.020 0.50 1.020 1.24 0.187 0.71 1.160 0.51 1.020 -1 .06 0.015 
FASLG -1.18 0.053 1.48 0.075 1.36 0.062 1.41 0.103 -0.39 1.260 0.64 1.110 J18'i ~; ::.q,OSZ 1.15 0.060 1.27 0.120 
GTF3A -0.04 1.440 1.27 0.061 1.32 0.064 1.37 0.057 1.08 0.024 1.18 -0.13 1.380 
-2.22 0.648 1.28 0.096 
Marker 1.07 0.Q25 1.11 0.Q21 X X -1.03 1.12 1.06 0.030 1.18 0.079 1.01 1.06 0.021 
D cont. 
TFDP2 
RALGPSI 
NCKAP 1 I NAP 1 
BAKI 
NSAP 1 I SYNCRIP 
CASP3 
Marker 
PTK2BIPKB 
BGN 
CD44 
SCFIKITLG 
1.11 0.025 
1.25 0.265 
-1.13 0.134 
1.12 0.083 
1.06 0.022 
-1.29 
-1.59 
1.23 
0.103 
0.266 
0.056 
-1.87 
-0.96 
-1.06 
0.111 
1.840 
0.013 
1.12 0.52 1.030 
-1.41 
-4.78 
0.05 
1.09 
0.271 
1.800 
1.240 
l.ll 0.061 -1.23 0.102 I _ .. -I -.--- I 
1.22 0.042 1.40 0.044 ·,Z.lt°:.:JtM't 
x X 1.13 0.041 
1.07 0.029 
1.35 
-0.39 
0.53 
1.290 
1.050 
UO 
0.50 
1.09 
1.03 0.015 1.13 
0.52 1.030 1.13 
1.20 0.089 1.39 
-1.03 0.022 0.46 
1.05 0.53 1.05 0.032 -.-- . I ----- .1 
-1.98 1.l00 -l.l0 0.055 1.30 0.346 -0.56 1.450 1.33 0.193, " _!~V I """_.,q 
-1.95 0.204 X X U8 0.030 1.20 0.017 1.07 X X 
1.04 0.040 1.32 0.122 -U7 0.024 1.31 0.127 1.20 0.078 1.22 0.061 
1.55 0.182 1.30 0.046 -1.04 0.034 -1.25 0.187 1.13 0.092 1.29 
1.05 0.021 0.51 1.020 -1.07 0.021 1.02 0.005 1.03 0.017 ___ _ 
-1.21 0.1l3 1.19 0.087 -1.18 0.059 1.27 0.139 0.54 1.030 ~I~ 
0.37 1.200 -1.41 0.023 0.17 -2.34 , O· X X 1.28 0.151 
1.42 0.071 -1.36 0.50 1.120 -2.72 1.940 0.52 1.050 -0.11 
0.53 1.070 1.21 1.10 0.035 1.39 0.067 0.53 1.020 1.12 
1.03 I 0.035 I 1.08 
l.l2 I 0.067 
1.07 
l.l5 0.025 1.04 
-0.28 1.430 -0.09 1.290 
-0.38 1.190 1.40 0.025 
1.23 0.220 1.27 0.040 
1.30 0.263 1.24 0.064 
-0.13 1.29 
0.58 1.070 1.17 0.090 
0.37 1.230 -1.26 0.113 
1.04 0.020 -0.34 1.170 -0.0 I 1.200 
1.44 0.076 1.33 0.103 1.21 0.088 
1.04 0.014 -0.36 l.l80 -0.67 1.140 
1.13 -0.33 1.180 
-1.88 0.673 1.52 0.042 
-1.10 0.076 1.16 
1.07 0.035 1.24 
-1.17 0.078 0.37 1.210 
-1.38 0.010 -0.36 1.240 
-1.37 0.065 0.09 1.280 
1.27 0.265 -3.56 1.170 1.37 0.095 
1.08 
1.37 
1.35 
1.09 
1.22 
0.58 
1.23 
0.63 
1.08 
0.34 
1.35 
0.151 
0.127 1.13 
0.012 0.07 
0.040 0.24 
1.060 -1.35 
0.024 -1.37 
0.021 
1.460 
1.580 
0.116 
0.107 
1.120 ~ . . V701 
0.033 
1.190 ,...;;...::.:..::""-• ....z.::= _ 1 
0.229 1.78 0.197 
0.33 
-1.21 
-1.13 
1.07 0.044 -0.32 1.190 
-1.22 0.229 -0.35 1.440 
-1.25 0.061 1.33 0.019 
U6 0.066 1.25 0.163 
0.52 1.020 0.50 1.010 
-2.91 1.240 ':r::]6 ji O.549'~ 
1.13 0.050 1.23 
1.11 0.029 
1.14 0.047 1.42 0.062 
1.09 0.039 -0.52 1.010 
-1.31 0.206 1.49 0.079 
-3 .08 0.670 0.64 1.130 
-1.59 0.493 -0.53 1.180 
0.00 1.200 -1.36 
0.32 1.210 1.04 
-1.06 0.042 0.61 
0.0 I 1.170 -0.33 
1.03 0.028 -0.34 
-1.26 0.116 1.18 
1.11 0.022 
1.080 
1.200 
1.170 
0.128 
-0.50 1.020 I '.J" I V.VUI 
0.01 1.170 
-1.22 0.104 ~._. 
-1.25 0.098 . ~1.0.348 
2.83 1.370 -1.28 0.135 
CA2 
SPP1 
SLC16A1 
FABP1 
TEAD4 
1L3 
CDKN1A 
ENC1 
CSPG2 
FAS 
VEGF 
CAST 
II, D cont. 
0.48 
-1.12 
0.55 
1.17 
1.19 
0.54 
1.10 
1.310 
0.034 
1.110 
0.071 
0.074 
1.020 
0.062 
1.04 
0.03 
1.17 
1.15 
1.37 
-1.47 
1.06 
1.31 
1.13 
1.33 
1.220 
0.036 
0.110 
0.010 
0.264 
0.036 
0.032 
0.055 
1.32 
-1.11 
-1.13 
-1.13 
-1 .25 
-4.23 
-1.12 
0.52 
1.13 
1.14 
1.29 
1.20 
1.18 
1.06 
X 
-0.01 
1.19 
0.02 
1.36 
1.250 
0.124 
0.010 
0.015 
0.043 
X 
1.190 
0.056 
l.180 
0.055 
-3.10 0.722 0.04 1.15 0.047 X X 
0.36 1.340 -1.33 0.150 -1.99 0.434 0.33 1.410 
0.08 -0.55 1.060 -1.38 0.Ql5 0.64 1.110 
1.08 
1.35 
1.16 
1.06 
1.13 
0.66 
0.56 
1.21 
-0.35 1.190 -0.01 -1.56 1.11 0.042 -0.50 
0.57 1.140 1.12 0.029 0.51 1.010 1.19 0.120 1.11 0.021 1.21 
-0.03 1.33 0.041 1.06 0.024 1.28 0.041 1.18 0.064 1.15 
-0.42 1.520 -1.36 0.116 -1.69 0.146 -92.60 138.000 1.18 -1.06 
1.20 0.068 1.42 0.035 -0.52 1.050 1.36 0.076 1.21 0.038 0.59 
0.32 1.250 1.19 0.062 1.26 0.079 
1.10 0.056 1.09 0.059 1.16 0.055 
0.105 
0.039 
0.079 
0.044 
1.24 
-1.08 
-1.39 
0.070 
0.038 
0.205 
1.500 
0.055 1 :'·-1.~2 : I" 0.13("1 -1.08 
1.120 
1.110 
-1.09 0.045 1.06 0.017 0.49 1.180 0.65 1.150 
1.14 0.39 1.270 1.30 0.126 1.40 0.063 1.47 
-0.42 1.360 -1.67 0.332 1.25 0.189 1.25 0.161 1.28 0.229 
1.31 0.303 -1.25 0.057 -1.21 0.128 -1.06 0.026 -1.55 0.255 
-1.21 0.058 0.02 -1.25 0.069 0.38 1.230 -1.07 0.050 1.03 0.017 -1.33 0.338 
-0.61 1.080 1.16 -1.14 0.065 1.09 0.010 1.24 0.026 -1.09 0.093 -3 .25 
1.14 
1.20 0.018 
1.09 0.019 
-1.14 0.095 
0.55 1.180 
-17.90 19.600 
-0.56 1.060 
-0.51 1.030 
-0.57 1.080 
0.55 1.080 
1.41 
1.16 
1.23 
0.66 
-0.20 
1.25 
1.19 
-1.56 0.904 I -16.04 
0.175 
0.052 
0.D75 
1.130 
1.480 
0.045 
0.056 
-3.18 0.876 -1.11 0.045 
-1.07 0.037 1.24 0.102 
-1.41 0.115 0.42 1.260 
0.01 1.22 0.133 
0.52 1.020 1.21 0.046 
-1.59 I. 730 -1.11 
-1.16 0.081 1.37 0.219 
-2.14 0.01 
1.15 0.039 
1.15 0.076 
-0.52 1.030 1.40 0.114 
-1.16 0.093 
-0.54 1.070 
0.62 1.130 
1.36 0.065 
-1.27 0.121 -1.05 0.026 -1.31 0.146 -1.33 0.158 0.03 -1.35 0.084 -!':": ' I...Y·M" I 
0.53 1.090 1.33 0.055 -0.63 1.180 1.32 1.15 0.076 0.6 1 1.100 l-:::..:. .............. ~~ 
-1.16 0.057 
1.17 0.072 
__ ppenUlX __ , ___ ..•. 
LAMIN A vs GFP EMERIN vs GFP LAMIN A vs EMERIN 
Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 
Gene symbol Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D. 
AMIDIPRG3 1.15 0.029 1.44 1.42 0.050 ·· 1:93 ~·  1.23 0.024 1.47 0.180 0.04 1.310 0.42 1.250 
.. 'i:S1 i1f1i • :O:O32"!¢ 
JPOl I LOC442l72 0.51 1.030 1.26 0.108 1.29 0.156 -0.32 1.230 1.35 0.062 ~iiX7:'" . 0.013" l .. ~f9.1 . .iIiI O.Ojf -1.24 0.126 1.18 0.087 
MXD3 0.01 1.170 X X 1.12 0.075 -0.54 1.040 X X 1.08 0.017 -1.10 0.055 0.37 1.200 -1.07 
MDM2 1.09 0.076 -0.51 1.030 -1.32 0.085 1.43 0.095 1.15 0.094 1.23 0.071 1.61 -0.57 1.070 0.06 
REGlB 0.53 1.050 1.19 0.048 -1.32 0.076 -0.34 1.280 1.07 0.033 1.02 0.021 .~ 1.'97j~: -[9I7 c -0.58 1.120 1.20 
SPl 1.01 0.005 1.04 0.51 1.020 -1.11 0.010 1.05 0.017 -0.01 1.170 -1.04 0.005 0.01 1.170 1.03 0.010 
RSAD2 -0.01 1.230 0.56 1.050 1.17 0.066 -1.20 0.114 1.16 0.075 1.12 0.029 1:12:SIt'i ~ 1 ... ~tS9' 0:318 'trss .' 0.286 . 
PLCB2 0.51 1.030 1.04 0.035 -1.04 0.013 -1.09 0.013 -1.01 0.015 -1.03 0.010 1.07 0.044 -1.07 -1.03 0.019 
FNlIFN 1.23 0.096 1.05 0.062 1.03 0.010 1.48 0.051 0.56 1.060 1.13 0.024 0.22 1.550 -0.55 1.050 1.01 
CASP7 1.24 0.115 1.30 0.065 -1.11 0.032 1.36 0.074 1.24 0.035 0.58 1.060 -1.14 0.072 -1.47 0.070 1.30 0.101 
NEBL 1.18 0.012 1.27 0.020 0.54 1.130 1.33 0.070 1.34 0.068 1.38 0.190 0.95 1.750 -1.32 1.24 0.052 
TCOFl -1.01 0.008 0.00 1.160 1:SQ'( '0:055 .'f 1".-aQ, 1>:147· -0.01 1.170 0.59 1.070 1.14 0.081 -1.05 0.040 -1.06 
MTIA 0.51 1.030 1.06 0.022 1.06 0.038 -1.07 0.010 1.06 0.021 0.52 1.020 -1.06 0.015 1.03 0.012 -0.34 1.190 
MUC2 1.19 0.059 -1.02 0.021 1.11 0.054 -1.08 0.006 -1.03 0.021 1.27 0.078 .;,. IJ~ 
• 
-0.49 1.090 -1.04 0.013 
SI 1.28 0.110 1.10 0.050 -0.65 1.620 -1.24 0.073 1.18 0.069 1.16 0.041 i ;}f51~{ O. 1.05 1.45 0.074 
CDX2 0.06 1.280 1.33 0.57 1.070 -1.10 0.097 1.12 0.Q21 1.03 0.013 3.15 -0.61 1.080 1.31 0.036 
EPHB2 -0.55 1.040 1.09 -1.21 0.101 1.17 0.081 1.10 0.054 1.16 0.046 2.01 .. 1: (r144., -1.58 1.09 
BAD 1.18 0.154 -0.35 1.180 -1.05 0.000 -0.01 1.170 -1.05 0.017 -1.03 0.017 1.45 0.198 -1.06 0.038 -1.07 0.021 
CEACAMl I BGP] 1.46 0.062 1.24 0.024 1.05 0.037 ~ 1'T.064. 1.15 0.026 0.00 1.170 ' ;:1;~~}> ~ Q.06" -1.02 -0.36 1.190 
XRCC3 1.02 0.012 1.07 0.025 -0.50 1.010 -1.04 0.024 0.01 1.180 l.l3 0.048 -1.56 0.065 -0.54 1.040 1.38 
TI8 1.47 0.124 l.l3 0.085 1.15 0.129 -1.80 1.54 0.127 0.93 1.300 .t.ll·· ~7. -92.00 155.000 -0.54 1.430 SLC2A] I GLUT] 
-0.35 l.l80 -1.01 0.008 1.32 0.042 ;.a':m O;~ 1.05 0.027 l.l7 0.024 1.42 0.280 -0.01 1.200 X X 
REFERENCES 
Aamio, M., Mecklin, J.P., Aaltonen, L.A, Nystrom-Lahti, M. and Jarvinen, H.J. (1995). 
Life-time risk of different cancers in hereditary non-polyposis colorectal cancer 
(HNPCC) syndrome. Int] Cancer 64(6): 430-433. 
Aaronson, R.P. and Blobel, G. (1975). Isolation of nuclear pore complexes in 
association with a lamina. Proc Natl Acad Sci USA 72(3): 1007-1011. 
Aebi, u., Cohn, J., Buhle, L. and Gerace, L. (1986). The nuclear lamina is a meshwork 
of intermediate-type filaments. Nature 323(6088): 560-564. 
Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, AF., Szabo, M., Cantor, 
A., Coppola, D. and Yeatman, T.1. (2002). Osteopontin identified as lead marker 
of colon cancer progression, using pooled sample expression profiling. ] Natl 
Cancer Inst 94(7): 513-521. 
Agrelo, R., Setien, F., Espada, J., Artiga, M.J., Rodriguez, M., Perez-Rosado, A, 
Sanchez-Aguilera, A, Fraga, M.F., Piris, M.A and Esteller, M. (2005). 
Inactivation of the Lamin AlC Gene by CpG Island Promoter Hypermethylation 
in Hematologic Malignancies, and Its Association With Poor Survival in Nodal 
Diffuse Large B-Ce11 Lymphoma.] Clin Oncol23(17): 3940-3947. 
AJCC (1997). Colon and rectum. In: American Joint Committee on Cancer: A]CC 
Cancer Staging Manual. Philadelphia: Lippincott-Raven, 5th ed., pp. 83. 
Akerblad, P., Mansson, R., Lagergren, A, Westerlund, S., Basta, B., Lind, U., Thelin, 
A, Gisler, R., Liberg, D., Nelander, S., Bamberg, K. and Sigvardsson, M. 
(2005). Gene expression analysis suggests that EBF-1 and PPARgamma2 induce 
adipogenesis of NIH-3T3 cells with similar efficiency and kinetics. Physiol 
Genomics 23(2): 206-216. 
Alden, T.D., Gianino, J.W. and Saclarides, T.J. (1996). Brain metastases from colorectal 
cancer. Dis Colon Rectum 39(5): 541-545. 
Alexander, F. and Weller, D. (2003). Evaluation of UK Colorectal Cancer Screening 
Pilot, Final Report. NHS executive, UK. 
Allen, T.D., Cronshaw, J.M., Bagley, S., Kiseleva, E. and Goldberg, M.W. (2000). The 
nuclear pore complex: mediator of translocation between nucleus and cytoplasm. 
] Cell Sci 113(Pt 10): 1651-1659. 
Altschul, S.F., Madden, T.L., Schaffer, AA, Zhang, J., Zhang, Z., Miller, W. and 
Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs. Nucleic Acids Res 25(17): 3389-3402. 
Alvarez-Reyes, M. (2003). Interactions between nuclear lamins and their binding 
partners in EDMD fibroblasts. In School of Biological and Biomedical Sciences 
Durham: University of Durham. 
Apel, E.D., Lewis, R.M., Grady, R.M. and Sanes, J.R. (2000). Syne-1, a dystrophin- and 
Klarsicht-related protein associated with synaptic nuclei at the neuromuscular 
junction.] BioI Chem 275(41): 31986-31995. 
Astler, V.B. and Coller, F.A (1954). The prognostic significance of direct extension of 
carcinoma of the colon and rectum. Ann Surg 139(6): 846-852. 
Atkin, W.S. (2002). Single flexible sigmoidoscopy screening to prevent colorectal 
cancer: baseline findings of a UK multi centre randomised trial. Lancet 
359(9314): 1291-1300. 
Bagley, S., Goldberg, M.W., Cronshaw, J.M., Rutherford, S. and Allen, T.D. (2000). 
The nuclear pore complex. ] Cell Sci 113(Pt 22): 3885-3886. 
Baker, S.1., Fearon, E.R., Nigro, J.M., Hamilton, S.R., Preis inger, AC., Jessup, J.M., 
vanTuinen, P., Ledbetter, D.H., Barker, D.F., Nakamura, Y., White, R. and 
189 
Vogelstein, B. (1989). Chromosome 17 deletions and p53 gene mutations in 
colorectal carcinomas. Science 244(4901): 217-221. 
Barker, N., Huls, G., Korinek, V. and Clevers, H. (1999). Restricted high level 
expression of Tcf-4 protein in intestinal and mammary gland epithelium. Am J 
PathoI154(1): 29-35. 
Basik, M., Mousses, S. and Trent, J. (2003). Integration of genomic technologies for 
accelerated cancer drug development. Biotechniques 35(3): 580-582,584,586 
passim. 
Batlle, E., Henderson, J.T., Beghtel, H., van den Born, M.M., Sancho, E., Huls, G., 
Meeldijk, J., Robertson, J., van de Wetering, M., Pawson, T. and Clevers, H. 
(2002). Beta-catenin and TCF mediate cell positioning in the intestinal 
epithelium by controlling the expression of EphB/ephrinB. Cell 111(2): 251-
263. 
Beaudouin, J., Gerlich, D., Daigle, N., Eils, R and Ellenberg, J. (2002). Nuclear 
envelope breakdown proceeds by microtubule-induced tearing of the lamina. 
Cell 108(1): 83-96. 
Becker, B., Bellin, R.M., Sernett, S.W., Huiatt, T.W. and Robson, RM. (1995). 
Synemin contains the rod domain of intermediate filaments. Biochem Biophys 
Res Commun 213(3): 796-802. 
Belgareh, N., Rabut, G., Bai, S.W., van Overbeek, M., Beaudouin, J., Daigle, N., 
Zatsepina, O.V., Pasteau, E, Labas, V., Fromont-Racine, M., Ellenberg, J. and 
Doye, V. (2001). An evolutionarily conserved NPC subcomplex, which 
redistributes in part to kinetochores in mammalian cells. J Cell BioI 154(6): 
1147-1160. 
Benavente, R., Krohne, G. and Franke, W.W. (1985). Cell type-specific expression of 
nuclear lamina proteins during development of Xenopus laevis. Cell 41(1): 177-
190. 
Benavente, Rand Krohne, G. (1986). Involvement of nuclear lamins in postmitotic 
reorganization of chromatin as demonstrated by microinjection of lamin 
antibodies. J Cell BioI 103(5): 1847-1854. 
Bellin, RM., Sernett, S.W., Becker, B., Ip, W., Huiatt, T.W. and Robson, RM. (1999). 
Molecular characteristics and interactions of the intermediate filament protein 
synemin. Interactions with alpha-actinin may anchor synemin-containing 
heterofilaments. J BioI Chem 274(41): 29493-29499. 
Berger, R, Theodor, L., Shoham, J., Gokkel, E., Brok-Simoni, F., Avraham, K.B., 
Copeland, N.G., Jenkins, N.A., Rechavi, G. and Simon, A.J. (1996). The 
characterization and localization of the mouse thymopoietinllamina-associated 
polypeptide 2 gene and its alternatively spliced products. Genome Res 6(5): 361-
370. 
Bhutani, M.S. and Pacheco, J. (1992). Metastatic colon carcinoma to oral soft tissues. 
Spec Care Dentist 12(4): 172-173. 
Biamonti, G., Giacca, M., Perini, G., Contreas, G., Zentilin, L., Weighardt, E, Guerra, 
M., Della Valle, G., Saccone, S., Riva, S. and et al. (1992). The gene for a novel 
human lamin maps at a highly transcribed locus of chromosome 19 which 
replicates at the onset of S-phase. Mol Cell BioI 12(8): 3499-3506. 
Bienz, M. and Clevers, H. (2000). Linking colorectal cancer to Wnt signaling. Cell 
103(2): 311-320. 
Bilak, S.R, Sernett, S.W., Bilak, M.M., Bellin, RM., Stromer, M.H., Huiatt, T.W. and 
Robson, RM. (1998). Properties of the novel intermediate filament protein 
synemin and its identification in mammalian muscle. Arch Biochem Biophys 
355(1): 63-76. 
190 
Bione, S., Tamanini, F., Maestrini, E., Tribioli, C., Poustka, A, Torri, G., Rivella, S. 
and Toniolo, D. (1993). Transcriptional organization of a 450-kb region of the 
human X chromosome in Xq28. Proc Natl Acad Sci USA 90(23): 10977-1098I. 
Bione, S., Maestrini, E., Rivella, S., Mancini, M., Regis, S., Romeo, G. and Toniolo, D. 
(1994). Identification of a novel X-linked gene responsible for Emery-Dreifuss 
muscular dystrophy. Nat Genet 8(4): 323-327. 
Bird, RP. (1987). Observation and quantification of aberrant crypts in the murine colon 
treated with a colon carcinogen: preliminary findings. Cancer Lett 37(2): 147-
15I. 
Bird, RP. and Good, C.K (2000). The significance of aberrant crypt foci in 
understanding the pathogenesis of colon cancer. Toxicol Lett 112-113: 395-402. 
Blixt, A, Mahlapuu, M., Aitola, M., Pelto-Huikko, M., Enerback, S. and Carlsson, P. 
(2000). A forkhead gene, FoxE3, is essential for lens epithelial proliferation and 
closure of the lens vesicle. Genes Dev 14(2): 245-254. 
Bodoor, K, Shaikh, S., Salina, D., Raharjo, W.H., Bastos, R, Lohka, M. and Burke, B. 
(1999). Sequential recruitment of NPC proteins to the nuclear periphery at the 
end of mitosis. J Cell Sci 112(Pt 13): 2253-2264. 
Bonne, G., Di Barletta, M.R, Vamous, S., Becane, H.M., Hammouda, E.H., Merlini, L., 
Muntoni, F., Greenberg, CR, Gary, F., Urtizberea, J.A, Duboc, D., Fardeau, 
M., Toniolo, D. and Schwartz, K (1999). Mutations in the gene encoding lamin 
AlC cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 
21(3): 285-288. 
Bonne, G., Mercuri, E., Muchir, A, Urtizberea, A, Becane, H.M., Recan, D., Merlini, 
L., Wehnert, M., Boor, R, Reuner, u., Vorgerd, M., Wicklein, E.M., Eymard, 
B., Duboc, D., Penis son-Besnier, I., Cuisset, J.M., Ferrer, x., Desguerre, I., 
Lacombe, D., Bushby, K, Pollitt, C, Toniolo, D., Fardeau, M., Schwartz, K 
and Muntoni, F. (2000). Clinical and molecular genetic spectrum of autosomal 
dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin 
AlC gene. Ann Neural 48(2): 170-180. 
Booth, C. and Potten, C.S. (2000). Gut instincts: thoughts on intestinal epithelial stem 
cells. J Clin Invest 105(11): 1493-1499. 
Bridger, J.M., Kill, I.R, O'Farrell, M. and Hutchison, C.J. (1993). Intemallamin 
structures within G 1 nuclei of human dermal fibroblasts. J Cell Sci 104(Pt 2): 
297-306. 
Broders, AC. (1925). The grading of carcinoma. Minnesota Med 8: 726-730. 
Bossie, C.A and Sanders, M.M. (1993). A cDNA from Drosophila melanogaster 
encodes a lamin C-like intermediate filament protein. J Cell Sci 104(Pt 4): 1263-
1272. 
Bouhouche, A, Benomar, A, Birouk, N., Mularoni, A, Meggouh, F., Tassin, J., Grid, 
D., Vandenberghe, A, Yahyaoui, M., Chkili, T., Brice, A and LeGuem, E. 
(1999). A locus for an axonal form of autosomal recessive Charcot-Marie-Tooth 
disease maps to chromosome lq2I.2-q2I.3. Am J Hum Genet 65(3): 722-727. 
Brodsky, G.L., Muntoni, F., Miocic, S., Sinagra, G., Sewry, C. and Mestroni, L. (2000). 
Lamin AlC gene mutation associated with dilated cardiomyopathy with variable 
skeletal muscle involvement. Circulation 101(5): 473-476. 
Broers, J.L., Raymond, Y., Rot, M.K, Kuijpers, H., Wagenaar, S.S. and Ramaekers, 
F.C (1993). Nuclear A-type lamins are differentially expressed in human lung 
cancer SUbtypes. Am J PathoI143(1): 211-220. 
Broers, J.L., Machiels, B.M., Kuijpers, H.J., Smedts, F., van den Kieboom, R., 
Raymond, Y. and Ramaekers, F.C. (1997). A- and B-type lamins are 
differentially expressed in normal human tissues. Histochem Cell BioI 107(6): 
505-517. 
191 
Broers, J.L., Machiels, B.M., van Eys, G.J., Kuijpers, H.J., Manders, E.M., van Driel, R. 
and Ramaekers, F.C. (1999). Dynamics of the nuclear lamina as monitored by 
GFP-tagged A-type lamins. J Cell Sci 112(Pt 20): 3463-3475. 
Broers, J.L., Peeters, E.A., Kuijpers, H.J., Endert, J., Bouten, C.V., Oomens, C.W., 
Baaijens, F.P. and Ramaekers, F.C. (2004). Decreased mechanical stiffness in 
LMNA-/- cells is caused by defective nucleo-cytoskeletal integrity: implications 
for the development of laminopathies. Hum Mol Genet 13(21): 2567-2580. 
Buendia, B., Courvalin, J.C. and Collas, P. (2001). Dynamics of the nuclear envelope at 
mitosis and during apoptosis. Cell Mol Life Sci 58(12-13): 1781-1789. 
Burke, B. and Gerace, L. (1986). A cell free system to study reassembly of the nuclear 
envelope at the end of mitosis. Cell 44(4): 639-652. 
Burkitt, H.G., Young, B. and Heath, J.W. (1993). Gastrointestinal tract. In: Wheater's 
Functional Histology: A Text and Colour Atlas. Edinburgh: Churchill 
Livingstone, pp. 247-270. 
Cance, W.G., Chaudhary, N., Worman, H.J., Blobel, G. and Cordon-Cardo, C. (1992). 
Expression of the nuclear lamins in normal and neoplastic human tissues. 1. Exp. 
CZin. Cancer Res. 11(4): 233-246. 
Cancer Research UK (October 2005). 
http://info.cancerresearchuk.org/cancerstatslincidence/ commoncancers/. 
Cancer Research UK (October 2005). 
http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/. 
Cao, H. and Hegele, R.A. (2000). Nuclear lamin AlC R482Q mutation in canadian 
kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 
9(1): 109-112. 
Capanni, C., Mattioli, E., Columbaro, M., Lucarelli, E., Parnaik, V.K., Novelli, G., 
Wehnert, M., Cenni, V., Maraldi, N.M., Squarzoni, S. and Lattanzi, G. (2005). 
Altered pre-Iamin A processing is a common mechanism leading to 
lipodystrophy. Hum Mol Genet 14(11): 1489-1502. 
Carlsson, L., Li, Z.L., Paulin, D., Price, M.G., Breckler, J., Robson, R.M., Wiche, G. 
and Thornell, L.E. (2000). Differences in the distribution of synemin, 
paranemin, and plectin in skeletal muscles of wild-type and des min knock-out 
mice. Histochem Cell Bioi 114(1): 39-47. 
Cartegni, L., di Barletta, M.R., Barresi, R., Squarzoni, S., Sabatelli, P., Maraldi, N., 
Mora, M., Di Blasi, c., Cornelio, F., Merlini, L., Villa, A., Cobianchi, F. and 
Toniolo, D. (1997). Heart-specific localization of emerin: new insights into 
Emery-Dreifuss muscular dystrophy. Hum Mol Genet 6(13): 2257-2264. 
Cattoretti, G., Pileri, S., Parravicini, C., Becker, M.H., Poggi, S., Bifulco, c., Key, G., 
D'Amato, L., Sabattini, E., Feudale, E. and et al. (1993). Antigen unmasking on 
formalin-fixed, paraffin-embedded tissue sections. J Patholl71(2): 83-98. 
Cavallo, R.A., Cox, R.T., Moline, M.M., Roose, J., Polevoy, G.A., Clevers, H., Peifer, 
M. and Bejsovec, A. (1998). Drosophila Tcf and Groucho interact to repress 
Wingless signalling activity. Nature 395(6702): 604-608. 
Chaudhary, N. and Courvalin, J.C. (1993). Stepwise reassembly of the nuclear envelope 
at the end of mitosis. J Cell Bioi 122(2): 295-306. 
Chellappan, S.P., Hiebert, S., Mudryj, M., Horowitz, J.M. and Nevins, J.R. (1991). The 
E2F transcription factor is a cellular target for the RB protein. Cell 65(6): 1053-
1061. 
Chen, L., Lee, L., Kudlow, B.A., Dos Santos, H.G., Sletvold, 0., Shafeghati, Y., Botha, 
E.G., Garg, A., Hanson, N.B., Martin, G.M., Mian, I.S., Kennedy, B.K. and 
Oshima, J. (2003). LMNA mutations in atypical Werner's syndrome. Lancet 
362(9382): 440-445. 
192 
Clarke, P.A., te Poele, R, Wooster, R and Workman, P. (2001). Gene expression 
micro array analysis in cancer biology, pharmacology, and drug development: 
progress and potential. Biochem PharmacoI62(1O): 1311-1336. 
Coates, PJ., Hobbs, RC., Crocker, J., Rowlands, D.C., Murray, P., Quinlan, R. and 
Hall, P.A. (1996). Identification of the antigen recognized by the monoclonal 
antibody BU31 as lamins A and C. J PathoI178(1): 21-29. 
Cohen, M., Lee, KK, Wilson, KL. and Gruenbaum, Y. (2001). Transcriptional 
repression, apoptosis, human disease and the functional evolution of the nuclear 
lamina. Trends Biochem Sci 26(1): 41-47. 
Collas, P., Thompson, L., Fields, A.P., Poccia, D.L. and Courvalin, lC. (1997). Protein 
kinase C-mediated interphase lamin B phosphorylation and solubilization. J BioI 
Chem 272(34): 21274-21280. 
Compagni, A. and Christofori, G. (2000). Recent advances in research on multistage 
tumorigenesis. Br J Cancer 83(1): 1-5. 
Csoka, A.B., English, S.B., Sirnkevich, C.P., Ginzinger, D.G., Butte, AJ., Schatten, 
G.P., Rothman, F.G. and Sedivy, J.M. (2004). Genome-scale expression 
profiling of Hutchinson-Gilford progeria syndrome reveals widespread 
transcriptional misregulation leading to mesodermal/mesenchymal defects and 
accelerated atherosclerosis. Aging Cell 3(4): 235-243. 
Cutler, D.L., Kaufmann, S. and Freidenberg, G.R (1991). Insulin-resistant diabetes 
mellitus and hypermetabolism in mandibuloacral dysplasia: a newly recognized 
form of partial lipodystrophy. J Clin Endocrinol Metab 73(5): 1056-1061. 
Dabauvalle, M.C., Loos, K, Merkert, H. and Scheer, U. (1991). Spontaneous assembly 
of pore complex-containing membranes ("annulate lamellae") in Xenopus egg 
extract in the absence of chromatin. J Cell Biol112(6): 1073-1082. 
Daigle, N., Beaudouin, J., Hartnell, L., Irnreh, G., Hallberg, E., Lippincott-Schwartz, J. 
and Ellenberg, J. (2001). Nuclear pore complexes form immobile networks and 
have a very low turnover in live mammalian cells. J Cell BioI 154(1): 71-84. 
Dechat, T., Gotzmann, J., Stockinger, A., Harris, c.A., Talle, M.A., Siekierka, JJ. and 
Foisner, R (1998). Detergent-salt resistance of LAP2alpha in interphase nuclei 
and phosphorylation-dependent association with chromosomes early in nuclear 
assembly implies functions in nuclear structure dynamics. Embo J 17(16): 4887-
4902. 
Dechat, T., Korbei, B., Vaughan, O.A., Vlcek, S., Hutchison, CJ. and Foisner, R 
(2000). Lamina-associated polypeptide 2alpha binds intranuclear A-type lamins. 
J Cell Sci 113(Pt 19): 3473-3484. 
de la Chapelle, A. (2004). Genetic predisposition to colorectal cancer. Nat Rev Cancer 
4(10): 769-780. 
De Sandre-Giovannoli, A., Chaouch, M., Kozlov, S., Vall at, J.M., Tazir, M., Kassouri, 
N., Szepetowski, P., Hammadouche, T., Vandenberghe, A., Stewart, C.L., Grid, 
D. and Levy, N. (2002). Homozygous defects in LMNA, encoding lamin AlC 
nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in 
human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 
70(3): 726-736. 
de Santa Barbara, P., van den Brink, G.R and Roberts, DJ. (2003). Development and 
differentiation of the intestinal epithelium. Cell Mol Life Sci 60(7): 1322-1332. 
Dessev, G., Iovcheva-Dessev, C., Bischoff, J.R., Beach, D. and Goldman, R (1991). A 
complex containing p34cdc2 and cyclin B phosphorylates the nuclear lamin and 
disassembles nuclei of clam oocytes in vitro. J Cell Biol112(4): 523-533. 
)hanasekaran, S.M., Barrette, T.R, Ghosh, D., Shah, R, Varambally, S., Kurachi, K, 
Pienta, KJ., Rubin, M.A. and Chinnaiyan, A.M. (2001). Delineation of 
prognostic biomarkers in prostate cancer. Nature 412(6849): 822-826. 
193 
Dharmsathaphom, K., McRoberts, J.A., Mandel, K.G., Tisdale, L.D. and Masui, H. 
(1984). A human colonic tumor cell line that maintains vectorial electrolyte 
transport. Am J Physiol246(2 Pt 1): G204-208. 
Dreifuss, F.E. and Hogan, G.R (1961). Survival in x-chromosomal muscular dystrophy. 
Neurology 11: 734-737. 
Drummond, S., Ferrigno, P., Lyon, C., Murphy, J., Goldberg, M., Allen, T., Smythe, C. 
and Hutchison, C.J. (1999). Temporal differences in the appearance of NEP-B78 
and an LBR-like protein during Xenopus nuclear envelope reassembly reflect 
the ordered recruitment of functionally discrete vesicle types. J Cell Biol144(2): 
225-240. 
Duband-Goulet, I., Courvalin, J.C. and Buendia, B. (1998). LBR, a chromatin and lamin 
binding protein from the inner nuclear membrane, is proteolyzed at late stages of 
apoptosis. J Cell Sci l11(Pt 10): 1441-1451. 
Dukes, C.E. (1932). The classification of cancer of the rectum. Journal of Pathology 
and Bacteriology 35: 323-332. 
Dunnigan, M.G., Cochrane, M.A., Kelly, A. and Scott, J.W. (1974). Familial 
lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med· 
43(169): 33-48. 
Dunstone, G.H. and Knaggs, T.W. (1972). Familial cancer of the colon and rectum. J 
Med Genet 9(4): 451-456. 
Dwyer, N. and BIobel, G. (1976). A modified procedure for the isolation of a pore 
complex-lamina fraction from rat liver nuclei. J Cell Biol70(3): 581-591. 
Dyer, J.A., Kill, I.R, Pugh, G., Quinlan, RA., Lane, E.B. and Hutchison, C.J. (1997). 
Cell cycle changes in A-type lamin associations detected in human dermal 
fibroblasts using monoclonal antibodies. Chromosome Res 5(6): 383-394. 
Dyer, J.A., Lane, B.E. and Hutchison, C.J. (1999). Investigations of the pathway of 
incorporation and function of lamin A in the nuclear lamina. Microsc Res Tech 
45(1): 1-12. 
Ellenberg, J., Siggia, E.D., Moreira, J.E., Smith, c.L., Presley, J.F., Worman, H.J. and 
Lippincott-Schwartz, J. (1997). Nuclear membrane dynamics and reassembly in 
living cells: targeting of an inner nuclear membrane protein in interphase and 
mitosis. J Cell Biol138(6): 1193-1206. 
Ellis, J.A., Yates, J.R, Kendrick-Jones, J. and Brown, c.A. (1999). Changes at P183 of 
emerin weaken its protein-protein interactions resulting in X-linked Emery-
Dreifuss muscular dystrophy. Hum Genet 104(3): 262-268. 
Emery, A.E. and Dreifuss, F.E. (1966). Unusual type of benign x-linked muscular 
dystrophy. J Neurol Neurosurg Psychiatry 29(4): 338-342. 
Erber, A., Riemer, D., Bovenschulte, M. and Weber, K. (1998). Molecular phylogeny of 
metazoan intermediate filament proteins. J Mol Evol47(6): 751-762. 
Eriksson, M., Brown, W.T., Gordon, L.B., Glynn, M.W., Singer, J., Scott, L., Erdos, 
M.R, Robbins, C.M., Moses, T.Y., Berglund, P., Dutra, A., Pak, E., Durkin, S., 
Csoka, A.B., Boehnke, M., Glover, T.W. and Collins, F.S. (2003). Recurrent de 
novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. 
Nature 423(6937): 293-298. 
Ethier, S.P. (1996). Human breast cancer cell lines as models of growth regulation and 
disease progression. J Mammary Gland Biol Neoplasia 1(1): 111-121. 
Farnsworth, C.c., Wolda, S.L., Gelb, M.H. and Glomset, J.A. (1989). Human lamin B 
contains a famesylated cysteine residue. J Biol Chem 264(34): 20422-20429. 
Fatkin, D., MacRae, c., Sasaki, T., Wolff, M.R, Porcu, M., Frenneaux, M., Atherton, 
J., Vidaillet, H.J., Jr., Spudich, S., De Girolami, U., Seidman, lG., Seidman, C., 
Muntoni, F., Muehle, G., Johnson, W. and McDonough, B. (1999). Missense 
mutations in the rod domain of the lamin NC gene as causes of dilated 
194 
cardiomyopathy and conduction-system disease. N Eng! J Med 341(23): 1715-
1724. 
Fawcett, D.W. (1966). On the occurrence of a fibrous lamina on the inner aspect of the 
nuclear envelope in certain cells of vertebrates. Am J Anal 119(1): 129-145. 
Fearon, E.R., Cho, K.R, Nigro, I.M., Kern, S.E., Simons, 1.W., Ruppert, 1.M., 
Hamilton, S.R, Preis inger, AC., Thomas, G., Kinzler, K.W. and et al. (1990). 
Identification of a chromosome 18q gene that is altered in colorectal cancers. 
Science 247(4938): 49-56. 
Fearon, E.R. and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. 
Cell 61(5): 759-767. 
Firmbach-Kraft, I. and Stick, R. (1993). The role of CaaX-dependent modifications in 
membrane association of Xenopus nuclear lamin B3 during meiosis and the fate 
ofB3 in transfected mitotic cells . J Cell Bioi 123(6 Pt 2): 1661-1670. 
Fisher, D.Z., Chaudhary, N. and Blobel, G. (1986). cDNA sequencing of nuclear lamins 
A and C reveals primary and secondary structural homology to intermediate 
filament proteins. Proc Nat! Acad Sci USA 83(17): 6450-6454. 
Fodde, R, Smits, Rand Clevers, H. (2001). APC, signal transduction and genetic 
instability in colorectal cancer. Nat Rev Cancer 1(1): 55-67. 
Fogh, 1. and Trempe, G. (1975). New Human Tumor Cell Lines. In: Human Tumor 
Cells In Vitro. Fogh, 1. (ed). New York: Plenum Press, pp. 115-159. 
Foisner, R. and Gerace, L. (1993). Integral membrane proteins of the nuclear envelope 
interact with lamins and chromosomes, and binding is modulated by mitotic 
phosphorylation. Cell 73(7): 1267-1279. 
Foisner, R. (2001). Inner nuclear membrane proteins and the nuclear lamina. J Cell Sci 
114(Pt 21): 3791-3792. 
Franke, W.W., Scheer, U., Krohne, G. and larasch, E.D. (1981). The nuclear envelope 
and the architecture of the nuclear periphery. J Cell Bio!91(3 Pt 2): 39s-50s. 
Fuchs, E. and Weber, K. (1994). Intermediate filaments: structure, dynamics, function, 
and disease. Annu Rev Biochem 63: 345-382. 
Fuller, G.N., Hess, K.R, Rhee, C.H., Yung, W.K., Sawaya, RA, Bruner, 1.M. and 
Zhang, W. (2002). Molecular classification of human diffuse gliomas by 
multidimensional scaling analysis of gene expression profiles parallels · 
morphology-based classification, correlates with survival, and reveals clinically-
relevant novel glioma subsets. Brain Patho!12(1): 108-116. 
Furukawa, K. and Hotta, Y. (1993). cDNA cloning of a germ cell specific lamin B3 
from mouse spermatocytes and analysis of its function by ectopic expression in 
somatic cells. Embo J 12(1): 97-106. 
Furukawa, K., Inagaki, H. and Hotta, Y. (1994). Identification and cloning of an mRNA 
coding for a germ cell-specific A-type lamin in mice. Exp Cell Res 212(2): 426-
430. 
Furukawa, K. (1999). LAP2 binding protein 1 (L2BPlfBAF) is a candidate mediator of 
LAP2-chromatin interaction. J Cell Sci 112(Pt 15): 2485-2492. 
Gabriel, V.B., Dukes, C. and Bussey, H.J.R. (1935). Lymphatic spread in cancer of the 
rectum. Br J Surg 23: 395. 
Galambos, J.T. (1973). Carcinoembryonic antigen and neoplastic disease. South Med J 
66(11): 1216-1217. 
Genschel, J., Bochow, B., Kuepferling, S., Ewert, R, Hetzer, R, Lochs, H. and 
Schmidt, H. (2001). A R644C mutation within lamin A extends the mutations 
causing dilated cardiomyopathy. Hum Mutat 17(2): 154. 
Georgatos, S.D., Pyrpasopoulou, A and Theodoropoulos, P.A (1997). Nuclear 
envelope breakdown in mammalian cells involves stepwise lamina disassembly 
195 
and microtubule-drive deformation of the nuclear membrane. J Cell Sci 1l0(Pt 
17): 2129-2140. 
Gerace, L., Blum, A. and Blobel, G. (1978). Immunocytochemical localization of the 
major polypeptides of the nuclear pore complex-lamina fraction. Interphase and 
mitotic distribution. J Cell Bioi 79(2 Pt 1): 546-566. 
Gerace, L. and Blobel, G. (1980). The nuclear envelope lamina is reversibly 
depolymerized during mitosis. Cell 19(1): 277-287. 
Gerace, L., Comeau, C. and Benson, M. (1984). Organization and modulation of nuclear 
lamina structure. J Cell Sci Suppll: 137-160. 
Gerace, L. (1986). Nuclear lamina and organisation of nuclear architecture. Trends 
Biochem Sci 11: 443-445. 
Gerace, L. and Burke, B. (1988). Functional organization of the nuclear envelope. Annu 
Rev Cell BioI 4: 335-374. 
Giles, R.H., van Es, J.H. and Clevers, H. (2003). Caught up in a Wnt storm: Wnt 
signaling in cancer. Biochim Biophys Acta 1653(1): 1-24. 
Goldberg, M., Harel, A. and Gruenbaum, Y. (1999). The nuclear lamina: molecular 
organization and interaction with chromatin. Crit Rev Eukaryot Gene Expr 9(3-
4): 285-293. 
Goldberg, M.W. and Allen, T.D. (1995). Structural and functional organization of the 
nuclear envelope. Curr Opin Cell Biol7(3): 301-309. 
Goldman, R.D., Gruenbaum, Y, Moir, R.D., Shumaker, D.K. and Spann, T.P. (2002). 
Nuclear lamins: building blocks of nuclear architecture. Genes Dev 16(5): 533-
547. 
Joldman, R.D., Shumaker, D.K., Erdos, M.R, Eriksson, M., Goldman, A.E., Gordon, 
L.B., Gruenbaum, Y, Khuon, S., Mendez, M., Varga, R and Collins, F.S. 
(2004). Accumulation of mutant lamin A causes progressive changes in nuclear 
architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 
101(24): 8963-8968. 
loldstein, MJ. and Mitchell, E.P. (2005). Carcinoembryonic antigen in the staging and 
follow-up of patients with colorectal cancer. Cancer Invest 23(4): 338-351. 
(olub, T.R. , Slonim, D.K., Tamayo, P., Huard, c., Gaasenbeek, M., Mesirov, J.P., 
Coller, H., Loh, M.L., Downing, J.R, Caligiuri, M.A., Bloomfield, C.D. and 
Lander, E.S. (1999). Molecular classification of cancer: class discovery and 
class prediction by gene expression monitoring. Science 286(5439): 531-537. 
'ordon, J.I. and Hermiston, M.L. (1994). Differentiation and self-renewal in the mouse 
gastrointestinal epithelium. Curr Opin Cell BioI 6(6): 795-803. 
ranger, B.L. and Lazarides, E. (1980). Synemin: a new high molecular weight protein 
associated with desmin and vimentin filaments in muscle. Cell 22(3): 727-738. 
ruenbaum, Y, Landesman, Y., Drees, B., Bare, J.W., Saumweber, H., Paddy, M.R., 
Sedat, J.W., Smith, D.E., Benton, B.M. and Fisher, P.A. (1988). Drosophila 
nuclear lamin precursor DmO is translated from either of two developmentally 
regulated mRNA species apparently encoded by a single gene. J Cell BioI 
106(3): 585-596 . 
. uenbaum, Y, Lee, K.K., Liu, J ., Cohen, M. and Wilson, K.L. (2002). The expression, 
lamin-dependent localization and RNAi depletion phenotype for emerin in C. 
elegans. J Cell Sci 115(Pt 5): 923-929. 
llenbaum, Y., Goldman, R.D., Meyuhas, R., Mills, E., Margalit, A., Fridkin, A., 
Dayani, Y., Prokocimer, M. and Enosh, A. (2003). The nuclear lamina and its 
functions in the nucleus. Int Rev Cyto1226: 1-62. 
uenbaum, Y., Margalit, A., Goldman, RD., Shumaker, D.K. and Wilson, K.L. 
(2005). The nuclear lamina comes of age. Nat Rev Mol Cell BioI 6(1): 21-31. 
196 
Guilly, M.N., Bensussan, A, Bourge, J.P', Bomens, M. and Courvalin, J.e. (1987). A 
human T lymphoblastic cell line lacks lamins A and C. Embo ] 6(12): 3795-
3799. 
Hammoud, M.A, McCutcheon, I.E., Elsouki, R., Schoppa, D. and Patt, YZ. (1996). 
Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. 
Ann Surg Oncol3(5): 453-463. 
Hardcastle, J.D., Chamberlain, J.O., Robinson, M.H., Moss, S.M., Amar, S.S., Balfour, 
T.W., James, P.D. and Mangham, C.M. (1996). Randomised controlled trial of 
faecal-occult-blood screening for colorectal cancer. Lancet 348(9040): 1472-
1477. 
Hatch, KF., Blanchard, D.K, Hatch, G.F., 3rd, Wertheimer-Hatch, L., Davis, G.B., 
Foster, R.S., Jr. and Skandalakis, J.E. (2000). Tumors of the appendix and colon. 
World J Surg 24(4): 430-436. 
Hazelbag, H.M., van den Broek, LJ., van Dorst, E.B., Offerhaus, GJ., Fleuren, GJ. and 
Hogendoom, P.e. (1995). Immunostaining of chain-specific keratins on 
formalin-fixed, paraffin-embedded tissues: a comparison of various antigen 
retrieval systems using microwave heating and proteolytic pre-treatments. ] 
Histochem Cytochem 43(4): 429-437. 
He, T.C., Sparks, AB., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, PJ., 
Vogel stein, B. and Kinzler, KW. (1998). Identification of c-MYC as a target of 
the APC pathway. Science 281(5382): 1509-1512. 
Hegele, R.A, Anderson, e.M., Wang, J., Jones, D.e. and Cao, H. (2000). Association 
between nuclear lamin NC R482Q mutation and partial lipodystrophy with 
hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res 10(5): 
652-658. 
Heitlinger, E., Peter, M., Haner, M., Lustig, A, Aebi, U. and Nigg, E.A (1991). 
Expression of chicken lamin B2 in Escherichia coli: characterization of its 
structure, assembly, and molecular interactions. ] Cell Biol113(3): 485-495. 
Heitlinger, E., Peter, M., Lustig, A, Villiger, W., Nigg, E.A and Aebi, U. (1992). The 
role of the head and tail domain in lamin structure and assembly: analysis of 
bacterially expressed chicken lamin A and truncated B2lamins. ] Struct Biol 
108(1): 74-89. 
Hemminki, A, Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A, 
Bignell, G., Warren, W., Aminoff, M., Hoglund, P., Jarvinen, H., Kristo, P., 
Pelin, K, Ridanpaa, M., Salovaara, R., Toro, T., Bodmer, W., Olschwang, S., 
Olsen, AS., Stratton, M.R., de la Chapelle, A and Aaltonen, L.A (1998). A 
serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 
391(6663): 184-187. 
Herman, J.G. and Baylin, S.B. (2003). Gene silencing in cancer in association with 
promoter hypermethylation. N Engl ] Med 349(21): 2042-2054. 
Herrmann, H. and Aebi, U. (2000). Intermediate filaments and their associates: multi-
talented structural elements specifying cytoarchitecture and cytodynamics. Curr 
Opin Cell Biol12(1): 79-90. 
Hewitt, R.E., McMarlin, A, Kleiner, D., Wersto, R., Martin, P., Tsokos, M., Stamp, 
G.W. and Stetler-Stevenson, W.G. (2000). Validation of a model of colon cancer 
progression. ] Pathol192(4): 446-454. 
Hirako, Y, Yamakawa, H., Tsujimura, Y., Nishizawa, Y, Okumura, M., Usukura, J., 
Matsumoto, H., Jackson, KW., Owaribe, K and Ohara, O. (2003). 
Characterization of mammalian synemin, an intermediate filament protein 
present in all four classes of muscle cells and some neuroglial cells: co-
localization and interaction with type III intermediate filament proteins and 
. ~<;. Cell Tissue Res 313(2): 195-207. 
197 
Hobdy, E.M., Ciesielski, T.E. and Kummar, S. (2003). Unusual sites of colorectal 
cancer metastasis. Clin Colorectal Cancer 3(1): 54-57. 
Hofemeister, H., Kuhn, C., Franke, W.W., Weber, K. and Stick, R. (2002). 
Conservation of the gene structure and membrane-targeting signals of germ cell-
specific lamin LUI in amphibians and fish. Eur J Cell Bioi 81(2): 51-60. 
Hoger, T.H., Grund, C., Franke, W.W. and Krohne, G. (1991). Immunolocalization of 
lamins in the thick nuclear lamina of human synovial cells. Eur J Cell Bioi 
54(1): 150-156. 
Hozak, P., Sasseville, AM., Raymond, Y. and Cook, P.R (1995). Lamin proteins form 
an internal nucleoskeleton as well as a peripheral lamina in human cells. J Cell 
Sci 108(Pt 2): 635-644. 
Hutchison, CJ., Alvarez-Reyes, M. and Vaughan, O.A (2001). Lamins in disease: why 
do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific 
disease phenotypes? J Cell Sci 114(Pt 1): 9-19. 
Hutchison, C.J. (2002). Lamins: building blocks or regulators of gene expression? Nat 
Rev Mol Cell Bioi 3(11): 848-858. 
Igarashi, H., Sugimura, H., Maruyama, K., Kitayama, Y., Ohta, 1., Suzuki, M., Tanaka, 
M., Dobashi, Y. and Kino, I. (1994). Alteration of immunoreactivity by hydrated 
autoclaving, microwave treatment, and simple heating of paraffin-embedded 
tissue sections. Apmis 102(4): 295-307. 
Iwashita, T., Kruger, G.M., Pardal, R, Kiel, MJ. and Morrison, SJ. (2003). 
Hirschsprung disease is linked to defects in neural crest stem cell function. 
Science 301(5635): 972-976. 
Jansen, M.P., Machiels, B.M., Hopman, AH., Broers, J.L., Bot, FJ., Arends, J.W., 
Ramaekers, F.e. and Schouten, H.e. (1997). Comparison of A and B-type lamin 
expression in reactive lymph nodes and nodular sclerosing Hodgkin's disease. 
Histopathology 31(4): 304-312. 
Jen, J., Powell, S.M., Papadopoulos, N., Smith, KJ., Hamilton, S.R, Vogel stein, B. and 
Kinzler, K.W. (1994). Molecular determinants of dysplasia in colorectallesions. 
Cancer Res 54(21): 5523-5526. 
Jenne, D.E., Reimann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Muller, 0., Back, 
W. and Zimmer, M. (1998). Peutz-Jeghers syndrome is caused by mutations in a 
novel serine threonine kinase. Nat Genet 18(1): 38-43. 
Jing, R, Pizzolato, G., Robson, RM., Gabbiani, G. and Skalli, O. (2005). Intermediate 
filament protein synemin is present in human reactive and malignant astrocytes 
and associates with ruffled membranes in astrocytoma cells. Giia 50(2): 107-
120. 
Johnston, P.G. (2004). Of what value genomics in colorectal cancer? Opportunities and 
challenges. J Clin OncoI22(9): 1538-1539. 
Jones, P.A and Laird, P.W. (1999). Cancer epigenetics comes of age. Nat Genet 21(2): 
163-167. 
Kahveci, Z., Minbay, F.Z., Noyan, S. and Cavusoglu, I. (2003). A comparison of 
microwave heating and proteolytic pretreatment antigen retrieval techniques in 
formalin fixed, paraffin embedded tissues. Biotech Histochem 78(2): 119-128. 
Karnovsky, MJ. (1965). A formaldehyde-glutaraldehyde fixative of high osmolarity for 
use in electron microscopy. J Cell Bioi 27: 137 A-138A 
Kaufmann, S.H., Mabry, M., Jasti, Rand Shaper, I.H. (1991). Differential expression 
of nuclear envelope lamins A and C in human lung cancer cell lines. Cancer Res 
51(2): 581-586. 
Kawai, K., Serizawa, A, Hamana, T. and Tsutsumi, Y. (1994). Heat-induced antigen 
retrieval of proliferating cell nuclear antigen and p53 protein in formalin-fixed, 
paraffin-embedded sections. Pathol Int 44(10-11): 759-764. 
198 
Kedinger, M., Lefebvre, 0., Duluc, 1., Freund, J.N. and Simon-Assmann, P. (1998). 
Cellular and molecular partners involved in gut morphogenesis and 
differentiation. Philos Trans R Soc Lond B Biol Sci 353(1370): 847-856. 
Kill, 1.R. and Hutchison, C.J. (1995). S-phase phosphorylation of lamin B2. FEBS Lett 
377(1): 26-30. 
Kinzler, KW. and Vogel stein, B. (1996). Lessons from hereditary colorectal cancer. 
Cell 87(2): 159-170. 
Korenjak, M. and Brehm, A. (2005). E2F-Rb complexes regulating transcription of 
genes important for differentiation and development. Curr Opin Genet Dev 
15(5): 520-527. 
Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R., Kinzler, KW., 
Vogelstein, B. and Clevers, H. (1997). Constitutive transcriptional activation by 
a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275(5307): 
1784-1787. 
Korkola, J.E., DeVries, S., Fridlyand, J., Hwang, E.S., Estep, A.L., Chen, Y.Y., Chew, 
KL., Dairkee, S.H., Jensen, R.M. and Waldman, F.M. (2003). Differentiation of 
lobular versus ductal breast carcinomas by expression microarray analysis. 
Cancer Res 63(21): 7167-7175. 
Korkola, J.E. , Houldsworth, J., Dobrzynski, D., Olshen, A.B., Reuter, V.E., Bosl, G.J. 
and Chaganti, R.S . (2005). Gene expression-based classification of 
nonseminomatous male germ cell tumors. Oncogene 24(32): 5101-5107. 
Krimm, 1., Ostlund, C., Gilquin, B., Couprie, J., Hossenlopp, P., Momon, J.P., Bonne, 
G., Courvalin, J.C., Worman, H.J. and Zinn-Justin, S. (2002). The Ig-like 
structure of the C-terminal domain of lamin NC, mutated in muscular 
dystrophies, cardiomyopathy, and partial lipodystrophy. Structure (Camb) 10(6): 
811-823. 
Lazarides, E. (1980). Intermediate filaments as mechanical integrators of cellular space. 
Nature 283(5744): 249-256. 
Leal, A., Morera, B., Del Valle, G., Heuss, D., Kayser, c., Berghoff, M., Villegas, R., 
Hernandez, E. , Mendez, M., Hennies, H.C., Neundorfer, B., Barrantes, R., Reis, 
A. and Rautenstrauss, B. (2001). A second locus for an axonal form of 
autosomal recessive Charcot-Marie-Tooth disease maps to chromosome 
19q13.3. Am J Hum Genet 68(1): 269-274. 
Lebel, S., Lampron, C. , Royal, A. and Raymond, Y. (1987). Lamins A and C appear 
during retinoic acid-induced differentiation of mouse embryonal carcinoma 
cells. J Cell Bioll05(3): 1099-1104. 
Lee, KK, Haraguchi, T., Lee, R.S., Koujin, T., Hiraoka, Y. and Wilson, KL. (2001). 
Distinct functional domains in emerin bind lamin A and DNA-bridging protein 
BAF. J Cell Sci 114(Pt 24): 4567-4573 . 
Lee, KK, Starr, D., Cohen, M., Liu, J., Han, M. , Wilson, KL. and Gruenbaum, Y. 
(2002). Lamin-dependent localization of UNC-84, a protein required for nuclear 
migration in Caenorhabditis elegans. Mol Biol Cell 13(3): 892-90l. 
Lehner, C.F., Stick, R. , Eppenberger, H.M. and Nigg, E.A. (1987). Differential 
expression of nuclear lamin proteins during chicken development. J Cell BioI 
105(1): 577-587. 
Leibovitz, A. (1963). The Growth and Maintenance of Tissue-Cell Cultures in Free Gas 
Exchange with the Atmosphere. Am J Hyg 78: 173-180. 
Leibovitz, A., Stinson, J.C., McCombs, W.B. , 3rd, McCoy, C.E., Mazur, KC. and 
Mabry, N.D. (1976). Classification of human colorectal adenocarcinoma cell 
lines. Cancer Res 36(12): 4562-4569. 
Lenz-Bohme, B., Wismar, J., Fuchs, S., Reifegerste, R., Buchner, E., Betz, H. and 
Schmitt, B. (1997). Insertional mutation of the Drosophila nuclear lamin DmO 
199 
gene results in defective nuclear envelopes, clustering of nuclear pore 
complexes, and accumulation of annulate lamellae. J Cell Bioi 137(5): 1001-
1016. 
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.l., Puc, J., Miliaresis, e., 
Rodgers, L., McCombie, R., Bigner, S.H., Giovanella, B.C., Ittmann, M., Tycko, 
B., Hibshoosh, H., Wigler, M.H. and Parsons, R. (1997). PTEN, a putative 
protein tyrosine phosphatase gene mutated in human brain, breast, and prostate 
cancer. Science 275(5308): 1943-1947. 
Libotte, T., Zaim, H., Abraham, S., Padmakumar, V.e., Schneider, M., Lu, W., Munck, 
M., Hutchison, e., Wehnert, M., Fahrenkrog, B., Sauder, u., Aebi, U., Noegel, 
AA and Karakesisoglou, I. (2005). Lamin NC-dependent localization of 
Nesprin-2, a giant scaffolder at the nuclear envelope. Mol Biol Cell 16(7): 3411-
3424. 
Lin, F. and Worman, H.J. (1993). Structural organization of the human gene encoding 
nuclear lamin A and nuclear lamin C. J Biol Chern 268(22): 16321-16326. 
Lin, F. and Worman, HJ. (1995). Structural organization of the human gene (LMNB1) 
encoding nuclear lamin B1. Genornics 27(2): 230-236. 
Lin, F. and Worman, H.J. (1997). Expression of nuclear lamins in human tissues and 
cancer cell lines and transcription from the promoters of the lamin NC and B 1 
genes. Exp Cell Res 236(2): 378-384. 
Liu, J., Rolef Ben-Shahar, T., Riemer, D., Treinin, M., Spann, P., Weber, K., Fire, A. 
and Gruenbaum, Y. (2000). Essential roles for Caenorhabditis elegans lamin 
gene in nuclear organization, cell cycle progression, and spatial organization of 
nuclear pore complexes. Mol Bioi Cell 11(11): 3937-3947. 
Loewinger, L. and McKeon, F. (1988). Mutations in the nuclear lamin proteins resulting 
in their aberrant assembly in the cytoplasm. Ernbo J 7(8): 2301-2309. 
Logan, C.Y. and Nusse, R. (2004). The Wnt signaling pathway in development and 
disease. Annu Rev Cell Dev Bioi 20: 781-810. 
Lynch, H.T. and de la Chapelle, A (1999). Genetic susceptibility to non-polyposis 
colorectal cancer. J Med Genet 36(11): 801-818. 
Lui, j. and et al. (2000). Essential roles of Caenorhabditis elegans lamin gene in nuclear 
organisation, cell cycle progression, and spatial organisation of nuclear pore 
complexes. Mol. BioI. Cell 11: 3937-3947. 
Mabry, M., Nakagawa, T., Nelkin, B.D., McDowell, E., Gesell, M., Eggleston, J.e., 
Casero, R.A, lr. and Baylin, S.B. (1988). v-Ha-ras oncogene insertion: a model 
for tumor progression of human small cell lung cancer. Proc Natl Acad Sci US 
A 85(17): 6523-6527. 
Machiels, B.M., Broers, 1.L., Raymond, Y., de Ley, L., Kuijpers, HJ., Caberg, N.E. and 
Ramaekers, F.C. (1995). Abnormal A-type lamin organization in a human lung 
carcinoma cell line. Eur J Cell Bioi 67(4): 328-335. 
Machiels, B.M., Zorenc, A.H., Endert, 1.M., Kuijpers, HJ., van Eys, GJ., Ramaekers, 
F.e. and Broers, 1.L. (1996). An alternative splicing product of the lamin NC 
gene lacks exon 10. J Biol Chern 271(16): 9249-9253. 
Machiels, B.M., Ramaekers, F.C., Kuijpers, HJ., Groenewoud, 1.S., Oosterhuis, 1.W. 
and Looijenga, L.H. (1997). Nuclear lamin expression in normal testis and 
testicular germ cell tumours of adolescents and adults. J PathoI182(2): 197-204. 
Mandel, 1.S., Bond, 1.H., Church, T.R., Snover, D.C., Bradley, G.M., Schuman, L.M. 
and Ederer, F. (1993). Reducing mortality from colorectal cancer by screening 
for fecal occult blood. Minnesota Colon Cancer Control StUdy. N Engl J Med 
328(19): 1365-1371. 
200 
Mandel, J.S., Church, T.R, Ederer, F. and Bond, J.H. (1999). Colorectal cancer 
mortality: effectiveness of biennial screening for fecal occult blood. J Natl 
Cancer Inst 91(5): 434-437. 
Manilal, S., Nguyen, T.M., Sewry, C.A. and Morris, G.E. (1996). The Emery-Dreifuss 
muscular dystrophy protein, emerin, is a nuclear membrane protein. Hum Mol 
Genet 5(6): 801-808. 
Manilal, S., Sewry, c.A., Pereboev, A., Man, N., Gobbi, P., Hawkes, S., Love, D.R and 
Morris, G.E. (1999). Distribution of emerin and lamins in the heart and 
implications for Emery-Dreifuss muscular dystrophy. Hum Mol Genet 8(2): 353-
359. 
Markiewicz, E., Dechat, T., Foisner, R, Quinlan, RA. and Hutchison, C.1. (2002). 
Lamin AlC binding protein LAP2alpha is required for nuclear anchorage of 
retinoblastoma protein. Mol Bioi Cell 13(12): 4401-4413. 
Marsh, D.1., Coulon, V., Lunetta, KL., Rocca-Serra, P., Dahia, P.L., Zheng, Z., Liaw, 
D., Caron, S., Duboue, B., Lin, A.Y., Richardson, A.L., Bonnetblanc, J.M., 
Bressieux, J.M., Cabarrot-Moreau, A, Chompret, A., Demange, L., Eeles, RA, 
Yahanda, A.M., Fearon, E.R, Fricker, J.P., Gorlin, R.I., Hodgson, S.V., Huson, 
S., Lacombe, D., Eng, C. and et al. (1998). Mutation spectrum and genotype-
phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two 
hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7(3): 
507-515. 
Marshman, E., Booth, C. and Potten, C.S. (2002). The intestinal epithelial stem cell. 
Bioessays 24(1): 91-98. 
Marton, M.1., DeRisi, J.L., Bennett, H.A., Iyer, V.R., Meyer, M.R, Roberts, C.1., 
Stoughton, R., Burchard, J., Slade, D., Dai, R., Bassett, D.E., Jr., Hartwell, L.H., 
Brown, P.O. and Friend, S.H. (1998). Drug target validation and identification 
of secondary drug target effects using DNA microarrays. Nat Med 4(11): 1293-
1301. 
McKeon, F.D., Kirschner, M.W. and Caput, D. (1986). Homologies in both primary and 
secondary structure between nuclear envelope and intermediate filament 
proteins. Nature 319(6053): 463-468. 
McKusick, V.A. (1963). Medical Genetics 1962. J Chronic Dis 16: 457-634. 
Meier, J., Campbell, KH., Ford, C.C., Stick, R and Hutchison, C.1. (1991). The role of 
lamin LUI in nuclear assembly and DNA replication, in cell-free extracts of 
Xenopus eggs. J Cell Sci 98(Pt 3): 271-279. 
Mighell, A.1., Robinson, P.A. and Hume, W.1. (1995). Patterns of immunoreactivity to 
an anti-fibronectin polyclonal antibody in formalin-fixed, paraffin-embedded 
oral tissues are dependent on methods of antigen retrieval. J Histochem 
Cytochem 43(11): 1107-1114. 
Miller, RG., Layzer, RB., Mellenthin, M.A, Golabi, M., Francoz, RA and Mall, J.e. 
(1985). Emery-Dreifuss muscular dystrophy with autosomal dominant 
transmission. Neurology 35(8): 1230-1233. 
Misiewicz, J.1., Bartram, e.I., Cotton, P.B., Mee, A.S., Price, A.B. and Thompson, 
RP .H. (1988). Diseases of the colon and rectum: A guide to diagnosis. In: 
Gastroenterology. Vol. 3. London: Gower Medical Publishing. 
Mislow, J.M., Kim, M.S., Davis, D.H. and McNally, E.M. (2002a). Myne-l, a spectrin 
repeat transmembrane protein of the myocyte inner nuclear membrane, interacts 
with lamin AlC. J Cell Sci 115(Pt 1): 61-70. 
Mislow, J.M., Holaska, lM., Kim, M.S., Lee, KK, Segura-Totten, M., Wilson, K.L. 
and McNally, E.M. (2002b). Nesprin-1alpha self-associates and binds directly to 
emerin and lamin A in vitro. FEBS Lett 525(1-3): 135-140. 
201 
Mittnacht, S. and Weinberg, R.A. (1991). G liS phosphorylation of the retinoblastoma 
protein is associated with an altered affinity for the nuclear compartment. Cell 
65(3): 381-393. 
Mizuno, Y, Thompson, T.G., Guyon, 1.R., Lidov, H.G., Brosius, M., Imamura, M., 
Ozawa, E., Watkins, S.C. and Kunkel, L.M. (2001). Desmuslin, an intermediate 
filament protein that interacts with alpha -dystrobrevin and desmin. Proc Natl 
Acad Sci USA 98(11): 6156-6161. 
Mizuno, Y, Guyon, 1.R., Watkins, S.c., Mizushima, K., Sasaoka, T., Imamura, M., 
Kunkel, L.M. and Okamoto, K. (2004). Beta-synemin localizes to regions of 
high stress in human skeletal myofibers . Muscle Nerve 30(3): 337-346. 
Moir, R.D., Donaldson, A.D. and Stewart, M. (1991). Expression in Escherichia coli of 
human lamins A and C: influence of head and tail domains on assembly 
properties and paracrystal formation. J Cell Sci 99(Pt 2): 363-372. 
Moir, R.D., Spann, T.P., Lopez-Soler, R.I., Yoon, M., Goldman, A.E., Khuon, S. and 
Goldman, R.D. (2000a). Review: the dynamics of the nuclear lamins during the 
cell cycle-- relationship between structure and function. J Struct Bioi 129(2-3): 
324-334. 
Moir, R.D., Yoon, M., Khuon, S. and Goldman, R.D. (2000b). Nuclear lamins A and 
Bl: different pathways of assembly during nuclear envelope formation in living 
cells. J Cell Bioi 151(6): 1155-1168. 
Morin, PJ., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B. and 
Kinzler, K.W. (1997). Activation of beta-catenin-Tcf signaling in colon cancer 
by mutations in beta-catenin or APC. Science 275(5307): 1787-1790. 
Moss, S.F., Krivosheyev, V., de Souza, A., Chin, K., Gaetz, H.P., Chaudhary, N., 
Worman, HJ. and Holt, P.R. (1999). Decreased and aberrant nuclear lamin 
expression in gastrointestinal tract neoplasms. Gut 45(5): 723-729. 
Mounkes, L.C., Kozlov, S., Hernandez, L., Sullivan, T. and Stewart, c.L. (2003). A 
progeroid syndrome in mice is caused by defects in A-type lamins. Nature 
423(6937): 298-301. 
Muchir, A., Bonne, G., van der Kooi, AJ., van Meegen, M., Baas, F., Bolhuis, P.A., de 
Visser, M. and Schwartz, K. (2000). Identification of mutations in the gene 
encoding lamins AlC in autosomal dominant limb girdle muscular dystrophy 
with atrioventricular conduction disturbances (LGMDIB). Hum Mol Genet 9(9): 
1453-1459. 
Muller, H.H., Heinimann, K. and Dobbie, Z. (2000). Genetics of hereditary colon 
cancer - a basis for prevention? Eur J Cancer 36(10): 1215-1223. 
Murakami, H. and Masui, H. (1980). Hormonal control of human colon carcinoma cell 
growth in serum-free medium. Proc Natl Acad Sci USA 77(6): 3464-3468. 
Murakami, S., Terakado, M., Hashimoto, T., Tsuji, Y, Okubo, K. and Hirayama, R. 
(2003). Adrenal metastasis from rectal cancer: report of a case. Surg Today 
33(2): 126-130. 
Nagano, A., Koga, R., Ogawa, M., Kurano, Y., Kawada, 1., Okada, R., Hayashi, Y.K., 
Tsukahara, T. and Arahata, K. (1996). Emerin deficiency at the nuclear 
membrane in patients with Emery-Dreifuss muscular dystrophy. Nat Genet 
12(3): 254-259. 
\fagase, H. and Nakamura, Y (1993). Mutations of the APC (adenomatous polyposis 
coli) gene. Hum Mutat 2(6): 425-434. 
Narayan, S. and Roy, D. (2003). Role of APC and DNA mismatch repair genes in the 
development of colorectal cancers. Mol Cancer 2: 41. 
Newport, J.W., Wilson, K.L. and Dunphy, W.G. (1990). A lamin-independent pathway 
for nuclear envelope assembly. J Cell Bioi 111(6 Pt 1): 2247-2259. 
202 
Nigg, E.A (1992). Assembly and cell cycle dynamics of the nuclear lamina. Semin Cell 
Bioi 3(4): 245-253. 
Nigro, J.M., Baker, S.J., Preis inger, AC., Jessup, J.M., Hostetter, R, Cleary, K., 
Bigner, S.H., Davidson, N., Baylin, S., Devilee, P. and et al. (1989). Mutations 
in the p53 gene occur in diverse human tumour types. Nature 342(6250): 705-
708. 
NiIi, E., Cojocaru, G.S., Kalma, Y., Ginsberg, D., Copeland, N.G., Gilbert, DJ., 
Jenkins, N.A, Berger, R, Shaklai, S., Amariglio, N., Brok-Simoni, F, Simon, 
AJ. and Rechavi, G. (2001). Nuclear membrane protein LAP2beta mediates 
transcriptional repression alone and together with its binding partner GCL 
(germ-cell-less). J Cell Sci 114(Pt 18): 3297-3307. 
NORCCAG (2004). Northern Region Colorectal Cancer Audit Group - 6th Annual 
Report. 
Novelli, G., Muchir, A, Sangiuolo, F, Helbling-Leclerc, A, D'Apice, M.R, Massart, 
C., Capon, F., Sbraccia, P., Federici, M., Lauro, R, Tudisco, C., Pallotta, R., 
Scarano, G., Dallapiccola, B., Merlini, L. and Bonne, G. (2002). Mandibuloacral 
dysplasia is caused by a mutation in LMNA-encoding lamin AlC. Am J Hum 
Genet 71(2): 426-431. 
Oguchi, M., Sagara, J., Matsumoto, K., Saida, T. and Taniguchi, S. (2002). Expression 
of lamins depends on epidermal differentiation and transformation. Br J 
DermatoI147(5): 853-858. 
Olson, T.M. and Keating, M.T. (1996). Mapping a cardiomyopathy locus to 
chromosome 3p22-p25. J Clin Invest 97(2): 528-532. 
Oster, S.K., Ho, C.S., Soucie, E.L. and Penn, L.Z. (2002). The myc oncogene: 
MarvelouslY Complex. Adv Cancer Res 84: 81-154. 
Ottaviano, Y. and Gerace, L. (1985). Phosphorylation of the nuclear lamins during 
interphase and mitosis. J Bioi Chem 260(1): 624-632. 
Ozaki, T., Saijo, M., Murakami, K., Enomoto, H., Taya, Y. and Sakiyama, S. (1994). 
Complex formation between lamin A and the retinoblastoma gene product: 
identification of the domain on lamin A required for its interaction. Oncogene 
9(9): 2649-2653. 
Padmakumar, V.C., Abraham, S., Braune, S., Noegel, AA, Tunggal, B., 
Karakesisoglou, I. and Korenbaum, E. (2004). Enaptin, a giant actin-binding 
protein, is an element of the nuclear membrane and the actin cytoskeleton. Exp 
Cell Res 295(2): 330-339. 
Paraskeva, C., Corfield, AP., Harper, S., Hague, A, Audcent, K. and Williams, AC. 
(1990). Colorectal carcinogenesis: sequential steps in the in vitro 
immortalization and transformation of human colonic epithelial cells. Anticancer 
Res 10(5A): 1189-1200. 
Parsons, R, Li, G.M., Longley, M.J., Fang, W.H., Papadopoulos, N., Jen, J., de la 
Chapelle, A, Kinzler, K.W., Vogelstein, B. and Modrich, P. (1993). 
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 
75(6): 1227-1236. 
Paulin-Levasseur, M., Scherbarth, A, Traub, U. and Traub, P. (1988). Lack of lamins A 
and C in mammalian hemopoietic cell lines devoid of intermediate filament 
proteins. Eur J Cell Bioi 47(1): 121-131. 
Paulin-Levasseur, M., Giese, G., Scherbarth, A and Traub, P. (1989). Expression of 
vimentin and nuclear lamins during the in vitro differentiation of human 
promyelocytic leukemia cells HL-60. Eur J Cell Bioi 50(2): 453-461. 
Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A, Pollack, 
J.R, Ross, D.T., Johnsen, H., Akslen, L.A, Fluge, 0., Pergamenschikov, A, 
Williams, C., Zhu, S.x., Lonning, P.E., Borresen-Dale, AL., Brown, P.O. and 
203 
Botstein, D. (2000). Molecular portraits of human breast tumours. Nature 
406(6797): 747-752. 
Peter, M., Nakagawa, J., Doree, M., Labbe, J.C. and Nigg, E.A. (1990). In vitro 
disassembly of the nuclear lamina and M phase-specific phosphorylation of 
lamins by cdc2 kinase. Cell 61(4): 591-602. 
Pinto, D., Gregorieff, A., Begthel, H. and Clevers, H. (2003). Canonical Wnt signals are 
essential for homeostasis of the intestinal epithelium. Genes Dev 17(14): 1709-
1713. 
Pinto, D. and Clevers, H. (2005). Wnt control of stem cells and differentiation in the 
intestinal epithelium. Exp Cell Res 306(2): 357-363. 
Potten, C.S. and Loeffler, M. (1990). Stem cells: attributes, cycles, spirals, pitfalls and 
uncertainties. Lessons for and from the crypt. Development 110(4): 1001-1020. 
Potten, C.S., Booth, C. and Pritchard, D.M. (1997). The intestinal epithelial stem cell: 
the mucosal governor. Int J Exp PathoI78(4): 219-243. 
Potter, J.D. (1999). Colorectal cancer: molecules and populations. J Natl Cancer Inst 
91(11): 916-932. 
Promega (2002). Wizard SV Gel and PCR Clean-Up System Technical Bulletin 
#TB308. 
Pugh, G.E., Coates, PJ., Lane, E.B., Raymond, Y. and Quinlan, R.A. (1997). Distinct 
nuclear assembly pathways for lamins A and C lead to their increase during 
quiescence in Swiss 3T3 cells. J Cell Sci 110 ( Pt 19): 2483-2493. 
Radtke, F. and Clevers, H. (2005). Self-renewal and cancer of the gut: two sides of a 
coin. Science 307(5717): 1904-1909. 
Raffaele Di Barletta, M., Ricci, E., Galluzzi, G., Tonali, P., Mora, M., Morandi, L., 
Romorini, A., Voit, T., Orstavik, KH., Merlini, L., Trevisan, c., Biancalana, V., 
Housmanowa-Petrusewicz, I., Bione, S., Ricotti, R., Schwartz, K, Bonne, G. 
and Toniolo, D. (2000). Different mutations in the LMNA gene cause autosomal 
dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J 
Hum Genet 66(4): 1407-1412. 
Rankin, F.W. and Broders, A.C. (1928). Factors influencing prognosis in carcinoma of 
the rectum. Surg Gynecol Obstet 46: 660-667. 
Raven, P.H. and Johnson, G.B. (1996). Cellular Mechanisms of Development. In: 
Biology. Dubuque: Wm. C. Brown Publishers, pp. 371-400. 
Rao, L., Perez, D. and White, E. (1996). Lamin proteolysis facilitates nuclear events 
during apoptosis. J Cell Bioi 135(6 Pt 1): 1441-1455. 
Reid, L., Holland, J., Jones, C., Wolfe, B., Niwayama, G., Williams, R., Kaplan, N. and 
Sato, G. (1978). Some of the variables affecting the success of transplantation of 
human tumours into the athymic nude mouse. In: Proceedings of the Symposium 
on the Use of A thymic (Nude) Mice in Cancer Research. Overje, A. (ed). New 
York: Fischer, pp. 107-121. 
Reintgen, D.S., Thompson, W., Garbutt, J. and Seigler, H.F. (1984). Radiologic, 
endoscopic, and surgical considerations of melanoma metastatic to the 
gastrointestinal tract. Surgery 95(6): 635-639. 
Reynolds, E.S. (1963). The use of lead citrate at high pH as an electron-opaque stain in 
electron microscopy. J Cell Bioi 17: 208-212. 
Riemer, D., Stuurman, N., Berrios, M., Hunter, C., Fisher, P.A. and Weber, K (1995). 
Expression of Drosophila lamin C is developmentally regulated: analogies with 
vertebrate A-type lamins. J Cell Sci 108(Pt 10): 3189-3198. 
Rober, R.A., Weber, K and Osborn, M. (1989). Differential timing of nuclear lamin 
NC expression in the various organs of the mouse embryo and the young 
animal: a developmental study. Development 105(2): 365-378. 
204 
Roncucci, L., Pedroni, M., Vaccina, F., Benatti, P., Marzona, L. and De Pol, A. (2000). 
Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell 
Prolif33(1): 1-18. 
Rowlands, D.C., Bunce, C.M., Crocker, J., Ayres, J.G., Johnson, G.D., Ling, N. and 
Brown, G. (1994). Expression of a nuclear envelope protein recognized by the 
monoclonal antibody BD31 in lung tumours: relationship to Ki-67 antigen 
expression. J PathoI173(2): 89-96. 
Sadler, T.W. and Langman, J. (2000). Langman's Medical Embryology, 8th ed. New 
York: Lippincott Williams & Wilkins. 
Salina, D., Bodoor, K., Eckley, D.M., Schroer, T.A., Rattner, J.B. and Burke, B. (2002). 
Cytoplasmic dynein as a facilitator of nuclear envelope breakdown. Cell 108(1): 
97-107. 
Sancho, E., Batlle, E. and Clevers, H. (2004). Signaling pathways in intestinal 
development and cancer. Annu Rev Cell Dev Bioi 20: 695-723. 
Sasseville, A.M. and Raymond, Y. (1995). Lamin A precursor is localized to 
intranuclear foci. J Cell Sci 108(Pt 1): 273-285. 
Scheer, D., Kartenbeck, J., Trendelenburg, M.F., Stadler, J. and Franke, W.W. (1976). 
Experimental disintegration of the nuclear envelope. Evidence for pore-
connecting fibrils. J Cell Bioi 69(1): 1-18. 
Scherf, D., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K., Tanabe, L., Kohn, K.W., 
Reinhold, W.C., Myers, T.G., Andrews, D.T., Scudiero, D.A., Eisen, M.B., 
Sausville, E.A., Pommier, Y., Botstein, D., Brown, P.O. and Weinstein, IN. 
(2000). A gene expression database for the molecular pharmacology of cancer. 
Nat Genet 24(3): 236-244. 
Schirmer, E.C., Guan, T. and Gerace, L. (2001). Involvement of the lamin rod domain 
in heterotypic lamin interactions important for nuclear organization. J Cell Bioi 
153(3): 479-489. 
Sgonc, R. and Gruber, J. (1998). Apoptosis detection: an overview. Exp GerontoI33(6): 
525-533. 
Shi, S.R. , Key, M.E. and Kalra, K.L. (1991). Antigen retrieval in formalin-fixed, 
paraffin-embedded tissues: an enhancement method for immunohistochemical 
staining based on microwave oven heating of tissue sections. J Histochem 
Cytochem 39(6): 741-748. 
Sigma (1999). Tri Reagent Technical Bulletin MB-205. 
Simha, V. and Garg, A. (2002). Body fat distribution and metabolic derangements in 
patients with familial partial lipodystrophy associated with mandibuloacral 
dysplasia. J Clin Endocrinol Metab 87(2): 776-785. 
Simha, V., Agarwal, A.K., Oral, E.A., Fryns, J.P. and Garg, A. (2003). Genetic and 
phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated 
lipodystrophy. J Clin Endocrinol Metab 88(6): 2821-2824. 
Sinensky, M., Fantle, K., Trujillo, M., McLain, T., Kupfer, A. and Dalton, M. (1994). 
The processing pathway of pre lam in A. J Cell Sci 107(Pt 1): 61-67. 
Siu, I.M., Pretlow, T.G., Amini, S.B. and Pretlow, T.P. (1997). Identification of 
dysplasia in human colonic aberrant crypt foci . Am J PathoI150(5): 1805-1813. 
Smythe, c., Jenkins, H.E. and Hutchison, C.J. (2000). Incorporation of the nuclear pore 
basket protein nup153 into nuclear pore structures is dependent upon lamina 
assembly: evidence from cell-free extracts of Xenopus eggs. Embo J 19(15): 
3918-3931. 
Sobotka-Briner, C. and Chelsky, D. (1992). COOH-terminal methylation of lamin B 
and inhibition of methylation by famesylated peptides corresponding to lamin B 
and other CAAX motif proteins. J Bioi Chem 267(17): 12116-12122. 
205 
Spann, T.P., Moir, R.D., Goldman, A.E., Stick, R. and Goldman, R.D. (1997). 
Disruption of nuclear lamin organization alters the distribution of replication 
factors and inhibits DNA synthesis. J Cell Biol136(6): 1201-1212. 
Spann, T.P., Goldman, A.E., Wang, C., Huang, S. and Goldman, R.D. (2002). 
Alteration of nuclear lamin organization inhibits RNA polymerase II-dependent 
transcription. J Cell BiolI56(4): 603-608. 
Speckman, R.A., Garg, A., Du, F., Bennett, L., Veile, R., Arioglu, E., Taylor, S.I., 
Lovett, M. and Bowcock, A.M. (2000). Mutational and haplotype analyses of 
families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent 
missense mutations in the globular C-terminal domain of lamin NC. Am J Hum 
Genet 66(4): 1192-1198. 
Stadelmann, B., Khandjian, E., Hirt, A., Luthy, A., Weil, R. and Wagner, H.P. (1990). 
Repression of nuclear lamin A and C gene expression in human acute 
lymphoblastic leukemia and non-Hodgkin's lymphoma cells. Leuk Res 14(9): 
815-82l. 
Stainier, D.Y. (2005). No organ left behind: tales of gut development and evolution. 
Science 307(5717): 1902-1904. 
Starr, D.A., Hermann, GJ., Malone, C.J., Fixsen, W., Priess, J.R., Horvitz, H.R. and 
Han, M. (2001). unc-83 encodes a novel component of the nuclear envelope and 
is essential for proper nuclear migration. Development 128(24): 5039-5050. 
Steen, R.L. and Collas, P. (2001). Mistargeting of B-type lamins at the end of mitosis: 
implications on cell survival and regulation of lamins NC expression. J Cell 
BiolI53(3): 621-626. 
Steinert, P.M., Chou, Y.H., Prahl ad, V., Parry, D.A., Marekov, L.N., Wu, K.c., Jang, 
S.l. and Goldman, R.D. (1999). A high molecular weight intermediate filament-
associated protein in BHK-21 cells is nestin, a type VI intermediate filament 
protein. Limited co-assembly in vitro to form heteropolymers with type III 
vimentin and type IV alpha-intemexin. J Biol Chem 274(14): 9881-9890. 
Stewart, C. and Burke, B. (1987). Teratocarcinoma stem cells and early mouse embryos 
contain only a single major lamin polypeptide closely resembling lamin B. Cell 
51(3): 383-392. 
Stick, R. and Hausen, P. (1985). Changes in the nuclear lamina composition during 
early development of Xenopus laevis. Cell 41(1): 191-200. 
Stick, R. (1988). eDNA cloning of the developmentally regulated lamin LUI of 
Xenopus laevis. Embo J 7(10): 3189-3197. 
Stick, R., Angres, B., Lehner, C.F. and Nigg, E.A. (1988). The fates of chicken nuclear 
lamin proteins during mitosis: evidence for a reversible redistribution of lamin 
B2 between inner nuclear membrane and elements of the endoplasmic reticulum. 
J Cell Bioll07(2): 397-406. 
Stoffler, D., Fahrenkrog, B. and Aebi, U. (1999). The nuclear pore complex: from 
molecular architecture to functional dynamics. Curr Opin Cell BiolH(3): 391-
40l. 
Stremmel, C., Wein, A., Hohenberger, W. and Reingruber, B. (2002). DNA 
microarrays: a new diagnostic tool and its implications in colorectal cancer. Int J 
Colorectal Dis 17(3): 131-136. 
Stadelmann, B., Khandjian, E., Hirt, A. , Luthy, A., Weil, R. and Wagner, H.P. (1990). 
Repression of nuclear lamin A and C gene expression in human acute 
lymphoblastic leukemia and non-Hodgkin's lymphoma cells. Leuk Res 14(9): 
815-82l. 
Stewart, C. and Burke, B. (1987). Teratocarcinoma stem cells and early mouse embryos 
contain only a single major lamin polypeptide closely resembling lamin B. Cell 
51(3): 383-392. 
206 
Stuurman, N., Heins, S. and Aebi, U. (1998). Nuclear lamins: their structure, assembly, 
and interactions. J Struct BioI 122(1-2): 42-66. 
Sullivan, K.M., Busa, W.B. and Wilson, K.L. (1993). Calcium mobilization is required 
for nuclear vesicle fusion in vitro: implications for membrane traffic and IP3 
receptor function. CeU73(7): 1411-1422. 
Sullivan, T., Escalante-Alcalde, D., Bhatt, H., Anver, M., Bhat, N., Nagashima, K., 
Stewart, C.L. and Burke, B. (1999). Loss of A-type lamin expression 
compromises nuclear envelope integrity leading to muscular dystrophy. J Cell 
BioI 147(5): 913-920. 
Sultana, S., Sernett, S.W., Bellin, RM., Robson, RM. and Skalli, O. (2000). 
Intermediate filament protein synemin is transiently expressed in a subset of 
astrocytes during development. Glia 30(2): 143-153. 
Sundermeyer, M.L., Meropol, N.I., Rogatko, A, Wang, H. and Cohen, S.I. (2005). 
Changing patterns of bone and brain metastases in patients with colorectal 
cancer. Clin Colorectal Cancer 5(2): 108-113. 
Takahashi, A, Musy, P.Y., Martins, L.M., Poirier, G.G., Moyer, RW. and Earnshaw, 
W.C. (1996). CrmA/SPI-2 inhibition of an endogenous ICE-related protease 
responsible for lamin A cleavage and apoptotic nuclear fragmentation. J BioI 
Chern 271(51): 32487-32490. 
Taylor, C.R, Shi, S.R, Chen, C., Young, L., Yang, C. and Cote, R.I. (1996). 
Comparative study of antigen retrieval heating methods: microwave, microwave 
and pressure cooker, autoclave, and steamer. Biotech Histochem 71(5): 263-270. 
Terry, P., Giovannucci, E., Michels, K.B., Bergkvist, L., Hansen, H., Holmberg, L. and 
Wolk, A (2001). Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J 
Natl Cancer Inst 93(7): 525-533. 
Thibodeau, S.N., Bren, G. and Schaid, D. (1993). Microsatellite instability in cancer of 
the proximal colon. Science 260(5109): 816-819. 
Tilli, C.M., Ramaekers, F.C., Broers, J.L., Hutchison, C.I. and Neumann, H.A (2003). 
Lamin expression in normal human skin, actinic keratosis, squamous cell 
carcinoma and basal cell carcinoma. Br J DermatoI148(1): 102-109. 
Titeux, M., Brocheriou, V., Xue, Z., Gao, J., Pellissier, J.F., Guicheney, P., Paulin, D. 
andLi, Z. (2001). Human synemin gene generates splice variants encoding two 
distinct intermediate filament proteins. Eur J Biochem 268(24): 6435-6449. 
Toms, J.R, (ed) (2004). CancerStats Monograph 2004. London: Cancer Research UK. 
Torosian, M.H., Botet, J.F. and Paglia, M. (1987). Colon carcinoma metastatic to the 
thigh--an unusual site of metastasis. Report of a case. Dis Colon Rectum 30(10): 
805-808. 
Touchette, N. (1994). Finding clues about how embryo structures form. Science 
266(5185): 564-565. 
Turnbull, RB., Jr., Kyle, K., Watson, F.R and Spratt, J. (1967). Cancer of the colon: 
the influence of the no-touch isolation technic on survival rates. Ann Surg 
166(3): 420-427. 
Tzur, Y.B., Hersh, B.M., Horvitz, H.R and Gruenbaum, Y. (2002). Fate of the nuclear 
lamina during Caenorhabditis elegans apoptosis. J Struct Bioi 137(1-2): 146-
153. 
van de Wetering, M., Cavallo, R, Dooijes, D., van Beest, M., van Es, J., Loureiro, J., 
Ypma, A, Hursh, D., Jones, T., Bejsovec, A, Peifer, M., Mortin, M. and 
Clevers, H. (1997). Armadillo co activates transcription driven by the product of 
the Drosophila segment polarity gene dTCF. Cell 88(6): 789-799. 
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hudstone, A, van 
der Hom, K., Batlle, E., Coudreuse, D., Haramis, AP., Tjon-Pon-Fong, M., 
Moerer, P., van den Born, M., Soete, G., Pals, S., Eilers, M., Medema, R. and 
207 
Clevers, H. (2002). The beta-cateninITCF-4 complex imposes a crypt progenitor 
phenotype on colorectal cancer cells. Cell 111(2): 241-250. 
van der Kooi, AJ., Ledderhof, T.M., de Voogt, W.G., Res, C.J. , Bouwsma, G., Troost, 
D., Busch, H.F., Becker, AE. and de Visser, M. (1996). A newly recognized 
autosomal dominant limb girdle muscular dystrophy with cardiac involvement. 
Ann Neural 39(5): 636-642. 
van der Kooi, AJ., van Meegen, M., Ledderhof, T.M., McNally, E.M., de Visser, M. 
and Bolhuis, P.A (1997). Genetic localization of a newly recognized autosomal 
dominant limb-girdle muscular dystrophy with cardiac involvement (LGMDIB) 
to chromosome lql1-21. Am ] Hum Genet 60(4): 891-895. 
Vaughan, A , Alvarez-Reyes, M., Bridger, J.M., Broers, J.L., Ramaekers, F.C. , 
Wehnert, M., Morris, G.E., Whitfield, W.G.F. and Hutchison, C.J. (2001). Both 
emerin and lamin C depend on lamin A for localization at the nuclear envelope. 
] Cell Sci 114(Pt 14): 2577-2590. 
Venables, RS., McLean, S., Luny, D., Moteleb, E., Morley, S., Quinlan, R.A , Lane, 
E.B. and Hutchison, C.J. (2001). Expression of individuallamins in basal cell 
carcinomas of the skin. BrJ Cancer 84(4): 512-519. 
Vigers, G.P. and Lohka, M.J. (1991). A distinct vesicle population targets membranes 
and pore complexes to the nuclear envelope in Xenopus eggs. ] Cell BioI 112(4): 
545-556. 
Vigouroux, c., Auclair, M., Dubosclard, E., Pouchelet, M. , Capeau, J., Courvalin, J.C. 
and Buendia, B. (2001). Nuclear envelope disorganization in fibroblasts from 
lipodystrophic patients with heterozygous R482QIW mutations in the lamin AlC 
gene. ] Cell Sci 114(Pt 24): 4459-4468. 
Virtanen, C., Ishikawa, Y., Honjoh, D., Kimura, M. , Shimane, M., Miyoshi, T., 
Nomura, H. and Jones, M.H. (2002). Integrated classification of lung tumors and 
cell lines by expression profiling. Proc Natl Acad Sci USA 99(19): 12357-
12362. 
Vogelstein, B., Fearon, E.R, Hamilton, S.R., Kern, S.E. , Preis inger, AC., Leppert, M., 
Nakamura, Y., White, R., Smits, AM. and Bos, J.L. (1988). Genetic alterations 
during colorectal-tumor development. N Engl ] Med 319(9): 525-532. 
Ward, G.E. and Kirschner, M.W. (1990). Identification of cell cycle-regulated 
phosphorylation sites on nuclear lamin C. Cell 61(4): 561-577. 
Weber, K, Plessmann, U. and Traub, P. (1989). Maturation of nuclear lamin A involves 
a specific carboxy-terminal trimming, which removes the polyisoprenylation site 
from the precursor; implications for the structure of the nuclear lamina. FEBS 
Lett 257(2): 411-414. 
leiss, L. and Ward, P.M. (1988). Effects of metastatic cascades on metastatic patterns: 
studies on colon-26 carcinomas in mice. IntJ Cancer 41(3): 450-455. 
einstein, J.N., Myers, T.G., O'Connor, P.M., Friend, S.H., Fornace, A.J. , Jr., Kohn, 
KW., Fojo, T., Bates, S.E., Rubinstein, L.V., Anderson, N.L., Buolamwini, 
J.K, van Osdol, W.W., Monks, AP., Scudiero, D.A, Sausville, E.A, 
Zaharevitz, D.W. , Bunow, B., Viswanadhan, V.N., Johnson, G.S., Wittes, R.E. 
and Paull, KD. (1997). An information-intensive approach to the molecular 
pharmacology of cancer. Science 275(5298): 343-349. 
dson, RG. (2001). Personal communication. 
'olpert, L. (1994). Do we understand development? Science 266(5185): 571-572. 
rulff, K, Ebener, U., Wehnert, C.S., Ward, P.A. , Reuner, U., Hiebsch, W., Herrmann, 
F.R. and Wehnert, M. (1997). Direct molecular genetic diagnosis and 
heterozygote identification in X-linked Emery-Dreifuss muscular dystrophy by 
heteroduplex analysis. Dis Markers 13(2): 77-86. 
208 
Wydner, K.L., McNeil, J.A, Lin, F., Wonnan, H.J. and Lawrence, J.B . (1996). 
Chromosomal assignment of human nuclear envelope protein genes LMNA, 
LMNB1 , and LBR by fluorescence in situ hybridization. Genornics 32(3): 474-
478. 
Xue, Z.G., Cheraud, Y, Brocheriou, V., Izmiryan, A, Titeux, M., Paulin, D. and Li, Z. 
(2004). The mouse synemin gene encodes three intennediate filament proteins 
generated by alternative ex on usage and different open reading frames. Exp Cell 
Res 298(2): 431-444. 
Yang, L., Guan, T. and Gerace, L. (1997). Integral membrane proteins of the nuclear 
envelope are dispersed throughout the endoplasmic reticulum during mitosis. J 
Cell Biol137(6): 1199-1210. 
Ye, Q., Callebaut, I., Pezhman, A, Courvalin, J.e. and Wonnan, H.J. (1997). Domain-
specific interactions of human HP1-type chromodomain proteins and inner 
nuclear membrane protein LBR. J Biol Chern 272(23): 14983-14989. 
Young, L.W., Radebaugh, J.F., Rubin, P., Sensenbrenner, J.A, Fiorelli, G. and 
McKusick, V.A (1971). New syndrome manifested by mandibular hypoplasia, 
acroosteolysis, stiff joints and cutaneous atrophy (mandibuloacral dysplasia) in 
two unrelated boys. Birth Defects Orig Artie Ser 7(7): 291-297. 
Zhang, Q. , Skepper, J.N., Yang, F., Davies, J.D., Hegyi, L., Roberts, R.G., Weissberg, 
P.L., Ellis, J.A and Shanahan, e.M. (2001). Nesprins: a novel family of 
spectrin-repeat-containing proteins that localize to the nuclear membrane in 
multiple tissues. J Cell Sci U4(Pt 24): 4485-4498. 
Zhen, YY, Libotte, T., Munck, M., Noegel, AA and Korenbaum, E. (2002). 
NUANCE, a giant protein connecting the nucleus and actin cytoskeleton. J Cell 
Sci US(Pt 15): 3207-3222. 
http://frodo. wi.mit.edu/primer3/primer3 _ code.html 
http://www.premierbiosoft.com!netprimer/index.html 
209 
